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Muscarinic acetylcholine receptors (MRs), a family of five G protein-coupled 
receptors (GPCRs), play an essential role in the regulation of mammalian physiology.  In 
the brain, MR-mediated neurotransmission is required for the control of movement and 
motivated behavior by the basal ganglia, and MR dysfunction may contribute to 
schizophrenia, Alzheimerʼs disease, and motor disorders.  Functional studies of the 
muscarinic receptors have been hampered by a lack of selective pharmacology, poor 
receptor immunoreactivity and a wide, overlapping pattern of expression.  MRs are 
characterized by the presence of a large third intracellular loop domain (i3), the 
sequence of which is divergent between MR subtypes.  The i3 is known to determine 
signaling and trafficking characteristics of GPCRs by binding to defined subsets of 
regulatory and effector proteins.  In an effort to discover novel, subtype-specific 
muscarinic receptor regulatory mechanisms, we performed yeast two-hybrid protein-
protein interaction screens with the five MR i3 regions.  An interaction between M5 and 
the Arf GAP protein AGAP1 was detected, and was observed to be specific to the M5 
subtype.  This interaction was confirmed in vitro, and was shown to mediate the binding 
of the AP-3 adaptor complex to the M5 i3.   Immunocytochemical and live cell imaging of 
primary rat hippocampal neurons revealed co-localization of M5 and AGAP1- or AP-3- 
positive vesicles after treatment with a muscarinic agonist.  Activity-induced receptor 
trafficking studies demonstrated that interaction with AGAP1 and activity of AP-3 were 
required for the endocytic recycling of M5 in neurons, the lack of which resulted in down-
regulation of cell surface receptor density.   M5 has been shown to be expressed in the 
dopaminergic neurons of the ventral midbrain and to function in the presynaptic 
modulation of dopamine release in the striatum.  Results from dopamine release studies 
suggest that the abrogation of AGAP1-mediated recycling decreases the magnitude of 
presynaptic M5-mediated release potentiation.  Our study demonstrates a novel, neuron-
specific trafficking function for AGAP1 and AP-3, and suggests the presence of a 
previously unknown receptor recycling pathway that may underlie mechanisms of 
sustained sensitivity of GPCRs. 
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INTRODUCTION
1.1  Acetylcholine and cholinergic neurotransmission
Acetylcholine, the first molecule identified as a chemical neurotransmitter, 
plays an essential role in the physiology of animals.  In the peripheral nervous 
system (PNS), acetylcholine (ACh) mediates the execution of voluntary 
movements via its release from motor neuron axon terminals at the 
neuromuscular junction.  Also in the PNS, ACh functions as the post-ganglionic 
neurotransmitter of the parasympathetic nervous system, innervating heart, 
smooth muscle and glandular tissue, and serving to stimulate functions such as 
bronchial constriction, heart rate decrease, salivation, digestive peristalsis and 
blood vessel dilation.  ACh further serves as the pre-ganglionic neurotransmitter 
for both the parasympathetic and sympathetic divisions of the PNS.  In the 
central nervous system (CNS), ACh plays a neuromodulatory role in nearly every 
region of the brain.  ACh neurotransmission is implicated in such processes as 
arousal, reward, learning, and memory.  In addition, ACh is known to exhibit 
hormone-like activity, with autocrine and/or paracrine functions described in such 
non-innervated tissues as skin, lymphocytes, and the endothelium, as well as in 
cancer cells (Wessler et al., 2003; Wess et al., 2007; Cheng et al., 2008).  The 
ubiquity of ACh is further demonstrated by its identification as a phylogenetically 
ancient molecule; ACh and its synthetic enzyme choline acetyltransferase (ChAT) 
have been detected in protozoa, algae, and even bacteria, and ACh is seen to 
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modulate such fundamental cellular processes as proliferation, migration, and 
morphology (Wessler et al., 1999).  
In the CNS, cholinergic projection and interneurons provide widespread, 
diffuse innervation of nearly every brain region.  Cholinergic afferents project 
from areas of the basal forebrain and brainstem; these neurons are further 
subdivided into eight nuclei based on location and targets (Ch1-Ch8), with 
anatomy generally conserved across mammalian species (Mesulam, 2004).  The 
basal forebrain nuclei provide the majority of cholinergic projection neuron 
innervation in the CNS.  Cholinergic neurons in the medial septal nucleus (Ch1) 
and the vertical nucleus of the diagonal band (Ch2) innervate the hippocampus, 
Ch3 neurons of the horizontal limb of the diagonal band project to the olfactory 
bulb, while cholinergic afferents originating in the nucleus basalis of Meynert 
(Ch4) project widely to the cerebral cortex, with particularly dense innervation of 
the sensory and limbic cortices in humans.  In the brain stem, cholinergic 
projection neurons in the pedunculopontine (Ch5) and laterodorsal tegmental 
(Ch6) nuclei project to the thalamus and regions of the basal ganglia, while Ch7 
and Ch8 neurons of the medial habenula and parabigeminal nucleus project to 
midbrain regions.  In contrast to this system of cholinergic projection neurons, the 
striatum receives little input from cholinergic afferents, but is characterized by 
extensive intrinsic innervation by giant aspiny cholinergic interneurons.  As 
judged by staining for cholinergic markers (ChAT and the extracellular ACh 
degradative enzyme acetylcholine esterase (AChE)), the striatum is in fact the 
2
brain region most heavily innervated by the cholinergic system (Zhou et al., 
2002a).      
The cellular effects of ACh are mediated by two classes of receptors: 
nicotinic (nAchR) and muscarinic (mAchR; MR), so named for their sensitivity to 
the tobacco alkaloid nicotine and the mushroom toxin muscarine, respectively.  
Nicotinic acetylcholine receptors are a family of homo- and hetero-pentameric 
ligand-gated cation channels.  In muscles, nAchRs are expressed post-
synaptically at the neuromuscular junction, and their activation by ACh results in 
contraction.  nAchRs mediate fast excitatory neurotransmission in PNS ganglia, 
while in the CNS, nAchRs serve a neuromodulatory function, most notably in the 
terminals of basal ganglia dopaminergic neurons (Dajas-Bailador and Wonnacott, 
2004; Zhang and Sulzer, 2004).  Muscarinic acetylcholine receptors, on the other 
hand, are metabotropic receptors belonging to the G protein coupled receptor 
superfamily; activation of MRs by ACh stimulates production of intracellular 
second messenger molecules, which in turn mediate cellular effects.  MRs, of 
which five subtypes are known to exist in mammals, are expressed in a complex, 
overlapping pattern in both the CNS and periphery; in fact, nearly every cell type 
is known to express multiple MR subtypes (Wess et al., 2007).  Adding to this 
complexity is the fact that MRs couple to multiple signaling pathways, leading to 
both convergent and divergent second messenger pathway activation in ACh-
stimulated cells (Nathanson, 2000).  In the following sections, we will discuss the 
structure, second messenger coupling, distribution, and regulatory characteristics 
of the muscarinic receptors in the context of this functional complexity.
3
1.2  G protein-coupled receptors: general characteristics
G protein-coupled receptors (GPCRs) are a structurally conserved gene 
superfamily, constituting the largest and most functionally diverse group of 
proteins in mammals and representing over 30% of identified drug targets to date 
(Oldham and Hamm, 2008).  GPCRs are multiple-pass integral membrane 
proteins consisting of seven transmembrane α-helices, an extracellular N-
terminus, a cytoplasmic C-terminal tail and three each of both extracellular and 
cytoplasmic loop regions positioned between the transmembrane helices.  The 
GPCR superfamily is generally divided into five main subgroups based on 
phylogeny: class A (rhodopsin-like), class B (secretin receptor-like) class C 
(metabotropic glutamate receptor-like), adhesion receptor-like and Frizzled family 
receptors (Fredriksson et al., 2003; Foord et al., 2005).  The rhodopsin-like group 
contains by far the greatest number of member GPCRs, including the muscarinic 
acetylcholine receptors.  Among members of this group, structural and sequence 
motifs are highly conserved, implying shared mechanisms of function 
(Rosenbaum et al., 2009).  GPCRs are activated by a variety of extracellular 
stimuli, including light (rhodopsin), volatile odorants and pheromones (olfactory 
and vomeronasal receptors, respectively) as well as small molecule, peptide, 
protein, ion and lipid ligands.
The classical mechanism by which GPCRs transduce extracellular signals 
to the cell interior relies on activation of heterotrimeric G proteins.  In the resting 
state, GDP-bound Gα (a small GTPase protein) forms a complex with Gβ and Gγ 
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subunits.  Upon activation, the GPCR is able to function as a GDP exchange 
factor (GEF) for the heterotrimeric G protein, catalyzing the exchange of GDP for 
GTP by the Gα subunit and leading to dissociation of activated Gα and the Gβγ 
dimer, thus allowing activation of effector proteins by Gα-GTP.  A recently 
described crystal structure of the light-sensitive GPCR opsin in a pseudo-active 
state suggests that activation-induced conformational changes in the GPCR 
allow direct binding to Gα (Scheerer et al., 2008).  Signaling is terminated upon 
hydrolysis of GTP to GDP by Gα, and subsequent re-assembly with the inhibitory 
Gβγ dimer into the inactive heterotrimeric complex.  As the intrinsic GTPase 
activity of Gα is low, termination of signaling is accelerated by the presence of 
RGS (regulator of G-protein signaling) proteins, which function as GTPase 
activating proteins (GAPs) for Gα (Hepler, 1999).  In addition, GPCRs typically 
undergo a stereotyped series of desensitization events subsequent to activation, 
including phosphorylation by GPCR kinases, binding of β-arrestin, and 
uncoupling of receptors from G-proteins; we describe this process in detail in 
section 1.3 of this chapter.
In contrast to the nearly 800 identified GPCRs in the human genome, far 
fewer G protein subtypes exist.  Functional categorization of Gα subunits reveals 
four classes of G-protein heterotrimers: Gi/o, Gs, Gq, and G12 (Simon et al., 
1991).  Gαi/o and Gαs are negatively and positively coupled, respectively, to the 
production of cyclic AMP (cAMP) by adenylate cyclase.  The second messenger 
cAMP, in turn, activates protein kinase A (PKA), which is able to act upon a wide 
variety of downstream targets, including enzymes, ion channels (Ca2+ and K+), 
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transcriptional regulators, and the signal integration protein DARPP-32 in the 
medium spiny neurons of the striatum (Greengard, 2001).  Activated Gαq 
stimulates the phospholipase C beta (PLC-β)-mediated cleavage of 
phosphatidylinositol-4,5-bisphosphate (PIP2), thereby generating the second 
messengers diacylglycerol (DAG) and inositol triphosphate (IP3).  Diffusible IP3 
stimulates intracellular Ca2+ release by the gating of channels located in the 
endoplasmic reticulum, while membrane-bound DAG, along with Ca2+, activates 
protein kinase C (PKC).  Ca2+ and PKC, in turn, act upon a number of 
downstream targets, including ion channels and the mitogen-activated protein 
(MAP) kinases.  Gα12 class proteins appear to signal mainly through Rho GEF to 
affect cellular morphology and motility by downstream modulation of actin 
cytoskeleton dynamics (Worzfeld et al., 2008).  Coupling specificity between G 
proteins and GPCRs is thought to arise from binding domains present on the 
cytoplasmic face of the receptors (Kostenis et al., 1997; Kostenis et al., 1999; 
Oldham and Hamm, 2008).  Factors complicating this model of GPCR signal 
transduction include 1) GPCRs may couple to multiple G protein subtypes 
(Maudsley et al., 2007); 2) GPCRs also stimulate non-Gα mediated signaling, 
such as the modulation of voltage-gated calcium channels by Gβγ and activation 
of the MAP kinase pathway by β-arrestin (McDonald et al., 2000; Dolphin, 2003); 
and 3) GPCRs may exist as functional heterodimers (Satake and Sakai, 2008).  
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1.3  The muscarinic acetylcholine receptor family
The muscarinic acetylcholine receptors are a family of five rhodopsin-type 
(group A) GPCRs in mammals (Bonner et al., 1987).  The family can be further 
subdivided into two groups based on G protein coupling: muscarinic receptors 1 
(M1), 3 (M3) and 5 (M5) signal predominantly through Gq, while MRs 2 (M2) and 
4 (M4) couple to Gi.  The MR family is distinguished structurally by the presence 
of large third intracellular loop (i3) regions which are conserved in sequence 
across species but highly divergent between subtypes, save for juxtamembrane 
regions likely involved in G protein recognition and / or binding  (figure 1.1) 
(Wess et al., 1995; Wess et al., 1997).  In contrast, the extracellular and 
transmembrane regions of the MRs, including the presumed ligand binding 
domain, show strong sequence similarity across subtypes (figure 1.1).  As a 
consequence of this similarity, the pharmacological specificity of cholinergic 
agonists and antagonists with respect to receptor subtype is poor; in addition, 
divergent regions of MRs appear to offer low antigenicity, precluding the 
successful development of subtype-specific antibodies (Wess et al., 2003; 
Jositsch et al., 2009).  Combined with the widespread, overlapping distribution 
pattern of MRs, these technical limitations have greatly hampered functional 
studies of individual muscarinic receptors in vivo.  The investigation of MR 
function in a subtype-selective manner has instead relied upon the use of single 
or double MR knockout mice (Wess et al., 2007).  Below, we summarize the 
current knowledge of MR subtype function in the CNS and periphery based on 
knockout loss-of-function and MR binding site studies combined with tissue-
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Figure 1.1 Muscarinic acetylcholine receptor topology and sequence 
alignment.  Top: Snake plot of rat M4 illustrating extracellular, transmembrane, 
and cytoplasmic domains (from www.GPCR.org).  i1,i2, i3: first, second and third 
intracellular loops, respectively; CT, C-terminal tail.  Bottom:  Alignment of five rat 
muscarinic receptor amino acid sequences, with i1, i2, i3, and CT regions 
highlighted.  Residues are colored according to shared physical properties.  
specific and global gene expression data (Oki et al., 2005; Regard et al., 2008; 
Ito et al., 2009).
1.3.1  M1
The M1 receptor is the most highly expressed muscarinic receptor 
subtype in the CNS, constituting the majority of MR radioligand binding sites and 
the entirety of ACh-stimulated Gq activation in the cortex and hippocampus 
(Porter et al., 2002; Oki et al., 2005).  Activation of post-synaptic M1 receptors is 
generally excitatory, and appears to exert this neuromodulatory effect through a 
number of distinct mechanisms.  First, activation of M1 (and other Gq-coupled 
receptors including M3 and M5) leads to membrane depolarization by inhibition 
of the voltage-dependent, outwardly-rectifying M-current (IM).  IM is mediated by 
KCNQ2/3 K+ channels, which require PIP2 for activation; stimulation of PLC-β by 
M1 / Gαq  hydrolyzes PIP2 and deactivates this hyperpolarizing current (Zhang et 
al., 2003).  Second, M1 activation can inhibit the activity of a number of voltage 
gated Ca2+ channels through a slow-acting mechanism involving diffusible 
second messengers such as PIP2 and/or PKC activation (Liu et al., 2006; Perez-
Burgos et al., 2008).  M1 receptors mediate the neuromodulatory effects of ACh 
in cortical pyramidal neurons (Gulledge et al., 2009) and post-synaptic M1 
receptors in CA3 neurons are required for induction of hippocampal gamma-
oscillations (Fisahn et al., 2002).  Additionally, M1 is the sole MR responsible for 
ACh-induced MAP kinase activation in the hippocampus, a process implicated in 
the mechanism of long-term plasticity (Berkeley et al., 2001).  Outside of the 
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CNS, M1 receptor expression is low, although deficits in PNS functions such as 
salivation and blood pressure homeostasis were observed in M1 knockout mice 
(Bymaster et al., 2003).  Behaviorally, M1-/- mice are moderately hyperactive, 
display subtle learning and memory deficits, and are insensitive to the seizure-
inducing muscarinic agonist pilocarpine (Hamilton et al., 1997; Miyakawa et al., 
2001; Bymaster et al., 2003).
1.3.2  M2
M2 receptors are the predominant MR expressed in heart myocytes, 
where they mediate the rate-slowing and atrial contraction strength-decreasing 
effects of ACh release by parasympathetic afferents.  The cardiac effects of M2 
are mainly transduced by Gβγ-stimulated opening of GIRK K+ channels, leading 
to membrane hyperpolarization.  M2 receptors are also expressed in smooth 
muscles, where they serve to potentiate the M3-mediated contractile effects of 
ACh via a cAMP-related mechanism (Stengel et al., 2000).  M2 is widely 
expressed in the CNS, and appears to function as the primary autoreceptor for 
ACh at cholinergic neuron terminals outside of the striatum (Zhang et al., 2002a).  
The autoinhibitory effects of M2 are largely mediated by fast-acting Gβγ binding-
induced inhibition of N- and P/Q- type Ca2+ channels (Shapiro et al., 2001).  M2 
also serves as an inhibitory autoreceptor and modulatory receptor at post-
ganglionic parasympathetic and sympathetic nerve terminals, respectively (Zhou 
et al., 2002b; Trendelenburg et al., 2003).  The M2 -/- mouse exhibits reduced 
sensitivity to the analgesia-inducing muscarinic agonist oxotremorine, altered 
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neuronal plasticity in the hippocampus, and deficits in memory and behavioral 
flexibility (Gomeza et al., 1999a; Tzavara et al., 2003; Seeger et al., 2004).
1.3.3  M3
M3 receptors are expressed in nearly all smooth muscle and glandular 
tissues, and are the primary MRs mediating the effects of ACh released by the 
parasympathetic PNS on blood vessels, the eye, the gastrointestinal, 
reproductive and urinary tracts, and in exocrine glands (Bymaster et al., 2003).  
In addition, M3 plays a key role in the regulation of glucose homeostasis by 
mediating the IP3-dependent potentiation of glucose-stimulated insulin release 
by pancreatic islet β cells (Gautam et al., 2006).  M3 receptors are expressed 
widely in the CNS, but appear to play a minor role in the regulation of neuronal 
excitability, although hypothalamic dysfunction has been noted in the M3 -/- 
mouse (Yamada et al., 2001b; Gautam et al., 2009).  Aside from exhibiting 
peripheral abnormalities associated with PNS dysfunction (and the glucose 
homeostasis phenotype described above in a β cell conditional knockout model), 
M3-/- mice exhibit feeding deficits, reduced serum leptin levels, and are 
abnormally small and lean (Yamada et al., 2001b; Gautam et al., 2009).
1.3.4  M4
M4 receptors are expressed at low levels outside of the CNS, where they 
play a minor, M2-like functional role in peripheral tissues and may be important 
for the motility of keratinocytes during wound healing (Zhou et al., 2002b; 
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Bymaster et al., 2003; Trendelenburg et al., 2003; Chernyavsky et al., 2004).  In 
the brain, M4 is a low-abundance autoinhibitory receptor at cortex and 
hippocampal cholinergic terminals, likely functioning similarly to M2 via a Ca2+ 
channel mechanism (Zhang et al., 2002a).  However, M4 is expressed at high 
levels in the striatum, where it functions both pre- and post-synaptically 
(discussed in further detail in section 1.2.8) (Zhang et al., 2002b; Oki et al., 
2005).  M4 -/- mice exhibit modest M2-like deficits in muscarinic agonist-induced 
analgesia, but are markedly hyperlocomotive and hypersensitive to the effects of 
D1 dopamine receptor agonists (Gomeza et al., 1999b; Gomeza et al., 2001).
1.3.5  M5
The M5 receptor is the least abundant muscarinic receptor expressed in 
mammals.  M5 comprises less than 2% of the total MR population in the brain 
and is functionally undetectable in peripheral tissues, though low levels of M5 
mRNA have been reported in skin and in some cancer cell lines (Kohn et al., 
1996; Oki et al., 2005; Ito et al., 2009).  However, M5 is the only muscarinic 
receptor for which expression is detected in the midbrain dopaminergic neurons 
of the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) 
(Weiner et al., 1990; Wess et al., 2007).  Both somatodendritic and pre-synaptic  
M5 receptors mediate the ability of ACh to potentiate dopamine release from SNc 
and VTA neurons (Yamada et al., 2001a; Forster et al., 2002).  In addition, M5 is 
the sole MR responsible for the dilatory action of ACh on cerebral arteries and 
arterioles, a function mediated by the M3 receptor elsewhere in the body 
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(Yamada et al., 2001a).  The M5 -/- mouse exhibits mild cognitive defects, 
decreased sensitivity to amphetamine and morphine, reduced cocaine self-
administration, and altered sensorimotor gating (Basile et al., 2002; Wang et al., 
2004; Thomsen et al., 2005; Araya et al., 2006).
1.3.6  Muscarinic receptor distribution and function in the striatum
  The basal ganglia (BG), a group of subcortical nuclei composed of the 
substantia nigra, pallidum, subthalamic nucleus, and striatum, play a critical role 
in the processing and integration of neuronally encoded information to produce 
motivated behaviors.  The striatum is the major input nucleus of the BG, 
consisting mainly (90-95%) of GABAergic medium spiny neurons (MSNs) 
projecting to the BG output nuclei.  The striatum can be divided functionally and 
anatomically along a dorsolateral to medioventral axis: dorsolateral areas, 
receiving glutamatergic afferents from sensorimotor cortex and dopaminergic 
input from the SNc, function mainly in the execution of movement and in spatial 
and procedural memory, while the medioventral striatum (including the nucleus 
accumbens) receives glutamatergic afferents mainly from limbic areas (including 
the hippocampus and amygdala) and dopaminergic input from the VTA, and 
plays a central role in motivation, reward, and the pathophysiology of drug 
addiction (Voorn et al., 2004).  Striatal anatomy can be further subdivided on the 
basis of MSN efferent pathways, illustrated in figure 1.2: “direct” striatonigral 
MSNs directly innervate the BG output nuclei (the substantia nigra pars reticulata 
(SNr) and globus pallidus internal capsule (GPi)), while “indirect” striatopallidal 
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MSNs project to an intervening inhibitory nucleus (the globus pallidus external 
capsule, or GPe) and ultimately innervate the SNr/GPi indirectly via the 
subthalamic nucleus (STN).  Importantly, direct pathway MSNs express 
excitatory D1 dopamine receptors, while indirect MSNs express inhibitory D2 
receptors.  This segregated expression pattern allows dopamine to potentiate the 
MSNsʼ disinhibition-mediated activation of thalamocortical output pathways 
(figure 1.2).  The balance of non-MSN neurons in the striatum is composed of 
GABAergic and cholinergic interneurons.  The giant aspiny cholinergic 
interneurons, comprising 2% of the total neuronal population of the striatum, are 
tonically active and provide both volumetric and synaptic innervation of MSNs 
through highly arborized axons (Pisani et al., 2007).  The interaction between 
cholinergic and dopaminergic activity in the striatum plays a major role in the 
regulation of MSN activity and plasticity, and in turn is required for proper 
coordination of motivated locomotor activity (Pisani et al., 2007).
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Figure 1.2 (following page), Cholinergic innervation and muscarinic 
receptor expression in the basal ganglia. Red, green, yellow and blue 
represent GABAergic, glutamatergic, cholinergic, and dopaminergic neurons  
and terminals, respectively. Small squares and circles represent dopamine  
and muscarinic receptors, respectively, with subtype noted by number. Green 
receptors are excitatory, while red receptors are inhibitory. Circles indicate 
neuron somatodendritic compartments, and axon terminals are indicated by 
triangles; non-synaptic terminals indicate volumetric ACh release (striatum) or 
diffuse innervation (thalamostriatal and thalamocoritical pathways, and 
cholinergic innervation of the cortex). GPe, globus pallidus external capsule; 
STN, subthalamic nucleus, SNr, substantia nigra pars reticulata, GPi, globus 
pallidus internal capsule, SNc, substantia nigra pars compacta, VTA, ventral 
tegmental area; MSN, medium spiny neuron. 
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Muscarinic receptors are expressed in a complex, overlapping pattern in 
the striatum, and play a central role in the mediation of AChʼs effects upon BG 
function (figure 1.2).  Giant aspiny interneurons receive input from SNc and VTA 
dopaminergic neurons and co-express the D2 and D5 dopamine receptor 
subtypes.  Activation of D2 receptors inhibit, while activation of D5 receptors 
stimulate, the firing rate and ACh release of aspiny interneurons; however, the in 
vivo coordination of these actions on individual cholinergic neurons is unknown 
(Yan et al., 1997; Yan and Surmeier, 1997).  Medium spiny neurons express 
dendritic M1 and M4 muscarinic receptors, with anatomical and functional 
evidence suggesting preferential expression of M4 receptors on direct pathway 
MSNs (Santiago and Potter, 2001).  MSN M1 activation is generally excitatory, 
although M1-stimulated Ca2+ / PKC activity can inhibit voltage-gated calcium 
channels (Calabresi et al., 2000).  Post-synaptic M4 activation is seen to inhibit 
GABA release by medium spiny projection neurons.  However, M4 also plays a 
key, striatum-specific autoinhibitory role at cholinergic interneuron terminals, 
functioning to reduce the ACh input to M1- and M4- expressing MSNs (Zhang et 
al., 2002a).  M2 and M3 are present at low levels in the striatum, with 
neurotransmitter release-modulating functions reported for these receptors at 
corticostriatal glutamatergic and GABAergic interneuron terminals, respectively 
(Zhang et al., 2002b).  In addition, cholinergic neurons themselves likely express 
somatodendritic M1 and M4 muscarinic receptors, with volumetrically released 
ACh providing input (Pisani et al., 2007).  
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Further complicating the system of muscarinic receptor function in the 
striatum is the fact that ACh can also exert influence on the release of dopamine 
by nigrostriatal and mesolimbic neurons (figure 1.2).  Studies of evoked 
dopamine release in MR knockout mice have shown that M4 and M5 receptors 
mediate the ability of ACh to potentiate evoked DA release in the striatum; M4 
likely exerts an indirect, trans-synaptic effect via receptors expressed on MSNs 
or cholinergic interneuron terminals, while ACh activation of dopaminergic 
terminal-localized M5 receptors is able to modulate dopamine release directly.  
M3 receptor activation was seen to indirectly inhibit evoked dopamine release, 
while a dopamine-modulatory role for M1 and M2 receptors was not observed 
(Zhang et al., 2002b).  In addition, muscarinic receptor M5, the only MR 
detectably expressed in midbrain dopaminergic neurons, was seen to mediate 
the ability of ACh released from brainstem afferents to stimulate prolonged 
dopamine release from mesolimbic neuron terminals (Forster et al., 2002).  Thus, 
while the overall effect of ACh on MSNs is to oppose the stimulatory action of 
dopamine on the disinhibition of thalamic output nuclei, the possibility of single-
neuron co-expression of excitatory and inhibitory MRs, the opposing effects of 
pre- and post-synaptically localized M4, and the complex nature of ACh-
regulated DA release leaves great uncertainty as to the precise roles of MR 
subtypes on striatal function.  Adding a final layer of complexity is the role of 
muscarinic receptors in the regulation of DARPP-32 in MSNs; although not 
directly examined, activation of the Gq-coupled M1 and Gi-coupled M4 receptors 
may lead to inhibition of PKA activity and altered intracellular Ca2+ levels, thus 
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modulating DARPP-32ʼs protein phosphatase-1 mediated effects on downstream 
receptor or transcriptional effectors (Svenningsson et al., 2004).  The exact role 
of muscarinic receptor in the function of the striatum and BG is thus incompletely 
understood, and underscores the the need for development of cell-specific and 
MR subtype-selective experimental tools.
1.3.7  Muscarinic receptors and CNS disease / dysfunction
Muscarinic receptor dysfunction has been implicated in a number of 
diseases of the CNS.  In Alzheimerʼs disease (AD), selective death of basal 
forebrain neurons leads to reduced cholinergic innervation of the hippocampus 
and cortex (Auld et al., 2002).  Although the M1-/- mouse exhibited only modest 
cognitive dysfunction, transgenic AD-model mice treated with an M1-preferring 
agonist showed both improvements in cognitive function and reductions in         
β-amyloid and Tau pathologies in the cortex and hippocampus (Caccamo et al., 
2006) and systemic administration of the non-selective muscarinic receptor 
antagonists scopolamine or atropine results in profound learning and memory 
inhibition in rodents and humans (Fibiger et al., 1991).  In addition, M2 -/- mice 
show substantial learning and memory deficits, and decreased short- and long-
term potentiation in hippocampal synapses (Tzavara et al., 2003; Seeger et al., 
2004).  
Although the pathophysiology of schizophrenia is most closely associated 
with dysfunction in mesolimbic neurotransmission, extra-dopaminergic symptom 
characteristics and the well-described interaction between the cholinergic and 
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dopaminergic systems suggest that ACh function may be clinically significant.  
The following observations argue for a role of muscarinic receptors in 
schizophrenia: 1) Post-mortem and in vivo imaging studies have identified 
decreased MR binding site density in the cortex, hippocampus and striatum of 
schizophrenic patients; 2) High doses of muscarinic antagonists lead to 
psychosis-like states, and N-desmethylclozapine, a metabolite of the widely used 
atypical antipsychotic clozapine, shows strong subtype-selective partial agonism 
towards M1 (Sur et al., 2003); 3) genetic linkage studies have implicated the M5-
encoding Chrm5 gene as a schizophrenia susceptibility locus; and 5) M5 -/- mice 
show alterations in schizophrenia-related sensorimotor gating behaviors (Wang 
et al., 2004; Thomsen et al., 2007).  Knockout mouse and genetic linkage studies 
have also implicated muscarinic receptors in the etiology of pain, drug addiction, 
type 2 diabetes, and PNS-related disorders (Wess et al., 2007).
Despite the potential of muscarinic receptors as drug targets for the 
treatment of CNS diseases, the utility of such compounds has been limited by the 
undesirable parasympathetic-related side-effect profile of MR agonists and 
antagonists.  The successful development of subtype-specific muscarinic drugs 
has been greatly hampered by the high conservation among MRs of the ACh 
(orthosteric) binding site.  Thus, although targeting of predominantly neuronally-
expressed MRs (M1, M4, and M5) could significantly reduce PNS-related off-
target effects, only non-selective muscarinic agonists and antagonists, as well as 
cholinergic transmission-enhancing AChE inhibitors, are currently in clinical use.  
Aside from their obvious utility in research applications and in the treatment of 
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diseases directly related to muscarinic receptor dysfunction, such subtype-
specific MR drugs could also show efficacy in the treatment of Parkinsonʼs 
disease, for which non-selective muscarinic antagonists were the first accepted 
treatment and are currently used to alleviate dystonia symptoms.  Parkinsonʼs 
disease is a movement disorder characterized by the death of SNc nigrostriatal 
dopaminergic neurons, leading to relative hyperactivity of the striatal cholinergic 
system.  M4-targeted drugs could alleviate hypercholinergia either by antagonism 
of post-synaptic M4 receptors distributed preferentially on direct pathway MSNs, 
or by stimulating interneuron M4 autoreceptors and decreasing striatal ACh tone.  
Additionally, development of M5-specific agonists could prove useful in the 
treatment of age-related cognitive impairment by increasing cerebral blood flow.
1.4  Regulation of muscarinic receptor function
The regulation of GPCR signaling efficacy in time and space is central to 
the ability of a cell to both respond and adapt to outside stimuli.  The steady-state 
density of cell surface receptor molecules, and the degree to which termination of 
ligand-induced GPCR signaling events is followed by receptor resensitization, 
are crucial in determining the effects of sustained stimulation on cellular 
physiology (Hanyaloglu and von Zastrow, 2008).  In neurons, such sensitivity-
tuning mechanisms are important for plasticity events underlying learning and 
memory (Wang et al., 2005; Wang et al., 2009a).  Despite the large number of 
GPCRs expressed in mammals, the basic mechanisms regulating nascent 
receptor delivery, plasma membrane sorting in polarized cells, steady-state cell 
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surface density, desensitization, resensitization and down-regulation of GPCRs 
are generally conserved.  Nonetheless, important receptor-, tissue-, and 
subcellular compartment-specific regulatory details exist.  A common theme 
binding these GPCR-modulating mechanisms is the importance of protein-protein 
interactions between receptors and trafficking, anchoring, or signal-regulating 
molecules.  As with functional studies of muscarinic receptors, however, the lack 
of subtype-specific antibodies and ligands has left us with a limited 
understanding of the mechanisms governing the regulation of muscarinic 
receptors in vivo.  Below, we discuss the regulation of MRs in the context of more 
thoroughly characterized GPCR systems.         
1.4.1  Cell-surface delivery of newly synthesized MRs
GPCRs newly translated in the endoplasmic reticulum are delivered to the 
plasma membrane via the Golgi complex largely through the unregulated 
secretory pathway (figure 1.3) (Achour et al., 2008).  Although the regulation of 
nascent GPCR expression is far less understood than the endocytic trafficking of 
mature cell surface receptors, a number of protein-protein binding events 
influencing plasma membrane delivery have been identified.  For example, 
interaction between the third intracellular loops of serotonin receptors 5-HT1B 
and 5-HT4 and the annexin II light chain protein p11 increases the cell surface 
expression of these receptors in a functionally significant manner (Svenningsson 
et al., 2006; Warner-Schmidt et al., 2009).  Similar chaperone-like interactions 
negatively or positively influencing surface expression of GPCRs have been 
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Figure 1.3  Summary of canonical GPCR trafficking pathways.  Upper left, 
clathrin-dependent endocytosis of an activated GPCR.  After endocytic vesicle 
uncoating, internalized receptors are delivered to the early  endosome and are 
sorted to the degradative pathway via the rab7-positive late endosome (bottom 
left) or to the recycling pathway via a fast, rab4/rab35-dependent pathway 
(middle left) or through a slow pathway via the rab11-positive endocytic recycling 
compartment (ERC; middle right).  Newly synthesized GPCR molecules are 
delivered to the plasma membrane from the trans-golgi network (TGN) via the 
unregulated secretory pathway (right) or through a regulated TGN-to-endosome 
pathway (middle right). 
described for the dopamine D1 receptor (DRiP78), the angiotensin AT2 receptor 
(ATBP50), and the thromboxane A2 receptor (RACK1) (Bermak et al., 2001; 
Wruck et al., 2005; Parent et al., 2008).  Heterooligomerization of GPCRs can 
also influence plasma membrane delivery: cell surface expression of the 
GABABR1 receptor is dependent upon co-expression, and physical interaction 
with, the GABABR2 receptor (Margeta-Mitrovic et al., 2000).  Finally, regulated 
delivery of D1 dopamine and δ-opioid receptors to the cell surface from 
intracellular pools has been described, and may represent a mechanism of 
receptor sensitization (Achour et al., 2008).             
A secondary, TGN-to-endosome mediated pathway of GPCR trafficking 
may also play a role in the regulated expression of newly synthesized receptors.  
Subcellular transport of GPCRs and other integral membrane protein cargo is 
mediated by a complex system of intracellular membrane trafficking, the details 
of which are still being elucidated.  The basic mechanism of intracellular receptor 
trafficking is as follows: Adaptor proteins, heterotetrameric complexes of which 
four are known to be expressed in mammals (AP-1 through AP-4), are recruited 
to specific intracellular membrane compartments, in many cases by interaction 
with GTP-bound Arf (ADP ribosylation factor) proteins.  There, the adaptor 
proteins are able to simultaneously bind to both cytoplasmic receptor domains 
containing specific amino acid motifs and membrane coat proteins, the most 
common of which is clathrin.  Cargo-containing, coated membrane buds are 
“pinched-off” from host membranes through the action of accessory proteins such 
as dynamin, endophillin and amphiphysin.  Endosomal vesicles are then 
23
transported to specific locations via interaction with motor proteins and the 
cellular cytoskeleton, and cargo proteins delivered to target membranes by coat 
disassembly and vesicle fusion.  The identity and functional characteristics of 
transport vesicles are regulated by membrane phospholipid content, and by the 
presence of specific Rab family proteins; these membrane-associated small 
GTPases recruit other functional and scaffolding proteins to specific vesicular 
compartments.  Rabs switch between GTP-bound “on” and GDP-bound “off” 
states, the cycling of which is regulated by the presence of specific GEF and 
GAP proteins.  TGN-to-endosome mediated transport of nascent GPCRs to the 
cell surface likely proceeds via an AP-1 and clathrin-dependent process, whereby 
the AP-1 complex recruits targeted receptors by binding to signal sequences 
present in intracellular regions (Nakatsu and Ohno, 2003).  Such a process may 
underlie the motif-dependent delivery of the V2R vasopressin and α2B 
adrenergic receptors to the cell surface, and in the targeting of GPCRs to apical 
or basolateral domains in polarized cells (Dong and Wu, 2006).  
Little is known regarding mechanisms regulating the cell surface delivery 
of newly translated muscarinic receptors.  It has been shown, however, that in 
the polarized Madin-Darby canine kidney cell line, M2 is targeted to the apical 
plasma membrane domain, while M3 is targeted basolaterally via a dominant 
sorting signal present in the third intracellular loop (Nadler et al., 2001).  
Additionally, a phenylalanine-rich motif in the M2 receptor C-terminal tail was 
shown to bind the ER-associated protein DRiP78, leading to intracellular receptor 
sequestration in an exogenous expression system (Bermak et al., 2001).  
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1.4.2  Stabilization of MRs in the plasma membrane
The cell surface localization and two-dimensional diffusion characteristics 
of GPCRs are regulated by interaction with scaffolding proteins, among other 
mechanisms.  Such regulation is particularly important in neurons, where 
localization of GPCRs to synaptic compartments and stabilization of receptors at 
the cell surface play a critical role in synaptic plasticity.  The scaffolding protein 
PSD-95 is the best characterized of these molecules; it is localized almost 
exclusively at the post-synaptic density, and serves to organize and stabilize 
synaptic proteins, most notably AMPA and NMDA glutamate receptors (Kim and 
Sheng, 2004).  PSD-95 can bind directly to the β1 adrenergic receptor via a C-
terminal tail PDZ-binding domain, and indirectly to metabotropic glutamate 
receptors mGluR1 and mGluR5 via the scaffolding adaptor protein Homer; both 
of these interactions were shown to stabilize the receptors at the cell surface 
(Xiao et al., 1998; Hu et al., 2000).  A second example of a scaffolding protein / 
GPCR interaction is the binding of the dopamine D2 and α2 adrenergic receptors 
via their i3 loops to spinophilin, an actin- and protein phosphatase-1-binding 
protein.  This interaction was shown to stabilize receptors in the basolateral 
membrane domain of polarized cells, and to regulate GPCR-stimulated Ca2+ 
signaling by the concurrent binding of RGS2 (Brady et al., 2003; Wang et al., 
2005).  To date, however, no specific interactions between scaffolding proteins 
and muscarinic receptors have been identified.  
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1.4.3  Agonist-induced desensitization and internalization
After activation, nearly all GPCRs undergo a similar series of molecular 
events that serve to desensitize the receptor to further stimulation.  In ligand 
gated receptors, the process was first identified in, and is best characterized for 
the β2 adrenergic receptor (β2AR) (Lohse et al., 1990; Gainetdinov et al., 2004; 
Hanyaloglu and von Zastrow, 2008).  Upon ligand binding and G protein 
heterotrimer dissociation, GPCRs undergo a conformational change leading to 
phosphorylation on serine and threonine residues present on the C-terminal tail 
and i3 loop by G protein-coupled receptor kinases (GRKs).  This phosphorylation 
induces binding of β-arrestin to cytoplasmic regions of the receptor, and serves 
to uncouple the GPCR from its cognate G protein complex by steric hindrance, 
leading to rapid desensitization of signaling.  The GPCR-bound β-arrestin 
molecule also functions to bind adaptor protein AP-2 complex subunits, thus 
recruiting the desensitized receptor to PIP2, clathrin and AP-2 enriched structures 
known as clathrin-coated pits.  Upon further binding of AP-2 subunits to tyrosine-
containing motifs on the GPCR C-terminal tail, recruitment of clathrin by AP-2 to 
the nascent vesicle, and membrane scission by a dynamin-dependent 
mechanism, the receptor-β-arrestin complex is internalized into a clathrin-coated 
vesicle (figure 1.3).  Variations to this generalized mechanism exist, however, and 
likely depend on the differential receptor-regulatory protein interactions based on 
the presence or absence of specific protein-protein binding motifs on GPCR 
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cytoplasmic regions.  Examples include constitutively internalized receptors, 
clathrin-, β-arrestin and/or dynamin-independent receptor internalization, 
dileucine motif-dependent internalization, and non-GRK mediated receptor 
phosphorylation (Pals-Rylaarsdam et al., 1997; Budd et al., 2000; Marchese et 
al., 2008).  In addition, 1) heterologous (ligand binding-independent) GPCR 
phosphorylation activity can influence receptor / G protein coupling, and 2) the 
degree to which receptors undergo activity-induced phosphorylation may 
regulate the strength of β-arrestin binding, leading to differential downstream 
resensitization characteristics (Daaka et al., 1997; Marchese et al., 2008).
With the exception of M5, the phosphorylation and agonist-induced 
internalization characteristics of the muscarinic acetylcholine receptors have 
been investigated in heterologous expression systems.  Muscarinic receptors M1 
through M4 are phosphorylated by GRK2 in an agonist-dependent manner, 
exhibit desensitization of G protein signaling after prolonged stimulation, and 
undergo agonist-induced internalization and sequestration, events that require 
the presence of the i3 loop region (van Koppen and Kaiser, 2003).  However, the 
mechanistic details of these events differ between subtypes.  Whereas M1, M3 
and M4 internalize via a β-arrestin- and clathrin-dependent mechanism, M2 
receptor internalization is β-arrestin-, dynamin- and clathrin-independent, 
although overexpression of β-arrestin or β-arrestin-2 was able to increase the 
rate of M2 endocytosis (Pals-Rylaarsdam et al., 1997).  In cardiac myocytes, 
internalization of endogenous M2 receptors was seen to be caveolin-dependent; 
however, M2 expressed exogenously in HEK-293 cells was not observed to 
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internalize through caveolae (Pals-Rylaarsdam et al., 1997; Dessy et al., 2000).  
Additional subtype specificity exists on the level of receptor phosphorylation.  For 
example, the kinase CK1α plays a major role in the agonist-induced 
phosphorylation of exogenously expressed M3.  This phosphorylation event 
appears to attenuate Gq, but not MAP kinase pathway coupling, and does not 
stimulate receptor internalization (Budd et al., 2000; Luo et al., 2008).  Agonist-
induced phosphorylation of M3 by CK2 and GRK6 has also been observed; 
however, involvement of these kinases was apparently expression system and 
cell type-dependent (Willets et al., 2003; Torrecilla et al., 2007).  A recent study 
has also demonstrated constitutive, non-agonist stimulated and i3 loop-
independent internalization of M3 receptors expressed in HeLa cells (Scarselli 
and Donaldson, 2009).  Finally, the i3 loops of M1, M3 and M5 were shown to 
bind selectively to the G protein signaling attenuator RGS2.  In M1, this receptor 
binding activity was required for the antagonism of agonist-stimulated PLCβ 
activity, suggesting that protein-protein binding mediated recruitment of RGS 
molecules to MRs may serve as a general mechanism of signaling 
desensitization (Bernstein et al., 2004).  Taken together, current evidence points 
to the regulation of muscarinic receptor desensitization and internalization by 
heterogenous, cell- and subtype-specific mechanisms, the details of which 
remain unclear. 
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1.4.4  Endocytic recycling
Resensitization of agonist-internalized GPCRs begins with dissociation of 
β-arrestin, receptor dephosphorylation, and delivery of receptors to the Rab5-and 
phosphatidylinostiol-3-phosphate- positive early endosome.  From this structure, 
signaling-competent receptors can be recycled to the cell surface through two 
general pathways (figure 1.3).  In the fast recycling route, Rab4 / Rab35 
endosomes return receptors to the plasma membrane directly from early 
endosomes.  In the slow endocytic recycling route, which is more highly 
regulated and the most common pathway for GPCR recycling, receptors are first 
delivered to the typically perinuclear, Rab11-positive tubulovesicular endocytic 
recycling compartment (ERC) before returning to the plasma membrane via 
recycling endosomes (Grant and Donaldson, 2009).  The ERC is likely composed 
of membrane and cargo proteins derived from matured membrane tubules 
extending from the early endosome; therefore, ERC-mediated receptor recycling 
is to some extent iterative / constitutive (Maxfield and McGraw, 2004).  However, 
sorting signal-mediated protein interactions do play a role in the targeting of 
GPCRs for recycling, although the exact nature of these signals and interacting 
proteins remain poorly characterized.  Recycling of the β1 and β2 adrenergic, the 
lutropin LH, and the κ-opioid receptors was seen to depend on interaction of 
distinct C-terminal tail motifs with PDZ domain-containing proteins (including 
PSD-95, NHERF-1, and GIPC) (Cao et al., 1999).  In addition, a recycling motif 
present in the dopamine D1 C-terminal tail was shown sufficient to re-route a 
second receptor from the degradative to recycling pathways when fused to its C-
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terminus (Vargas and Von Zastrow, 2004).  In neurons, the endocytic recycling 
system is specialized; for example, rab11-positive recycling endosomes are 
present in dendrites and axons, and their translocation to dendritic spines plays a 
critical role in the mechanism of long-term potentiation (Park et al., 2004; Park et 
al., 2006; Wang et al., 2008).  The neuronal endocytic recycling system serves a 
key function in the maintenance of axon / somatodendritic polarity by the targeted 
sorting of endocytosed plasma membrane proteins.
 The endocytic recycling of muscarinic receptors has not been extensively 
studied.  Agonist-internalized M1, M3 and M4 receptors expressed exogenously 
in HEK-293 cells were observed to undergo efficient endocytic recycling and 
signaling resensitization (Vogler et al., 1998; Krudewig et al., 2000).  The 
endocytic recycling of M4 receptors was shown to depend on a 21-amino acid 
region in the i3 loop; fusion of this motif to a recycling-negative muscarinic 
receptor conferred upon it recycling activity (Krudewig et al., 2000; Hashimoto et 
al., 2008b).  In addition, endocytic recycling of endogenous, predominantly M3-
like muscarinic receptors in SH-SY5Y neuroblastoma cells was observed 
(Szekeres et al., 1998a); however, desensitization and resensitization of M3 
receptors expressed exogenously in CHO cells was seen to proceed 
independently of receptor internalization and recycling (Tobin et al., 1992).  Thus, 
similar to desensitization, endocytic recycling of muscarinic receptors appears to 
be subtype- and cell-specific but is poorly characterized in endogenous systems.  
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1.4.5  Lysosomal targeting and down-regulation
Upon agonist-induced endocytosis, GPCRs may be targeted for 
proteolytic degradation in lysosomes as opposed to cell surface recycling-based 
resensitization (figure 1.3).  Degradative pathway targeting results in a decrease 
of overall receptor protein levels and forms a major component of the GPCR 
down-regulation response, a process distinct from that of rapid receptor 
desensitization and central to cellular adaptations to chronic stimulation, 
including those observed in the drug-addicted brain.  The sorting of lysosomally-
targeted GPCRs to Rab7-positive late endosomes occurs mainly at the early 
endosome level and is dependent on a number of relatively well-characterized 
protein-protein interactions between trafficking molecules and targeting motifs 
present in GPCR cytoplasmic regions.  Many GPCRs contain lysosomal sorting 
signals in their C-terminal tails conforming to tyrosine-based YXXΦ (with Φ 
representing bulky hydrophobic residues) or dileucine-based [D/E]XXXL[L/I] 
motifs (Bonifacino and Traub, 2003).  These signals confer lysosomal targeting 
by binding to adaptor protein complexes, and are critical to the constitutive 
degradation of endocytosed GPCRs.  Similarly, the binding of GPCR-associated 
sorting proteins (GASPs) with C-terminal tail sequences is required for lysosomal 
targeting of endocytosed δ-opioid receptors, as well as a variety of other GPCRs 
(Whistler et al., 2002; Heydorn et al., 2004).  Finally, covalent addition of ubiquitin 
to cytoplasmic lysine residues of GPCRs can serve as a degradative signal, 
functioning to direct sorting to lysosomes via the late endosome / multivesicular 
body through interaction with ESCRT complex proteins (Marchese et al., 2008).  
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In β2 adrenergic receptor-expressing cells treated chronically with agonist, 
receptor ubiquitination leads to diversion of endocytosed β2AR from the recycling 
to the lysosomal pathway, resulting in proteolytic down-regulation of the receptor 
(Shenoy et al., 2001).     
YXXΦ and DXXXLL lysosomal targeting sequence-like motifs are present 
in the C-terminal tails of muscarinic receptors M2/M4 and M1, respectively.  In 
addition, GASP-1 and GASP-2, members of a 10-protein family sharing a GPCR 
interaction domain, were observed to bind M1 and M2 C-terminal tails in vitro 
(Simonin et al., 2004)  However, among the M1-M4 receptor subtypes, only M2 
has been shown to undergo degradative down-regulation (Krudewig et al., 2000).  
Mutation of the M2 C-terminal tail tyrosine residue was seen to reduce receptor 
down-regulation but did not effect agonist-induced endocytic sequestration 
(Goldman and Nathanson, 1994).  Down-regulation of muscarinic receptor 
binding sites was observed in cultured chick retina and rat cerebellar granule 
neurons after chronic agonist stimulation (Siman and Klein, 1983; Xu and 
Chuang, 1987).  Finally, cocaine self-administration was shown to down-regulate 
muscarinic receptor binding sites in the mouse striatum; however, the magnitude 
this down-regulation was paradoxically increased in GASP-1-/- mice (Boeuf et al., 
2009).  As is the case with other aspects of muscarinic receptor regulation, the 
study of MR down regulation in a cell- and receptor-specific manner remains 
complicated by overlapping subtype expression patterns and a lack of 
appropriate experimental tools.
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1.5  Summary and study rationale                  
Muscarinic receptors influence the function of nearly every cell in the 
mammalian body.  As metabotropic G protein-coupled receptors that transduce 
the effects of extracellular acetylcholine, MRs mediate such varied physiological 
responses as cell growth and motility, glandular secretion, smooth muscle 
contraction, neuronal excitability, synaptic plasticity, and dopamine release.  The 
five muscarinic receptors share with other GPCRs common signaling and 
regulatory pathways; therefore, the general characteristics governing activity of 
the MR family are well known.  However, an understanding of MR subtype-
specific functional mechanisms remains elusive.  Muscarinic receptors are highly 
similar in sequence throughout much of their structure, including that of the 
orthosteric ligand binding domain; as a result, few truly subtype-selective small 
molecule agonists and antagonists have been identified.  In addition, the MRs 
have proven particularly resistant to the development of subtype-selective 
antibodies useful for the identification and analysis of receptors expressed in 
vivo.  In combination with the fact that nearly every cell type expresses at least 
two distinct MRs, this lack of subtype-selective tools has greatly limited our ability 
to precisely study muscarinic receptor signaling and regulation.  The 
physiological effects of ACh are clearly not homogenous with respect to tissue 
and cell type; thus, our knowledge of this ubiquitous and fundamental 
neurotransmitter system remains incomplete.
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The structure of muscarinic receptors is notable for the presence of a 
large third intracellular (i3) loop region whose sequence, in contrast to that of the 
remaining structural domains, is highly divergent between subtypes.  In other 
GPCRs, the i3 loop region has been shown to mediate the binding of signaling, 
regulatory and trafficking proteins.  These protein-protein interactions are largely 
responsible for determining the effector coupling, distribution, and re- or de-
sensitization characteristics of a given GPCR.  Although many of these protein 
binding events are determined by the presence of conserved amino acid motifs 
on the receptor i3 loop regions, the precise nature of most protein-GPCR 
interactions are unknown.  Given the strongly divergent nature of the muscarinic 
receptor i3 loops, we reasoned that subtype-specific receptor-protein interactions 
may exist, and that knowledge of such interactions could shed light upon 
signaling and/or regulatory mechanisms heretofore unknown as a result of the 
paucity of MR experimental tools.  In addition, identification of muscarinic 
receptor-interacting proteins could provide novel intracellular targets for the 
subtype- or tissue-specific modulation of MRs in vivo.  In an effort to discover 
such MR-interacting proteins, we performed a series of unbiased yeast two-
hybrid protein-protein interaction screens using as “baits” the five MR i3 loop 
regions.  A protein identified in the M5 i3 loop screen, AGAP1, was subsequently 
shown to be a bona fide, subtype-selective M5 receptor interacting protein.  We 
further demonstrated that interaction with AGAP1 was required for the endocytic 
recycling of M5, and that this trafficking proceeded through a novel, tissue-
specific mechanism.  Physiological experiments suggest that interaction with 
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AGAP1 is required for the normal function of the M5 muscarinic receptor in the 
regulation of striatal dopamine release.      
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2 IDENTIFICATION OF NOVEL MUSCARINIC RECEPTOR 
BINDING PROTEINS BY YEAST TWO-HYBRID SCREEN
2.1 Summary
Muscarinic acetylcholine receptors are GPCRs characterized by the 
presence of large, unstructured third intracellular loops that are divergent in 
sequence between receptor subtypes.  Binding of proteins to intracellular regions 
of GPCRs is required for normal signaling, desensitization, and trafficking 
functions.  In an effort to uncover proteins regulating muscarinic receptor function 
in a subtype-specific manner, we performed yeast two-hybrid screens employing 
as “baits” the third intracellular loop regions of the five muscarinic receptors.  
Using a diploid mating strategy, we achieved full coverage of the rat and human 
brain cDNA “prey” libraries used in the screens.  Based on confirmation of 
positive interactions by prey plasmid retransformation and by identification and 
analysis of positive clone cDNA sequences, we selected three putative 
muscarinic receptor- interacting candidate proteins for further study.
2.2  Introduction
The yeast two-hybrid (Y2H) system allows for detection of protein-protein 
interactions by transcriptional activation of reporter genes (Fields and Song, 
1989; Chien et al., 1991).  The genesis of the Y2H system was based on the 
following observations:  First, the DNA binding and transcriptional activator 
functions of eukaryotic transcriptional regulatory proteins were shown to be 
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separable and functionally compartmentalized (Hope and Struhl, 1986; Keegan 
et al., 1986).  Second, it was shown that fusion of DNA-binding repressors with 
transcriptional activator proteins (Gal4) or fragments thereof could allow 
activation of transcription downstream of the bound repressor sequence (Brent 
and Ptashne, 1985; Ma and Ptashne, 1988).  Finally, it was observed that native 
transcriptional activators need not directly bind DNA; for example, the herpes 
simplex VP16 protein activates transcription by binding to DNA-bound host 
proteins (Triezenberg et al., 1988), and c-Fos activates transcription as part of 
the AP-1 complex by binding to c-Jun (Curran and Franza, 1988).  
In the first demonstrated example of the Y2H assay, a fusion of the Gal4p 
DNA binding domain (BD; Gal41-147) and the protein kinase SNF1 was co-
expressed in the yeast Saccharomyces cerevisiae with the Gal4p transcription 
activation domain (AD; Gal4768-881) in fusion with SNF4, a known binding partner 
of SNF1 (Fields and Song, 1989).  The yeast strain used included a lacZ 
transgene under control of a Gal4 binding sequence (UASG) and carried 
mutations for the Gal4 AD and BD plasmid markers HIS3 and LEU2 (Fields and 
Song, 1989).  Whereas co-expression of the Gal4-AD and Gal4-BD was unable 
to activate transcription from UASG, binding of the fused proteins SNF1:Gal4-BD 
and SNF4:Gal4-AD in the yeast nucleus was able to reconstitute GAL4 activity, 
allowing colorimetric detection of the lacZ protein product β-galactosidase.  
Subsequently, the Y2H system was shown to be able to reconstitute a known 
homo-dimeric interaction by using a SIR4:GAL4-BD fusion protein to screen a 
GAL4-AD-yeast genomic DNA library (Chien et al., 1991).  
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A number of important improvements to the Y2H system have since been 
developed.  The modern Y2H screen was introduced with the addition of an 
auxotrophic reporter gene under Gal4 transcriptional control, GAL1-HIS3, to the 
lacZ reporter described above.  This system allowed for the successful screening 
of a GAL4-AD-human lymphocyte cDNA library for clones interacting with a 
GAL4-BD-”bait” fusion protein by positive growth selection and colorimetric 
confirmation (Durfee et al., 1993).  Next, Y2H “interaction trap” screening 
systems employing a bacterial LexA-based DNA BD and reporter genes under 
transcriptional control of the lexA operator (LexA-OP) were developed (Gyuris et 
al., 1993; Vojtek et al., 1993; Zervos et al., 1993).  Such screening systems are 
compatible with bait libraries fused with yeast GAL4, viral VP16, and bacterial 
B42 ADs (Ruden et al., 1991; Vojtek et al., 1993; Dagher and Filhol-Cochet, 
1997).  Advantages of the LexA system include lack of endogenous DNA binding 
sites and protein binding partners for the bacterial DNA-BD, avoidance of the 
toxic effects of GAL4 overexpression, and ease of titering reporter gene 
sensitivity by varying copy number of the upstream LexA-OP sequences (Gyuris 
et al., 1993; Toby and Golemis, 2001).  In addition, the development of Y2H 
screens in diploid yeast after mating of bait and prey strains provided a simplified 
method for the exhaustive coverage of library complexity (Bendixen et al., 1994; 
Fromont-Racine et al., 1997).  
The strength of the Y2H system is illustrated clearly by the number of 
studies employing the technique for the identification and characterization of 
novel protein-protein interactions.  Y2H screens have yielded important findings 
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pertaining to signaling cascades.  For example, the small GTPase H-Ras was 
shown to interact directly with its kinase effectors c-Raf and A-Raf (Vojtek et al., 
1993); the G1 and S phase protein phosphatase Cdi1 was discovered to interact 
with the cyclin-dependent kinase Cdk2 (Gyuris et al., 1993).  Y2H screen results 
have led to insight into the regulation of cytoskeletal dynamics; the rho GEF Lfc 
was identified as a binding partner of the actin- and protein phosphatase 1- 
binding protein spinophilin and was shown to regulate dendritic spine morphology 
through this interaction (Ryan et al., 2005).  Using cytosolic protein fragments as 
baits, functionally significant protein-protein interactions of transmembrane 
molecules have also been identified.  Most notably, a Y2H screen identified the 
postsynaptic density protein PSD-95 as a binding partner for the C-terminal tail of 
the NMDA receptor subunit NR2 (Kornau et al., 1995). Similar screens identified 
the small GTPase RhoA as a binding partner of the delayed rectifier potassium 
channel Kv1.2, which was shown to play a central role in the receptor-mediated 
tyrosine kinase mechanism of Kv1.2 suppression (Cachero et al., 1998) and 
RGS2 as a TRPV6 Ca2+ channel interactor and functional inhibitor (Schoeber et 
al., 2006).  More recently, large-scale Y2H screening programs have yielded 
genome-level binary protein-protein interaction maps (interactomes) for S. 
cerevisiae (Yu et al., 2008) Plasmodium falciparum (LaCount et al., 2005) 
Caenorhabditis elegans (Li et al., 2004) and an inter-species map between 
herpesviral and human proteomes (Uetz et al., 2006).  
Of particular significance to our current project are the success of Y2H 
screens in the identification of novel GPCR-binding proteins.  Numerous studies 
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utilizing cytoplasmic fragments of GPCRs as Y2H baits have uncovered protein-
protein interactions shown subsequently to affect the signaling, localization, and 
stimulation-dependent and -independent trafficking properties of the receptors.  
For example, Y2H screens using GPCR c-terminal tail baits have demonstrated 
the following functionally significant interactions:  The α1a adrenergic receptor 
and ezrin, affecting agonist-induced receptor recycling (Stanasila et al., 2006); 
the prostacyclin IP receptor and PDE6δ, involved in receptor trafficking and 
recycling (Wilson and Smyth, 2006); and the thromboxane A2β receptor and 
RACK1, shown to be important for ER-to-plasma membrane receptor delivery 
(Parent et al., 2008).   Similarly, the literature contains examples of GPCR i3 loop 
interactions uncovered by Y2H screens, including the binding of the protein 
kinase C-zeta interacting protein (ZIP) to dopamine receptor D2, mediating 
receptor down-regulation by trafficking to lysosomes (Kim et al., 2008);             
up-regulation of the D3 dopamine receptor through binding to ALG-2 interacting 
protein 1 (AIP1) (Zhan et al., 2008) and filamin-A (Lin et al., 2001); and promotion 
of agonist-induced endocytosis of the β1 adrenergic receptor though binding to 
endophilin 1/2/3 (Tang et al., 1999).       
Our laboratory has successfully utilized the Y2H screen in numerous 
studies identifying novel binding partners of brain-expressed GPCRs.  p11, an 
S100 family protein, was discovered in a Y2H screen to interact with the 5HT1b 
serotonin receptor i3 loop, to regulate 5HT1b surface expression and signaling 
properties, and to be required for the 5HT1B-mediated behavioral response to 
antidepressant drugs in mice (Svenningsson et al., 2006).  A subsequent directed 
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Y2H study identified the 5HT4 serotonin receptor as a second p11 binding 
partner; interaction with the i3 loop regulated receptor activity and drug 
responses in a manner similar to that of 5HT1b (Warner-Schmidt et al., 2009).  A 
second Y2H screen using the c-terminal tail of the adenosine A2A receptor 
identified an interaction with the tyrosine kinase fibroblast growth factor receptor 
(FGFR); this interaction was demonstrated to underlie the synergistic effects of 
FGF / adenosine co-stimulation on MAP kinase signaling, dendritic spine 
morphogenesis, and synaptic plasticity (Flajolet et al., 2008).  Additionally, a Y2H 
screen performed with the c-terminal tail of the metabotropic glutamate receptor 
mGluR5 identified binding to the neuron-specific protein norbin (neurochondrin); 
this interaction was shown to potentiate mGluR5 surface expression, and to 
affect mGluR5-related synaptic plasticity and behavior (Wang et al., 2009b).
The Y2H system holds a number of significant advantages over other 
biochemical or genetic protein-protein interaction screening techniques with 
regard to its ability to detect GPCR-interacting molecules.  Most notable of the 
competing methodologies, affinity purification and mass spectrometry (AP-MS) 
allow for proteomic identification of individual proteins from isolated complexes 
(Domon and Aebersold, 2006; Gingras et al., 2007).  Affinity matrices composed 
of glutathione-S-tansferase (GST) fusions of cytosolic GPCR fragments 
immobilized on glutathione resins have been used to purify and identify serotonin 
5HT2C C-terminal tail- and muscarinic M4 i3 loop- binding proteins by MALDI-
TOF MS (Becamel et al., 2002; McClatchy et al., 2002).  In addition, 
immunoprecipitation of native metabotropic glutamate mGluR5 receptors from rat 
41
brain was used to identify co-purified proteins by liquid chromatography-tandem 
mass spectrometry (Farr et al., 2004).  Compared to the Y2H system, however, 
AF-MS is inherently less sensitive to both low-affinity and low-abundance protein 
interactions; the Y2H system is sensitive to interactions with Kd constants as high 
as 10-7, and, as it is a genetic screen, is unaffected by physiological target protein 
abundance (Phizicky et al., 2003).  Affinity purification by GST-fusion protein is 
limited to recombinant proteins well-expressed in Escherichia coli, and is prone 
to high non-specific binding (Maurice et al., 2008; Daulat et al., 2009).  In 
addition, immunoprecipitation strategies are hampered by the need to solubilize 
receptors under detergent conditions that may disrupt GPCR-protein interactions, 
and the fact that few high-affinity GPCR antibodies exist (the latter point 
especially true for the muscarinic receptors) (Daulat et al., 2009).  Other well-
characterized protein-protein interaction methods, such as phage-display and 
protein microarrays, have not as of yet been utilized in a whole-genome / whole-
proteome screen for GPCR-interacting proteins (Smith, 1985; Stephen and Lane, 
1992; Heydorn et al., 2004; Fam et al., 2005).  
An important consideration in the design of a Y2H screen for GPCR-
interacting proteins is the fact that full-length receptors are inappropriate as baits.  
As alluded to above, soluble cytoplasmic regions, either C-terminal tails or 
intracellular transmembrane loops, are most commonly employed as DNA-BD 
fusions in Y2H studies.  Useful bait fusion proteins must also be able to enter the 
yeast nucleus, and must lack intrinsic transcriptional activation activity (Toby and 
Golemis, 2001).  As described in section 1, while rat muscarinic receptors contain 
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relatively short (from 23 to 42 amino acid) C-terminal tails, their i3 cytoplasmic 
loops are large (157 to 240 amino acid), lack secondary structure (Rasmussen et 
al., 2007; Rosenbaum et al., 2007) and are divergent in sequence between 
receptor subtypes (table 1.1).  The i3 loops of muscarinic receptors have 
previously been shown to be substrates for agonist dependent-phosphorylation 
(Tobin and Nahorski, 1993; Budd et al., 2000; Torrecilla et al., 2007), involved in 
activity-induced receptor internalization (Maeda et al., 1990), and required for 
basolateral membrane sorting of MRs (Nadler et al., 2001).  The i3 loop has also 
been shown to be important for coupling of muscarinic receptors to signaling 
pathways (Singer-Lahat et al., 1996; Wess et al., 1997; Mitchell et al., 2003) and 
to mediate binding of Gαi/o and Gβγ subunits (Wess et al., 1997; Wu et al., 2000) 
and regulatory proteins such as RGS2 (Bernstein et al., 2004) to MRs.  Thus, in 
an effort to identify novel binding proteins of the five muscarinic receptors, we 
performed Y2H screens using i3 loop-DNA BD proteins as baits.
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Figure 2.1 Summary of Y2H screen strategy (following page). The use of 
mating type MATa yeast strains (CG1945, L40) for expression of MRi3-DNA BD 
“bait” fusions in concert with the expression of a brain cDNA library-AD fusion in 
a mating type MATα strain (Y187) provided for simplified library coverage by 
formation of bait / prey diploids through mating. The presence of dual 
transcriptional reporters allowed for confirmation of HIS3+ clones by assay for 
lacZ expression by the colorimetric X-Gal assay. Doubly-positive, sequenced 
clones were verified by retransformation in the appropriate reporter strain with 
positive (MRi3-pASIIΔΔ) or negative (empty pASIIΔΔ) controls and X-Gal lift 
assay. 
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2.3  Results
  Y2H screens were performed on rat brain cDNA libraries (BD Clontech) 
with rat MRi3 baits for subtypes M1, M2, M4, and M5.  A human M3i3 bait 
sequence was used to screen a human brain cDNA library (BD Clontech), as the 
hM3 cDNA clone was previously available in the laboratory.  The bait DNA BD 
protein contained an intrinsic nuclear localization signal (NLS), while the prey 
Gal4 AD protein was fused with the SV40 T antigen NLS (Durfee et al., 1993).    
Before performing screens, we first checked for bait fusion protein toxicity by 
examining yeast colony growth rates on -Trp media.  All bait strains exhibited 
normal growth rates (data not shown).  Bait strains were then plated on -Trp-His 
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screen type clones screened(total diploid CFUs)
positive 
clones (His
+ / β-Gal+)
positive 
clones 
in-frame
rM1 Gal4 2.5x107 49 25
rM1 LexA 5.6x107 126 26
rM2 Gal4 2.7x107 7 0
rM2 LexA 4.7x107 15 10
hM3 Gal4 (human) 1.8x107 64 27
rM4 Gal4 2.0x108 234 37
rM5 Gal4 1.8x107 32 11
Table 2.1  Y2H screen characteristics.  Screens were performed on rat or 
human MRi3 loops in fusion with the Gal4 or LexA DNA binding domains.  Total 
diploid colony forming units (CFUs) indicate the number of prey clones screened. 
HIS3+ / lacZ+ clones with in-frame ORF fusions were identified by sequencing.
media to confirm that bait protein fusions did not exhibit reporter gene 
autoactivation; no colony growth was observed (data not shown).  
Screens were first performed with the Gal4 system according to the 
strategy outlined in figure 2.1.  After mating of prey and bait strains, library 
coverage was estimated by quantifying diploid colony growth on -Leu-Trp media; 
in all cases, mating efficiency was sufficient for full coverage of pACT2 cDNA 
library complexity (Table 2.1).  Where indicated, screens were repeated in the 
higher-sensitivity LexA system using MRi3 loop - LexA DNA BD fusion baits in 
the L40 strain, allowing use of the pACT2-containing library strains (table 2.1).  
Screen results for each MRi3 bait are described below.
2.3.1 rM1
A screen of 25 million rat brain cDNA clones with a GAL4 DNA BD-rM1i3 
fusion bait yielded 49 doubly-positive yeast colonies (HIS3+, lacZ+) (table 2.1).  
Twenty five of these positive colonies were identified by PCR as containing a 
pACT2 library clone falling within a gene-coding open reading frame (ORF) (table 
2.1).  Of the seven genes represented, one was of a recognized Gal4 screen 
false-positive (Asrgl1) (M. Flajolet, personal communication), and one coded for 
DNA-binding zinc finger protein (Zfp61); along with Rpsp and Cenpc, these clone 
plasmids were not rescued (table 2.2).  Three pACT2 library clones were rescued 
and amplified: one (coding for Kat5) was β-Gal negative upon retransformation 
with pASII∆∆-rM1i3 in Y187 yeast, while one (coding for Ppp3r1) exhibited false-
positive activation with empty pASII∆∆ co-transformation and β-Gal lift assay 
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ID description
# 
clones
rescue
M1     ctl
(Gal4 screen)
Olfm2 olfactomedin 2 4 + -
Kat5 lysine acetyltransferase 5 1 -
Ppp3r1 calcineurin B type I 10 + +
Zfp61 zinc finger protein 61 3
Rpsp 30S ribosomal protein S16 2
Asrgl1 asparaginase like 1 4
Cenpc centromere autoantigen C 1
(LexA screen)
Olfm2 olfactomedin 2 3 + -
Kat5 lysine acetyltransferase 5 4 + -
8 genes represented by 1-2 clones 9 - -
Ywhab tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta 
polypeptide (14-3-3β)
3
Sharpin SHANK-associated RH domain 
interactor
1
Sdhd succinate dehydrogenase complex, 
subunit D
1
Apoe apolipoprotein E 1
XM_347156 1
xm_222273 1
rgd1560070 1
xm_216178 1
Table 2.2  rM1i3 screen results.  Identity of HIS3+ / lacZ+ clones as 
determined by PCR are listed in columns 1 and 2, with total number of clones for 
each gene indicated.  “+”, β -Gal+; “-”, β -Gal- after prey plasmid rescue and 
retransformation in yeast strain Y187 with bait plasmid (M1) or empty  vector 
control (ctl).  Gene names without + / - entries indicate positive clones from the 
rM1i3 screens for which prey plasmid isolation was either unsuccessful or not 
attempted.  Green / red indicates successful / unsuccessful control experiment 
result, respectively.  Format applies to results listed in tables 2.3-2.6.
(table 2.2).  A rescued clone, representing one of four positive clones coding for a 
fragment of the Olfm2 ORF, passed positive and negative retransformation lift 
assays (table 2.2).  Olfm2, coding for the Noelin-2 (Ofactomedin-2) protein, is a 
member of the olfactomedin family of secreted glycoproteins (Barembaum et al., 
2000). 
In an effort to obtain a greater number of M1i3-interacting clones, we 
repeated the rM1i3 screen using an LexA-rM1i3 fusion as bait in the L40 strain.  
The protein-protein interaction detection sensitivity of the LexA screen was 
anticipated to be higher, as HIS3 activation in L40 is less stringent than in 
CG1945, and because the bait plasmid pLEX9 contained a LexA-OP-lacZ 
reporter (Vojtek et al., 1993).  The rM1i3-LexA screen covered 56 million 
independent library clones, of which 126 were HIS+ / lacZ+.  PCR analysis 
showed 26 of these positive clones to contain in-frame ORF cDNAs (table 2.1).  
pACT2-library plasmid rescue failed for clones representing the genes Ywhab 
and Sharpin, and was not attempted for Sdhd, Apoe, and 4 uncharacterized 
genes (table 2.2). 10 pACT2 library clones were successfully rescued; of these, 8 
were β-Gal negative upon retransformation with rM1i3-pLexA (table 2.2).  In the 
X-Gal lift assay, two clones were β-Gal+ / β-Gal- upon retransformation with 
pLex9-rM1i3 and empty pLex9 vector, respectively: Olfm2, representing 3 of the 
26 total positive screen colonies, and Kat5, representing 4 of the positive 
colonies (table 2.2).  Kat5 encodes lysine acetyltransferase 5 / TIP60, a histone 
acetyltransferase shown to function in DNA damage repair, transcriptional 
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control, and chromatin remodeling (Squatrito et al., 2006).  Olfm2 / Noelin-2 is 
described above.
2.3.2 rM2
  An initial screen of 27 million independent rat brain cDNA library clones 
with a Gal4 DNA BD-rM2i3 bait yielded 7 His+ / lacZ+ colonies (Table 2.1).  
However, PCR analysis indicated no clones representing in-frame ORF 
sequences (table 2.1).  We thus repeated the screen in the less-stringent LexA 
system, as described above.  The LexA-rM2i3 screen covered 47 million 
independent rat brain cDNA library clones, and yielded 15 His+ / lacZ+ colonies.  
Of these, 10 clones represented in-frame ORF sequences, covering 3 genes 
(table 2.1, 2.3).  Rescue and retransformation in L40 yeast with pLex9-rM2i3 
gave negative β-Gal activation results for two of the recovered clones, 
representing the genes Ppp1ca and Cldn10 (table 2.3).  The remaining rescued 
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ID description
# 
clones
rescue
M2     ctl
(Gal4 screen)
- 0
(LexA screen)
snx20 sorting nexin 20 8 + -
Ppp1ca protein phosphatase 1, catalytic subunit, 
alpha isoform
1 - -
Cldn10 claudin 10 1 - -
Table 2.3, rM2i3 screen results
clone, encoding a 3ʼ fragment of Snx20, represented 8 of the 10 positive / ORF 
in-frame screen colonies and was β-Gal+ / β-Gal- upon retransformation with 
pLex9-rM2i3 and empty pLex9 vector, respectively (table 2.3).  SNX20 (sorting 
nexin 20) is a member of the sorting nexin family, and was recently shown to bind 
to and regulate the distribution of P-selectin glycoprotein ligand-1 (PSGL-1) 
(Worby and Dixon, 2002; Schaff et al., 2008).
2.3.3 hM3
A screen of 28 million human brain cDNA clones with a GAL4 DNA BD-
hM3i3 fusion bait yielded 64 doubly-positive yeast colonies (HIS3+, lacZ+) (table 
2.1).  Twenty seven of these 64 positive clones were found by PCR analysis to 
contain in-frame human ORF sequences, covering 17 unique genes (table 2.1, 
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ID description
# 
clones
rescue
M3     ctl
Mllt3 myeloid/lymphoid or mixed-lineage 
leukemia; translocated to, 3
1 + -
Pou2f1 POU class 2 homeobox 1 3 + +
PCDHGA5 protocadherin gamma subfamily A, 5 1 + +
KIAA1012 1 + +
9 genes covered 12 -
Psmc1 proteasome (prosome, macropain) 26S 
subunit, ATPase, 1
3
THUMPD3 THUMP domain containing 3 2
Aff4 AF4/FMR2 family, member 4 2
Ranbp9 RAN binding protein 9 2
Table 2.4  hM3i3 screen results
2.4).  pACT2 library plasmids covering 13 of these genes were rescued and 
retransformed in Y187 yeast with pASII∆∆-hM3i3 bait constructs; of these, 9 
clones failed to activate β-Gal activity in the lift assay (table 2.4).  Rescued 
clones containing coding sequences for Pou2f1, PCDHGA5, and KIAA1012 were 
lacZ+ with both hM3i3 and control (empty vector) baits, indicating false-positive 
interactions (table 2.4).  One clone, containing coding sequence from the gene 
Mllt3 and representing a single positive colony from the hM3i3 screen, was        
β-Gal+ / β-Gal- upon retransformation with positive and negative control baits, 
respectively (table 2.4).  MLLT3 encodes a transcription factor implicated in the 
pathology of leukemia and in the fating of human erythroid cell types (Iida et al., 
1993; Pina et al., 2008).  Rescue of prey plasmids encoding an additional 4 
genes (Psmc1, THUMPD3, Aff4, and Ranbp9) was not successful (table 2.4).
2.3.4 rM4
A screen of 200 million human brain cDNA clones with a GAL4 DNA BD-
rM4i3 fusion bait yielded 234 doubly-positive yeast colonies (HIS3+, lacZ+) (table 
2.1).  Thirty seven of the 234 positive clones were found by PCR to contain in-
frame ORF sequences, covering 11 unique genes (table 2.1, 2.5).  pACT2 bait 
plasmids for 6 positive clones (representing 31 of the 37 total positive colonies 
from the screen) were rescued and amplified for use in the retransformation lift 
assay in Y187 yeast.  A rescued clone encoding Ube2i failed to show lacZ 
activation when co-expressed with the Gal4 DNA BD-rM4i3 bait fusion protein 
(table 2.5).  Rescued pACT2 clones coding for segments of NRBP2, Pclo, and 
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Ccar1 were indicated as false-positives, as co-transformation with empty 
pASII∆∆ vector led to β-Gal activity (table 2.5).  Rescued prey clones encoding 3ʻ 
fragments of the UHRF1BP1L and Rbp3 ORFs (representing 2 and 14 of the 31 
identified in-frame positive clones, respectively) were confirmed in the 
retransformation lift assay as β-Gal+ with the rM4i3 bait and β-Gal- with empty 
vector.  UHRF1BP1L, or UHRF1 binding protein like 1 (also annotated as 
KIAA0701), is uncharacterized; however, the UHRF1 protein is known to function 
as an E3 ubiquitin ligase and to affect cell proliferation (Bronner et al., 2007).  
Rbp3 (retinol  binding protein 3; also known as Interphotoreceptor retinol-binding 
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Table 2.5  rM4i3 screen results.  (*) Isolation of Dynlt1-encoding prey plasmid 
from yeast clones was not successful; indicated results are for full-length rat 
Dynlt1 coding sequence amplified by PCR from a rat brain cDNA library and 
cloned into the pACT2 prey vector.
ID description
# 
clones
rescue
M4     ctl
UHRF1BP1L UHRF1 binding protein 1-like 
(KIAA0701)
14 + -
Rbp3 retinol binding protein 3, interstitial 2 + -
NRBP2 nuclear receptor binding protein 2 4 + +
Pclo piccolo (presynaptic cytomatrix protein) 3 + +
Ccar1 cell division cycle and apoptosis 
regulator 1
5 + +
Ube2i ubiquitin-conjugating enzyme E2I 3 - -
Dynlt1 dynein light chain Tctex-type 1 2* - +
E4f1 E4F transcription factor 1 1
Zcchc17 zinc finger, CCHC domain containing 17 1
Nap1l5 nucleosome assembly protein 1-like 5 1
Sult4a1 sulfotransferase family 4A, member 1 1
protein / IRBP) is an extracellular glycoprotein found in the interphotoreceptor 
matrix of the retina, and functions to shuttle chromophore molecules between 
cells of the retinal pigment epithelium and photoreceptors (Liou et al., 1982; Jin 
et al., 2009).  Clones representing 4 genes (E4f1, Zcchc17, Nap1l5, and Sult4a) 
were not rescued.  Rescue of a clone encoding Dynlt1 failed; however, the full-
length cDNA for this gene was amplified from a rat brain cDNA library by PCR 
and was cloned into the pACT2 prey plasmid for use in the retransformation lift 
assay.  Dynlt1 exhibited lacZ reporter activity with empty pASII∆∆ bait plasmid, 
but not with the rM4i3 bait construct (table 2.5).
2.3.5 rM5
A screen of 18 million human brain cDNA clones with a GAL4 DNA BD-
rM5i3 fusion bait yielded 32 doubly-positive yeast colonies (HIS3+, lacZ+) (table 
2.1).  Eleven of these 32 positive clones were found by PCR analysis to contain 
in-frame ORF sequences, representing 4 unique genes (table 2.1, 2.6).  A clone 
containing a 3ʻ fragment of the AGAP1 ORF (representing 4 of the 11 total 
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ID description
# 
clones
rescue
M5     ctl
AGAP1 AGAP1 / centaurin, gamma 2 4 + -
Ddrgk1 DDRGK domain containing 1 3
RGD1566093 similar to Fusion (involved in t(12;16) in 
malignant liposarcoma)
2
E4f1 E4F transcription factor 1 2
Table 2.6  rM5i3 screen results.
characterized positive screen colonies) was rescued and confirmed to interact 
with the Gal4 DNA BD-rM5i3 bait in the X-gal lift assay; the negative control co-
transformation with empty bait vector showed no lacZ activation (table 2.6).  
AGAP1 (also known as centaurin γ2 / Centg2) is a phospoinositide-dependent 
Arf GAP shown to regulate endocytic trafficking (Nie et al., 2002; Nie et al., 
2003).  Rescue of pACT2 plasmids from the remaining prey clones (representing 
three additional genes; Ddrgk1, RGD1566093, and E4f1) was not attempted 
(table 2.6).   
2.4  Discussion
In this section, we have described screens performed with the yeast two-
hybrid system in an effort to detect proteins interacting with the five muscarinic 
acetylcholine receptors.  The prey / bait strain mating protocol, as opposed to co-
transformation techniques, allowed us to easily generate a high number (>18 
million) of diploid clones in each screen (Bendixen et al., 1994; Fromont-Racine 
et al., 1997).  As the oligo-dT-primed pACT2 cDNA libraries used contained 
approximately 3.6 million independent clones (BD Clontech), our screens 
achieved multiple-fold coverage of the approximately 1.2 million in-frame Gal4 
AD-cDNA fusions potentially present.  For each receptor, a number of potential 
interacting clones were isolated and identified by PCR sequencing.  Narrowing 
this list of candidate MR-interacting proteins was necessary in order to focus our 
subsequent experimental efforts. 
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There are important limitations to the Y2H method that must be 
considered in order to properly evaluate candidate MR-interacting clones 
(Phizicky and Fields, 1995; Toby and Golemis, 2001; Lin et al., 2005; Daulat et 
al., 2009).  First, unlike proteomic approaches, the Y2H system is sensitive only 
to binary protein-protein interactions; multi-protein complexes are not detected.  
Second, in order to activate transcription of reporter genes, bait-prey interactions 
occur in the yeast nucleus.  Prey fusion proteins unable to translocate to the 
nucleus, such as proteins containing transmembrane domains, will not be 
detected in Y2H screens.  Third, expression of mammalian proteins in yeast may 
be inefficient or lead to toxicity and growth retardation. Although we observed no 
toxic effects of either the DNA BD-MRi3 or AD-cDNA library fusions, it was 
impossible to determine to what extent library clones were under-represented as 
a result of poor expression or slow yeast growth.  Expression of bait or prey 
proteins as hybrid fusions may interfere with their native structure and/or 
function.  Additionally, proteins expressed in yeast may be subject to misfolding, 
and may lack characteristic post-translational modifications such as 
phosphorylation, glycosylation, and nitrosylation found in their native 
environment.  Finally, as described earlier, the Y2H system is compatible only 
with soluble proteins.  This necessitated the use of cytoplasmic fragments of the 
MRs, rather than the full-length receptors as bait, and implied that library cDNAs 
containing coding regions for protein transmembrane domains were not 
represented in the screens.
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The presence of false-negative results are a result of the Y2H technical 
considerations listed above.  There are a number of known, physiological GPCR-
protein interactions that would not be expected to be detected in our screening 
system.  For example, binding of G proteins to GPCRs requires both formation of 
heterotrimeric complexes and interaction to second and third intracellular loop 
regions present in the native receptor conformation (Bluml et al., 1994; Wess et 
al., 1995)  Homo- and hetero- dimerization and oligomerization of native 
receptors has been described for muscarinic receptors (Zeng and Wess, 1999; 
Park and Wells, 2003) as well as for GPCRs such as GABAB (Kaupmann et al., 
1998; Margeta-Mitrovic et al., 2000), β2-adrenergic and opioid receptors (Jordan 
et al., 2001) and many others (Gurevich and Gurevich, 2008); these interactions 
would not be indicated in the Y2H system, although detection of transmembrane 
receptor association by cytoplasmic domain interactions is possible (Flajolet et 
al., 2008).  In addition, binding of β-arrestin to GPCRs occurs only after activation 
and receptor phosphorylation by GRKs (Lohse et al., 1990; Luttrell and 
Lefkowitz, 2002), post-translational modifications that are unlikely to be present 
in MRi3 loops expressed in yeast.  Indeed, we did not detect in our Y2H screens 
a number of proteins demonstrated previously (by alternate methodologies) to 
interact with MRi3s, such as RGS2, SET, and eEF1A2 (McClatchy et al., 2002; 
Bernstein et al., 2004; Simon et al., 2006).  Thus, the absence of clones present 
in our Y2H screens was not diagnostic of absence of interaction with a given 
gene product.  Nevertheless, for the reasons described earlier, we considered 
Y2H screens employing i3 loop regions as a desirable methodology for the 
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detection of physiologically and functionally relevant MR- interactions.  It should 
be noted, however, that in the period since the performance of our screens, a 
number of technologies have come into use that address some of the difficulties 
inherent to the study of MR protein-protein interactions, such as the high-affinity 
tandem affinity purification technique (TAP) for the purification of protein 
complexes associated with tagged, full-length MRs (Daulat et al., 2007; Lyssand 
et al., 2008). 
Additional characteristics of the Y2H system are responsible for the 
occurrence of false-positive clones in screens.  First, prey protein fusions 
exhibiting binding to the Gal4 or LexA DNA BDs could indicate interaction by 
reporter gene activation despite lack of binding to the i3 loop portion of the bait 
fusion protein.  We therefore confirmed interacting clones by retransformation of 
rescued plasmids in the presence of both bait (DNA BD-i3 loop) and negative 
control (empty bait vector) plasmids.  Clones displaying β-Gal activity in the 
presence of DNA-BD alone were excluded from further consideration (tables 
2.2-2.6).  Second, the Y2H transcriptional activation reporter system is sensitive 
to interference by bait fusions exhibiting transcriptional activation activity, and bait 
fusion proteins displaying DNA binding affinity.  We confirmed that our DNA BD-
MRi3 bait fusion proteins did not activate transcription of HIS3 by observing lack 
of growth on -His media of bait plasmid-transfected yeast strains.  Based on 
known or predicted function of sequenced positive clones, we also excluded from 
further consideration genes encoding transcription factors, transcriptional 
transactivators, or proteins with other known DNA-binding activity.  These clones 
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included the transcription factor E4f1 from the M4 and M5 screens; the zinc-
finger proteins Zcchc17 and  Zfp61 from the M4 and Gal4-M1 screens, 
respectively; the centromere autoantigen Cenpc (Earnshaw et al., 1987) from the 
M1i3-Gal4 screen; and the transcription factors Mllt3 and Aff4 from the M3 screen 
(tables 2.2-2.6).
A third factor responsible for the occurrence of false-positive results in 
Y2H screens is the fact that, while able to interact when co-localized in the yeast 
nucleus, putative interacting proteins may not co-localize spatially or temporally 
under normal physiological conditions in the mammalian cell.  Thus, for positive 
clones with known or predicted function, we considered functional plausibility as 
a factor in the ranking of candidates for priority of further study.  Based on the 
false-positive selection criteria described above, no rescued candidate clones 
remained from the M3 screen.  Candidates remaining for the other four MRi3 
screens are discussed in the following paragraphs.
In the initial M1i3 screen in the Gal4 system, the only rescued clone 
passing positive and negative retransformation controls encoded a C-terminal 
fragment of the secreted glycoprotein Olfactomedin / Noelin 2 (Barembaum et al., 
2000).  Noelin 1/2 has been shown to be expressed during development in the 
brain, retina and other structures in the chick, mouse, and zebrafish, and to be 
important for early and late brain developmental events (Barembaum et al., 2000; 
Moreno and Bronner-Fraser, 2002; Lee et al., 2008).  Mutations in human Olfm2 
have also been implicated in the genetics of a form of glaucoma (Funayama et 
al., 2006).  Based on this knowledge of Noelin 2 distribution and function, a 
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functional interaction with M1 was determined to be physiologically unlikely, and 
we considered the interaction with M1i3 to be false-positive.  In the hope of 
identifying additional M1i3-interacting proteins, we repeated the screen with the 
higher-sensitivity LexA reporter system.  Two positive clones emerged from this 
screen: Noelin 2 and the lysine acetyltransferase Kat5.  Kat5, also known as 
TIP60, is a histone acetyltransferase that functions as part of the conserved 
NuA4 complex which was shown to be recruited to chromatin by binding to to the 
transcription factor MYC, and to play a role in the DNA damage response 
pathway and in tumorigenesis (Frank et al., 2003; Squatrito et al., 2006; Gorrini 
et al., 2007; Bhoumik et al., 2008).  These functions also led us to discount the 
Kat5 interaction with M1i3 as a probable false-positive result.  Thus, no rescued 
clones emerged as likely physiological binding partners of M1 from our screens, 
although it was interesting to note the reproducibility of our screen results: Noelin 
2 was identified as a positive clone in both screens, and Kat5, the confirmed 
positive clone from the LexA screen, was also identified as a HIS3+ / lacZ+ clone 
in the initial Gal4 screen, although re-transformation failed to display β-Gal 
activation (table 2.2).  It is also worth noting the greater number of false-positive 
clones obtained in the LexA screen as opposed to the Gal4, which is consistent 
with the greater stringency of the Gal4 reporter system and illustrates the 
tradeoffs between sensitivity and false-positive rate that is important to consider 
in the design and analysis of Y2H screens (Phizicky and Fields, 1995; Toby and 
Golemis, 2001).  
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The M2i3 screen performed in the Gal4 system yielded no positive in-
frame clones, and was thus repeated in the LexA system.  Eight positive clones 
encoding a C-terminal fragment of SNX20 (sorting nexin 20) were confirmed to 
interact with M2i3 by plasmid rescue and retransformation (table 2.3).  SNX20, 
also annotated as SLIC-1, is a member of the sorting nexin family, proteins 
characterized by the presence of a phosphoinositide-binding phox homology 
(PX) domain (Xu et al., 2001; Worby and Dixon, 2002).  Proteins in the sorting 
nexin family, of which 33 members have been identified in mammals, have been 
shown to function in endocytosis, endosomal sorting of cargo proteins, regulation 
of endosomal structure, and coordination of endosomal signaling (Worby and 
Dixon, 2002; Cullen, 2008).  A recent study (employing the Y2H screen 
technique, but subsequent to the analysis of our results) demonstrated SNX20 
binding to the P-selectin glycoprotein ligand-1 (PSGL-1) cytoplasmic tail; this 
binding is thought to regulate the endosomal distribution of PSGL-1 (Schaff et al., 
2008).  As functionally significant interactions of trafficking molecules with 
GPCRs are well established (Tan et al., 2004) and since sorting nexins have 
been shown to bind to and regulate the trafficking of low-density lipoprotein 
receptors, EGF receptors, and protease-activated receptor 1 (Kurten et al., 1996; 
Stockinger et al., 2002; Wang et al., 2002), among others, we considered the 
identified interaction of SNX20 with M2i3 as a physiologically plausible result and 
an intriguing candidate for further study.
 The M4i3 screen yielded two positive clones that passed subsequent 
retransformation controls: Rbp3 (interstitial retinol-binding protein) and 
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UHRF1BP1L (table 2.5).  Rbp3, known more commonly as interphotoreceptor 
retinol binding protein (IRBP), is a glycoprotein secreted by photoreceptor cells 
into the interphotoreceptor matrix of the retina (Liou et al., 1982; Gonzalez-
Fernandez, 2003).   IRBP functions to shuttle all-trans-retinol and 11-cis-
retinaldehyde molecules between cells of the retinal pigment epithelium and 
photoreceptors, and is critical for resensitization of photoreceptors after light 
exposure (Carlson and Bok, 1992; Qtaishat et al., 2005; Jin et al., 2009).  Based 
on the extracellular distribution and described function of IRBP, we discounted 
this M4i3 screen clone as a likely false-positive result.  
Fourteen clones encoding two different C-terminal fragments of 
UHRF1BP1L (UHRF1 binding protein 1-like) were detected and confirmed by 
rescue and retransformation in our M4i3 screen.  UHRF1BP1L, also annotated 
as KIAA0701,  is an uncharacterized protein with no putative functional domains, 
named for its sequence similarity to the uncharacterized protein UHRF1BP1.  
UHRF1, known also as ICBP90 and Np95, is a multidomain protein containing a 
RING-finger ubiquitin E3 ligase domain, and was shown to bind directly to 
methylated DNA sequences and to be important for the maintenance of histone 
and DNA methylation states (Bronner et al., 2007; Sharif et al., 2007; Hashimoto 
et al., 2008a).  Though false-positive Y2H results as a result of multiple protein 
complex formation is unlikely, the relation of UHRF1BP1L to a known DNA-
binding protein was of concern.  Nevertheless, as down-regulation of β2 
adrenergic receptors has been shown to be mediated by ubiquitination by an E3 
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ligase (Shenoy et al., 2001), and since the function of UHRF1BP1L is unknown, 
we selected UHRF1BP1L for further study with respect to its binding to M4.
The M5i3 screen yielded positive clones encoding a C-terminal fragment 
of AGAP1 that passed positive and negative retransformation control 
experiments (table 2.6).  AGAP1 (an acronym for Arf GAP containing GTP 
binding protein-like domain, ankyrin repeats and pleckstrin homology domain 1), 
also annotated as centaurin γ2, is a member of both the AZAP and centaurin 
protein families (Jackson et al., 2000; Nie et al., 2002).  AGAP1 is a 
phosphoinositide-dependent GAP for members of the small GTPase protein 
family Arf, proteins that function to regulate mechanisms of intracellular 
membrane trafficking and actin cytoskeleton dynamics (Nie et al., 2002).  AGAP1 
was shown to bind to and regulate the function of the AP-3 adapter / coat protein 
complex, in turn affecting the trafficking of the lysosome-associated protein 
LAMP1 (Nie et al., 2003).  A number of AZAP and centaurin family proteins have 
been shown to affect trafficking of plasma membrane receptors:  ACAP1 binds to 
sorting signals on the transferrin receptor and integrin β1, promoting their 
endocytic recycling (Dai et al., 2004; Li et al., 2005); ASAP1 accelerates the 
recycling of internalized EGF receptors (Nie et al., 2006); and centaurin α1 
inhibits internalization of the β2 adrenergic receptor (Lawrence et al., 2005).  In 
addition, the protein PIKE-L / centaurin γ1 mediates the anti-apoptotic effects of 
the metabotropic glutamate receptor mGluR1 activation via Homer-coupled 
binding to the mGluR1 C-terminal tail (Rong et al., 2003).  Taken together, the 
known functions of AGAP1 and AZAP / centaurin family proteins led us to 
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consider an interaction between M5 and AGAP1 as physiologically plausible, and 
so we selected AGAP1 for continued study.
Based on the criteria described above for selecting candidates by the 
likelihood of their physiologically relevant interaction with MRs, there were a 
number of notable clones identified in our screens for which prey plasmid rescue 
failed.  From the M1i3-LexA screen, Ywhab- (14-3-3β) and Sharpin- coding 
clones were not rescued (table 2.2).  The Sharpin protein localizes to the post-
synaptic density and interacts with Shank (Lim et al., 2001), while 14-3-3 proteins 
serve as molecular scaffolds for signaling regulation, and bind to phosphoserine 
motifs and the β1 adrenergic receptor (Tutor et al., 2006; Obsilova et al., 2008).  
In addition, it is possible that clones such as Ppp1ca (coding for the catalytic 
subunit of protein phosphatase 1a) that failed to exhibit β-Gal activity upon 
retransformation with bait plasmid were displaying an MRi3 interaction weak 
enough to activate transcription of HIS3, but not the more stringent lacZ (table 
2.3).  Nonetheless, the group of three candidate MRi3-interacting proteins 
described above - SNX20, AGAP1, and to a lesser extent UHRF1BP1L - were 
deemed sufficiently promising to allow us to proceed with experiments examining 
the characteristics of their binding to MRs.   
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3 ANALYSIS OF THE M5-AGAP1 PROTEIN-PROTEIN 
INTERACTION
3.1 Summary
The binding characteristics of muscarinic receptor- interacting protein 
candidates identified in Y2H screens were investigated using complementary 
protein-protein interaction techniques.  We performed deletion mapping using 
directed Y2H assays to confirm candidate / MR i3 loop interactions, and to 
determine minimum domains of interaction.  The interaction between M5i3 and 
AGAP1 was determined to be unique to the M5 receptor subtype, and was 
shown to require a 23-residue region in the M5i3 loop.  Similar mapping 
experiments demonstrated that AGAP1 was unique among its most closely 
related family members in its association with M5i3, and that a 60-residue region 
in the split pleckstrin homology domain region was required for M5i3 binding.  In 
vitro binding of exogenously expressed AGAP1 to recombinant GST-MRi3 fusion 
proteins recapitulated a M5-specific binding pattern across MR subtypes.  GST-
fusion proteins containing fragments of M5i3 and AGAP1 were also able to 
interact, in a DOI-specific manner, with AGAP1 and full-length M5, respectively.  
Endogenous AGAP1 from rat brain lysate bound to a GST-M5i3 fusion protein, as 
did members of the heteromeric AP-3 adaptor complex.  Parallel protein-protein 
interaction experiments with SNX20 and M2i3, and with UHRF1BP1L and M4i3 
did not provide strong evidence for specific interaction of these proteins.  The 
results provide support for a subtype-specific interaction of M5 with AGAP1, and 
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suggest utility of a M5 DOI-deletion mutant receptor as a tool for the study of 
AGAP1-dependent M5 function.
3.2 Introduction
The validation of putative interacting proteins identified in yeast two-hybrid 
screens by independent protein-protein interaction techniques is critical.  The 
Y2H system is subject to artifactual false-positive results as a result of the yeast 
nuclear environment, misfolding of mammalian proteins, and DNA BD / AD fusion 
junction effects (Van Criekinge and Beyaert, 1999; Lin et al., 2005).  While no 
protein-protein interaction technique is free from false-positive interference, the 
use of complementary techniques (genetic and biochemical; in vitro and in vivo) 
provides the strongest evidence for the existence of a physiological protein 
complex.  “Pull-downs” from cell or tissue lysates using immobilized affinity 
matrices of recombinantly expressed glutathione-S-transferase (GST) fusion 
proteins are a commonly used and well-characterized method for detecting and 
analyzing protein-protein or protein-complex interactions (Lee and Liu, 2005; 
Chen et al., 2006; Flajolet et al., 2008; Warner-Schmidt et al., 2009).  Co-
immunoprecipitation of solubilized receptors expressed exogenously in tissue 
culture cells or from endogenous sources is an additional method commonly 
employed to verify and study the binding of protein or complexes with receptors, 
and is particularly well-suited to the detection of receptor-protein complexes from 
native tissues (Hall, 2005; Svenningsson et al., 2006; Daulat et al., 2007; Daulat 
et al., 2009).  A number of other in vitro techniques are also available for the 
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confirmation and analysis of putative protein binding partners, including protein 
and peptide arrays (Kung and Snyder, 2006), “Far Western” overlay blots and 
arrays (Mahlknecht et al., 2001; Hall, 2004) and peptide competition binding 
assays (Badtke et al., 2006).              
Protein-protein interactions are commonly dependent on amino acid motifs 
or conserved functional binding domains.  A large number of short peptide 
sequences conferring binding affinity to trafficking, signaling or scaffold proteins 
have been characterized; examples include dileucine and YXXΦ (Φ representing 
the bulky hydrophobic residues L,I,V,M, or F) motif binding to AP-1 and AP-2 
adaptor protein complexes, respectively (Rapoport et al., 1997; Rapoport et al., 
1998) and proline-rich motif binding to the WW and SH3 domains (Pawson and 
Nash, 2003).  Similarly, many conserved functional domains capable of binding 
proteins (as well as lipids and ions) have been described; as these domains are 
typically able to fold correctly independent of N- and C- terminal context, they 
exhibit modular function and occur repeatedly throughout the proteome (Pawson 
and Nash, 2003).  Common protein-protein interaction domains include PDZ, 
found in  the post-synaptic density scaffold protein PSD-95 and important for the 
assembly of excitatory synapses (Kim and Sheng, 2004), and the proline-rich 
peptide-binding SH3 domain (Kaneko et al., 2008).  
In the current study, two of the putative MR-interacting proteins identified 
by Y2H screen contain conserved binding domains.  SNX20 contains a phox 
homology (PX) domain, a defining characteristic of the entire sorting nexin family 
(Worby and Dixon, 2002).  PX domains are mainly implicated in the binding of 
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phospholipids and phosphoinositides (Xu et al., 2001), although instances of 
protein-protein interactions mediated by PX domains have been observed 
(Worby and Dixon, 2002; Abdul-Ghani et al., 2005). The PX domain of of SNX20 
was shown to bind most strongly to phosphatidylinositol 4-phosphate, 
phosphatidylinositol 5-phosphate, and phosphatidylinositol 3,5-bisphosphate; in 
addition, PX phospholipid binding was seen to be required for endosomal 
localization of SNX20 (Schaff et al., 2008).  AGAP1 contains multiple functional 
domains, two of which (pleckstrin homology (PH) and ankyrin repeat) potentially 
participate in protein-protein interactions (see figure 3.2A).  The PH domain is 
found in a variety of signaling and membrane-associated molecules; it is known 
to bind phospholipids, but is also able to participate in protein-protein interactions 
with Arf1 and G-protein βγ subunits (Lodowski et al., 2003; Godi et al., 2004; 
Lemmon, 2004).  In AGAP1, the PH domain is split by intervening sequence into 
N- and C- terminal halves (Nie et al., 2002).  The C-terminal end of AGAP1 also 
contains a series of ankyrin repeats; the ankyrin domain occurs widely and is 
able to mediate binding to a diverse array of protein targets (Li et al., 2006).        
The primary goal of the experiments described in this chapter was to 
confirm the presence of protein-protein interaction between muscarinic receptors 
and the three putative MR-binding proteins identified by Y2H screening.  We 
used the complementary protein-protein interaction experimental techniques of 
directed Y2H, GST pull-down and co-immunoprecipitation to investigate the 
binding of AGAP1, SNX20, and UHRF1BP1L to muscarinic receptors M5, M2, 
and M4, respectively.  Using a similar experimental approach, we also 
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determined the specificity of MR-candidate protein interactions with respect to 
MR subtype and interacting protein family members.  Finally, we performed Y2H 
domain-of-interaction mapping of MRi3 loops and candidate interacting proteins 
in an effort to determine residues or regions responsible for their binding.  In 
doing so, our hope was 1) to gain insight into the molecular and/or cellular 
implications of MR-protein interactions by identifying known amino acid motifs or 
interaction domains mediating binding, and 2) to develop molecular tools for 
subsequent study of the function of MRs in a loss-of-interaction context.
3.3  Results
3.3.1   AGAP1 interaction with M5i3 is subtype-specific and is mediated by 
discrete binding domains
We first investigated the specificity of the putative AGAP1- M5i3 
interaction by Y2H lift assay.  Co-transformation of Y187 yeast with the AGAP1-
coding pACT2 clone obtained from the Y2H screen and with pASII∆∆ bait 
plasmid encoding each of the five MRi3s (or empty vector) revealed lacZ reporter 
gene activation only with the M5i3 bait (figure 3.1A).  We then sought to map the 
domain of M5i3 critical to interaction with AGAP1 by deletion mutagenesis and 
directed Y2H assays, an approach used successfully in previous domain of 
interaction (DOI) studies (Miller et al., 2004; Lin et al., 2005; Flajolet et al., 2008; 
Hsu et al., 2009).  First, we determined that a prey plasmid encoding a rat 
AGAP1 fragment spanning residues 552 to 645 was able to activate β-Gal 
activity with a full length M5i3 bait in the Y2H lift assay (table 3.1B).  Next, we 
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Figure 3.1  AGAP1 interacts with a defined region of the M5 i3 loop in a 
receptor subtype-specific manner.  (A)  Right, X-Gal lift assay results for Y2H 
interaction assay between rat MRi3-Gal4 bait proteins and the rat AGAP1 clone 
isolated in the M5i3 screen.  pAS2∆∆, negative control.  (B)  Cartoon 
summarizing X-Gal lift assay results from Y2H interaction assays.  M5(214-442) 
represents the rM5 i3 loop region.  Truncation and deletion mutants were 
assayed for AGAP1(542-645) interaction as indicated.  Dark blue, strong lacZ 
activation; light blue, weak lacZ activation; white, negative result.  (C)  Multiple 
species alignment of the identified M5 i3 domain of interaction with AGAP1.  R, 
m, h; rat, mouse, human, respectively.  Yellow box indicates minimum domain of 
interaction.  Residues are colored by shared amino acid characteristics.
used PCR cloning to construct a series of three M5i3 deletion mutants spanning 
the 229-residue length of the i3 loop.  Only the C-terminal end fragment, M5 
(354-442), displayed interaction with AGAP1 (552-645) (figure 3.1B).  We then 
constructed a series of deletion mutants in order to determine the C-terminal 
extent of the putative AGAP1-M5i3 binding domain.  While the M5 (354-386) i3 
loop bait fragment displayed X-Gal staining intensity with AGAP1 (552-645) prey 
equal to that of the full-length i3 sequence, an M5 fragment truncated by a further 
3 residues (M5 (354-383)) produced greatly reduced X-Gal staining (figure 3.1B).  
Using a similar N-terminal end truncation approach, we observed that an M5 
(364-393) bait fragment exhibited full-length i3 X-Gal staining intensity, while 
truncation by a further 5 residues (M5 (369-393)) greatly reduced reporter activity 
(figure 3.1B).  Thus, a 23-amino acid region of M5i3 was identified as a possible 
minimum domain of interaction with AGAP1 in the Y2H assay.  To confirm this 
result, we constructed an M5i3 bait construct spanning the identified binding 
region but deleted for an 18-amino acid stretch within this region, M5 (354-413 
∆369-386).  This deletion-mutant bait construct showed no lacZ activation in the 
Y2H assay with the AGAP1 (552-645) prey, indicating successful disruption of 
the AGAP1 binding domain (figure 3.1B).  Multiple-species alignment of the M5 
amino acid sequences available in Genbank revealed the putative critical region 
of interaction to be strongly conserved suggesting the presence of a functionally 
significant domain (figure 3.1C).  This 23-residue M5i3 sequence displayed no 
homology with sequences of the other four MRs (figure 1.1).
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We next used deletion mutagenesis and the Y2H lift assay to investigate 
the residues on AGAP1 required for interaction with the M5 i3 loop.  The pACT2 
clone (JI17) isolated from the M5i3 Y2H screen encoded a C-terminal fragment of 
rat AGAP1 spanning residues 520-861 (figure 3.2A).  A series of truncation 
mutants spanning the C-terminal region of AGAP1 covered by the JI17 clone 
were tested against the full-length M5i3 bait.  An AGAP1 fragment (552-646) that 
included the entire C-terminal half of the split PH domain was found to interact 
strongly with M5i3 in the X-Gal lift assay (figure 3.2A).  Further refinement of the 
M5i3-interacting domain of AGAP1 indicated that a 59-amino acid region 
spanning residues 552-609 was the minimum domain sufficient for M5i3 binding 
in the Y2H assay.  The entire C-terminal half of the split PH domain was required 
for M5i3 interaction, as an N-terminal truncation of 8 amino acids was sufficient 
to eliminate lacZ reporter activation (figure 3.2A).  Alignment of the rat AGAP1 
(552-609) region sequence with that of other species revealed very high 
conservation, with >98% amino acid identity between rat, mouse and human 
sequences (figure 3.2B).
3.3.2  M5i3 alanine mutagenesis reveals residues critical for AGAP1 interaction
Based on the previous results, we performed site-directed mutagenesis of 
residues falling within the M5i3 domain identified as critical for interaction with 
AGAP1.  We identified charged and/or bulky hydrophobic residues in this region 
that displayed strong conservation across species, and constructed a series of 
alanine point mutants of the M5 (332-419) bait construct (figure 3.2B, figure 
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B
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Figure 3.2  AGAP1 domain-of-interaction mapping.  (A) Cartoon summarizing 
X-Gal lift assay results from Y2H interaction assays.  Top, AGAP1 functional 
domains.  Below, rat AGAP1 truncation mutants were assayed for M5i3 
interaction as indicated.  Dark blue, strong lacZ activation; white, negative result. 
(B)  Multiple species alignment of the identified AGAP1 domain of interaction with 
M5i3.  R, m, h; rat, mouse, human, respectively.  Yellow box indicates minimum 
domain of interaction.  Residues are colored by shared amino acid 
characteristics.
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Figure 3.3  Specificity of the AGAP1 / M5 i3 interaction.  (A) Alanine point 
mutants were generated from the rat M5 (332-419) bait construct and tested for 
interaction with rat AGAP1 (552-645) in the Y2H lift assay.  Dark blue, strong lacZ 
activation; white, negative result.  (B) Top, multiple species sequence alignment 
of rat AGAP1, 2 and 3, and human AGAP4.  Yellow box, consensus sequence 
corresponding to the AGAP1 domain of interaction with M5i3.  Residues are 
colored by shared amino acid characteristics.  Bottom, Y2H X-Gal lift assay 
results.  Dark blue, strong lacZ activation; white, negative result. 
3.3A).  The Y2H lift assay identified two series of mutations, Y378A K379A 
F380A and L382A V383A, that completely eliminated AGAP1 interaction as 
measured by β-Gal activity (figure 3.3A).  Notably, the mutated YKF and LV 
sequences resembled YXXΦ and LL motifs, respectively, which are known to 
target membrane proteins for endosomal and lysosomal compartments via 
interaction with adaptor protein complexes (Canfield et al., 1991; Vowels and 
Payne, 1998; Bonifacino and Traub, 2003). 
3.3.3  M5i3 interaction with AGAP family proteins is limited to AGAP1
The AGAP subfamily contains four characterized proteins: AGAP1, 
AGAP2 (Centaurin γ1) AGAP3 (Centaurin γ3) and AGAP4 (MRIP2 / Centaurin γ-
like family 1).  AGAP4 is present only in humans, and is included in the Centaurin 
γ-like family of 7 genes and pseudogenes present as a result of a likely gene 
duplication event on chromosome 10q (Kahn et al., 2008).  We cloned regions of 
AGAP family members homologous to the C-terminal split PH domain-containing 
AGAP1 region of interaction (AGAP1 (552-609) from rat brain cDNA library 
(AGAP2 and AGAP3) and human brain cDNA library (AGAP4), and tested them 
for interaction with the rat M5i3 bait in the Y2H lift assay (figure 3.3B).  Only 
AGAP1 displayed X-Gal staining, indicating that the putative interaction between 
M5 and AGAP1 is AGAP subtype-specific (figure 3.3B). 
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3.3.4  AGAP1 interacts with M5i3 in vitro
In order to confirm the Y2H assay M5i3 / AGAP1 interaction results in a 
complementary system, we performed in vitro binding studies using recombinant 
MRi3 proteins as affinity matrices.  MRi3 regions for the five rat MRs were 
expressed in E. coli as N-terminal fusions of the Glutathione-S-transferase 
protein (GST).  Recombinant GST proteins were purified and immobilized by 
affinity chromatography with a glutathione-conjugated resin.  The GST-MRi3 (or 
native GST) affinity matrices were then used in “pull-down” assays to examine 
interaction with AGAP1 proteins, with detection by autoradiography or 
immunoblot.  We first used an in vitro transcription-translation kit to produce 
[35S]Met-labeled protein from the JI17 clone DNA template (AGAP1 520-861).  
This AGAP1 fragment was seen to interact most strongly with the GST-M5i3 
protein, though binding to GST-M3i3 and GST-M4i3 was also observed.  No 
binding to native GST was apparent (figure 3.4A).  Next, we exogenously 
expressed full-length AGAP1 with a C-terminal myc tag in COS-7 cells.           
Pull-downs of AGAP1-myc- containing lysates and analysis by anti-myc 
immunoblot again showed AGAP1 to interact with GST-M5i3 but not native GST, 
with weaker interactions between AGAP1 and GST-M1i3, GST-M3i3 and GST-
M4i3 observed (figure 3.4A).
We next performed pull-down experiments to confirm the Y2H domain-of-
interaction mapping data described above.  We purified GST fusion proteins 
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Figure 3.4  AGAP1 interacts with M5 in vitro.  (A) through (D)  Cell or tissue 
lysates were incubated with indicated GST-fusion proteins immobilized on 
glutathione resin, and bound proteins were detected by immunoblot or 
autoradiography.  Where indicated, GST proteins were detected by  coomassie 
blue or ponceau red stains.  Molecular weights are listed in kilodaltons (kD). 
(A)  Top, autoradiograph of in vitro synthesized [35S]methionine-labeled rat 
AGAP1(520-861) protein.  Middle, immunoblot detecting myc-tagged AGAP1 
expressed in COS-7 cells.  (B) and (C)  Lysates from COS-7 cells expressing 
myc-tagged rat AGAP1 proteins were incubated with indicated M5i3-GST 
truncation or point mutant proteins.  (D) Indicated GST proteins were incubated 
with rat brain lysate (top 7 panels) or human neuroblastoma SK-N-MC  cell lysate 
(bottom panel).
containing M5i3 fragments with (M5 (354-393), M5 (354-413)) and without (M5 
(354-413) ∆369-386) the critical domain of interaction with AGAP1 as determined 
above by Y2H assay.  These immobilized proteins were then used in pull-down 
assays with lysates from COS-7 cells overexpressing full-length or truncated 
(546-861) AGAP1 tagged with the myc epitope.  Immunoblot revealed that both 
M5 (354-393) and M5 (354-413) proteins were able to pull down full-length 
AGAP-myc, whereas the domain of interaction deletion mutant and native GST 
were not (figure 3.4B).  This pattern of interaction was also observed for the 
AGAP1 (546-861)-myc protein, a truncation mutant missing the GLD and N-
terminal half of the split PH domain, but retaining the critical domain of M5i3 
interaction identified in Y2H experiments (figure 3.4B).  Interestingly, exogenous 
expression of the AGAP1 (546-861) protein yielded a second myc-
immunoreactive band, likely corresponding to a predicted 21-kD truncation 
protein formed by translation from a strong internal translation initiation site 
(AGAP1 (675-861)).  This lower band exhibited no binding to the GST-M5i3 
proteins, consistent with the absence of the M5 domain-of-interaction in this 
hypothesized protein (figure 3.4B).  
Finally, GST-M5i3 fusion proteins containing the alanine point mutations 
identified in Y2H experiments as sufficient to disrupt AGAP1 binding were tested 
for interaction with AGAP1-myc and AGAP1 (546-861)-myc in the pull-down 
assay.  While the Y378A K379A F380A mutation was observed to eliminate 
binding of AGAP1 proteins, the L382A V383A mutation reduced, but did not 
completely eliminate, AGAP1 interaction with M5i3 (figure 3.4C).  Taken together, 
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the Y2H and in vitro binding data therefore strongly supported the M5i3 YKF 
sequence as critical for binding of AGAP1.
3.3.5  Endogenous AGAP1 and AP-3 interact with M5i3 in vitro 
Using the GST, GST-M5 (354-413) and GST-M5 (354-413 ∆369-386) 
recombinant affinity matrices described above, we next attempted to detect 
interaction of M5i3 with endogenous proteins in rat brain lysate by pull-down and 
immunoblot analysis.  Consistent with our previous data, we observed interaction 
of GST-M5 (354-413), but not GST-M5 (354-413 ∆369-386) or native GST, with 
AGAP1 (figure 3.4D).  Interestingly, the AGAP1 antibody used in this study 
detected by immunoblot a multiplet band running at the predicted AGAP1 protein 
size (94.5 kD), the significance of which is unknown (figure 3.4D).   
AGAP1 has been shown to specifically bind to, and to influence the 
activity of, the AP-3 adaptor protein complex (Nie et al., 2003; Nie et al., 2005).  
Heterotetrameric adaptor complexes mediate trafficking of membrane-bound 
cargo proteins by binding to both target and vesicle coat proteins, as well as 
phospholipids and accessory proteins such as the Arf small GTPases (Nakatsu 
and Ohno, 2003; Lefrancois et al., 2004).  The AP-3 adaptor complex, consisting 
of the adaptin subunits δ, β3, µ3, and σ3, is present in mammals as ubiquitous 
(AP-3a) and neuron-specific (AP-3b) isoforms (Dell'Angelica et al., 1997; Newell-
Litwa et al., 2007).  Whereas the ubiquitous AP-3 complex is important for 
trafficking of proteins to late endosomes, lysosomes, and lysosomal-like 
compartments such as melanosomes and platelet dense granules, the neuron-
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specific form of AP-3 is required for the biogenesis of, and trafficking of certain 
membrane proteins to, endosomally-derived synaptic vesicles (Ooi et al., 1997; 
Bonifacino and Dell'Angelica, 1999; Blumstein et al., 2001; Salazar et al., 2004b). 
Using antibodies directed at subunits of AP-3a and AP-3b, we tested the 
hypothesis that an AGAP1/AP-3 complex could interact with the M5i3 loop.  
Subunits of both the ubiquitous (µ3A) and neuron-specific (β3B / β-NAP) AP-3 
adaptor complexes were detected in pull-downs using GST-M5 (354-413), but 
not GST-M5 (354-413 ∆369-386) or native GST (figure 3.4D).  However, M5i3 
interaction with the AP-3 large subunit δ-adaptin was not observed (figure 3.4D).  
The association of the AP-3 adaptor complex with M5i3 appeared to be specific, 
as AP-1 and AP-2 complex subunits did not bind to GST-M5 (354-413) (figure 
3.4D).   
The AP-3 adaptor complex interacts physically and functionally with the 
heteromeric complex BLOC-1 (biogenesis of lysosome-related organelles 
complex 1) (Salazar et al., 2006; Salazar et al., 2009).  Mutations in human 
genes encoding members of either the AP-3 complex or BLOC-1 are responsible 
for Hermansky-Pudlak syndrome, a genetically heterogeneous set of related 
autosomal recessive disorders characterized by albinism, platelet storage pool 
deficits, and prolonged bleeding (Wei, 2006).  A mutation in one of these genes, 
DTNBP1, is responsible for Hermansky-Pudlak syndrome type 7 (Li et al., 2003).  
The DTNBP1 gene product dysbindin (dystrobrevin binding protein 1) is an 
essential member of BLOC-1, and was shown to bind directly to AP-3 via the 
µ3A subunit (Li et al., 2003; Taneichi-Kuroda et al., 2009).  In order to determine 
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whether dysbindin was part of the AGAP1/AP-3 complex that we observed to 
interact with M5i3 in vitro, we tested lysate prepared from cultured SK-N-MC 
neuroblastoma cells in the GST-M5i3 pull-down assay (use of human tissue was 
necessitated by the lack of rat- or mouse- immunoreactivity of our commercially-
sourced dysbindin antibody).  Immunoblotting for human dysbindin revealed 
modest but specific binding to GST-M5 (354-413) (figure 3.4D).  Taken together, 
our in vitro binding data confirm the the Y2H results indicating a subtype-specific 
and domain-delineated interaction between M5 and AGAP1, and suggest that 
AGAP1 binding may be mediating the interaction of a larger AP-3 / BLOC-1 - 
containing complex with the M5i3 loop.
3.3.6  Intact AP-3 or phospholipid binding activity of AGAP1 is not required for its 
interaction with M5i3
We investigated whether AP-3 could play a role in mediating the binding of 
AGAP1 to M5.  Although false-positive interaction in the Y2H assay as a result of 
an endogenous multi-protein complex is unlikely, our in vitro pull-down 
experiments could not exclude the possibility that the observed interaction of 
AGAP1 to M5 was indirect, perhaps as a result of AP-3 binding to the YXXΦ or 
dileucine-like motifs in the M5i3 domain of interaction.  As an indirect measure of 
this, we performed co-immunoprecipitations of full-length and truncated forms of 
myc-tagged AGAP1 expressed in HEK-293T cells.  Full-length AGAP1 was seen 
to co-immunoprecipitate the AP-3 subunit µ3A, as previously reported (figure 
3.5A) (Nie et al., 2003).  However, the AGAP1(546-861) mutant, in which the 
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Figure 3.5  AGAP1 interacts with AP-3 and phospholipids.  (A)  Myc-tagged 
rat AGAP1 proteins were expressed in NIH-3T3 cells, immunoprecipitated with 
anti-myc antibodies, and immunoprecipitates were analyzed by immunoblot. 
(B)  Top, Phospholipid dot-blot arrays were incubated with [35S]methionine-
labeled AGAP1 proteins as indicated, and bound proteins were visualized by 
autoradiography.  Bottom, [35S]methionine-labeled AGAP1 proteins used above 
were analyzed by SDS-PAGE and autoradiography.
GLD and N-terminal half of the split PH domain are deleted, was unable to co-
immunoprecipitate AP-3 µ3A (figure 3.5A).  As both full-length and truncated 
forms of AGAP1 were able to bind to M5i3 in the pull-down and Y2H assays, the 
co-immunoprecipitation data indicated that AP-3 binding was not required for the 
interaction of AGAP1 with M5.
AGAP1 exhibits phosphoinositide-dependent Arf GAP activity, and 
contains a PH domain, a functional motif known to exhibit phospholipid binding 
activity (Nie et al., 2002; Lemmon, 2004).  To investigate the role of 
phospholipids in the interaction of AGAP1 with M5, we performed a lipid array 
overlay assay using [35S]Met-labeled full-length AGAP1 and the 
AGAP1(546-861) N-terminal deletion mutant prepared by in vitro coupled 
transcription-translation.  Full-length AGAP1 showed binding to a variety of 
phospholipids, phosphatidic acid, and phosphatidylserine, with strongest 
apparent binding to phosphatidylinositol-4-phosphate and phosphatidylinositol-
(3,5)-bisphosphate (figure 3.5B).  However, AGAP1(546-861), in which the split 
PH domain is disrupted but the domain of M5i3 interaction is maintained, 
displayed no phospholipid binding (figure 3.5B).  Thus, we determined that 
AGAP1 does indeed bind phospholipids via its split PH domain, but that this 
activity is dispensable for binding to M5.
3.3.7  Studies of M5 / AGAP1 interaction by co-immunoprecipitation
In an effort to demonstrate interaction of M5 receptors with AGAP1 under 
physiological conditions, we attempted to co-immunoprecipitate M5 and AGAP1 
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Figure 3.6  Co-immunoprecipitation studies of AGAP1-M5 interaction. 
COS-7 cells co-expressing rat AGAP1(546-861) and wild-type, point-, or domain-
of-interaction- mutant rat M5-GFP receptors were left untreated (A) or were 
treated as indicated with carbachol (CCh; 1mM) for 30 minutes.  Lysates were 
incubated with anti-GFP antibodies, and immunoprecipitates were analyzed by 
immunoblot for GFP and myc tags.  M5-GFP receptors present in COS-7 cell 
lysates were detected predominantly as dimers (A) or monomers (B).
proteins from intact cells.  As no specific antibodies appropriate for 
immunoprecipitation from native tissue sources exist for M5, we performed the 
experiments using M5 receptors fused with GFP on their C-termini expressed in 
exogenous cell systems.  A number of different detergent conditions for M5 
solubilization were employed, including a digitonin-cholate system described 
previously as yielding monomeric, non-denatured receptors (Haga and Haga, 
1985; Peterson et al., 1995).  Although small amounts of AGAP1(546-861)-myc 
were seen to co-immunoprecipitate with M5-GFP expressed in tissue culture 
cells using anti-GFP antibodies, the specificity of this association did not reflect 
our in vitro binding data: neither the Y378A K379A F380A  nor ∆369-386 M5 
mutations were able to interfere with apparent AGAP1(546-861)-myc binding 
(figure 3.6).  The specific co-immunoprecipitation of AGAP1 with M5-GFP after 
agonist (carbachol) stimulation of M5 (figure 3.6B), in the presence of a protein 
cross-linking reagent, or using primary cultured rat neurons as the exogenous 
expression system was not observed (data not shown).  We therefore were 
unable to corroborate our Y2H and in vitro binding data with demonstration of 
specific M5/AGAP1 co-immunoprecipitation.
        
3.3.8  Domain mapping and in vitro binding: SNX20 and M2i3
 Using a strategy similar to that described for the study of AGAP1/M5 
interaction, we investigated the characteristics and specificity of the putative 
interaction of the M2 i3 loop with SNX20.  Y2H domain-of-interaction mapping 
confirmed the positive interaction with the pACT2 prey clone isolated in the Y2H 
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Figure 3.7  SNX20 domain-of-interaction mapping and in vitro binding. 
(A)  Cartoon summarizing X-Gal lift assay results from Y2H interaction assays. 
Top, SNX20 sequence indicating position of the PX domain. Below, rat SNX20 
truncation mutants were assayed for M2i3 interaction as indicated.  Dark blue, 
strong lacZ activation; white, negative result. (B)  [35S]methionine labeled SNX20 
synthesized in vitro (top; input = 10% of total) or lysate of COS-7 cells expressing 
myc-tagged SNX20 (middle; input = 1% of total) were incubated with GST-fusion 
proteins immobilized on glutathione resin, and bound proteins were detected by 
autoradiography or immunoblot, respectively.  Total GST proteins were detected 
by coomassie blue staining (lower panel). (C) Rat M2-GFP or M4-GFP receptors 
were co-expressed in COS-7 cells with myc-tagged SNX20, cells were treated as 
indicated, and MR-GFP proteins immunoprecipitated after cross-linking. 
Immunoprecipitates were analyzed by immunoblot with GFP and myc tag 
antibodies as indicated.
screen (JK1, encoding SNX20 residues 92-313) (figure 3.7A).  We observed no 
reporter gene activation by JK1 when co-expressed with the LexA-M1i3 bait in 
L40 yeast (data not shown).  Despite extensive coverage of the SNX20 protein 
by truncation mapping, we were able to identify only a single mutant, 
SNX20(97-313), that exhibited lacZ activation with the pLexA-M2i3 bait in the 
Y2H lift assay (figure 3.7A).  Additionally, truncation mutants containing both the 
SNX20(97-313) domain and an intact PX domain showed no interaction with 
M2i3 in this assay (figure 3.7A).  We therefore surmised that either SNX20 
interaction with M2i3 was dependent on a large protein domain and that the 
presence of an active PX domain was able to interfere with the readout of this 
interaction in yeast, or that the observed SNX20-M2i3 interaction was a result of 
an artifactual sequence present at the fusion junction between the DNA-BD and 
M2i3 proteins.
We next attempted to detect binding of full-length SNX20 to GST-M2i3 in 
vitro.  Using either [35S]Met-labeled SNX20 prepared by in vitro coupled 
transcription-translation or lysate from tissue culture cells overexpressing 
epitope-tagged SNX20-myc, we performed GST pull-down assays with the five 
GST-MRi3 proteins or native GST as affinity matrices.  Neither [35S]Met-SNX20 
or SNX20-myc displayed specific binding to M2i3 (figure 3.7B).  We also 
attempted to co-immunoprecipitate M2-GFP receptors with SNX20-myc 
expressed in tissue culture cells, with and without carbachol treatment and using 
the cell-permeable protein crosslinker DSP prior to solubilization.  Using GFP 
antibodies for immunoprecipitation, no specific co-immunoprecipitation of 
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SNX20-myc was observed (figure 3.7B).  Taken together, our data do not provide 
strong biochemical support for the existence of a physiological interaction 
between SNX20 and M2.     
3.3.9  Domain mapping and in vitro binding: UHRF1BP1L and M4i3
The M4i3 Y2H screen yielded β-Gal positive prey clones encoding 
UHRF1BP1L with two distinct AD-fusion N-terminal junctions: clones JA54 
(UHRF1BP1L(2034-1469)) and JA71 (UHRF1BP1L(1123-1469)) (figure 3.8A).  
These clones were observed to activate lacZ reporter activity with the M4i3 bait, 
but not the remaining four MRi3 baits, in the Y2H lift assay (data not shown).  
However, UHRF1BP1L fragments with N-terminal truncations between (residue 
1116) or past (residue 1188) the junctions present in the JA54 and JA71 clones 
failed to display interaction with M4i3 (figure 3.8A).         
We performed a GST-MRi3 pull-down experiment using COS-7 cell lysate, 
in which endogenous UHRF1BP1L (KIAA0701) protein was detectable by 
immunoblot using a commercial antibody.  Although weak interaction of 
UHRF1BP1L with GST-M4i3 was observed, stronger pull-down with the GST-
M3i3 and GST-M5i3 affinity matrices was apparent, in contrast to the M4i3 
interaction specificity observed in the Y2H system (figure 3.8B).  We also 
attempted to detect interaction of endogenous UHRF1BP1L in COS-7 cells with 
exogenously expressed M4-GFP by DSP cross-linking and immunoprecipitation 
with GFP antibodies.  We observed no co-immunoprecipitation of UHRF1BP1L 
protein with M4-GFP, either with or without carbachol treatment prior to receptor 
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Figure 3.8  UHRF1BP1L domain-of-interaction mapping and in vitro binding. 
(A)  Cartoon summarizing X-Gal lift assay results from Y2H interaction assays. 
Rat UHRF1BP1L-encoding clones derived from the M2i3 Y2H screen, or 
UHRF1BP1L truncation mutants were assayed for M2i3 interaction as indicated. 
Dark blue, strong lacZ activation; white, negative result. (B) Lysate from COS-7 
cells expressing myc-tagged rat UHRF1BP1L was incubated with GST-fusion 
proteins immobilized on glutathione resin, and bound proteins were detected by 
immunoblot, respectively.  (C) Rat M4-GFP receptors were co-expressed in 
COS-7 cells with myc-tagged UHRF1BP1L, cells were treated as indicated, and 
MR-GFP proteins immunoprecipitated after cross-linking.  Immunoprecipitates 
were analyzed by immunoblot with GFP and myc tag antibodies as indicated.
solubilization (figure 3.8C).  Thus, the in vitro binding studies combined with our 
Y2H data do not strongly support the existence of a specific, domain-delineated 
interaction between M2i3 and URHF1BP1L.
3.4  Discussion
In this chapter, we provide biochemical evidence for the physical 
interaction of muscarinic receptor M5 with AGAP1.  The observed interaction was 
unique to the M5 muscarinic receptor subtype, and was mediated by a conserved 
23-residue region on the M5 i3 cytoplasmic loop sharing no sequence homology 
with muscarinic receptors 1 through 4.  Similarly, three closely-related AGAP 
proteins did not exhibit M5i3 interaction, and the AGAP1 domain mediating this 
binding is highly conserved in sequence across species.  We are the first to 
report direct binding between an AGAP protein and a GPCR, although a related 
AZAP family protein ACAP1 has been shown to interact with a number of non-
GPCR transmembrane receptors (Dai et al., 2004; Li et al., 2005).  We also 
observed that, at least in vitro, the M5i3 domain critical for interaction with 
AGAP1 was able to bind subunits of the ubiquitous and neuron-specific isoforms 
of the AP-3 adaptor complex.  As the interaction between AGAP1 and M5 was 
apparently direct, and since AGAP1 is known to bind directly to AP-3 (Nie et al., 
2003), we surmised that AGAP1 was mediating binding of AP-3 to M5i3.  This 
suggested the possibility that in vivo, the identified interaction domain of M5i3 
mediates binding of an AGAP1/AP-3 trafficking complex to the receptor, perhaps 
implicating the identified protein-protein interaction in the regulated trafficking of 
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M5.  Indeed, we also detected binding of dysbindin protein to the M5i3 AGAP1-
interaction domain; dysbindin is a sub-member of BLOC-1, a complex known to 
interact physically and functionally with AP-3 (Li et al., 2003; Taneichi-Kuroda et 
al., 2009).  It should be cautioned, however, that our in vitro data does not 
distinguish between binding of a native, pre-formed AGAP1/AP-3/BLOC-1 super-
complex to M5i3 and recruitment of AP-3 / BLOC-1 components to M5i3-bound 
AGAP1; in addition, we did not observe M5i3 binding of the large AP-3 subunit δ-
adaptin in our assays.
Site-directed mutagenesis implicated a YKF motif in M5i3 as critical for 
AGAP1 binding to M5i3.  Phenylalanine- and tyrosine- residue clusters on the 
transferrin receptor cytoplasmic tail were similarly shown to be critical for ACAP1 
binding and/or endocytic recycling of the receptor (McGraw et al., 1991; Dai et 
al., 2004).  The YKF sequence resembles, but does not fulfill the functional 
identity of, the commonly occurring and well-characterized YxxΦ sorting signal, 
which targets host proteins for endocytosis and localization to lysosomes or 
lysosome-like compartments via interaction with adaptor protein complex µ 
subunits (Rapoport et al., 1997; Ohno et al., 1998; Bonifacino and Traub, 2003).  
We also identified by site-directed mutagenesis a leucine-valine residue pair 
whose mutation interfered with AGAP1 binding.  Although lacking the upstream 
acidic residues, this motif resembles the [DE]XXXL[LI] and DXXLL dileucine-type 
sorting signals known to mediate receptor internalization, lysosomal targeting 
and TGN-to-endosome transport by binding to adaptor protein complex subunits 
(Johnson and Kornfeld, 1992; Letourneur and Klausner, 1992; Bonifacino and 
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Traub, 2003; Janvier et al., 2003).  Notably, dileucine and dileucine-like (LI, LV) 
motifs lacking upstream acidic residues have been shown to function as AP-1- 
and AP-3-binding lysosomal targeting motifs in yeast and mammals (Rapoport et 
al., 1998; Vowels and Payne, 1998; Kyttala et al., 2005).  Although our Y2H and 
in vitro binding data demonstrate direct binding of AGAP1 to M5i3, and though 
AP-3 subunits bind AGAP1, our data cannot discount the possibility of a direct 
AP-3 / M5i3 interaction, perhaps mediated by the leucine-valine motif.
Co-immunoprecipitation of endogenous proteins from native tissue 
sources is typically considered the “gold-standard” for proof of molecular 
interaction in vivo (Hall, 2005).  Such an experiment is not possible in the case of 
M5, as no antibodies currently exist that are appropriate for either 
immunoprecipitation or immunoblotting, and the receptor is expressed at very low 
levels in the brain and periphery (Wess et al., 2003).  We investigated a number 
of N-terminal, C-terminal, and internal epitope tags on the M5 receptor for their 
suitability in immunoprecipitation and immunoblotting experiments in exogenous 
expression systems; a C-terminal GFP tag was identified as most appropriate.  
However, we were unable to identify conditions under which the wild-type M5-
GFP receptor, but not the Y378A K379A F380A, L382A V383A or ∆369-386 M5-
GFP receptors, was able to co-immunoprecipitate either truncated or full-length 
forms of AGAP1.  Detergent solubilization of M5 receptors was a continuing 
technical difficulty; the degree to which the non-denaturing digitonin-cholate 
system purified monomeric or oligomeric forms of M5 protein was reagent batch-
dependent (see figure 3.6), and more stringent solubilization conditions were 
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avoided in fear of disrupting the putative AGAP1-M5 complex.  Attempts to 
stabilize the putative low-affinity AGAP1-M5 complex by chemical cross-linking 
also failed, in part due to insolubility of AGAP1 proteins after DSP treatment and 
poor reduction of the disulfide crosslink bond under conditions necessary to 
avoid M5 aggregation during SDS-PAGE.  However, due to the agreement 
between in vitro binding and Y2H interaction data and the existence of clearly-
delineated interaction domains, we took our results to indicate the existence of a 
low-affinity interaction between M5 and AGAP1.  Weak protein-protein 
interactions are typical of the transient binding of trafficking or signaling 
complexes with their cellular targets (Vaynberg and Qin, 2006).  Indeed, 
physiologically relevant trafficking complex binding to receptor targeting motifs 
has been revealed by a combined Y2H / GST pull-down strategy (Voglmaier et 
al., 2006) and binding of targeting motif-containing peptides to adaptor complex 
proteins was shown to require cryopreservation and/or photo-crosslinking for 
detection (Rapoport et al., 1997; Rapoport et al., 1998).
Our data do not provide strong support for the existence of the putative 
SNX20-M2i3 and UHRF1BP1L-M4i3 interactions detected in the Y2H screens.  
DOI mapping and in vitro binding results cannot rule out the possibility that the 
detected interactions were false-positive artifacts of the Y2H system, bait or prey 
fusion proteins, or some combination thereof.  In the case of SNX20, it is curious 
that the presence of a functional PX domain abrogates lacZ reporter activity in 
the Y2H lift assay.   The possibility exists that phospholipid binding activity of the 
AD-SNX20 prey fusion prevents nuclear localization, M2i3 interaction, or AD 
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activity in yeast.  Nonetheless, based on the strength of the interaction data, our 
experimental focus from this point forward was on the functional consequences 
of the AGAP1 / M5 protein-protein interaction.  As co-immunoprecipitation data 
were lacking, we chose to employ the domain-of-interaction deletion mutant 
(∆369-386) to study AGAP1 interaction-dependent M5 function, since this mutant 
was most likely to maintain the AGAP1 binding loss-of-function observed in yeast 
and in vitro. 
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4AGAP1 & M5: DISTRIBUTION
4.1  Summary
We demonstrate in this chapter co-localization of M5 receptors with 
AGAP1 in endosomal-like compartments of cultured neurons.  Exogenous co-
expression of AGAP1-myc and M5-GFP in rat primary hippocampal neurons 
revealed a population of partially overlapping AGAP1- and M5- positive puncta 
after agonist induced internalization of M5.  Live imaging in cultured neurons 
indicated a dynamic relationship between mobile, M5-GFP- and AGAP1- or 
AP-3B-positive vesicles.  Co-immunostaining in cultured neurons confirmed 
transit of agonist-internalized M5 through AP-3-positive endosomes and the 
recycling and/or degradative trafficking pathways.  Results obtained from 
membrane fractionation of rat brain tissue are consistent with the association of 
AGAP1 with AP-3 endosomes.  As AGAP1 is likely a ubiquitously expressed 
protein, our results support the cellular and sub-cellular co-localization of AGAP1 
and M5, further arguing for their physical interaction in vivo.  Our data also 
suggest a functional role for AGAP1 in the activity-induced trafficking of M5 in 
neurons.
4.2  Introduction
The M5 muscarinic receptor is by far the lowest expressed and most 
poorly characterized MR in mammals.  Though the lack of subtype-selective 
ligands and antibodies appropriate for detection of M5 by immunohistochemistry 
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or immunoblotting has hampered investigation of the receptor, a number of 
studies have demonstrated functionally significant expression of M5.  In the 
mouse, M5 mRNA was detected almost exclusively in the brain, with particular 
enrichment in the hypothalamus, hippocampus, and striatum, although small 
amounts of M5 transcript were detected both in mouse skin and in a human 
melanoma cell line (Kohn et al., 1996; Regard et al., 2008).  Radioligand 
detection of MR sites immunoprecipitated from rat brain using subtype-selective 
antibodies suggested that M5 receptors contribute to less than 2% of the total 
MR population, a result confirmed more recently in the M5 knockout mouse 
(Yasuda et al., 1993; Oki et al., 2005).  In situ hybridization studies in mouse and 
rat brain confirm a low overall level of M5 transcription; interestingly, however, M5 
mRNA, but not M1-4 mRNA, was detected in the midbrain dopaminergic neurons 
of the SNc and VTA (figure 4.1) (Weiner et al., 1990; Lein et al., 2007).  
Phenotypic (loss-of-function) analysis of the M5 knockout mouse has indicated 
functional expression of M5 in two main areas: first, in both pre- and post-
synaptic terminals of midbrain dopaminergic neurons innervating the dorsal and 
ventral striatum (Yeomans et al., 2001; Forster et al., 2002; Zhang et al., 2002b), 
and second, in cerebral arteries and arterioles (Yamada et al., 2001a).  The 
subcellular distribution of M5 has not been directly investigated.  However, MR 
1-4 have been shown to localize to the plasma membrane of tissue culture cells, 
and undergo the stereotypical GPCR trafficking cycle of agonist-induced 
internalization, followed by either endocytic recycling or targeting for lysosomal 
degradation, depending on subtype (Tolbert and Lameh, 1996; Volpicelli et al., 
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Figure 4.1  Allen Mouse Brain Atlas in situ hybridization data.  Sagittal 
C57BL/6J mouse brain sections labeled with digoxigenin-conjugated riboprobes 
for indicated genes were obtained from the on-line Allen Mouse Brain Atlas 
(Seattle (WA): Allen Institute for Brain Science. ©2009. Available from: http://
mouse.brain-map.org).  Arrow indicates substantia nigra pars compacta region 
labeled with ChrM5 riboprobe.
ChrM5AGAP1
AP3 !3A AP3 !3B
2001; Delaney et al., 2002; Popova and Rasenick, 2004).     
AGAP1 is an AP-3-associated Arf GAP protein expressed widely in 
mammalian tissues.  Expression of AGAP1 mRNA was detected at equal levels 
in a variety of human organs, including brain, by RT-PCR (Nie et al., 2005).  
Northern blot analyses of AGAP1 mRNA isolated from human and mouse tissues 
have described the presence of large (9 kb), medium (4.5 kb) and small (2.4 kb) 
transcripts expressed at various levels in a number of tissues; as Genbank 
indicates a message length of 9.5 kb and 4.5 kb for mouse and human AGAP1 
mRNAs, these results likely indicate the presence of splice forms, the 
significance of which is unclear (Xia et al., 2003; Meurer et al., 2004).  AGAP1 
protein was also detected in lysates from human cell lines derived from 
lymphocyte, epithelial, gastric, liver, and glial sources (Nie et al., 2005).  In the 
mouse brain, AGAP1 mRNA is highly expressed in the fore- and mid-brain during 
development (Xia et al., 2003), and exhibits a ubiquitous and uniform pattern of 
expression in adults (figure 4.1) (Lein et al., 2007).  Epitope-tagged AGAP1 
expressed exogenously in tissue culture cells was shown to exhibit either a 
uniform or punctate distribution pattern, apparently depending on host cell type 
and overexpression levels (Nie et al., 2002; Xia et al., 2003).  These AGAP1 
puncta were shown by biochemical and immunocytological methods to 
correspond to a population of AP-3-positive endosomes (Nie et al., 2003).
The heterotetrameric adaptor protein complex AP-3 exists as ubiquitous 
and neuron-specific isoforms.  The ubiquitous AP-3A, composed of the large 
adaptin subunits δ and β3A, the medium subunit µ3A, and the small subunit σ3A/
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B, is expressed in all mammalian cells and tissues, including the brain (figure 
4.1) (Dell'Angelica et al., 1997; Lein et al., 2007).  The neuron-specific AP-3B 
isoform shares the δ and σ3A/B subunits with the ubiquitous form, and includes 
the neuron-specific subunit proteins β3B / β-NAP and µ3B (Newman et al., 1995; 
Seong et al., 2005).  β3B is likely expressed in all CNS and peripheral neurons 
(figure 4.1) (Newman et al., 1995; Lein et al., 2007).  AP-3 is distributed 
subcellularly in both cytosolic and membrane-bound pools, the latter consisting of 
clathrin- and non-clathrin- coated vesicles seen to associate by biochemical and 
immunofluorescence techniques with TGN- and endosome-like structures 
(Dell'Angelica et al., 1997; Simpson et al., 1997; Dell'Angelica et al., 1998).  An 
immuno-electron microscopy study of δ-adaptin in tissue culture cells found AP-3 
localized to early endosome-associate membrane tubules co-localized with the 
lysosome-target protein LAMP1, but found no evidence for AP-3 localization in 
the TGN (Peden et al., 2004).  In neurons, distribution of the ubiquitous AP-3A 
isoform is apparently restricted to neuronal soma, whereas the neuron-specific 
AP-3B is distributed in axons and dendrites, and is associated with nerve 
terminal vesicles (Newman et al., 1995; Seong et al., 2005).
Using biochemical methods, we identified AGAP1 as an M5-interacting 
protein, potentially present as a part of an AGAP1/AP-3 complex.  In this chapter, 
we describe experiments examining the cellular and subcellular distribution of 
M5, AGAP1, and AP-3.  As antibodies appropriate for immunocytological labeling 
of AGAP1 and M5 are not available, we used epitope tags for the 
immunofluorescent localization of M5 and AGAP1 expressed exogenously, under 
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both basal and agonist-stimulation conditions expected to induce internalization 
and endocytic traffic of the M5 receptor.  Using a similar strategy, we also studied 
the distribution of M2 and SNX20.  We used both tissue culture cells and rat 
primary hippocampal neurons for exogenous expression, the latter due to the 
possible involvement of the functionally divergent, neuron-specific AP-3B 
complex in the interaction of AGAP1 with M5.  In primary neurons, we took 
advantage of the recently developed monomeric red fluorescent protein 
derivative mCherry (Shaner et al., 2004), along with M5-GFP, to perform two-
color live imaging of M5, AGAP1, or AP-3.  Finally, we investigated the 
distribution of M5, AP-3 and AGAP1 in comparison to membrane-associated 
endosomal markers in an effort to further characterize the distribution of these 
proteins.  The main goal of this chapterʼs experiments was to confirm the 
temporal and spatial co-localization of M5 and AGAP1, and possibly AP-3, that is 
required for the existence in vivo of the proteinsʻ physical interaction.  A 
secondary goal was to gain knowledge as to the functional implications of 
AGAP1 interaction with M5, with particular attention paid to trafficking pathways.
4.3  Results
4.3.1  AGAP1 mRNA exhibits widespread expression in mouse tissues and brain 
subregions
We first analyzed mouse AGAP1 mRNA distribution by Northern blot to 
confirm the widespread pattern of AGAP1 expression described previously in 
human and mouse tissues (Xia et al., 2003; Meurer et al., 2004; Nie et al., 2005).  
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Using a [33P]-labeled antisense riboprobe targeting the 3ʼ-UTR of mouse 
AGAP1, we detected hybridization signals in most of the tissues represented 
(figure 4.2A).  An AGAP1 transcript of approximately 9.5 kilobases (kb) was 
expressed predominantly in brain, while a 4.4 kb message was most prevalent in 
kidney, and a smaller, approximately 3.5 kb transcript was detected only in testis 
(figure 4.2A).  Additionally, immunoblot detection of AGAP1 protein revealed 
AGAP1 expression in all tested tissue sources, including tissue culture cells 
derived from a variety of species (human, rat, mouse, chinese hamster, african 
green monkey) and pre- and post-natal rat and mouse brain tissues (data not 
shown), in agreement with previous reports examining AGAP1 expression in 
human cell lines (Nie et al., 2005).
Next, we performed in situ hybridizations of adult mouse brain tissues 
using the same [33P]-labeled AGAP1 3ʼ-UTR antisense riboprobe described 
above.  AGAP1 mRNA was detected widely, with an autoradiography signal 
consistent with brain subregion cell body density (figure 4.2B).  A control sense-
strand riboprobe prepared from the AGAP1 3ʼ-UTR template produced no signal 
(data not shown).  The uniform expression of AGAP1 mRNA in the rodent brain is 
consistent with previously published mouse brain gene expression atlas data 
(figure 4.1) (Lein et al., 2007).  Thus, the expression of AGAP1 mRNA and 
protein products was confirmed to be widespread in mammals both across 
tissues and within the brain.
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Figure 4.2  AGAP1 mRNA expression.  (A) Mouse Multiple Tissue Northern blot 
hybridized with [33P]-labeled AGAP1 antisense riboprobe.  Transcript size is 
indicated in kilobases.  (B) Autoradiograph of C57BL/6 mouse brain coronal (top) 
and sagittal (bottom) sections labeled by in situ hybridization using the [33P] 
AGAP1 riboprobe from (A). 
4.3.2  Exogenously expressed M5-GFP and AGAP1-myc do not extensively co-
localize in tissue culture cells
In the next series of experiments, we aimed to investigate by confocal 
microscopy the degree to which M5 receptors and AGAP1 co-localize when 
overexpressed in mammalian tissue culture cells.  Since detection of 
endogenous M5 and AGAP1 proteins in cultured cells was not possible due to 
the lack of antibodies suitable for immunocytochemistry, we performed 
immunofluorescence experiments using exogenously expressed epitope-tagged 
M5 and AGAP1 proteins.  An M5 receptor tagged at the cytosolic C-terminus with 
GFP was seen to localize predominantly at the plasma membrane when 
expressed in a variety of mammalian tissue culture lines (CHO, COS-7, 
HEK293T) after fixation and detection with anti-GFP antibodies (figure 4.3A).  In 
addition, treatment of M5-GFP -transfected cells with the muscarinic agonist 
carbachol (CCh) led to a predominantly intracellular, punctate GFP 
immunofluorescence pattern, consistent with agonist-induced internalization of 
surface M5 receptors into endocytic vesicles, as has been described in similar 
systems for muscarinic receptor subtypes 1-4 (Tolbert and Lameh, 1996; 
Volpicelli et al., 2001; Delaney et al., 2002; Popova and Rasenick, 2004).
In previous studies, exogenously expressed AGAP1 protein exhibited 
either a uniform/cytosolic or punctate distribution, apparently depending on the 
degree to which the protein was overexpressed (Nie et al., 2002; Nie et al., 2003; 
Xia et al., 2003).  In experiments examining the immunocytological distribution of 
overexpressed rat AGAP1-myc, we observed a mainly uniform expression 
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Figure 4.3  Immunofluorescence staining of AGAP1 and M5 in 
tissue culture cells.  (A) CHO cells were transiently transfected with 
M5-GFP construct, treated with (right) or without (left) 100µM carbachol  
for 30 minutes, fixed, immunostained for GFP and imaged by confocal 
microscopy.  (B) COS-7 cells were transiently transfected with AGAP1-
myc construct, extracted with detergent (right) or not (left), fixed, immu-
nostained for myc tag and imaged by confocal microscopy.  (C) COS-7 
cells were transiently co-transfected with M5-GFP and AGAP1-myc 
constructs.  Cells were treated with 100µM carbachol for 1 hour, 
extracted with detergent, fixed, immunostained for GFP (green) and 
myc tag (red) and imaged by confocal microscopy.  Scale bars = 50µm.
pattern consistent with cytosolic localization (figure 4.3B).  In some cases, higher 
expression levels of AGAP1-myc led to what appeared to be a punctate 
localization pattern, as had been previously reported (Nie et al., 2003); however, 
AGAP1-enriched puncta were localized to numerous peripheral membrane blebs 
of cells displaying unusual gross morphology, indicating that such cells may have 
been apoptotic (Coleman et al., 2001).  In some cases (including that of the 
AZAP protein ACAP1), cytosol extraction prior to fixation and immunostaining 
can reveal the otherwise-obscured membrane-bound pool of membrane-
associated proteins (Morris and Cooper, 2001; Dai et al., 2004).  We observed a 
punctate, vesicular-like distribution of AGAP1-myc when overexpressing cells 
were subjected to a mild detergent extraction before fixation (figure 4.3B).
We next investigated whether M5 and AGAP1 co-localized under 
conditions in which subcellular vesicle-like distribution patterns were evident.  We 
co-expressed M5-GFP and AGAP1-myc in tissue culture cells, treated with CCh 
to induce M5 internalization, and performed cytosol extraction before fixation and 
immunostaining.  Although both M5-GFP and AGAP1-myc were seen to localize 
mainly to subcellular puncta, little overlap was observed between the M5- and 
AGAP1- positive compartments in this expression system (figure 4.3C).  
4.3.3  AGAP1-myc co-localizes with endocytosed M5-GFP in primary cultured 
neurons
Our previous data confirmed the biochemical association of AGAP1 with 
the AP-3 adaptor complex (Nie et al., 2003).  The neuron-specific isoform of AP-3 
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exhibits distinct functions from that of ubiquitous AP-3, and the complex isoforms 
are expressed in neurons in a spatially-segregated manner (Seong et al., 2005; 
Newell-Litwa et al., 2007).  Immunocytological studies have indicated association 
of AGAP1 protein with AP-3-positive endocytic compartments in tissue culture 
cells; however, the subcellular localization of AGAP1 in neurons has not been 
reported (Nie et al., 2003; Nie et al., 2005).  In order to investigate both the 
localization and spatial overlap of M5 and AGAP1 in neurons, we transfected 
primary rat embryonic hippocampal neurons with AGAP1-myc and M5-GFP, and 
analyzed cells by confocal microscopy.  M5-GFP was seen to localize to the 
soma, dendrites, and axons of transfected neurons (figure 4.4A).  Whereas M5-
GFP was localized mainly to the plasma membrane of neurons, treatment of cells 
with CCh led to an endosomal-vesicle-like distribution of M5-GFP (figure 4.4B).  
Detergent extraction prior to fixation revealed a punctate, vesicular-like 
distribution of AGAP1-myc in neuronal soma and processes that was otherwise 
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Figure 4.4 Co-localization of agonist-internalized M5 with AGAP1 and AP-3 
in cultured neurons (following page). (A) Neurons were transfected with 
AGAP1-myc and M5-GFP plasmids, fixed and immunostained for myc tag (red) 
and GFP (green), and imaged by confocal microscopy. Scale bar = 20 μm. 
(B and C) Neurons were transfected as in (A) and treated without (ctl) or with 
1mM carbachol (CCh) for indicated times. Cells were fixed, immunostained for 
GFP (green) and myc (red) and imaged by confocal microscopy. In (C), cytosolic 
extraction with 0.03% saponin was performed prior to fixation to visualize the 
membrane-bound pool of exogenously expressed AGAP1-myc. Yellow arrows 
indicate green / red puncta overlap. Scale is bar in top panel of (B) = 5 μm and 
applies to all images in (B) and (C). (D) Neurons were transfected with M5-GFP 
and treated without (ctl) or with 1mM CCh for 60 minutes, followed by fixation 
and immunostaining for GFP (green) and the AP-3a / AP-3b subunit δ-Adaptin 
(red) Yellow arrows indicate green / red puncta overlap. Scale is identical to (B). 
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obscured by the predominant cytosolic AGAP1 pool (figure 4.4C).  In cells fixed 
after 30 or 60 minutes of CCh treatment, we observed overlap of M5-GFP- and 
AGAP1- positive puncta in neuronal projections (figure 4.4C).  We therefore 
concluded that in neurons, agonist-internalized M5 co-localized with AGAP1, 
possibly in an endocytic vesicle compartment.
4.3.4  Agonist-internalized M5-GFP appears in AP-3-positive vesicles
In an effort to confirm the identity of vesicular compartments containing 
internalized M5 and AGAP1 as AP-3-positive endosomes, we performed CCh 
agonist treatments and immunostaining on M5-GFP- and/or AGAP1- transfected 
primary rat hippocampal neurons as described above.  Staining with a δ-Adaptin 
antibody as a marker for AP-3, we observed in neuronal processes some 
instances of overlap between agonist-internalized M5-GFP and AP-3 puncta, 
suggesting transit of M5-GFP through AP-3-positive endosomal compartments 
(figure 4.4D).  However, we were unable to confirm the identity of AGAP1-
containing puncta as AP-3 endosomes, as both AGAP1 overexpression and 
cytosol extraction appeared to interfere with the normal pattern of AP-3 
distribution, as indicated by δ-adaptin and µ3A immunostaining (data not shown).
4.3.5  Live imaging in cultured neurons reveals association of M5- and AGAP1- 
or β3B- positive vesicles
To further investigate the dynamic relationship between the population of 
M5-, AGAP1-, and AP-3- positive endosomes observed in immunofluorescent 
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staining of fixed specimens, we performed live imaging studies of GFP- or 
mCherry- tagged proteins expressed in primary cultured rat hippocampal 
neurons.   In apparent axons and dendrites of transfected neurons, near-
simultaneous two-color live imaging revealed mobile populations of M5-GFP- and 
AGAP1-mCherry- positive puncta (figure 4.5A).  In general, vesicular motility was 
observed to be highest in axon-like processes, and AGAP1-mCherry puncta 
appeared less mobile than those containing M5-GFP.  In some cases, we were 
able to observe events resembling fission of doubly-positive compartments into 
separate M5-GFP and AGAP1-mCherry compartments, and transient overlap of 
highly mobile M5-GFP and AGAP1-mCherry vesicles (figure 4.5A).  Although not 
extensively observed, the results were consistent with the co-localization of M5 
and AGAP1 in an endosome-like vesicular compartment.
We also investigated the association of M5-GFP and AP-3 vesicles using 
the neuron-specific AP-3B complex marker mCherry-AP3β3B expressed in 
primary cultured neurons.  Although mCherry-AP3β3B puncta were difficult to 
detect, we did observe instances of apparent juxtaposition of AP-3- and M5-GFP- 
positive vesicles both with and without CCh agonist treatment; in addition, 
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Figure 4.5 Live imaging of M5, AGAP1 and AP-3 β3B in cultured neurons 
(following page). Primary cultured rat hippocampal neurons were cotransfected 
with M5-GFP (green) and AGAP1-mCherry (A; red) or mCherry-AP3β3B (B and 
C; red) plasmids, treated with 1mM carbachol for 1 hour (A and C), and imaged 
by two-color spinning disk confocal microscopy at two second intervals. Images 
on right depict time-lapse series of enlarged areas from images at left. Red, 
green and yellow arrows indicate mobile GFP, mCherry, or GFP + mCherry 
puncta, respectively. Scale bars = 10μm. 
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fission-like events between these vesicles were observed (figure 4.5B,C).  In 
both of these cases, although cytosolic expression was apparent in neuronal 
projections, AP3β3B puncta were clearly visible only in soma or soma-proximal 
areas.  In addition, the appearance of M5-GFP in dynamic, tubular-like structures 
after agonist treatment in an imaged cell soma is indicative of their presence in 
tubular-vesicular recycling endosomes (Stoorvogel et al., 1996; Grant and 
Donaldson, 2009).  Although these results are consistent with the co-localization 
of M5- and AP-3- positive vesicle populations, we were unable to successfully 
image simultaneously AGAP1-mCherry and AP-3 (using GFP-AP3β3A and GFP-
AP3β3B markers) in single neurons.  Additionally, despite previous reports 
suggesting that the distribution in neurons of the ubiquitous AP-3 isoform was 
restricted to soma (Seong et al., 2005), we observed in neurons expressing both 
GFP-AP3β3A and mCherry-AP3β3B somatic, dendritic and axonal localization of 
these ubiquitous and neuron-specific AP-3 isoform markers, respectively (figure 
4.6C). 
4.3.6  Agonist-internalized M5-GFP traffics through characterized endocytic 
compartments
We next performed co-immunostainings of primary cultured neurons 
expressing M5-GFP to investigate the endocytic compartments encountered by 
agonist-internalized receptor.  After 60 minutes of CCh treatment, numerous 
puncta co-labeled for M5-GFP and transferrin receptor (TfrR) are apparent (figure 
4.6A).  TfrR is a constitutively recycled receptor with distribution in neurons 
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restricted to the somatodendritic compartment (West et al., 1997a); thus, 
internalized M5-GFP is trafficked at least partially through this recycling pathway.  
We also observed in CCh-treated neurons some instances of co-localization of 
M5-GFP with the early endosome marker rab5 in dendrite-like compartments, but 
little overlap between M5-GFP and the late endosome marker rab7 (figure 4.6A).  
Thus, our data suggested that endocytosed M5 may traffic mainly through the 
recycling pathway. 
4.3.7  AP-3 endosomes are perisynaptically localized in axons
 Our previous data demonstrated overlap of M5-GFP and AGAP1 puncta 
in axon-like neuronal processes, although the AP-3 content of these puncta was 
not determined (figure 4.4B).  The neuron-specific isoform of AP-3 as been 
shown to function in the biogenesis of synaptic vesicles from endosomes and in 
the targeting of synaptic vesicle proteins such as the vesicular zinc (ZnT3) and 
GABA (VGAT) transporters (Faundez et al., 1998; Blumstein et al., 2001; 
Nakatsu et al., 2004; Salazar et al., 2004b).  In addition, the neuronal AP-3 
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Figure 4.6 Distribution of M5 and endocytic markers in cultured rat 
hippocampal neurons (following page). (A) Neurons were transfected with 
M5-GFP plasmid, treated with 1mM carbachol for 30 (Transferrin receptor, TfrR) 
or 60 (Rab5, Rab7) minutes, fixed, co-immunostained for GFP (green) and with 
antibodies as indicated (red) and imaged by confocal microscopy. Scale bars, 
20μm (top) and 5μm (bottom). (B) Neurons were fixed and co-immunostained for 
Synapsin I (red) and δ -Adaptin (green) and imaged by confocal microscopy. 
Scale is identical to (A). (C) Primary cultured rat hippocampal neurons were co-
transfected with mCherry-AP3β3B (red) and GFP-AP3β3A (green) plasmids and 
imaged by two-color spinning disk confocal microscopy. Scale bar, 10μm. 
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subunit β3B (β-NAP) was shown to associate with nerve terminal vesicles 
(Newman et al., 1995).  To investigate the distribution of AP-3 endosomes in 
axons, we performed co-immunostaining of long-term cultures of primary rat 
hippocampal neurons containing mature synapses.  We observed numerous 
instances of AP-3-positive puncta juxtaposed, but not superimposed, with 
synapsin I-positive varicosities of thin, aspiny projections, consistent with a 
perisynaptic distribution of AP-3 endosomes in axons (figure 4.6B).  As AP3β3A/
B antibodies appropriate for immunostaining were not available, however, we 
were unable to determine whether the observed AP-3 endosomes were of the 
ubiquitous or neuron-specific subtype.
4.3.8  Subcellular fractionation analysis of AGAP1 and AP-3 content of rat brain 
membranes
In order to take advantage of the wider array of antibodies available for 
immunoblotting of native AGAP1 and AP-3 proteins, we performed a biochemical 
separation of rat brain membranes by iodixanol step gradient centrifugation (Lee 
et al., 2003).  Immunoblot analysis of separated membrane fractions revealed a 
distribution of AGAP1, the ubiquitous AP-3 isoform marker µ3A, and the neuron-
specific AP-3 marker β3B roughly similar to that of the early, late and recycling 
endosome markers Rab5, Rab7, and Rab11 (figure 4.7).  The fractional 
distribution of the TGN-associated, AP-1 adaptor subunit γ-adaptin and the 
integral plasma membrane protein Na+,K+ ATPase β2 were distinct (figure 4.7).  
We noted 1) that the pattern of AGAP1 membrane association resembled that of 
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AP3β3B most closely, 2) AP3µ3A exhibited a considerable distribution in low-
density membrane fractions, and 3) AP-3β3B, rab7 and γ-adaptin shared peak 
immunoreactivity at fraction 24 (figure 4.7).  Thus, the fractionation data confirm 
that AGAP1 is associated with AP-3 like endosomal membranes, and suggest 
that neuron-specific AP-3 endosomes may differ physically from that of 
ubiquitous AP-3 endosomes, perhaps resembling late endosomal or TGN-like 
compartments.
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Figure 4.7  Subcellular fractionation analysis of AGAP1 and AP-3 content of 
rat brain membranes.   Total rat brain membranes were separated by iodixanol 
density gradient centrifugation as described.  Membrane fractions were analyzed 
for protein content by immunoblot as indicated. 
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4.3.9  Agonist-internalized M2-GFP associates with SNX20-positive vesicles
Finally, we investigated the subcellular distribution of muscarinic receptor 
M2 and its putative interactor SNX20.  Expression of SNX20 in COS-7 cells 
revealed a predominant distribution in vesicle-like structures, with some cytosolic, 
perinuclear, and nuclear staining variously present, consistent with reports 
published subsequent to the performance of these experiments (figure 4.8) 
(Schaff et al., 2008).  While M2 receptors C-terminally tagged with GFP exhibited 
plasma membrane localization in untreated cells, agonist stimulation with CCh 
induced internalization and redistribution to endosome-like compartments (figure 
4.8).  Extensive co-localization of M2-GFP- and SNX20- positive vesicles was 
apparent after 15 and 60 minutes of agonist treatment (figure 4.8).  Thus, 
although our biochemical data was inconclusive with regard to the physical 
interaction of M2i3 and SNX20, the current results strongly suggest that agonist-
induced internalization of M2 leads to trafficking through an SNX20-positive 
endosomal compartment.
4.4  Discussion
 Our data provide qualitative evidence for the co-localization of agonist-
internalized M5 muscarinic receptors with AGAP1 in an endosomal compartment. 
The demonstration of such co-localization was a primary goal of this chapterʼs 
experiments, and suggests that AGAP1 and M5 are temporally and spatially 
juxtaposed in a manner consistent with, or conducive to, their physical 
interaction.   Although we were unable to study the distribution of natively 
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Figure 4.8  Co-localization of agonist-internalized M2 with SNX20 in 
COS-7 cells.  COS-7 cells were transiently co-transfected with M2-GFP and 
SNX20-myc constructs, treated with 100µM carbachol for 0 (top) 15 (middle) or 
60 (bottom) minutes, fixed, immunostained for GFP (green) and myc tag (red) 
and imaged by confocal microscopy.  Scale bar = 20 µm.  
expressed M5 receptors, the use of epitope-tagged GPCRs in exogenous 
expression systems has been widely used to study the constitutive and activity-
dependent trafficking of a number of receptors (Cao et al., 1999; Oksche et al., 
2000; Hanyaloglu and von Zastrow, 2008).  In light of our biochemical data 
demonstrating a specific, but likely low-affinity interaction between M5 and 
AGAP1, our observation of a partially-overlapping pool of AGAP1- and agonist-
internalized M5- positive vesicles, including apparent instances of fusion, fission, 
and budding-like events in AGAP1-mCherry and/or M5-GFP vesicles in live 
neurons, suggests that AGAP1 may play a functional role in the trafficking of M5.  
Importantly, 1) this vesicular overlap was observed only in neurons, and 2) 
associative evidence supports the identification of AGAP1 vesicles as AP-3 
endosomes.  As the function of neuronal AP3B is distinct from that of AP3 in non-
neuronal tissues (Newell-Litwa et al., 2007), our results suggest that an AGAP1/
AP-3B complex may mediate the activity-induced trafficking of M5 by binding to 
recognition sequences in the M5 i3 loop.  Interestingly, we also observed 
apparent interaction of M5-GFP- and mCherry-AP3β3B in unstimulated neurons, 
perhaps due to the presence of constitutive receptor endocytosis.  To our 
knowledge, interaction-mediated trafficking of a membrane protein by AGAP1 
has not been described; however, the AZAP family Arf GAP ACAP1 was shown 
to direct the endocytic recycling of TfrR and integrin β1 by binding to sorting 
signals present in their cytoplasmic regions (Dai et al., 2004; Li et al., 2005), and 
interaction with AP-3 was shown to direct the intracellular localization of the 
cannabinoid CB1 receptor in neurons (Rozenfeld and Devi, 2008) and is known 
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to mediate the sorting of lysosome-targeted proteins such as LAMP1 and CD63 
(Dell'Angelica et al., 1999; Peden et al., 2004).  In addition, we observed in tissue 
culture cells a clear co-localization of agonist-internalized M2-GFP with SNX20 in 
vesicle-like structures; in light of the inconclusive SNX20-M2 biochemical data, 
however, we continued to focus our experimental efforts on the study of the M5-
AGAP interaction.
Although M5 co-localization with AGAP1 and AP-3 was apparent in 
neurons, we were unable to extend these findings to the determination of the 
functional ramifications of AGAP1 / M5 interaction.  Our efforts were 
compromised by a number of technical limitations inherent to the experimental 
system we employed.  First, AGAP1 overexpression was seen to adversely effect 
cell morphology and viability in both tissue culture and primary neuronal cells, 
likely as a result of its effect on the critical secretory pathway regulator Arf1 and 
by its previously reported actin cytoskeleton-modulating function (Nie et al., 2002; 
D'Souza-Schorey and Chavrier, 2006).  Additionally, we did not observe 
restriction of the AP-3A complex (visualized with β3A fluorescent fusion proteins) 
to the soma of cultured neurons, as has been previously described (Seong et al., 
2005); overexpression may have played a role in this distribution pattern.  
Second, visualization of membrane-associated exogenous AGAP1 or AP3β3 in 
the presence of M5 required either cytosol extraction in fixed cells, or the use of 
mCherry fusions in live cells.  Cytosol extraction left only a minority of neurons 
morphologically intact, and the mCherry tag provided a low contrast signal, and 
though reportedly monomeric, was seen to induce immobile aggregates when 
118
fused to the proteins investigated in this study (the vesicular association of both 
AP3β3A and B were more readily visualized with GFP fusion tags; however, M5-
mCherry aggregated to an unacceptable degree).  Third, as the localization and 
trafficking characteristics of native M5 have not been described, it was 
impossible to determine whether the C-terminal GFP tag interfered with the 
normal trafficking of the receptor.  It should be noted, however, that M5-GFP was 
clearly plasma-membrane localized and underwent agonist-induced 
internalization, and that the GFP tag was seen to offer superior performance to 
that of a number of extracellular and intracellular epitope tagging strategies 
attempted on M5.  Although we attempted to investigate the effect of AGAP1 
interaction on localization and/or activity-induced trafficking of M5 through the 
use of the AGAP1 interaction (∆369-386) deletion mutant, no gross differences 
were apparent, and due to the selective nature of neurons imaged, quantitative 
analysis was not successful.  We thus elected to pursue a biochemical approach 
to the study of AGAP1/AP-3 - dependent M5 function and activity-induced 
trafficking, as described in the following chapter.     
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5 REGULATION OF M5 ENDOCYTIC RECYCLING BY AGAP1
5.1  Summary
We studied the effect of AGAP1 interaction loss-of-function on the steady-
state and activity-induced trafficking of the M5 muscarinic receptor.  In tissue 
culture cells, the total protein level and cell surface expression of the AGAP1 
domain-of-interaction mutant M5∆ was higher than that of wild-type receptor.  
AGAP1 knockdown decreased surface expression of both M5wt and M5∆.  Both 
mutant and wild-type M5 receptors underwent agonist-induced internalization 
and subsequent endocytic recycling to the plasma membrane after washout, the 
magnitude of which was similar between M5wt and M5∆.  In primary cultured 
neurons, however, the M5∆ receptor displayed a significant endocytic recycling 
deficit as compared to wild-type.  Knockdown of AGAP1 or the neuron-specific 
AP-3 subunit β3B reduced the extent of M5wt recycling, as did treatment with the 
AP-3 inhibitor brefeldin-A.  In addition, chronic agonist treatment in cultured 
neurons significantly increased down-regulation of cell surface M5∆ compared to 
wild-type.  The results demonstrate a novel, neuron-specific function of AGAP1 / 
AP-3 in the mechanism of M5 receptor endocytic recycling.  This function 
suggests that in vivo, AGAP1 interaction is required for sustained M5 signaling in 
neurons.    
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5.2  Introduction
Cell-surface receptor density and localization is a key determinant of 
GPCR signaling sensitivity.  As described in chapter 1, trafficking of GPCRs to 
and from the plasma membrane by functionally and spatially defined classes of 
subcellular membrane vesicles or endosomes regulates the surface expression 
of receptors in both a constitutive and activity-dependent manner.  The Rab and 
Arf families of small GTPases regulate the trafficking of transmembrane proteins 
by recruitment of effector proteins in their GTP-bound “on” state, serving to 
regulate the formation, motion, fission, fusion, and functional identity of 
subcellular membrane vesicles (D'Souza-Schorey and Chavrier, 2006; Stenmark, 
2009).  The heterotetrameric adaptor protein complexes are a class of Arf 
effectors that mediate transmembrane protein traffic by binding to both signal 
sequences in cargo proteins and to membrane coat proteins (Nakatsu and Ohno, 
2003).  In the current report, we have described a physical interaction between 
the Arf GAP AGAP1 and the i3 intracellular loop of the M5 muscarinic receptor.  
As AGAP1 binds to the adaptor protein complex AP-3 (Nie et al., 2003) and was 
observed to interact with M5 as part of an AGAP1-containing complex, we 
hypothesized that in vivo, AGAP1 functions as an adaptor complex scaffold 
protein by binding to recognition sequences in the M5 i3 loop and targeting the 
receptor for AP-3-dependent trafficking. 
Much of the initial knowledge of AP-3ʼs cellular function has resulted from 
study of spontaneously occurring mutants in flies, humans, and mice.  The 
Drosophila melanogaster eye color mutant garnet exhibits a reduced number of 
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pigment granules in the eye and other tissues as a result of a near-null mutation 
in the δ-adaptin coding Ap3d1 gene (Ooi et al., 1997).  Similarly, the mouse coat 
color mutants mocha and pearl were found to result from null mutations in the 
Ap3d1 and Ap3b1 (coding for the ubiquitously expressed AP3 β3A subunit) 
genes, respectively (Kantheti et al., 1998; Feng et al., 1999).  Both pearl and 
mocha are categorized as platelet storage pool deficiency phenotypes, 
characterized by hypopigmentation, lysosome abnormalities, and deficient 
storage ability of platelet dense granules leading to prolonged bleeding (Lane 
and Deol, 1974; Novak et al., 1984; Kantheti et al., 1998; Feng et al., 1999).  In 
humans, the Hermansky-Pudlak syndrome (HPS) is a collection of related 
autosomal recessive platelet storage pool deficiency disorders (Wei, 2006).  Of 
the 8 genetically unique forms of HPS yet described, one (HPS-2) is caused by a 
near-null mutation in the Ap3b1 gene, while another (HPS-7) is due to a mutation 
in DTNBP1, encoding dysbindin, a member of the AP-3 associated BLOC-1 
complex (Dell'Angelica et al., 1999; Li et al., 2003).
The ubiquitously expressed AP-3A isoform functions mainly to traffic 
membrane proteins to lysosomes and lysosome-like organelles (figure 5.1).  In 
fibroblasts derived from HPS-2 patients (in which function of the ubiquitous AP-3 
complex is disrupted), the lysosomal membrane proteins Lamp-1, Lamp-2 and 
CD63 were seen to mis-localize to the plasma membrane (Dell'Angelica et al., 
1999).  Similarly, intact AP-3 function in yeast was shown to be required for 
vacuole localization of membrane proteins containing a lysosome targeting 
sequence (Vowels and Payne, 1998).  An AP-3-dependent trafficking mechanism 
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Figure 5.1  AP-3-dependent trafficking pathways.  Inset, GTP-bound Arf1 
recruits AP-3 to membranes.  Subsequent binding of AGAP1 catalyzes hydrolysis 
of GTP to GDP, resulting in dissociation of AP-3 (and AGAP1) and release of 
integral membrane cargo proteins.  Top, endocytosed membrane proteins are 
delivered to early / sorting endosomes and are trafficked to specific cellular 
compartments by recognition of sorting motifs by AP-3.  The ubiquitously 
expressed AP-3A isoform targets membrane proteins such as Tyrosinase or 
LAMP-1 to melanosomes or the lysosome limiting membrane, respectively.  The 
neuron-specific isoform AP-3B is responsible for both biogenesis of endosomally-
derived synaptic vesicles (SVs) and for delivery of proteins such as ZnT3 to 
these SVs.
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has also been demonstrated for cannabinoid CB1 receptor localization to late 
endosome-like compartments (Rozenfeld and Devi, 2008), delivery of Notch to 
the limiting (outer) lysosomal membrane in Drosophila (Wilkin et al., 2008), and 
the targeting of tyrosinase to melanosomes (Huizing et al., 2001).  AP-3- 
dependent targeting to lysosomes or lysosome-like organelles is mediated by 
recognition of dileucine-like or tyrosine-based sorting signals present on 
cytoplasmic regions of cargo proteins (Ohno et al., 1998; Vowels and Payne, 
1998; Bonifacino and Traub, 2003; Janvier et al., 2003).  An immuno-EM study 
identified AP-3 localized to membrane buds emanating from early endosome-
associated, recycling compartment-like tubular structures; no AP-3 
immunoreactivity was detected in the TGN, however (Peden et al., 2004).  The 
lysosomal membrane protein Lamp-1, apparently in transit from the plasma 
membrane, was seen to co-localize with AP-3 at these budding structures 
(Peden et al., 2004).  Additionally, although some AP-3 trafficking events appear 
to proceed via non-clathrin coated vesicles, AP-3 is able to bind clathrin in vitro 
and is seen to partially co-localize to clathrin-positive vesicular structures 
(Dell'Angelica et al., 1998; Vowels and Payne, 1998; Peden et al., 2004).  Thus, 
the current model of AP-3-dependent sorting suggests that targeted proteins first 
undergo delivery to the plasma membrane, followed by endocytosis and 
trafficking from the early endosome to a recycling endosome-like structure, after 
which target proteins are sorted to and sequestered in distinct clathrin or non-
clathrin coated vesicles by AP-3 (in concert with the associated trafficking 
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complex BLOC-1), followed finally by delivery to lysosomal or lysosome-like 
organelle membranes.
The neuron-specific AP-3B isoform, consisting of the ubiquitously 
expressed δ and σ3 subunits and neuron-specific µ3B and β3B, is functionally 
distinct from the ubiquitous AP-3A complex (figure 5.1).  In vitro studies 
demonstrated that AP-3B, but not AP-3A, is able to mediate the formation of 
synaptic vesicles from endosomes (Faundez et al., 1998; Blumstein et al., 2001).  
In Ap3b2-/-, Ap3m2-/- or Ap3d1-/- (mocha) mutant mice, the zinc transporter ZnT3 
and the vesicular GABA transporter VGAT are absent from a subpopulation of 
synaptic vesicles, resulting in impaired GABA release and reduced zinc content 
in the hippocampus and cortex (Kantheti et al., 1998; Nakatsu et al., 2004; 
Salazar et al., 2004b).  In addition, the chloride channel ClC-3, the vesicular 
glutamate channel Vglut1, TI-VAMP and phosphatidylinositol-4-kinase type IIα 
were seen to be absent from a subpopulation of synaptic vesicles in cells derived 
from mocha mice or after disruption of AP-3 targeting with by the Arf GEF 
inhibitor brefeldin-A (Martinez-Arca et al., 2003; Salazar et al., 2004a; Salazar et 
al., 2005a; Salazar et al., 2005b; Scheuber et al., 2006).  Ap3b2-/-, Ap3m2-/- and 
mocha mice are hyperactive and epileptic (Newell-Litwa et al., 2007).  Mocha 
mice display deficient spontaneous and evoked glutamate release in 
hippocampal synapses (Scheuber et al., 2006) and decreased synaptic vesicle 
recycling rates under high-frequency stimulation conditions (Voglmaier et al., 
2006); in addition, GABAergic neurotransmission was seen to be disrupted in 
Ap3m2-/- mice (Nakatsu et al., 2004).  It should be noted, however, that the 
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phenotypic penetrance of the Ap3b2-/- and Ap3m2-/- mutations does not reach 
that of mocha (Ap3d1-/-), suggesting a neuron-specific functional role for the 
ubiquitous AP-3A complex (Newell-Litwa et al., 2007). Additionally, the assembly 
of neuron-specific and ubiquitous β3 and µ3 subunits into AP-3A and AP-3B 
heterotetramers may not be exclusive (Peden et al., 2002).
AP-3 is targeted to membranes via recruitment by GTP-bound Arf1 
(Lefrancois et al., 2004).  The proper function of AP-3 in the transport of cargo 
proteins requires its coating and uncoating of membrane vesicles in a regulated 
manner.  The Arf1 GAP AGAP1 plays a key role in this process, as release of the 
AP-3 coat requires hydrolysis of GTP to GDP by Arf1, and the intrinsically low 
GTPase activity of Arf1 necessitates stimulation by GAPs (Nie et al., 2002; Nie 
and Randazzo, 2006).  AGAP1 binds directly to the AP-3 complex via its PH 
domain, spatially coordinating Arf1 GAP activity with the AP-3 coat (Nie et al., 
2003).  Up- or down- regulation of AGAP1 levels interferes with the targeting of 
AP-3 to vesicles and with the trafficking of the lysosomal cargo protein Lamp-1 
(Nie et al., 2003).  In addition, the PH domain of AGAP1 confers upon it 
membrane lipid-binding activity and phospholipid-dependent GAP activity, and 
AGAP1 / AP-3 binding was seen to be specific with regard to related adaptor 
protein complexes (Nie et al., 2002; Nie et al., 2005).  Although AGAP1 thus 
plays an indirect role in the AP-3-dependent trafficking of target proteins, an 
intrinsic cargo recognition or AP-3-independent trafficking function of AGAP1 has 
not been described.  However, the related AZAP protein ACAP1 was 
demonstrated to bind to recognition sequences in the cytoplasmic tails of the 
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transferrin receptor and integrin β1, and to be required for their endocytic 
recycling to the plasma membrane (Dai et al., 2004; Li et al., 2005). In addition, 
the AGAP1-related protein centaurin α1 was shown to inhibit the agonist-induced 
internalization of the β2 adrenergic receptor (Lawrence et al., 2005).
Although the steady state and activity-induced trafficking characteristics of 
muscarinic receptors 1 through 4 have been described, the trafficking pattern of 
the M5 receptor is unknown.  In this chapter, we describe experiments 
investigating the basal and agonist-induced trafficking of M5 in exogenous 
cellular expression systems.  We employed both the AGAP1 region-of-interaction 
deletion mutant  M5(∆369-386) (M5∆) and RNAi-mediated knockdown of 
endogenous AGAP1 to study the effects of AGAP1 interaction loss-of-function on 
the trafficking of M5.  Knockdown of ubiquitous and brain-specific AP-3 subunits 
was used to investigate the hypothesized involvement of this trafficking pathway 
on M5 regulation.  We took advantage of the availability of a hydrophilic, cell-
impermeant muscarinic antagonist radioligand [3H]-N-methyl-scopolamine to 
quantitatively monitor cell surface M5 receptor density in intact, living cells 
(Toews, 2000).  This approach allowed for the measurement of M5 surface 
density under basal conditions, and allowed us to indirectly monitor the rate of 
internalization and endocytic recycling of M5 receptors after agonist stimulation.    
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5.3  Results
5.3.1  Transfected M5(∆369-386) is expressed at higher levels than M5wt in 
tissue culture cells
We first examined the effect of the AGAP1 domain-of-interaction (DOI) i3 
loop deletion on the expression of M5 in mammalian tissue culture cells.  
HEK-293T or CHO cells were transiently transfected with equal quantities of 
M5wt-GFP and M5∆-GFP coding plasmids, and then assayed for total M5 protein 
content by GFP immunoblot 48 hours later.  We observed, on average, a nearly 
2.5-fold greater amount of M5∆-GFP than M5wt-GFP protein present in cell 
lysates, a pattern also present with M5 receptors extracellularly-tagged with the 
HA epitope, and in cell lines stably expressing wild-type and ∆369-386 M5 (figure 
5.2A; data not shown).  Next, to determine whether the mutant M5 receptor also 
exhibited an increased abundance at the cell surface compared to wild-type, we 
performed radioligand binding experiments on intact, transiently transfected 
HEK-293T cells using the cell-impermeant tritiated muscarinic antagonist [3H]-N-
methyl-scopolamine ([3H]NMS) to quantitatively label extracellular M5 ligand 
binding sites (we previously detected negligible specific [3H]NMS binding to the 
cell lines used in these experiments).  We observed a significantly higher surface 
expression of the non-GFP-tagged AGAP1 DOI mutant M5∆ compared to M5wt 
(figure 5.2B).  
The increased total and surface levels of deletion-mutant receptor protein 
suggested that AGAP1 interaction may function to decrease expression of M5 in 
our system.  To test this, we performed siRNA-mediated knockdown concurrent 
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Figure 5.2  Expression of wild-type and ∆369-386 M5 receptors in HEK-293T 
cells.  (A) HEK-293T cells were transiently transfected with GFP-tagged wild-
type or domain-of-interaction deletion mutant constructs, and lysates were 
analyzed by quantitative immunoblot for GFP with data normalized to M5wt-GFP. 
(B)  HEK-293T cells were transiently transfected with M5wt or M5∆ constructs, 
and cell surface muscarinic receptor density was assayed by  [3H]NMS 
radioligand binding.  (C)  HEK-293T cells were transiently  transfected with siRNA 
targeting AGAP1 or with non-targeting control, and 24 hours later transfected 
with M5wt-GFP or M5∆-GFP constructs.  Left, surface receptors density was 
assayed as in (B).  Right, representative immunoblot displaying AGAP1 
knockdown.  Lower panels, Actin loading controls.  (*): P< 0.05, paired two-tailed 
Studentʼs ratio T-test.
to exogenous expression of M5wt- or M5∆- GFP, and assayed for surface MR 
sites by [3H]NMS binding in HEK-239T cells.  We predicted that, due to the 
inability of the DOI mutant receptor to physically interact with AGAP1, knockdown 
of AGAP1 would increase surface expression of M5wt but not effect M5∆ levels.  
As with rat brain tissue, the AGAP1 antibody detected a multiplet band by 
immunoblot in lysate from the human HEK-293T cell line; siRNA targeting 
hAGAP1 was able to knock down AGAP1 expression with moderate efficacy 
compared to transfection of a non-targeting siRNA duplex (figure 5.2C).  
However, AGAP1 knockdown decreased cell-surface binding of [3H]NMS in both 
M5wt-GFP and M5∆-GFP transfected cells (figure 5.2C).  We also observed a 
decrease in M5wt-, M5∆, and M3-GFP total protein levels after AGAP1 
knockdown (data not shown).  This result argued against an AGAP1-related 
mechanism for the increased expression of M5∆ compared to wild-type receptor 
in this system.
5.3.2  M5wt and M5∆ exhibit similar patterns of activity-induced trafficking in 
HEK-293T cells
We asked whether deletion of the AGAP1 ROI in M5 could affect activity-
induced trafficking of the receptor.  We expressed wild-type and ∆369-386 M5 
receptors exogenously in HEK-293T or CHO cells, treated cells with the 
cholinergic agonist carbachol (CCh) for various times in the presence of the 
translation inhibitor cycloheximide (to eliminate interference from the appearance 
of newly-synthesized M5 protein) and assayed intact cells for surface M5 
130
131
30min CCh 60min washout
60
70
80
90
100
M5wt
M5!
* *
A
B
0 10 20 30 40 50 60 70
0
1000
2000
3000
4000
5000
6000
7000
M5wt
M5!
minutes
Figure 5.3  Activity-induced trafficking of M5 receptors in HEK-293T cells. 
HEK-293T cells were transiently  transfected with M5wt or M5∆ contructs, and cell 
surface M5 receptors were assayed by [3H]NMS radioligand binding as 
described.  (A)  Time course of M5 receptor internalization after treatment with 
0.1mM carbachol (CCh) for indicated periods.  (B) Receptor recycling assay. M5-
expressing cells were left untreated, or treated with 0.1mM CCh for 30 minutes 
with or without a subsequent 60 minute washout period.  Cell surface M5 
receptors were assayed as in (A), with data expressed as a percent of untreated 
control values. (*): P< 0.05, two-way ANOVA (treatment).
receptor binding sites by [3H]NMS radioligand binding.  In these experiments, we 
observed a time-dependent reduction of cell-surface [3H]NMS binding after CCh 
incubation for both M5wt and M5∆, confirming the agonist-induced internalization 
of these receptors (figure 5.4A).  However, the temporal characteristics and 
magnitude of CCh-induced internalization did not differ between M5wt and M5∆ 
(figure 5.3A,B).  Next, we examined endocytic recycling of agonist-internalized 
M5 expressed in HEK-293T cells using an experimental system similar to the one 
described above.  Cycloheximide-pretreated cells were left untreated, treated 
with 100µM CCh for 30 minutes to induce M5 internalization, or CCh-treated 
followed by a 1-hour washout period to allow for endocytic recycling of 
internalized receptors.  An increase of cell surface [3H]NMS binding sites after 
washout was taken as a quantitative measure of M5 recycling.  Wild-type and 
deletion-mutant M5 receptors did not differ in the degree to which they were 
recycled to the cell surface after agonist-induced internalization (figure 5.3B).  
We therefore concluded that the AGAP1 ROI deletion, and presumably 
interaction with AGAP1, did not play a role in the activity-dependent trafficking of 
M5 in HEK-293T and CHO cells.
5.3.3  Development of a primary cultured neuron system for the study of 
exogenous M5 receptor trafficking
Our previous data suggested that the function of M5/AGAP1 interaction 
may be neuron-specific, as we observed activity-induced co-localization of M5-
GFP-positive and AGAP1-positive vesicles in neurons only, and since the M5 i3 
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Figure 5.4  Primary cultured neuron radioligand binding assay 
development.  (A)  Rat embryonic cortico-hippocampal neurons were 
nucleofected with M5wt, M5∆, or empty vector control plasmids (ctl) and cultured 
for 12 days.  Radioligand binding was performed in the presence of various 
concentrations of AF-DX 384, and IC50 values for displacement of [3H]NMS 
binding were calculated by non-linear curve fitting to a one-site competition 
binding model (GraphPad Prism).  (B)  Representative immunoblots of AGAP1, 
AP3β3B and δ -Adaptin knockdown by target-specific shRNA constructs in 
nucleofected primary neuron cultures.  Lower panels, Actin loading controls. 
loop physically interacted with the neuron-specific AP3B complex, whose role in 
membrane protein trafficking is distinct from that of the ubiquitously expressed 
AP-3A complex (Danglot and Galli, 2007).  We wished to study the trafficking of 
exogenously expressed M5 receptors in cultured neurons, as endogenous M5 
sites are both low in abundance and pharmacologically indistinguishable from 
non-M5 MRs with currently available tools (Wess et al., 2007).  We were able to 
achieve exogenous expression of wild-type and mutant M5 receptors in primary 
cultured cortico-hippocampal cultures using the nucleofection technique to 
introduce expression plasmids (Gartner et al., 2006).  However, the detection of 
exogenous M5 by [3H]NMS radioligand binding was complicated by the presence 
of a considerable amount of endogenous muscarinic receptor binding sites; 
based on radioligand binding studies of MR knockout mouse cortex and 
hippocampus, these receptors are predominantly M1/M2 subtypes, with little to 
no endogenous M5 present (Oki et al., 2005).  With the aim of improving the M5-
to-non-M5 “signal-to-noise” ratio of our cell surface radioligand binding assay, we 
identified an antagonist, AF-DX 384, displaying 10-fold less binding affinity for the 
M5 receptor than endogenous, non-M5 sites present in nucleofected primary 
neurons, in accordance with previous pharmacological reports (figure 5.4A) 
(Dorje et al., 1991).  Importantly, the binding affinity (measured by the 
concentration-dependent ability to displace [3H]NMS binding) of AF-DX 384 for 
M5wt and M5∆ was identical (figure 5.4A).  Therefore, by preferentially displacing 
[3H]NMS binding to non-M5 sites, the inclusion of an appropriate concentration 
(5 µM) of AF-DX in the radioligand binding assay allowed for an M5-to-non-M5 
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signal sufficient to allow quantitative analysis of cell surface M5 site densities 
(figure 5.4A).  
Next, we investigated the feasibility of performing RNAi-mediated 
knockdown experiments in primary cultured neurons.  Though nucleofection of 
primary hippocampal neurons can, under ideal conditions, yield up to 70% of 
cells positive for transgene expression (Gartner et al., 2006), near-pure 
populations of nucleofected cells are most appropriate for gene knockdown 
experiments to be analyzed biochemically.  Immunosorbent strategies for the 
enrichment of nucleofection-positive cells from a mixed population have been 
described (Tahvanainen et al., 2006).  We observed previously that puromycin 
selection of primary neurons nucleofected with a plasmid encoding the 
puromycin resistance gene was able to effectively enrich for a transgene-
expressing population of neurons (data not shown).  We designed a series of 
puromycin-selectable short hairpin RNA (shRNA)-encoding plasmids targeting rat 
AGAP1, AP3β3B, and δ-adaptin sequences and tested them for knockdown 
efficiency in mature (12-14 DIV) rat cortico-hippocampal cultures after 
nucleofection and puromycin selection.  With at least one shRNA per gene, we 
were able to effectively knock down endogenous protein levels, with nearly 100% 
efficiency observed for AP3β3B and δ-adaptin compared to a non-targeting 
control shRNA (figure 5.4B).
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5.3.4  Increased expression of M5∆ in primary neurons is not mediated by 
AGAP1 or AP-3
 Using the M5-specific radioligand assay and shRNA knockdown method 
described in the preceding section, we first investigated the effect of AGAP1/
AP-3 disruption on the steady-state surface expression of M5.  As in tissue 
culture cells, nucleofection of equal quantities of M5wt- or M5∆- coding 
expression plasmids resulted in a near two-fold greater surface expression of the 
AGAP1 DOI mutant as measured by cell-surface [3H]NMS radioligand binding 
(2-way ANOVA p<.01) (figure 5.5A,B,C).  However, knockdown of either AGAP1 
or the neuron-specific AP-3B subunit β3B had no effect on the surface 
expression of either the wild-type or deletion mutant receptor (figure 5.5A,B).  
Knockdown of ubiquitously expressed δ-adaptin, a component of both the AP-3A 
and AP-3B complexes, was seen to decrease M5 surface expression; however, 
M5wt and M5∆ receptors were affected to a similar extent (figure 5.5C).  Thus, 
our data did not support a role for AGAP1 / AP-3 interaction in the steady-state 
surface expression of M5 in cultured neurons.
5.3.5  M5wt, but not M5∆, undergoes efficient endocytic recycling in cultured 
neurons
We next investigated whether disruption of the AGAP1 binding site on the 
M5 i3 loop affected the activity-induced trafficking of the receptor in neurons.  
M5wt and ∆ receptors were expressed exogenously in primary cortico-
hippocampal neurons, subjected to agonist-induced internalization, recycling, or 
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Figure 5.5  AGAP1- and AP-3-dependent surface expression of wild-type 
and ∆ 369-386 M5 receptors in primary cultured neurons.  Rat embryonic 
cortico-hippocampal neurons were co-nucleofected with M5wt, M5∆, or empty 
vector control plasmids and targeting or non-targeting control shRNA plasmids 
and cultured for 13 days.  Cell surface muscarinic receptors were assayed by 
[3H]NMS radioligand binding and M5-specific signal was calculated as described. 
Knockdown of AGAP1, AP3β3B and δ-Adaptin proteins was verified by 
immunoblot. (**): P< 0.01, two-way ANOVA (receptor).
control conditions as described in section 5.3.2, and assayed for surface 
[3H]NMS sites as described above.  We observed that the M5∆ receptor was 
deficient in its ability to recycle to the cell surface after a 60 minute washout of 
agonist treatment as compared to M5wt (figure 5.6A).  To control for the 
possibility that this recycling deficiency was related to the overall higher level of 
M5∆ present, we repeated the experiment under slightly altered nucleofection / 
culture conditions, in which we observed no difference in the steady-state surface 
expression of M5wt and M5∆ (figure 5.6B, inset).  Although overall M5 endocytic 
recycling levels were slightly lower, the M5∆ recycling deficiency phenotype was 
maintained (figure 5.6B).
5.3.6  Knockdown of AGAP1 or AP3β2 in neurons inhibits endocytic recycling of 
wild-type M5 receptors
To confirm that the observed deficit in the ability of M5∆ to undergo 
endocytic recycling after activity-induced internalization was due to an AGAP1-
dependent mechanism, we repeated the experiment described in section 5.3.5 
after shRNA-mediated knockdown of endogenous AGAP1 protein (figure 5.4B).  
Although AGAP1 protein was not completely eliminated, we observed a 
significant decrease in the extent of recycling of M5wt in primary cultured 
neurons co-nucleofected with AGAP1 shRNA plasmid (figure 5.7A).  Importantly, 
there was no significant difference in the degree to which the M5∆ receptor 
recycled after AGAP1 knockdown, as would be predicted for the interaction loss-
of-function mutant with a mechanism of trafficking requiring recognition of i3 loop 
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Figure 5.6  Deficient endocytic recycling of M5∆ receptors expressed in 
cultured neurons. (A)  Rat embryonic cortico-hippocampal neurons were 
nucleofected with M5wt, M5∆, or empty  vector control plasmids and cultured for 
13 days.  Cells were left untreated, or treated with 0.1mM CCh for 30 minutes 
with or without a subsequent 60 minute washout period.  Cell surface muscarinic 
receptors were assayed by [3H]NMS radioligand binding and M5-specific signal 
was calculated as described.  Data are expressed as a percent of untreated 
control values.  (*/**): P< 0.05/ P< 0.01, Bonferroni post-test / two-way ANOVA. 
(B)  Experiment in (A) performed with equalized M5wt and M5∆ steady-state 
surface receptor levels (inset).  Data are expressed as a percent of CCh-
internalized receptors recycled after 1 hour washout.  (*): P< 0.05, paired two-
tailed Studentʼs T-test.
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Figure 5.7  Knockdown of AGAP1 or AP3β3B inhibits endocytic recycling of 
M5 receptors in cultured neurons.  Rat embryonic cortico-hippocampal 
neurons were co-nucleofected with M5wt, M5∆, or empty vector control plasmids 
and targeting or non-targeting control shRNA plasmids and cultured for 13 days. 
Cells were left untreated, or treated with 0.1mM CCh for 30 minutes with or 
without a subsequent 60 minute washout period. Cell surface muscarinic 
receptors were assayed by [3H]NMS radioligand binding and M5-specific signal 
was calculated as described.  Knockdown of AGAP1 and AP3β3B proteins was 
verified by  immunoblot.  Data are expressed as a percent of CCh-internalized 
receptors recycled after 1 hour washout.  (A)(*): P< 0.05, Bonferroni post-test / 
two-way ANOVA. (B)(*): P< 0.05, one-sample T-test (versus 100).
sorting signals by AGAP1 (figure 5.7A).  
To test whether the endocytic recycling of M5wt was AP-3-dependent, we 
performed the same experiment after knockdown of the neuron-specific AP-3B 
subunit β3B.  Similar to the AGAP1 results, AP3β3B knockdown reduced 
recycling of agonist-internalized M5wt, but did not effect M5∆ (figure 5.7B).  
Although the reduction in receptor recycling values did not reach significance by 
two-way ANOVA, AP3β3B knockdown significantly reduced M5wt, but not M5∆ 
recycling as measured by the Studentʼs T-test (p<.05) and only M5wt co-
nucleofected with non-coding shRNA did not differ significantly from a 
hypothesized recycling rate of 100% (one-sample T-test, p<.05).  Thus, we 
concluded that efficient endocytic recycling of M5 in neurons requires interaction 
with AGAP1 and AP-3B, likely as part of a single trafficking complex.
5.3.7  Inhibition of AP-3 activity reduces endocytic recycling of M5 in an AGAP1 
ROI-dependent manner
The fungal metabolite brefeldin-A (BFA) is an Arf1 GDP exchange factor 
(GEF) that has been used previously to chemically inhibit the assembly, 
membrane targeting and/or function of the AP-3 complex (Donaldson et al., 1992; 
Ooi et al., 1998; Salazar et al., 2004b).  To further test whether the mechanism of 
M5 endocytic recycling is AP-3- dependent, we performed the M5 internalization / 
recycling assay in primary cortico-hippocampal neuron cultures nucleofected with 
wild-type or deletion-mutant M5 receptors after a 2 hour pre-incubation with BFA 
or vehicle.  BFA treatment was able to eliminate M5wt recycling, but had no effect 
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Figure 5.8  Activity-induced trafficking characteristics of M5 receptors in 
cultured neurons.  Rat embryonic cortico-hippocampal neurons were 
nucleofected with M5wt, M5∆, or empty vector control plasmids, cultured for 13 
days, and treated as indicated.  Cell surface muscarinic receptors were assayed 
by [3H]NMS radioligand binding and M5-specific signal was calculated as 
described.  (A)  Cultures were pre-treated with 5µM brefeldin-A (BFA) for two 
hours before assaying for endocytic recycling as in figure 5.7.  Data are 
expressed as a percent of CCh-internalized receptors recycled after 1 hour 
washout.  (*): P< 0.05, Bonferroni post-test / two-way ANOVA.  (B) Cultures were 
treated for 4 days with 10µM CCh and assayed for cell-surface M5 receptor 
binding.  (*): P< 0.05, paired two-tailed Studentʼs T-test.  (C) Cultures were 
treated with 45mM KCl for 5 minutes, with and without a subsequent 1 hour 
washout.  (*): P< 0.05, paired two-tailed Studentʼs T-test.
on the levels of M5∆ recycled to the cell surface after 1 hour washout from a 30-
minute CCh treatment (figure 5.8A).  This result further supports the hypothesis 
that M5 undergoes endocytic recycling via an AP-3-dependent mechanism, and 
suggests that residual recycling seen in the AGAP1 DOI deletion mutant may 
proceed by an alternate, AP-3 independent mechanism.
5.3.8  Down-regulation of cell surface M5 receptors after chronic agonist 
treatment is increased in the M5∆ mutant
Long-term activation of GPCRs can result in their down-regulation by 
targeting of agonist-stimulated receptors for lysosomal degradation (Tsao and 
von Zastrow, 2000).  The striatum, in which M5 receptors are present in midbrain 
dopaminergic afferent terminals, is characterized by the presence of tonically 
active, extensively arborized cholinergic interneurons, and has the highest 
acetylcholine tone found in the CNS (Zhou et al., 2002a; Pisani et al., 2007).  As 
the M5∆ receptor was observed to be deficient in its ability to undergo endocytic 
recycling after agonist-induced internalization, we asked whether its long-term 
activation could lead to down-regulation as a result of aberrant targeting to the 
lysosomal degradative pathway.  We treated primary cultured neurons 
expressing wild-type of AGAP1 ROI mutant M5 receptors with a moderate dose 
(10µM) of the non-hydrolyzable ACh analogue carbachol for 4 days, and then 
assayed for cell surface M5 receptor sites by radioligand binding as described 
above.  As a percentage of untreated controls, we observed a significantly 
greater reduction in the density of cell surface M5∆ receptors as compared to 
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M5wt (figure 5.8B).  This result supports the hypothesis that AGAP1-mediated 
recycling is required for maintenance of surface M5 expression under sustained 
ACh stimulation conditions.
5.3.9  Chemical depolarization decreases surface density of M5 receptors 
expressed in primary cultured neurons
AP-3 is known to be required for the targeting of certain proteins (ZnT3, 
VGAT) to nerve-terminal synaptic vesicles (Nakatsu et al., 2004; Salazar et al., 
2004b).  One interpretation of our recycling data is that M5 is trafficked to a 
synaptic vesicle-like compartment via an AGAP1 / AP-3 sorting mechanism, and 
that stimulation with CCh serves to increase cell surface M5 density by 
depolarization-induced exocytosis of receptors held in subcellular stores.  To test 
this, we expressed M5wt or M5∆ in cultured neurons, and 1) chemically induced 
depolarization with 45mM KCl for 5 minutes, 2) depolarized with KCl, followed by 
a 60-minute washout / recovery, or 3) left cells untreated.  We observed a 
decrease in surface M5 [3H]NMS binding sites that was significantly greater after 
5 minutes of KCl treatment in the wild-type as compared to deletion mutant 
receptors (Studentʼs paired two-tail T-test, p<.05; however, 2-way ANOVA 
showed a significant difference (p<.05) only between M5wt and M5∆ groups) 
(figure 5.8C).  After washout / recovery, surface levels of both mutant and wild-
type M5 increased (figure 5.8C).  These results do not support depolarization-
dependent synaptic vesicle fusion as a mechanism for M5 surface expression 
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up-regulation.  The significance of the differential response of M5wt and M5∆ to 
neuronal depolarization with regard to endocytic recycling is unclear.
5.3.10  M5∆ couples normally to downstream signaling pathways
To insure that the i3 loop AGAP1 ROI deletion (∆369-386) did not interfere 
with the coupling of M5∆ to signaling effectors, we compared the Gq and MAP 
kinase responses of the M5 wild-type and M5∆ receptors.  In HEK-293T cells 
transiently transfected with M5wt, M5∆, or control expression plasmids, cells 
were stimulated with various concentrations of CCh, and PLC-β activation was 
assayed by the accumulation of the inositol-3-phosphate metabolite inositol-1-
phosphate.  No difference in agonist efficacy (EC50) was observed between wild-
type and mutant receptors, while signal magnitude was greater in M5∆ than wild-
type, in line with its pattern of surface expression (figure 5.9A).  Similarly, CCh 
was able to stimulate intracellular calcium release in cells stably transfected with 
both M5wt or M5∆ receptors, with a larger signal magnitude in the higher-
expressing M5∆ line (figure 5.9B).  We also observed that both M5wt and M5∆ 
were able to activate the MAP kinase pathway in HEK-293T cells (as measured 
by phosphorylation of Erk 1/2) after stimulation with CCh in a similar range of 
concentrations (figure 5.9C). 
5.3.11  Analysis of M5 trafficking by subcellular membrane fractionation
Finally, we performed subcellular membrane fractionation of nucleofected 
cultured primary neurons in an effort to further understand the activity-induced 
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Figure 5.9  The ∆369-386 mutation does not affect M5 signaling properties. 
(A)  HEK-293T cells transiently transfected with M5wt, M5∆ or empty  vectors were 
stimulated with various concentrations of CCh and assayed for inositol-1-
phosphate accumulation as described.  EC50 values were calculated by non-
linear curve fitting to a sigmoidal dose-response model (GraphPad Prism). 
(B)  HEK-293T cells stably expressing M5wt or M5∆ receptors monitored for 
intracellular Ca2+ concentration by Fluo-3 fluorometry.  Cells were stimulated 
with CCh (1mM) at the indicated time point.  (C) HEK-293T cells transiently 
transfected with M5wt, M5∆ or empty vectors were stimulated with various 
concentrations of CCh for 10 minutes.  Activated (phospho-Tyr 202/204; pErk 1/2) 
and total Erk 1/2 were detected from cell lysates by immunoblot. 
trafficking of M5 receptors.  In the first experiment, primary cultured cortico-
hippocampal neurons expressing wild-type or deletion-mutant M5-GFP were 
treated with CCh for 1 hour, homogenized, and then subject to glycerol velocity 
gradient centrifugation in order to synaptic vesicle-containing fractions (West et 
al., 1997b).  The isolation of synaptic vesicle-containing membrane fractions was 
confirmed by immunoblot for synaptophysin; however, neither M5wt- nor M5∆-
GFP protein was detected in a pattern consistent with enrichment in a synaptic 
vesicle-like compartment, arguing against an AP-3 mediated endosome-to-
synaptic vesicle pathway in the recycling of M5 to the cell surface (figure 5.10A).  
In the second experiment, membrane fractionation was performed in an 
effort to confirm the hypothesis that agonist-internalized M5∆ is mistargeted to 
the late endosome / lysosome degradative pathway.  Primary cultures expressing 
M5wt- or M5∆-GFP were incubated with CCh in the presence of the lysosomal 
protease inhibitor leupeptin for 4 hours, and then fractionated by self-forming 
percoll density gradient centrifugation (Schaub et al., 2005).  A dense membrane 
fraction corresponding to late endosomes / lysosomes was observed by 
immunoblot to be relatively enriched in the late endosome marker rab7, but 
showed little AGAP1 or plasma membrane marker (Na+,K+ ATPase β2) 
immunoreactivity (figure 5.10B).  While small amounts of M5wt- and M5∆-GFP 
protein were detected in the peak lysosomal membrane fraction, their overall 
lysosome-like distribution was similar (M5wt-GFP, 6.7% of total immunoreactivity; 
M5∆-GFP, 4.1%) (figure 5.10B).  We therefore could not conclude from this 
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Figure 5.10  Analysis of M5 receptor trafficking in cultured neurons by 
subcellular fractionation.  Rat embryonic cortico-hippocampal neurons were 
nucleofected with M5wt-GFP or M5∆-GFP plasmids, and cultured, treated and 
fractionated as indicated.  (A) 14 DIV cultures were treated with 0.1mM CCh for 1 
hour and synaptic vesicle-like membranes were isolated by glycerol velocity 
gradient centrifugation.  Isolated membranes and post-nuclear supernatant (PNS) 
were analyzed by immunoblot.  (B)  21 DIV cultures were treated for 4.5 hours 
with 1mM CCh and 0.1mM leupeptin.  Membranes were fractionated through a 
self-forming Percoll density gradient, and fractions were analyzed by immunoblot 
as indicated. 
experiment that the AGAP1 DOI deletion mutant M5 receptor is targeted to the 
degradative pathway upon agonist induced stimulation.
5.4  Discussion
This chapter describes evidence of an AGAP1-dependent, neuron-specific 
mechanism for the recycling of agonist-internalized M5 muscarinic receptors to 
the plasma membrane.  Induction of AGAP1 interaction loss-of-function by 
deletion of the M5 i3 loop region of interaction or by RNAi-mediated depletion of 
endogenous AGAP1 protein decreased the magnitude of cell surface M5 binding 
site reappearance after agonist-induced intracellular sequestration, indicating 
inhibition of M5 endocytic recycling.  The recycling deficit was reproduced by 
both knockdown of the brain-specific AP-3B subunit β3B and by chemical 
inhibition of AP-3 membrane recruitment with the Arf GEF inhibitor brefeldin-A, 
demonstrating that M5 endocytic recycling proceeds through an AP-3-dependent 
pathway.  Taken together with our biochemical and imaging data demonstrating 
physical, spatial and temporal interaction between M5 and an AGAP1/AP-3 
complex, our results strongly suggest that efficient endocytic recycling of M5 is 
mediated by recognition of i3 loop trafficking motifs by an AGAP1/AP-3B 
complex, and that this mechanism is specific to the M5 muscarinic receptor 
subtype.  This proposed mechanism, whereby AGAP1 serves as a cargo-
interacting scaffold protein for the AP-3 complex, has not been described.  
However, AP-3 -dependent trafficking of the cannabinoid CB1 GPCR to 
intracellular compartments was reported (Rozenfeld and Devi, 2008), as was 
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endocytic recycling of membrane proteins by the AGAP1-related AZAP family 
protein ACAP1 (Dai et al., 2004; Li et al., 2005).
Further details of the mechanism by which AGAP1 and AP-3 mediate 
recycling of M5 receptors await elucidation.  Muscarinic receptors M1-4 have 
been reported to undergo agonist-induced endocytosis via clathrin-dependent 
and -independent mechanisms (Tolbert and Lameh, 1996; Vogler et al., 1998; 
Delaney et al., 2002; Popova and Rasenick, 2004; Madziva et al., 2005).  
Though we did not determine the mechanism of M5 internalization, clathrin and 
non-clathrin endocytic routes may imply differing downstream trafficking 
pathways (Weigert et al., 2004).   As we were unable to detect M5 recycling after 
short-duration agonist washout periods in pilot experiments (data not shown), the 
route of receptor recycling is likely not through the Rab4- / Rab35- dependent 
“fast” route, but rather via the Rab11-dependent “slow” endocytic recycling 
pathway (Grant and Donaldson, 2009).  Since the slow pathway requires transit 
of cargo proteins through the tubulovesicular endocytic recycling compartment 
(ERC), and since ubiquitous AP-3A was seen to localize to membrane buds in 
ERC-like compartments (Peden et al., 2004), we speculate that in neurons, 
agonist internalized M5 is targeted to a recycling pathway by sorting from the 
ERC to an AGAP1/AP-3B-positive compartment.  We found no evidence that 
internalized M5 is localized to synaptic vesicle-like structures; therefore, M5 may 
sort to recycling endosomes for transit back to the plasma membrane.  In 
addition, our biochemical assays employed a heterogeneous neuronal cell 
population for exogenous expression, and could not distinguish between 
150
trafficking events occurring in axonal and somatodendritic compartments.  As 
neuron sub-class and axon-specific trafficking mechanisms are known to exist 
(Yap et al., 2008), studies employing purified cell populations and/or single-cell 
analysis could help identify the mechanisms of AGAP1-mediated M5 trafficking 
with further precision.    
The mechanism responsible for the increased total and cell surface 
expression of M5∆ receptors compared to M5 wild-type remains unclear.  The 
phenotype seemed to be unrelated to interaction with AGAP1 or AP-3, since 
knockdown of AGAP1 or β3B had no effect on steady-state M5 surface 
expression in neurons, and δ-adaptin and AGAP1 knockdown did not 
differentially effect M5 expression in neurons or tissue culture cells, respectively.  
It is possible that a second, unknown trafficking motif was inadvertently 
eliminated in the deletion of the AGAP1 ROI from the M5 i3 loop, or that mutation 
of the M5 coding sequence disrupted an miRNA binding site that served to down-
regulate wild-type M5 in vivo.  Although the degree of M5 overexpression in 
neurons was not high (M5 binding site density was comparable to that of 
endogenously expressed MRs), it is also possible that the increase in M5∆ 
expression compared to wild-type was related to transient expression conditions.
The use of primary cultured neurons as an exogenous expression system 
for radioligand assays, along with an enhanced protocol for RNAi-based 
expression knockdown in long-term cultures, were novel technical developments 
that proved crucial to the identification of the AGAP1-dependent endocytic 
recycling pathway.  We used cell-surface radioligand binding as an indirect 
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measure of M5 trafficking, as related methodologies (including biotinylation, 
antibody feeding / stripping, and covalent receptor labeling) proved either 
unfeasible or lacking adequate sensitivity for use in this experimental system.  
Based on pilot experiments in tissue culture cells and primary cultured neurons, 
we chose time points for agonist treatment and receptor recycling (washout) 
conditions that corresponded to steady-state MR binding site labeling.  It should 
be noted that 1) our assay could not identify the origin of binding sites appearing 
at the cell surface after agonist washout, and 2) the agonist-internalized receptor 
values reflect not the total percentage of cell surface receptors internalized, but 
rather the surface density reached by virtue of steady-state balance between 
rates of internalizing and recycling M5 (Szekeres et al., 1998b).  Given the time 
frame of our primary neuron experiments compared to their time of culture, and 
since interference from newly synthesized receptors was reduced by 
cycloheximide inhibition in tissue culture cell experiments, M5 surface density 
values obtained after agonist washout almost certainly reflect the re-appearance 
of endocytically recycled receptors.  Additionally, since we observed M5∆ to be 
deficient in terms of the magnitude of receptor reappearance after agonist 
washout, differential internalization rates are likely not confounding our 
interpretation of the recycling assay data.    
We observed a significantly larger reduction in the steady-state surface 
expression of M5∆ receptors compared to wild-type after chronic (4-day) agonist 
treatment.  This result implies that AGAP1-dependent endocytic recycling may 
play a role in the avoidance of M5 receptor down-regulation under conditions of 
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sustained stimulation.  To test this hypothesis directly would require 
determination of the effects of AGAP1-mediated trafficking abrogation on 
signaling pathways coupled to M5 activation.  The cultured neuron exogenous 
expression system is not appropriate for such experiments, as the presence of 
non-M5 muscarinic receptors and the stoichiometric effects of overexpression 
greatly complicate data interpretation.  In addition, endogenous M5 receptors are 
expressed at very low abundance in neurons, and M5-selective agonists do not 
exist.  The dopaminergic neurons of the ventral midbrain have been reported to 
express M5 receptors to the exclusion of other MR subtypes, and their activation 
potentiates the release of dopamine (Weiner et al., 1990; Yeomans et al., 2001).  
However, the heterogeneous nature of primary midbrain cultures precludes their 
use in biochemical assays of M5 effector activation.  In the following chapter, we 
describe an experimental approach whereby dopamine release magnitude is 
examined as a functional readout of endogenous M5 receptor activity in genetic 
models of M5 and AP-3 dysfunction.      
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6 ACETYLCHOLINE-STIMULATED DOPAMINE RELASE: 
PHYSIOLOGICAL CONSEQUENCES OF AGAP1-MEDIATED M5 
RECYCLING
6.1  Summary
Acetylcholine modulates the release of dopamine in the striatum through a 
complex pattern of muscarinic and nicotinic receptor-mediated mechanisms.  In 
this chapter, we describe ongoing, collaborative experiments examining the role 
of AGAP1 / AP-3-mediated endocytic recycling on the function of M5 in the 
striatum.  We use mouse models of M5 and AP-3 dysfunction to investigate 
stimulated dopamine release in the context of muscarinic receptor activation.  We 
confirm in vitro and ex vivo that presynaptic M5 is required for the dopamine 
release-potentiating activity of muscarinic receptor agonists in the striatum.  
Preliminary data suggest that loss of AGAP1 / M5 i3 loop interaction leads to a 
long-term down-regulation of M5 signaling efficacy, resulting in decreased levels 
of stimulated dopamine release.       
6.2  Introduction
The M5 muscarinic acetylcholine receptor mediates the ability of ACh to 
potentiate dopamine release from midbrain dopaminergic neurons.  M5 is the 
only muscarinic receptor detectably expressed in ventral tegmental area (VTA) 
and substantia nigra pars compacta (SNc) dopaminergic neurons of the 
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nigrostriatal and mesolimbic pathways, respectively (Weiner et al., 1990).  These 
midbrain dopaminergic neurons are innervated somatodendritically by brainstem 
Ch5/Ch6 cholinergic afferents, and receive modulatory ACh input at striatal 
presynaptic terminals through the synaptic or volumetric action of the giant 
aspiny cholinergic interneurons.  An in vivo electrochemical study demonstrated 
that electrical stimulation of Ch5/Ch6 cholinergic nuclei resulted in a slowly 
activating, sustained release of dopamine in the nucleus accumbens (NAcc).  
This ACh-stimulated dopamine release event was observed in wild-type mice and 
rats, was blocked by the muscarinic receptor antagonist scopolamine, and was 
completely abolished in M5 -/- mice (Yeomans et al., 2001; Forster et al., 2002).  
In addition, infusion of either the muscarinic antagonist atropine or antisense 
oligonucleotides directed against M5 into the rat ventral midbrain was seen to 
decrease the behavioral sensitivity to rewarding hypothalamic stimulation, a 
process dependent on the mesolimbic dopamine system (Yeomans et al., 2001).  
Electrophysiological studies indicate that sustained activation of midbrain 
dopaminergic neuron muscarinic receptors increases firing rate and bursting 
activity as a result of depolarization, most likely through an inhibition of  K+ 
currents (Gronier and Rasmussen, 1998; Fiorillo and Williams, 2000).
M5 muscarinic receptors also mediate the presynaptic modulatory actions 
of ACh on dopaminergic neurons projecting to the striatum.  In studies of 
superfused acute mouse striatal slices, the genetic ablation of M5 was seen to 
decrease the ability of a muscarinic receptor agonist to potentiate K+-stimulated 
dopamine release.  As this M5-mediated potentiation mechanism was insensitive 
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to the action potential blocker tetrodotoxin, receptors located at dopaminergic 
neuron terminals were implicated (Yamada et al., 2001a; Zhang et al., 2002b).  
Further support for a presynaptic M5 receptor mechanism came from studies of 
dopamine release from rat striatum synaptosomes (an isolated nerve terminal 
preparation); the muscarinic agonist oxotremorine-M was seen to be release-
potentiating in the absence of intact neurons.  In the synaptosomal system, MR-
mediated dopamine release potentiation was dependent on KCNQ2/3 K+ channel 
activity; thus, local depolarization via Im inhibition is likely responsible for M5ʼs 
activity at the dopaminergic presynaptic terminal (Martire et al., 2007). 
In the preceding chapters, we demonstrated that interaction between 
AGAP1 and M5 is required for efficient endocytic recycling of agonist-internalized 
receptors in neurons.  By maintaing cell surface pools of signaling-competent 
receptors, this endocytic recycling mechanism may underlie the ability of M5 to 
maintain activity under conditions of sustained stimulation.  In this chapter, we 
describe experiments examining the role of AGAP1 / AP-3 mediated recycling of 
presynaptic M5 receptors in the potentiation of dopamine release.  In 
collaboration with outside laboratories, we studied evoked striatal dopamine 
release using the techniques of synaptosome superfusion and fast scan cyclic 
voltammetry.  While the former technique allows definitive isolation of presynaptic 
mechanisms, the latter electrochemical approach provides high temporal 
resolution and quantitative dopamine concentration measurements in a tissue 
system with intact local morphology.  To model M5 activity and/or trafficking 
dysfunction, we used the M5 -/- (knockout) and the spontaneous δ-Adaptin-null 
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mocha mouse models.  The development of an AGAP1 -/- mouse was not 
pursued, as we reasoned that genetic deletion of this protein would result in a 
generalized and severe secretory pathway disruption phenotype as a result of 
Arf1 dysregulation.  Instead, we developed a mouse in which the previously 
characterized M5∆ receptor was expressed in place of wild-type M5.  We 
hypothesized that inhibition of AGAP1 or AP-3 function would inhibit recycling of 
desensitized M5 receptors at striatal dopaminergic terminals, resulting in a 
decreased basal or activity-dependent sensitivity to MR-stimulated dopamine 
release.      
6.3  Results
6.3.1  Generation of the M5 ∆369-386 mouse
In order to study the effect of AGAP1-mediated trafficking on the function 
of the M5 muscarinic acetylcholine receptor in vivo, we generated a mutant 
mouse in which the domain-of-interaction deleted M5 ∆369-386 receptor (M5∆) 
was expressed in place of wild-type M5.  A homologous recombination-based 
“knock-in” approach was used to replace the single-exon wild-type Chrm5 coding 
sequence with the mutant Chrm5∆369-386 allele in C57BL/6 mouse ES cells.  The 
targeting strategy was designed and M5∆ mutant mouse generation was 
performed by Ozgene Pty. Ltd. (Bentley, Australia) as summarized in figure 6.1A.  
Targeted ES cell colonies were sequenced to confirm deletion of the M5 369-386 
coding region.  Blastocyst injection of targeted ES cells resulted in germline 
transmission of the Chrm5∆369-386 allele.  The resultant mouse was subsequently 
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Figure 6.1 M5∆369-386 knock-in mouse generation.  (A)  Targeting and 
screening strategy was designed by Ozgene, Pty. Ltd.  Top, wild-type M5 
(Chrm5) locus; middle, targeted (Chrm5 ∆369-386  / M5∆) locus; bottom, ∆Neo 
locus after Cre-mediated excision of LoxP-flanked selection cassette.  Restriction 
fragment lengths indicate expected band sizes for Southern blot screening of 
targeted ES clones.  (figures courtesy of Ozgene) (B) PCR genotyping of mice 
using primers flanking the ∆369-386 site.  (C) RT-PCR from total RNA extracted 
from midbrains of M5 ∆/∆ and wt/wt mice.  Primer set was identical to (C).  RT, 
reverse transcriptase.  (D)  [3H]NMS binding to mouse cerebral blood vessel 
membranes isolated from mice of indicated genotypes.  Data represent a single 
experiment performed in triplicate on tissue pooled from two animals.
mated to a Cre recombinase-expressing transgenic line to excise the loxP site-
flanked neomycin selection cassette from the Chrm5 locus (figure 6.1A).  From 
these founder animals, a congenic C57BL/6 background M5∆ mouse colony was 
established.  M5 ∆/∆ animals were healthy and fertile, and we observed no 
obvious phenotypic differences (gross appearance or home cage behavior) 
between ∆/∆, ∆/wt and wt/wt mice.  Polymerase chain reaction (PCR)-based 
genotyping of mouse tail genomic DNA using oligonucleotide primers flanking the 
deleted region of M5∆369-386 yielded products of expected sizes for M5 ∆/∆, ∆/
wt and wt/wt mice (figure 6.1B).  We next confirmed that the M5 ∆ mRNA was 
expressed in vivo by reverse transcription PCR (RT-PCR) of total RNA isolated 
from midbrains of M5 ∆/∆ and wt/wt mice.  Using the genotyping primer set, we 
detected PCR products of the expected sizes from reverse transcribed ∆/∆ and 
wt/wt mouse RNA (figure 6.1C).  Confirmation of M5∆ protein expression was 
complicated by the lack of subtype-selective antibodies or radioligands 
appropriate for the detection of low-abundance native M5 receptors.  Since M5 is 
the sole muscarinic receptor responsible for the dilatory effects of ACh on 
cerebral arteries and arterioles (Yamada et al., 2001a), we reasoned that an 
absence of M5 expression would be detectable in this tissue by quantification of 
the total MR population.  To test this, we prepared membranes from cerebral 
blood vessels isolated by density centrifugation from M5 wt/wt, ∆/∆, and -/- 
mouse brains and assayed for muscarinic receptor density by [3H]NMS 
radioligand binding.  In a single experiment consisting of tissue pooled from two 
animals of each genotype, binding of [3H]NMS was greater in both wt/wt and ∆/∆ 
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blood vessel membranes than in -/-, consistent with the expression of M5 
receptor protein in M5 ∆/∆ animals (figure 6.1D).
6.3.2  Expression of AP-3 and AGAP1 in dopaminergic neuron terminals
As we wished to study the effects of AGAP1- and AP-3-mediated 
endocytic recycling on presynaptic M5 receptor function at striatal dopaminergic 
terminals, we first examined the distribution of the AP-3 complex in primary 
cultured rat midbrain dopaminergic neurons.  Mature (14 DIV) midbrain cultures 
yielded a heterogeneous population of neurons, of which 25-50% were positive 
for the dopaminergic marker tyrosine hydroxylase (TH) (figure 6.2A).  We 
observed punctate δ-Adaptin staining in thin, aspiny processes of TH-positive 
neurons, consistent with the presence of AP-3 endosomes in the axons of 
dopaminergic neurons (figure 6.2A).  Next, we prepared synaptosomes from 
wild-type mouse striatal tissue in order to confirm the presence of AP-3 and 
AGAP1 proteins in presynaptic terminal compartments.  Immunoblot analysis of 
synaptosome-containing fractions detected the presence of AGAP1, ubiquitously 
expressed AP3µ3A, and brain-specific AP3β3B, with possible enrichment of 
AGAP1 and AP3β3B indicated (figure 6.2B).  The results of these experiments 
were consistent with the imaging data presented in chapter four, which 
demonstrated δ-Adaptin localization in presynaptic-adjacent compartments of 
cultured hippocampal neurons.   
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Figure 6.2  Expression of AGAP1 and AP-3 in dopaminergic neurons and 
nerve terminals.  (A) Primary cultured rat ventral midbrain neurons were fixed, 
immunostained and imaged by confocal microscopy. Left: Cells immunostained for 
the dopaminergic neuron marker tyrosine hydroxylase (TH; green) and the pan-
neuronal marker MAP-2 (red).  Right: Cells immunostained for !-adaptin (green) 
and TH (red), with area enlarged as indicated.  Scale bars = 50 µm.  (B) AGAP1, 
ubiquitous AP3µ3A, neuron-specific AP3"3B and the synaptic vesicle marker syn-
aptophysin were detected by immunoblot in synaptosomes prepared from mouse 
striatum.  H, homogenate; S1, supernatant 1 fraction; P1, pellet 1 fraction; P2!, 
synaptosome fraction.  Protein content of each fraction was equalized before 
SDS-PAGE separation.
6.3.3  M5 receptor activation potentiates stimulated dopamine release from 
striatal synaptosomes
In order to confirm previous reports of a dopamine release-potentiating 
function of M5 receptors localized to presynaptic dopaminergic terminals, 
neurotransmitter release experiments were performed in collaboration with Dr. 
Hugh Hemmings (Weill Cornell Medical School, New York).  Synaptosomes 
isolated from the striata of M5 wt/wt or M5 -/- animals were loaded with 
[3H]dopamine and [14C]glutamate, and stimulated release of neurotransmitter 
was measured in a superfusion device.  Incubation of striatal synaptosomes with 
the muscarinic receptor agonist oxotremorine-M (oxo-M) significantly potentiated 
the K+-stimulated release of [3H]dopamine from wild-type, but not M5 -/- animals 
(figure 6.3A).  Oxo-M treatment did not alter the magnitude of [14C]glutamate 
release in either M5 wt/wt or -/- animals (figure 6.3B).  Thus, activation of 
presynaptic M5 muscarinic receptors potentiated stimulated dopamine release in 
a neurotransmitter-specific manner, confirming previous studies performed in 
wild-type and M5 -/- mouse striatal slices (Yamada et al., 2001a) and in rat 
striatal synaptosomes (Martire et al., 2007).
6.3.4  Fast scan cyclic voltammetric studies of striatal dopamine release
Although the neurotransmitter release studies described above positively 
identified presynaptic M5 as a dopamine release-modulating receptor, the 
relatively low (≥ 2 minute) temporal resolution and in vitro nature of synaptosome 
superfusion limits the utility of this experimental system to the study of trafficking-
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Figure 6.3  Activation of M5 receptors potentiates dopamine release from 
mouse striatum synaptosomes.   Striatal synaptosomes prepared from mice of 
indicated genotypes and were simultaneously loaded with [3H]dopamine and 
[14C]glutamate.  K+-stimulated neurotransmitter outflow was measured in the 
presence and absence of oxotremorine-M.  (*): (A)(*): P< 0.05, Bonferroni post-
test / two-way ANOVA P= 0.06.  
dependent functions of M5.  To overcome this, we collaborated with Dr. David 
Sulzer (Columbia University, New York) to perform fast scan cyclic voltammetric 
(CV) recordings of stimulated dopamine release from acutely prepared mouse 
striatal slices.  We first compared dopamine release magnitude after electrical 
stimulation in M5 -/- and wild-type mouse dorsolateral striatum, an area primarily 
innervated by nigrostriatal dopaminergic neurons projecting from the SNc.  An 
approximately 40% reduction in the extracellular concentration of released 
dopamine was observed in M5 -/- mice as compared to wild-type (figure 6.4A).  
Next, we performed experiments in which striatal dopaminergic terminals were 
repeatedly electrically stimulated before and after the addition of the non-
selective muscarinic receptor agonist oxo-M to the perfusion buffer.  In contrast 
to our observations in superfused synaptosomes, oxo-M rapidly and strongly 
decreased the concentration of dopamine released after electrical stimulation in 
both wild-type and M5 -/- slices.  However, this effect was larger in magnitude for 
M5 -/- as compared to wild-type mouse striata, consistent with a release-
potentiating function of M5 receptors (figure 6.4B).  
Next, we examined the role of AGAP1 interaction and AP-3 in the 
dopamine release-potentiating function of M5.  We first used striatal slices from 
M5∆ mice to model M5 recycling dysfunction through AGAP1 interaction loss-of-
function.  Extracellular concentrations of dopamine released after electrical 
stimulation were decreased in M5 ∆/∆ striata compared to wild-type controls, with 
a magnitude comparable to that seen in M5 -/- animals (figure 6.4A).  However, 
we observed no difference in magnitude or pattern of stimulated dopamine 
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Figure 6.4  Analysis of dopamine release in M5 -/- and M5 ∆/∆  animals by 
fast-scan cyclic voltammetry.  (A)  Measurement of dopamine release evoked 
from single electrical stimuli in striatal slices prepared from mice of indicated 
genotypes.  (B) and (C) Evoked dopamine release from M5 +/+, -/- and ∆/∆ 
striata was measured at two minute intervals after addition of 10µM 
oxotremorine-M (oxo-M) to the perfusion bath where indicated.  In (C), oxo-M 
treatment is followed by a 20-minute washout period.  Data are normalized to 
release at time=0.
release inhibition between M5 ∆/∆ and wild-type striata after either ten minutes of 
oxo-M administration or subsequent washout (figure 6.4C).  We next examined 
the suitability of the mixed genetic background, Ap3d1-null mutant mocha (mh) 
mouse as a model for neuronal AP-3 dysfunction.  Immunoblot analysis of whole-
brain lysate from Ap3d1 wt/wt, wt/mh, and mh/mh mice confirmed the absence of 
both ubiquitous and brain-specific AP-3 subunits in mh/mh animals, with 
decreased AP-3A and AP-3B subunit abundance apparent in wt/mh 
heterozygotes as compared to Ap3d1 wt/wt or C57BL/6 controls.  AGAP1 protein 
levels were not affected by Ap3d1 genotype, however (figure 6.5A).  We 
observed no difference in the ability of oxo-M to inhibit stimulated striatal 
dopamine release between Ap3d1 mh/mh and mh/wt heterozygote mice, 
although the overall degree of oxo-M inhibition was larger than that observed in 
C57BL/6N background mice (figure 6.5B).  Taken together, these preliminary 
data suggest a decreased steady-state activity of M5∆ receptors as compared to 
M5 wild-type, but do not support the involvement of either AGAP1 interaction or 
AP-3 activity in the dynamic regulation of presynaptic M5 function.
6.4  Discussion
The experiments described in this chapter examined muscarinic receptor 
modulation of dopamine release as a functional readout of M5 receptor activity.  
We confirmed a presynaptic function of the M5 muscarinic acetylcholine receptor 
in the potentiation of stimulated dopamine release through superfusion of nerve 
terminal isolates (synaptosomes) derived from wild-type and M5 -/- mice.  By 
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Figure 6.5  Analysis of dopamine release in mocha mice by fast-scan cyclic 
voltammetry.  (A) Immunoblot detection of AP-3 subunits and AGAP1 from 
mouse brain lysates of indicated genotypes.  (B)  Evoked dopamine release from 
mocha (Ap3d1 mh/mh) or heterozygous control (+/mh) mouse striatum was 
measured at two minute intervals after addition of 10µM oxotremorine-M (oxo-M) 
to the perfusion bath where indicated.  Data are normalized to release at time=0. 
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examining this phenomenon in striatal slices with the quantitative and temporally 
sensitive CV method, we determined that elimination of M5 receptors 1) 
decreased the concentration of dopamine released by electrical stimulation, and 
2) increased the degree to which a saturating concentration of the non-selective 
muscarinic agonist oxo-M depressed evoked dopamine release.  These novel 
observations are consistent with a presynaptic release-potentiating function of 
M5, and indicate that this potentiation occurs within an overall context of MR-
mediated inhibition of dopamine release.  
Our subsequent experiments in the CV system aimed to determine the 
effect of the AGAP1 domain-of-interaction deletion and the absence of AP-3 on 
the identified M5-mediated dopamine release effect.  Although the results 
described have not been finalized, a number of trends are clear.  Stimulated 
dopamine release is decreased in the M5 ∆/∆ mouse compared to wild-type, 
suggesting that M5∆ receptor signaling efficacy is down-regulated.  However, 
oxo-M treatment did not differentially attenuate stimulated dopamine release in 
M5 ∆/∆ and wild-type mice, nor was desensitization-like rundown of dopamine 
release potentiation observed for ∆/∆.  Similarly, we observed no difference 
between mocha mutants (mh/mh) and heterozygous controls (mh/wt) in the oxo-
M treatment experiment.  In the latter case, we chose to use mh/wt controls, as 
the Ap3d1wt allele is maintained in repulsion to the recessive grizzled (gr) 
mutation in this strain.  Homozygous gr/gr animals are sub-viable, and the 
genetic mechanism resulting in the grizzled phenotype has not been determined 
(Burwinkel et al., 1998).  We are currently examining evoked and oxo-M 
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modulated dopamine release for animals of all genotypes in the mocha strain 
(mh/mh, mh/wt, and wt/wt).  However, interpretation of these dopamine release 
data may be complicated by the generalized dysfunction of nerve terminals in 
Ap3d1 -/- animals (Newell-Litwa et al., 2007).  In addition, examination of oxo-M-
induced [3H]dopamine outflow from synaptosomes prepared from M5 ∆/∆ striata 
may lend further support for our model of down-regulation of M5∆ receptors in 
vivo.                
While our preliminary data do not support a role of either AGAP1 
interaction or AP-3 in the short-term maintenance of M5 sensitivity under 
sustained agonist stimulation, the evoked release of dopamine was apparently 
lower in animals expressing the M5∆ receptor.  If these results are confirmed in 
further experimental replicates, how do we reconcile the seemingly M5 -/- -like 
evoked release and +/+ -like oxo-M stimulated release results observed in       
M5 ∆/∆ striata?  Based on our observation that long-term agonist stimulation of 
M5 receptors expressed in cultured neurons leads to significant down-regulation 
of M5∆, but not M5 wild-type, receptors, we propose the following mechanism: 
Under normal conditions, dopaminergic terminal M5 receptors receive constant 
ACh input from the highly arborized, tonically active giant aspiny cholinergic 
interneurons.  A slow, AGAP1-dependent recycling mechanism is required for the 
maintenance of cell-surface M5 receptor density under this constant stimulation 
condition.  In the absence of AGAP1 interaction, activated M5 receptors fail to 
recycle, leading to long term down-regulation of plasma membrane receptors.  In 
our evoked dopamine release experiments, a moderate striatal ACh tone results 
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in partial receptor occupancy and stimulation; the greater surface density of M5 
wild-type as compared to M5∆ receptors leads to an increase in Gαq-stimulated 
PIP2 hydrolysis and greater KCNQ2/3 channel inhibition, resulting in enhanced 
membrane depolarization and an increase in the magnitude of dopamine release 
detected.  In the oxo-M stimulation experiments, however, the agonist was 
applied at a high concentration, leading to saturation of the Gαq-PIP2-KCNQ2/3 
signaling pathway even at the low M5 surface receptor density hypothesized to 
exist in the M5 ∆/∆ mouse.  Further complicating interpretation of the latter 
experiment was the fact that muscarinic receptor agonist application is expected 
to decrease tonic ACh release through activation of cholinergic interneuron M4 
autoreceptors, which may in turn influence the activity of nicotinic ACh receptors 
present on dopaminergic terminals.  Confirmation of our proposed model 
mechanism awaits further experimental replicates; in addition, the use of 
muscarinic and/or nicotinic antagonists in the electrically-evoked dopamine 
release experiments could provide evidence supporting a role of M5 receptor 
density in the observed M5 ∆/∆ phenotype.
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7 CONCLUSIONS AND FUTURE DIRECTIONS
Muscarinic receptors play an essential role in the regulation of mammalian 
physiology.  Nearly every tissue in the body depends on the regulated 
transduction of cholinergic signals by a combination of muscarinic receptors for 
normal function.  In the brain, mediation of cholinergic neurotransmission by 
muscarinic receptors is required for such basic processes as attention, arousal, 
movement, motivation, learning and memory, the disruption of which is implicated 
in the pathology of a number of currently intractable diseases.  However, the 
ubiquity of MRs, their overlapping mechanisms of signal transduction, and their 
pharmacological similarity have greatly hindered progress towards understanding 
the cell- and subtype-specific function and regulation of these receptors.  Indeed, 
development of compounds or techniques capable of identifying or modulating 
the activity of individual muscarinic receptor subtypes in isolated populations of 
cells would be of great use both scientifically and clinically.
The function of GPCRs depends critically on temporally and spatially 
coordinated protein-protein interactions between cytoplasmic receptor domains 
and signal-transducing and/or regulatory molecules.  In the muscarinic receptors, 
one of these cytoplasmic regions, the third intracellular loop, is exceptionally 
large and divergent in sequence across the five MR subtypes.  Although some 
functions have been assigned to the MR i3 loops, the phylogenetic sequence 
conservation of this region implies the presence of critical protein interaction 
domains that have yet to be identified.  In an effort to uncover such molecules, 
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we performed yeast two-hybrid screens using as baits the five muscarinic 
receptor i3 loop domains.  We isolated three potential muscarinic receptor 
interacting proteins, AGAP1, SNX20, and UHRF1BP1L, on which biochemical 
protein-protein interaction analysis was performed with the intention of identifying 
a single candidate for subsequent investigation.  We chose to study the M5i3 
binding protein AGAP1, as we observed clear, domain-delineated interaction 
between M5 and AGAP1 in vitro, and since published functional characterizations 
of this Arf GAP protein suggested a potential role in receptor trafficking.
The M5 muscarinic receptor is the least-expressed MR in mammals, and 
its molecular biology and regulation have been little studied.  Thus, a number of 
our basic findings on the expression and trafficking patterns of this receptor were 
novel.  For instance, we demonstrate that exogenously expressed M5 receptors 
undergo endocytic recycling in HEK-293T cells, with a time course consistent 
with trafficking through the “slow” endocytic recycling compartment-dependent 
pathway (Grant and Donaldson, 2009).  We also show that M5 receptors 
expressed in primary cultured hippocampal neurons distribute uniformly in the 
plasma membrane and are not excluded from either the somatodendritic or 
axonal compartments.  On the functional level, we confirmed a dopamine 
release-potentiating activity of M5 receptors localized to nigrostriatal and 
mesolimbic neuron terminals.  Although this presynaptic modulatory function was 
previously examined in [3H]dopamine release experiments performed on rat 
striatum synaptosomes and both wild-type and M5 -/- mouse striatal slices 
(Yamada et al., 2001a; Martire et al., 2007), our study is the first to apply the fast 
172
scan cyclic voltammetry method to the examination of M5-specific modulation of 
endogenous dopamine release in mouse striatum.
Of greatest overall significance, however, is our demonstration of a 
neuron-specific trafficking function for the AGAP1-M5 interaction.  Our results 
demonstrate that in the primary cultured rat neuron exogenous expression 
system, interaction with AGAP1 is required for efficient endocytic recycling of M5 
receptors after agonist-stimulated endocytosis.  In non-neuronal cells, AGAP1 
was previously demonstrated to regulate the trafficking of lysosomally-targeted 
integral membrane proteins by virtue of its ability to bind to the AP-3 adaptor 
protein complex (Nie et al., 2003).  We found that subunits of both the 
ubiquitously expressed AP-3A and neuron-specific AP-3B complexes associated 
with the M5 i3 loop in an AGAP1-dependent manner, and that the endocytic 
recycling of M5 in neurons was sensitive to depletion of AP-3B.  The AP-3A 
complex has been shown to regulate the endocytic trafficking of membrane 
proteins to lysosomes and lysosome-like organelles, while in neurons the AP-3B 
complex is known to mediate the formation of a subset of synaptic vesicles, and 
is required for the targeting of certain membrane proteins to the nerve terminal 
(Kantheti et al., 1998; Blumstein et al., 2001; Salazar et al., 2004b).  To our 
knowledge, however, neither AGAP1, AP-3A nor AP-3B have been implicated in 
the mechanism of endocytic recycling, although the AGAP-like protein ACAP1 
was found to promote the recycling of internalized transferrin receptors (Dai et 
al., 2004).  Our observation of AGAP1- and AP-3-dependent M5 receptor 
recycling is therefore indicative of a previously undescribed GPCR trafficking 
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pathway.  In addition, our results strongly suggest that the mechanism of M5 
recycling in neurons relies upon a protein-protein binding event between the M5 
i3 loop and an AGAP1-AP-3B complex.  Thus, AGAP1 may possess target-
recognition properties in addition to its characterized Arf1 regulatory function, 
which further suggests that members of the AP-3 holocomplex (such as AGAP1 
and BLOC-1) may function in the recognition of sorting signal sequences to a 
greater degree than previously recognized.           
Further characterization of the AGAP1-mediated recycling of M5 receptors 
may reveal sorting signals or regulatory mechanisms important for the function of 
other classes of GPCRs.  We identified a 23-amino acid region in the i3 loop of 
M5 that was required for AGAP1 interaction and efficient endocytic recycling in 
neurons.  We also identified a series of residues in this i3 loop domain of 
interaction whose mutation eliminated or reduced AGAP1 binding activity.  The 
sequence of these critical residues resembled, but did not exactly conform to 
recognized tyrosine- and dileucine-based sorting signals commonly present on 
GPCR i3 loop or C-terminal tail regions (Bonifacino and Traub, 2003).  To date, 
relatively few endocytic targeting motifs have been identified; thus, the precise 
identification of an AGAP1 binding motif would expand our understanding of the 
structural determinants of GPCR recycling, and could help identify other GPCRs 
whose endocytic traffic is AGAP1-dependent.  In addition, a deeper mechanistic 
understanding of AGAP1 / AP-3-mediated M5 recycling could potentially reveal 
points at which this putative trafficking pathway is regulated.  The targeting of 
endocytosed GPCRs to the degradative or recycling pathways plays a critical 
174
role in determining the effect of sustained stimulation on surface receptor density, 
and in turn the magnitude of second messenger responses to neurotransmitters.  
An emerging model of neuronal plasticity implicates regulation of glutamate 
channel trafficking as a key mechanism of signal “gain”-tuning, by which a 
neuronʼs up- or down-regulation of surface receptor levels acts to alter its 
response to a given synaptic input (Turrigiano, 2008).  An analogous mechanism 
has been shown to tune GPCR signaling responses in neurons and other cells, 
the regulation of which may occur at the level of GPCR targeting sequence 
recognition (Hanyaloglu and von Zastrow, 2008).  For example, activity-induced 
receptor ubiquitination was shown to shift targeting of a GPCR from the recycling 
to the degradative pathways (Shenoy et al., 2001) and phosphorylation of the 
AGAP1-like molecule ACAP1 is required for its binding to, and its recycling 
pathway targeting of β-Integrin (Li et al., 2005).  Continuing biochemical and cell 
biological studies of the M5 - AGAP1 interaction may shed light upon such post-
translational modifications regulating M5 trafficking.
 The study of M5 function in vivo is complicated by the receptorʼs low 
abundance relative to other muscarinic receptors and the lack of pharmacological 
tools appropriate for the isolation of subtype-specific signaling events.  In order to 
better understand the physiological consequences of AGAP1-dependent M5 
receptor recycling, we generated an i3 loop domain-of-interaction mutant (M5∆) 
mouse.  M5 is the only muscarinic receptor detectably expressed in midbrain 
dopaminergic neurons, in which it mediates the dopamine release-potentiating 
activity of ACh (along with ionotropic nicotinic ACh receptors) (Forster et al., 
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2002).  From terminals of these neurons present in striatal slices, we detected a 
decrease in the magnitude of evoked dopamine release in mice expressing M5∆ 
receptors as compared to wild-type.  As we observed chronic agonist treatment 
to result in surface density down-regulation of M5∆, but not M5 wild-type 
receptors in vitro, we hypothesized that abrogation of AGAP1 / AP-3-mediated 
endocytic recycling of M5 results in down-regulation of M5 receptor signaling at 
striatal dopaminergic terminals in vivo.  If these data are indeed confirmed by 
additional replicates, our model predicts an important role for the AGAP1-M5 
interaction in the maintenance of tonic basal ganglia function.  The interaction 
between cholinergic and dopaminergic activity in the striatum influences the 
activity and plasticity of the medium spiny output neurons, and is in turn required 
for proper coordination of motivated locomotor activity (Pisani et al., 2007).  As 
the giant aspiny cholinergic interneurons provide a constant ACh tone in the 
striatum, an efficient endocytic recycling mechanism may be required for the 
maintenance of M5 signaling efficacy at the presynaptic dopaminergic terminal.  
Our experiments examined the release-modulating functions of dopaminergic 
nerve terminal receptors.  However, M5 receptors localized to somatodendritic 
compartments of midbrain dopaminergic neurons also function to stimulate 
dopamine release (Yeomans et al., 2001; Miller and Blaha, 2005).  Indeed, Ch5/
Ch6 cholinergic afferent-stimulated dopamine release from VTA neurons is 
characteristically prolonged in duration, suggesting that M5 endocytic recycling 
may play a role in sustaining sensitivity to ACh (Forster et al., 2002).  In vivo 
chronamperometric measurements of dopamine release in the M5∆ mouse could 
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reveal AGAP1 interaction-dependent postsynaptic functions of M5, as could 
electrophysiological or Ca2+ imaging studies of isolated dopaminergic neurons. 
In the process of examining the functional role of the putative AGAP1-M5 
interaction, we developed novel technical approaches whose application extends 
beyond the present project.  First, the use of primary cultured rat neurons as an 
expression system for the analysis of exogenously-expressed receptors by 
radioligand binding has, to our knowledge, not been described.  Such a system 
may prove useful for experiments involving brain-expressed receptors, as many 
GPCRs are regulated in a cell type-specific manner, and the more commonly 
utilized tissue culture cell systems may not adequately model neuronal 
physiology.  We also describe in this report a selection-based method for the 
enrichment of shRNA-expressing primary neurons.  For some targeted proteins, 
we were able to achieve knockdown efficiencies of near 100%, which is a 
considerable improvement upon previously reported techniques (Zeitelhofer et 
al., 2007).  We have recently developed cell-penetrating peptides targeting the 
M5i3 domain of interaction with AGAP1, with the aim of using these molecules in 
vitro and in vivo to acutely inhibit binding of AGAP1 to M5.  In combination with a 
recently described M5 receptor positive allosteric modulator with >30-fold 
selectivity over the other four muscarinic receptor subtypes (Bridges et al., 2009), 
such tools may greatly facilitate the investigation of M5-specific and AGAP1-
dependent physiology.    
The dysfunction of both M5 receptors and the AP-3 complex have been 
linked to the pathophysiology of schizophrenia.  Schizophrenia is associated with 
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increased activity of the mesolimbic dopaminergic pathway, and neuroleptic 
drugs used to treat the disorder typically target the D2 dopamine receptor.  The 
M5 -/- mouse displays abnormalities in schizophrenia-related sensorimotor 
behaviors, and is hyposensitive to psychostimulants, a condition indicative of a 
reduction in striatal dopamine levels and consistent with a release-potentiating 
effect of VTA M5 receptors (Wang et al., 2004; Thomsen et al., 2005; Thomsen et 
al., 2007).  Alterations in synaptic terminal morphology and function, including 
decreased abundance of the AP-3 associated BLOC-1 protein Dysbindin, have 
been observed in both schizophrenic humans and in the AP-3 null mocha mouse 
(Talbot et al., 2004; Harrison and Weinberger, 2005).  In addition, genetic linkage 
studies have implicated variations of the M5 (Chrm5) and Dysbindin (Dtnbp1) 
genes as conferring susceptibility to schizophrenia, the former in combination 
with the dopaminergic neuron-expressed α7 nicotinic acetylcholine receptor 
(Chrna7) gene (Schwab et al., 2003; De Luca et al., 2004).  While the function of 
AGAP1 had not been previously associated with the pathology of schizophrenia, 
we observed binding of Dysbindin to the M5 i3 loop (presumably through an 
indirect AGAP1/AP-3 interaction), and our data suggest a dopamine release-
related functional link between M5 and an AGAP1/AP-3 trafficking protein 
complex.  Intriguingly, a recent genome-wide association study of common 
variants linked with schizophrenia susceptibility in populations of European 
ancestry identified the AGAP1 gene as the strongest single locus association, 
though below the studyʼs significance threshold (P<5x10-8)  (Shi et al., 2009).  
Given these observations, further studies of the relationship between the M5 / 
178
AGAP1 interaction and schizophrenia are warranted, including 1) direct 
examination of the role of Dysbindin in M5 trafficking; 2) investigation of the 
dopamine release characteristics of mesolimbic tract terminals in the 
medioventral striatum of M5∆ mice; 3) behavioral analyses of M5∆ mice; and 4) 
determination of whether variations in the Chrm5, Dtnbp1, and AGAP1 genes 
interact to confer schizophrenia risk.
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8 MATERIALS AND METHODS
8.1  Rodent Strains
All procedures involving animals were performed in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals 
and were approved by the Rockefeller University Institutional Animal Care and 
Use Committee.  Female adult (3-6 month old) timed pregnant Sprague-Dawley 
rats were obtained from Charles River Labs or Taconic Labs.  Breeding pairs of 
C57Bl/6N mice were obtained from Charles River, and were bred in-house.  The 
M5-/- strain was a kind gift from Jürgen Wess (National Institute of Diabetes and 
Digestive and Kidney Disease, Bethesda MD), generated as described (Yamada 
et al., 2001a).  The M5-/- strain was extensively backcrossed (>10 generations) 
onto the C57Bl/6N background before receipt; mice were maintained as -/- 
homozygotes, and heterozygote matings were performed when necessary for 
generation of wild-type littermates.  STOCK gr +/+ Ap3d1mh/J mice carrying the 
mocha allele (mh), a spontaneous null mutation of the Ap3d1 gene (Lane and 
Deol, 1974; Kantheti et al., 1998), were obtained from the Jackson Laboratory.  
In this strain, the Ap3d1mh allele is maintained on a mixed background in 
repulsion to the pigmentation mutant gr allele.  Mice were maintained as 
heterozygotes, as mh homozygotes were observed to be infertile.  The Chrm5∆/∆ 
strain was generated and maintained as described below.
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8.2  Genotyping of Mice
Tail biopsies (0.5mm) of 3-4 week old weanling mice were solubilized 
overnight at 55℃ in 130µl DirectPCR tail lysis reagent containing 0.75mg/ml 
proteinase-K (Viagen Biotech).  Proteinase K was deactivated at 85℃ for 45 
minutes, and crude lysates (0.6µl) were used directly as template DNA for PCR 
reactions (12µl).  For PCR genotyping of the M5- allele (in which the Neo 
selection cassette was still present (Yamada et al., 2001a)) a single PCR reaction 
(annealing temp. 55℃) included a set of 3 primers: a Neo-specific forward primer 
(5ʼ-TGG ATG TGG AAT GTG TGC GAG G), M5wt forward (5ʼ-TCC GTC ATG 
ACC ATA CTC TA), and an M5 reverse primer (5ʼ-CCC GTT GTT GAG GTG 
CTT CTA C) in a region of the M5 gene 3ʼ to the NEO disruption.  For PCR 
genotyping of the M5∆ allele, forward (5ʼ-AAG CCA AGG CCA CTG ACC CTG 
TCT TTC A) and reverse (5ʼ-CCA GGC CTT TTG TTG AAG GGT CTT TGG ACA) 
primers flanking the deleted region were used with a 61℃ annealing step.  PCR 
products were resolved by electrophoresis through a 2.5% agarose gel and 
detected by UV illumination in the presence of ethidium bromide.  Direct 
sequencing of M5wt and M5∆ loci was performed on 2 purified PCR products 
(QIAquick PCR purification kit, Qiagen) spanning the M5 coding sequence 
amplified from tail DNA prepared as described above.  Forward (5ʼ-AGA GGG 
GAG GTA GCT CCA AAC AGA GAG TAG) and reverse (5ʼ-AGT TGG TAA CCT 
GCT CAG CCT TTT CCC AGT) primer pairs for the 5ʼ product, and forward (5ʼ-
TGG CAG AAG TCA AGA AGA GAA AAC CGG CTC ) and reverse (5ʼ-GGC AGA 
TGA CAT TCC TTT AAC AAG CAA ACC) primer pairs for the 3ʼ product were 
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amplified with the Expand High Fidelity PCR System (Roche) according to the 
manufacturerʼs protocol, with 60.4℃ annealing steps.  Mocha (+ Ap3d1mh / + 
Ap3d1mh), grizzled (gr + / gr +) and heterozygote (+ Ap3d1mh / gr +) mice were 
identified by coat color phenotype.
8.3  Generation of the M5∆369-386 Mutant Knock-in Mouse 
Mutant mice carrying an AGAP1-domain-of-interaction deletion mutation in 
the Chrm5 gene (“M5∆”) were generated by a homology-based “knock-in” 
strategy by Ozgene, Inc.  Briefly, PCR cloning from C57Bl/6 genomic DNA was 
used to generate a targeting vector containing a PKG promoter-driven neomycin 
resistance cassette (Neo) flanked by loxP sites , and 5ʻ and 3ʻ homology arms 
used to target homologous recombination of the construct to the endogenous M5 
locus.  The 5ʻ homology arm contained the single M5 exon, in which the region 
coding for residues 369-386 was deleted by PCR mutagenesis.  In order to 
facilitate screening of target clones, an SphI restriction site was engineered 
following the 5ʼ LoxP sequence, and KpnI and BglII sites engineered following 
the 3ʼ LoxP sequence.  C57Bl/6-derived ES cells were electroporated with the 
linearized targeting vector, and neomycin-resistant colonies were selected with 
G418.  Resistant clones were screened for proper homologous recombination by 
Southern blot using a Neo probe with EcoRV digestion, and probes external to 
the 5ʼ and 3ʼ targeting regions derived by PCR from C57Bl/6 genomic DNA: 5ʻ 
probe (SphI digestion), 5ʼ-CTT TAG AAG GAA TGG TTT CAG GGC (forward), 5ʼ-
CAT ACC TGG ATG GAA GGA CAT GG (reverse); 3ʻ probe (KpnI digestion), 5ʻ-
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CCT TAT TAG CAC TTG TCT GCT TCC G (forward), 5ʼ-AGG CTA TGT AGG 
TAG GGA GAT GGC (reverse).  Integration of the mutant M5∆ locus was 
confirmed in targeted ES clones by sequencing, and clones were injected into 
C57BL/6J-TyrcBrd blastocysts and implanted into pseudopregnant females.  
Strongly chimeric male mice were crossed to transgenic C57Bl/6-Cre 
recombinase females, and offspring were tested by Southern blot for 
transmission of the M5∆ allele (with 5ʼ and 3ʼ probes as described above) and for 
excision of the Neo cassette with BglII digestion using a probe directly 5ʼ to the 
remaining LoxP site (PCR primers for probe were 5ʼ-TGT TAC GCT CTC TGC 
AAC AGA ACC (forward), 5ʼ-TAT CTG GAG GTG CAA CTG GCT TAC (reverse)).  
Males carrying the M5∆/∆Neo allele were crossed to C57Bl/6 females, and offspring 
of genotype M5∆/∆Neo / ∆Cre were selected for breeding.
8.4  Constructs
The following expression vectors were used: for mammalian expression,  
pcDNA 3.1(+) myc/His (Invitrogen), pEGFP-N3 and -C2 (BD Biosciences 
Clontech), and pAAV-MCS (Stratagene); for yeast expression, pACTII, pAS2∆∆ 
and pLEX9 (Fromont-Racine et al., 1997); for bacterial expression, pGEX-4T and 
pGEX-5X (Amersham / GE Life Sciences).  For subcloning and/or TA cloning, 
pCR Zero Blunt and pCR II Topo (Invitrogen) vectors were used, the latter 
employing Taq polymerase for PCR amplification, and ligated according to the 
manufacturerʼs protocol.  The following plasmids were kind gifts, and were used 
as templates for PCR cloning into appropriate expression vectors: pRSET-B-
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mCherry (R. Tsien), pCD-hM1,2,& 3 (E. Hulme), pcDNA3.1(-)-rM4 and pCD2-rM2 
(T. Bonner).  
Plasmid constructs were prepared using standard molecular cloning 
techniques.  PCR amplification was performed with Accuprime Pfx polymerase 
(Invitrogen), and ligations with the Rapid DNA Ligation Kit (Roche).  For 
amplification of protein coding sequences from mouse, rat or human cDNA 
libraries, a 2-step nested PCR approach was used to generate PCR products 
with 5ʼ and 3ʼ restriction sites, allowing direct cloning into expression vectors 
(primer sets are summarized in table 9.5).  Most mammalian expression 
constructs included a Kozak translation initiation sequence (5ʼ-GCC-ACC-ATG-
G-3ʼ) engineered into the coding sequence start position.  mCherry N- and C- 
terminal fusion mammalian expression vectors were generated by PCR 
amplification of the mCherry coding sequence and cloning into the XhoI PspOMI 
or Asp718I and HindIII sites of pcDNA3.1(+) A, respectively.  C-myc epitope tags 
and GFP / mCherry fusions were created by in-frame cloning of cDNA PCR 
products into appropriate vectors, with stop / start codons omitted as required.  
N- or C-terminal HA or FLAG epitope tags were introduced by appending PCR 
primers (HA, 5ʼ- TAT CCA TAT GAC GTC CCA GAC TAT GCC; FLAG, 5ʼ- GAT 
TAC AAG GAT GAC GAC GAT AAG).  Short (<75nt) coding sequences were 
cloned by ligation of oligo duplexes containing 5ʼ and 3ʼ overhangs into 
complimentary restriction sites.  Sequences of all cloned fragments derived by 
PCR or oligo duplex ligation were confirmed by sequencing.  
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Point mutations were generated by site-directed mutagenesis from 
plasmid DNA template using the Quick Change kit (Stratagene), DpnI digestion 
of template DNA, and primer sets summarized in table 9.4.  Deletion mutants and 
internal HA tags were generated by amplification of appropriate 5ʻ and 3ʻ PCR 
products containing, respectively, complimentary 3ʻ and 5ʻ sites for the 3ʼ distal 
cutter BbsI, and subsequent 3-way ligation into expression vectors.  Point- or 
deletion- mutated regions were validated by sequencing, and restriction 
fragments containing the desired mutations subcloned into the parent plasmid.  
Truncation mutants for Y2H domain-of-interaction mapping were generated by 
PCR from full-length template and cloned into pAS2∆∆ or pACT2.  
Short hairpin RNAs (shRNAs; 19nt) targeting rat AGAP1, AP3β3B, and    
δ-Adaptin (or non-targeting negative control) were designed using Oligoengine 2 
software.  Oligonucleotides were annealed and ligated into the BglII and XhoI 
sites of pSuper.puro (Oligoengine) according to the manufacturerʼs protocol.  
Transcribed shRNAs included a hairpin loop sequence of 5ʼ-UUC AAG AGA, and 
yielded cleaved dsRNA products of 19nt with 3ʼ UU overhangs.  At least 3 
shRNA constructs for each target were created, and validated for target 
knockdown by immunoblot before use in functional experiments.  Targeted 
sequences used for this study were 5ʼ-ACC CTA GAC GTG TCT CTC C 
(AGAP1), 5ʼ-AAC GCA TCG ACC TGA TTC A (AP3β3B), GAG GAA ATG AAG 
ACC ACG C (δ-Adaptin), and 5ʼ-GTT CCG AAC ACA CGC ACA A (non-targeting 
control).
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8.5  RT-PCR
Wild-type, M5-/-, and M5∆/∆ mice were sacrificed by CO2 inhalation, and 
ventral midbrains were dissected and snap-frozen in LN2.  Tissue was 
homogenized in 0.6ml TRIzol (Invitrogen) and total RNA extracted and EtOH-
precipitated according to the manufacturerʼs protocol.  RNA pellets were 
dissolved in 45µl nuclease-free ddH20 and treated with 2U TURBO DNase 
(Ambion) at 37℃ for 30 minutes.  DNase was deactivated and RNA isolated by 
TRIzol extraction / EtOH precipitation, and RNA pellets dissolved in 20µl ddH20.  
RNA content was quantified by 260nm absorbance with a Nanodrop 
spectrophotometer (Thermo Scientific), and 2µg total RNA was denatured and 
reverse-transcribed with the High Capacity RNA-to-cDNA kit (Applied 
Biosystems) according to the manufacturerʼs protocol.  Negative control reactions 
that omitted reverse transcriptase enzyme were performed in parallel.  1µl 
reverse-transcribed cDNA (or negative controls) was used as template for a PCR 
reaction performed exactly as described for the genotyping of M5∆ animals. 
8.6  Yeast Methods
Saccharomyces cerevisiae haploid strains CG1945, Y187 and L40 were 
obtained from BD Clontech, and used as described below (genotypes are listed 
in table 9.7).  The bait plasmid pAS2∆∆ and the prey plasmid pACTIIst were 
derived from pAS2 and pACTII (BD Clontech), respectively, the former by 
deletion of the CYH2 gene and HA fusion epitope (Fromont-Racine et al., 1997).  
The pLEX9 bait plasmid was derived from pBTM116 (Vojtek et al., 1993).  
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For transformation of yeast with plasmid DNA, cultures were grown in YPD 
medium at 30℃ until log-growth phase (OD600 = 0.5-0.8).  Cells were collected 
by centrifugation (2000g, 10 minutes), washed with ddH20, centrifuged again, 
and washed in TE-LiOAc (10mM tris, pH=7.5, 1mM EDTA, 100mM LiOAc).  Cells 
were centrifuged and resuspended in TE-LiOAc containing 45% polyethylene 
glycol, 40µg heat-denatured herring testes carrier DNA, and 1µg plasmid DNA.  
The transformation mixtures were incubated at 30℃ for 45 minutes, heat 
shocked at 42℃ for 15 minutes, and the cells were collected by centrifugation.  
After a final ddH20 wash and centrifugation, cells were plated on YNB-agar plates 
supplemented with appropriate selection mixtures:  For pAS2∆∆ and pLEX9 
contructs, CSM-Trp; for pACTII contructs, CSM-Leu; for co-transformation, CSM-
Trp-Leu.  Yeast plates were incubated at 30℃ for 3 days before assay or 
isolation of clonal inoculum.
β-Galactosidase activity in yeast was determined by an X-Gal lift assay.  
Yeast colonies were transfered from agar plates to Hybond-C membranes 
(Amersham / GE Healthcare).  Membranes were subjected to 2 freeze-thaw 
cycles in LN2 to lyse yeast cells, and were then transferred to filter paper 
saturated with Z-buffer (60mM Na2HPO4, 60mM NaH2PO4, 10mM KCl, 1mM 
MgSO4, pH=7.0) containing 0.35% (v/v) β-mercaptoethanol, 1.67% (v/v) DMF 
and 0.33 mg/ml X-Gal.  Filters were incubated in sealed containers at 37℃ for 
indicated intervals, and X-Gal chromogen development was fixed by incubation 
of filters in 1M Na2CO3 for 1 minute, followed by a 1 minute rinse in ddH2O.   
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Yeast two-hybrid (Y2H) screens were performed using a mating protocol 
as previously described (Fromont-Racine et al., 1997; Flajolet et al., 2000).  Y187 
yeast was transformed as described above with pACTIIst or pACTII cDNA 
libraries (rat and human, respectively), in which cDNAs were cloned-in frame with 
the Gal4 AD.  For each library, 20 million transformant colonies were collected, 
pooled in YPD, and frozen in aliquots at -80℃.  Rat or human MR i3 loops were 
cloned into pAS2∆∆ or pLex9 vectors in-frame with the Gal4 or LexA DNA BD, 
respectively, and transformed into the CG1945 or L40 strains, respectively.  For 
each screen, transformed bait strains were cultured to log growth in YNB + CSM-
Trp, and then mixed with a single thawed vial of the appropriate prey library 
strain.  Yeast were plated onto YPD-agar plates, and mating was allowed to 
proceed for 4.5 hours at 30℃.  Yeast was then collected in ddH20 and distributed 
to 40 YNB-agar +CSM-Trp-Leu-His plates.  A small amount of each screen was 
reserved for plating on control YNB-agar+CSM plates: -Trp, total bait CFUs; -Leu, 
total prey CFUs; and -Trp-Leu, total diploids (measuring mating efficiency).  
Screen plates were incubated at 30℃ for 3-4 days, until interaction-positive 
diploid colonies were observed on the His -selective media.  [His+] colonies were 
counted, and then assayed for activation of the LacZ reporter by X-Gal overlay: 
10ml of warm liquid X-Gal mixture (0.5% (w//v) agar, 0.1% (w/v) SDS, 6% (v/v) 
DMF, 0.04% (w/v) X-Gal was poured on each of the screen plates, allowed to 
solidify, and incubated at 30℃ for 30 minutes to 18 hours (depending on speed 
of color development).  Blue colonies were then streaked onto -Trp-Leu-His 
plates, grown for 3 days at 30℃, and β-Galactosidase activity was confirmed by 
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lift assay as described above.  Yeast cells from [His+][LacZ+] clones were 
collected, lysed by heat and mechanical disruption, and cDNA library fragments 
from pACTII plasmid DNA were amplified by PCR with the primer set 5ʼ-CGC 
GTT TGG AAT CAC TAC AGG GAT G (forward) and 5ʼ-GAA ATT GAG ATG GTG 
CAC GAT GCA C (reverse).  PCR products were sequenced and analyzed by 
BLAST.  Clones with in-frame ORF sequences were cultured for 3 passages in 
liquid YNB+CSM-Trp media, yeast was collected at log-phase growth by 
centrifugation, extracts were prepared by heat and mechanical disruption of cells, 
and DNA purified by NH4OAc precipitation.  Rescued prey plasmid was 
transformed into E. coli, amplified, and purified with standard techniques. 
8.7  Mammalian Cell Culture and Transfection
Mammalian tissue culture cell lines unavailable from Greengard Lab 
cryopreserved stocks were obtained from the American Type Culture Collection.  
Cells were maintained in a humidified 5% CO2 atmosphere incubator, passaged 
by trypsinization (0.25% [w/v] trypsin, 1mM EDTA in HBSS [Invitrogen]) every 3-4 
days, and were cultured in the following media:  HEK-293T, COS7 and A2058, 
10% (v/v) in DMEM; CHO, 10% FBS in F12K; NIH-3T3, 10% BCS in DMEM; 
RIN-m5f, 10% FBS in RPMI-1640.  Cells were transfected with plasmid DNA 
according to the manufacturerʼs protocols using Lipofectamine 2000 (Invitrogen) 
for NIH-3T3 and RIN-m5f cells, or Fugene6 (Roche) for all other cell lines.  
Lipofectamine 2000 was used for transfection of siRNA (Stealth; Invitrogen) in all 
cell lines, with the medium GC Stealth control duplex (Invitrogen) used for 
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negative controls.  Stable transfection of neomycin resistance-containing 
plasmids in CHO or HEK-293T cells was achieved by selection with 1mg/ml 
G-418 (Invitrogen) 72 hours after transfection.  After die-off was complete 
(approximately 10 days), G-418 was reduced to a maintenance concentration of 
100µg/ml, and individual clones were selected for growth by dilution plating and 
subsequent cloning ring isolation. 
8.8  Rat Hippocampal Neuron Primary Culture and Transfection
The culture of embryonic rat hippocampal neurons was performed 
essentially as described (Goslin et al., 1998).  Hippocampi from embryonic day 
18-19 Sprague-Dawley rat embryos were dissected into 4℃ Ca+2 / Mg+2 -free 
HBSS.  The collected tissue was dissociated in 0.25% (w/v) trypsin / 1mM EDTA / 
HBSS  at 37℃ for 30 minutes.  Hippocampi were rinsed twice in plating media 
(Neurobasal medium [Invitrogen] containing 10% (v/v) FBS and 0.5mM L-
glutamine), dissociated by trituration with a fire-polished Pasteur pipette, strained 
through a 40µm filter, and collected by centrifugation.  Cells were counted and 
plated (at 10,000 cells / cm2 or 50,000 cells / cm2 for transfection experiments) in 
plating media on either poly-L-Lysine -coated glass coverslips (BD Biosciences) 
or poly-L-Lysine (PLL) -coated glass-bottomed dishes (Mattek) that had been re-
coated with 1mg/ml PLL.  Cells were cultured in 24-well dishes at 37℃ in a 
humidified 5% CO2 tissue culture incubator.  After 24 hours, plating media was 
replaced with NBM complete media (Neurobasal medium containing 2% B27 and 
1% N2 supplements [Invitrogen], 0.5mM L-glutamine, and 10µM                         
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5-fluorodeoxyuridine [FDU]).  Subsequently, 50% of the media was changed 
every 5-6 days.
Mature hippocampal neurons (DIV 10-13) were transfected according to a 
modified calcium phosphate method (Jiang and Chen, 2006) using a commercial 
transfection kit (Invitrogen).  Growth media was reserved and replaced with new 
NBM complete.  Plasmid DNA (1µg) combined with CaCl2 was added slowly to 
2x HBS, mixed gently, and incubated for 15-20 minutes.  Precipitates were added 
to coverslips or glass-bottomed dishes, and neurons were incubated for 2.5 
hours.  Media was then removed and replaced with NBM complete previously 
equilibrated in a 10% CO2 incubator, after which dishes were immediately 
returned to the 5% CO2 incubator.  After 30 minutes, precipitates were observed 
to be largely dissolved and the acidulated media had returned to normal pH; 
media was then replaced with reserved NBM complete.  Experiments were 
performed on neurons 24 hours after transfection.
8.9  Rat Cortico-hippocampal Culture and Nucleofection
Rat embryonic cortico-hippocampal tissue was dissected, trypsinized, and 
dissociated as described above, except that trypsinization proceeded for 1 hour, 
and 10% (v/v) FBS in DMEM was used as plating media.  Cells were centrifuged, 
and media was aspirated and replaced with 100µl supplemented rat neuron 
nucleofection solution (Amaxa) per 5 million cells, according to the 
manufacturerʼs protocol.  DNA (either 3µg receptor-coding plasmid, or 2µg each 
receptor-coding and shRNA-coding) along with 100µl cell suspension was added 
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to an amaxa cuvette and electroporated with program O-03.  Cells were 
immediately removed to FBS/DMEM, and plated in 24-well dishes pre-coated 
with 0.1mg/ml PLL.  Plating density was 1 million cells / well for shRNA 
experiments, and 800,000 cells / well for all other experiments.  After 24 hours, 
media was removed and replaced with NBM complete.  For shRNA experiments, 
NBM complete was supplemented with 1µg/ml puromycin.  Cultures were 
maintained for up to 14 days, with 50% media changes (NBM complete) 
performed every 3 days.
8.10  Mouse Midbrain Dopaminergic Neuron Culture
Mouse midbrain dopaminergic cultures were prepared according to the 
method of Sulzer (Rayport et al., 1992) with modifications (Brewer and Torricelli, 
2007).  One to three- day old mouse pups were euthanized by CO2, and 
sterilized by immersion in 70% EtOH.  Brains were removed to ice-cold HABG 
media (Hibernate-A media (BrainBits LLC) supplemented with 2% B27 and 
0.5mM L-glutamine), meninges were removed, and ventral midbrains were 
dissected and chopped.  Tissue was rinsed in Hibernate-A -Ca+2 (BrainBits LLC), 
and then digested with 34 units / ml papain (Worthington) in Hibernate-A -Ca+2 
containing 0.5mM kynurenic acid (Sigma) with stirring for 1.5h at 37℃.  The 
digested tissue was then rinsed twice in HABG, and dissociated by 3 rounds of 
trituration with a fire-polished Pasteur pipette followed by straining through a 
40µm filter.  Cells were collected by centrifugation and resuspended in DAergic 
media (Neurobasal-A [Invitrogen] containing 2% B27, 0.5mM L-Glutamine, 
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0.5mM kynurenic acid, 1mM HCl, and 1% (v/v) heat-inactivated FBS).  Viable 
cells were indicated by trypan blue dye exclusion, counted, and cells were plated 
on PLL -coated glass coverslips at a density of 100,000 cells / coverslip.  24 
hours after plating, coverslips were moved to new DAergic media containing 
10ng/ml GDNF (Millipore).  One to two days later (or when glia were observed to 
be nearly confluent), 10µM FDU was added; 50% media changes were 
performed every 3 days thereafter.
8.11  Immunoblotting and Sample Preparation
Rodent brain lysates were prepared in RIPA buffer (PBS, pH=7.4, 1% (v/v) 
Triton X-100, 0.5% (w/v) sodium deoxycholate, 0.1%(w/v) SDS, 1% (v/v) 
protease inhibitor cocktail III (Calbiochem), 0.5mM PMSF) including phosphatase 
inhibitors (50mM NaF, 200µM Na3VO4, 2mM EDTA, 5mM Na4P2O7) by 
homogenization in a Potter-Elvehjem tissue grinder, incubation at 4℃ for 1 hour, 
and centrifugation at 20,000xg for 30 minutes (pellets were discarded).  Lysates 
from other tissues were prepared as indicated.  When required, protein content 
was determined with a bicinchoninic acid (BCA) assay kit (Pierce / Thermo 
Scientific).  Samples were resuspended in 1x LDS buffer (Invitrogen) containing 
100mM DTT and incubated at 70℃ for 10 minutes.  Samples to be blotted for 
muscarinic receptors were incubated at 24℃ for 1 hour, as heating led to 
aggregation of receptor protein.  Reduced samples were loaded onto NuPage 
Bis-Tris 4-12% polyacrylamide gels (Invitrogen), separated by SDS-PAGE, and 
electro-transferred to nitrocellulose membranes.  To visualize transferred 
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proteins, membranes were rinsed in ddH2O, incubated in 0.5% ponceau red / 5% 
HOAc for 1 minute, rinsed in ddH2O, and scanned.  For visualization by 
enhanced chemiluminescence (ECL), membranes were blocked either 1h at 
24℃ or overnight at 4℃ in PBST (0.1% Tween-20 in PBS, pH=7.4) containing 
5% nonfat dry milk (w/v).  Membranes were then incubated with primary 
antibodies (see table 8.2) diluted in blocking buffer for either 1 hour at 24℃ or 
overnight at 4℃, followed by 4 washes with PBST.  Appropriate horseradish 
peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch) were 
diluted in PBST (1:10,000) and incubated with membranes for 1h at 24℃, 
followed by 4 washes in PBST and a final rinse in PBS.  Immunoreactive signals 
were detected by ECL (Perkin Elmer) and exposure to BioMax XAR film (Kodak).  
For ECL detection of M3-phospho-S577, 3% (w/v) BSA / 0.1% (v/v) Tween-20 / 
TBS (pH=8.0) was used for blocking and dilution of primary antibody.  For 
detection by infrared fluorescence, membranes were blocked in Odyssey 
blocking buffer (Li-Cor Biosciences) for 1 hour at 24℃, followed by overnight 
incubation at 4℃ with antibodies diluted in Odyssey blocking buffer containing 
0.1% Tween-20.  After washing, blots were incubated 45 minutes with IR-dye 
conjugated secondary antibodies diluted in Odyssey blocking buffer / 0.1% 
Tween-20.  Membranes were then washed and visualized by scanning on an 
Odyssey infrared imager (Li-Cor Biosciences) for fluorescent emission at 680 
and 800 nm.
194
8.12  Coomassie Staining
Samples were prepared and separated by SDS-PAGE as for 
immunoblotting.  Gels were either stained 1 hour in 40% (v/v) MeOH / 10% (v/v) 
HOAc / 0.25% (w/v) Coomassie R-250, followed by overnight destaining in 40% 
MeOH / 10% HOAc, or rinsed 3 times in ddH2O, followed by 1 hour staining in 
SimplyBlue SafeStain (Invitrogen) followed by overnight destaining in ddH2O.
8.13  Immunofluorescence Staining
Cells grown on glass coverslips were rinsed and fixed either in 4% (w/v) 
paraformaldehyde / 4% (w/v) sucrose in PBS (pH=7.4) for 30 minutes at 24℃ , 
or with -20℃ MeOH for 2.5 minutes, followed by rinsing in PBS.  In some cases, 
cells were pre-extracted before fixation with 0.03% saponin in cytosolic buffer 
(25mM HEPES-KOH, pH=7.4, 25mM KCl, 2.5mM Mg acetate, 5mM EGTA, 
150mM K-glutamate) for 30 seconds at 37℃, rinsed at 37℃ with intracellular 
buffer, and fixed for 30 minutes at 24℃ with 4% (w/v) paraformaldehyde in 
cytosolic buffer (Morris and Cooper, 2001).  Fixed cells were permeabilized with 
0.25% (v/v) Triton X-100 in PBS for 10 minutes, rinsed in PBS, and blocked for 
30 minutes in antibody diluent (2% [w/v] BSA, 0.05% (v/v) Triton X-100, 0.02% 
NaN3 in PBS), followed by incubation with primary antibodies diluted in antibody 
diluent for either 1.5 hours (24℃) or overnight (4℃) in a humidified chamber 
(table 8.1).  Coverslips were washed 4 times in PBS containing 0.05% (v/v) Triton 
X-100, and were incubated with appropriate fluorescent dye - conjugated 
secondary antibodies diluted in antibody diluent for 45 minutes at 24℃.  After 
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washing, coverslips were mounted in Fluoromount-G (Southern Biotech) and 
imaged with a LSM510 confocal system (Zeiss Microimaging) using either 40x 
1.3NA or 100x 1.4NA oil objectives.  In some cases, staining was limited to 
extracellular epitopes by eliminating the permeabilization step and excluding all 
detergents from the staining procedure.
8.14  Live Imaging of Primary Cultured Hippocampal Neurons
Primary cultures of embryonic rat hippocampal neurons were prepared as 
described above, and plated on glass-bottom tissue culture dishes (MatTek).  DIV 
10-13 cultures were transfected with GFP- and/or mCherry- tagged expression 
constructs by the calcium phosphate method.  Twenty four hours after 
transfection, media was replaced with imaging buffer (Hibernate-E low 
fluorescence [BrainBits LLC], 2% B27, 0.5mM L-glutamine) and pre-incubated 30 
minutes at 37℃ in an ambient CO2 incubator.  Cells were imaged at 37℃ with a 
Axiovert 200M microscope (Zeiss Microimaging) equipped with an UltraView 
spinning disk confocal head (Perkin Elmer), EMCCD camera (Hamamatsu), 
piezo-actuated specimen stage (Prior Scientific) and 100X 1.46NA α-Plan-
Apochromat objective (Carl Zeiss Microimaging).  CCh (1mM) was added to the 
imaging buffer as indicated.  Near-simultaneous GFP and mCherry emission was 
detected with a FITC / Texas Red filter set, respectively, and acquired and 
analyzed using Metamorph software (Molecular Devices).  
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8.15  Production of Recombinant GST-fusion Protein
Desired cDNA fragments were cloned into pGEX 4T or 5X vectors in-
frame with the glutathione-S-transferase (GST) coding sequence (under 
transcriptional control from the Lac operon) as described above, and transformed 
into the E. coli strain BL21(DE3)pLysS.  Cultures were grown at 37℃ in Luria-
Bertani media until log-phase, induced with 1mM of the allolactose analogue 
IPTG, and incubated at 24℃ for 3 hours.  Bacteria were collected by 
centrifugation, and lysed by a freeze-thaw cycle in LN2 followed by incubation at 
4℃ in lysis buffer (PBS, pH=7.4, 1% (v/v) Triton X-100, 1mM DTT, 1% (v/v) 
protease inhibitor cocktail III (Calbiochem), 0.5mM PMSF, 1 mg/ml lysozyme).  
The lysate was sonicated to disrupt genomic DNA, and was then cleared by 
centrifugation at 20,000g for 30 minutes.  Recombinant GST-fusion proteins were 
then purified by batch affinity chromatography using Glutathione Sepharose 4B 
(Amersham / GE Life Sciences) at 4℃ for 12 hours.  The affinity matrix was then 
washed 3 times in lysis buffer with decreasing detergent concentrations (0.5%, 
0.1%, 0%), and then stored at -20℃ in 1:1 (v/v) PBS:glycerol.  Purity, integrity, 
and concentration of recombinant GST proteins were analyzed by SDS-PAGE 
and coomassie staining as described above (with standardized BSA included as 
necessary for quantification).       
8.16  GST Pulldown Assay
For pulldown of exogenously expressed proteins, COS-7 or HEK-293 cells 
were transfected with c-myc -tagged protein expression plasmids as indicated.  
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48 hours later, cells were lysed for 1 hour at 4℃ in L-100 buffer (PBS, pH=7.4, 
100mM KCl, 0.5% (v/v) Triton X-100, 1mM DTT, 1% (v/v) protease inhibitor 
cocktail III (Calbiochem), 0.5mM PMSF).  Lysates were cleared by centrifugation, 
a sample was reserved (“input”), and remaining lysate (1ml) was incubated with 
5µg glutathione sepharose-bound GST fusion proteins overnight at 4℃.  
Alternatively, [35S]methionine-labeled proteins were prepared from cDNA 
templates using the TNT quick coupled transcription-translation kit as described 
for the phospholipid binding assay, and labeled proteins were diluted in L-100 
buffer and incubated with sepharose-bound GST proteins as described above.  
The affinity matrix was washed 3 times for 5 minutes at 4℃ with respective lysis 
buffers, and bound proteins were eluted in 2X LDS loading buffer / 100mM DTT.  
Eluted and input samples were processed for immunoblotting as described 
above, with GST fusion protein content verified by ponceau staining, and bound 
proteins detected by anti-HA 3F10, rabbit anti-GFP, or anti-c-myc  9E10 primary 
antibodies as indicated.
For pulldown of endogenously expressed proteins from rodent brain 
lysates, whole mouse or rat brains were homogenized in L-100 buffer containing 
0.1% (v/v) Triton X-100 with a Potter-Elvehjem tissue grinder and incubated at 
4℃ for 1 hour.  Lysates were cleared by centrifugation at 20,000g for 30 minutes, 
Triton X-100 concentration was adjusted to 0.5% (v/v), and GST-pulldown 
experiments were performed as described above, except using 40µg GST fusion 
proteins per 1ml lysate, performing 2 washes, and using indicated primary 
antibodies against endogenous rodent brain proteins as indicated.
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8.17  Co-Immunoprecipitation
For co-immunoprecipitation of proteins with muscarinic receptors, tissue 
culture cells (HEK-293T, COS-7, CHO) or primary cultured rat cortico-
hippocampal neurons were transfected / nucleofected with expression vectors for 
GFP- or HA- tagged MRs with or without co-transfection / co-nucleofection of 
myc-tagged putative interacting protein expression plasmids as indicated.  Cells 
were treated with CCh as indicated, and were lysed on ice in Co-IP buffer (50mM 
Tris-HCl, pH=8.0, 50mM NaF, 200µM Na3VO4, 1% (v/v) protease inhibitor 
cocktail III (Calbiochem), 0.5mM PMSF) including either 0.86% (w/v) digitonin / 
0.17% (w/v) Na Cholate, 1% (w/v) CHAPSO, or 0.5% (w/v) Triton X-100.  For 
cross-linking experiments, cells were rinsed twice in PBS, incubated with 0.2 mg/
ml of the disulfide-cleavable bifunctional crosslinker Dithiobis[succiniminyl 
propionate] (DSP) (Pierce / Thermo Scientific) for 20 minutes at 24℃, washed/
quenched for 15 minutes in TBS, and solubilized in RIPA buffer.  Lysates were 
cleared by centrifugation, an aliquot was reserved (“input”), and lysates were 
incubated with anti-GFP antibodies (1:500 rabbit polyclonal ab290 (Abcam); 
mouse monoclonal (19C8 10.2ul 19F7 3.4ul) (M. Heiman)) or 20ul HA.11-
agarose slurry (Covance) for 3 hours at 4℃.  GFP immunocomplexes were 
precipitated by incubation with protein A- (Amersham / GE Life Sciences) or 
protein A/G- (Pierce / Thermo Scientific) sepharose for 2 hours at 4℃, all resins 
were washed 3 times in respective lysis buffer (or 0.1% (w/v) digitonin), and 
proteins eluted by incubation at room temperature with LDS loading buffer / DTT 
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as described above.  Samples were analyzed by immunoblotting for immuno- 
and co-immuno- precipitated proteins as described above.  
Co-immunoprecipitation of AP-3 components with myc-tagged AGAP1 
was performed as previously described (Nie et al., 2003).  Briefly, NIH-3T3 cells 
transfected with expression plasmids encoding full length or truncated AGAP1-
myc were lysed in 3T3 buffer (25mM tris, pH=8.0, 100mM NaCl, 1% (v/v) Triton 
X-100, 10% (v/v) glycerol, 1% (v/v) protease inhibitor cocktail III (Calbiochem), 
0.5mM PMSF) with 3 freeze-thaw cycles in LN2.  Lysates were cleared by 
centrifugation, and then incubated with 20µl / ml anti-myc 9E10 agarose 
(Covance) for 14 hours at 4℃.  The affinity matrix was washed 3 times with 3T3 
buffer, proteins were eluted with LDS sample buffer / DTT at 70℃, and samples 
analyzed by immunoblotting as described above.
8.18  Subcellular Fractionation Experiments
Subcellular fractionation of cultured primary neurons by glycerol velocity 
gradient centrifugation was performed essentially as described (West et al., 
1997b).  Rat cortico-hippocampal neurons (25 million cells) were nucleofected 
with indicated M5 expression plasmids, plated in PLL-coated 100mm dishes, and 
cultured as described above for 14 days.  A 7-step 5-30% (v/v) gradient of 
glycerol in SV buffer (10mM HEPES pH=7.4, 150mM NaCl, 1mM EGTA, 1mM 
MgCl2) was prepared and allowed to diffuse at 24℃ for 2 hours during 
membrane preparation.  Cells were treated with 0.1mM CCh for 1 hour, washed 
once in SV buffer, collected in SV buffer, and pelleted by centrifugation at 5500g 
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for 5 minutes.  Pellets were resuspended in ice-cold ddH20, homogenized with 12 
strokes of a teflon-glass homogenizer at 500 rpm, adjusted to 1X SV buffer, and 
centrifuged at 1000g for 5 minutes.  The supernatant was collected, 
supplemented with 1% (v/v) Protease Inhibitor Cocktail III (Calbiochem) and 
0.5mM PMSF, loaded on top of the previously prepared glycerol gradient, and 
was ultracentrifuged for 66 minutes at 48,000 rpm in a sw50.1 rotor (Beckman 
Coulter).  Fractions (8) were unloaded from the top of the gradient.  For 
immunoblot analysis, fraction volume was adjusted to 1.3ml with SV buffer, 
fractions were ultracentrifuged for 2 hours at 150,000g, pellets were solubilized in 
LDS sample buffer / 100mM DTT, and samples were processed as described 
above.  For analysis of M5 content by radioligand binding, fractions (250µl) were 
diluted to a total volume of 500µl with SV buffer, and incubated with 1nM [3H]3-
quinuclidinyl benzilate (Perkin Elmer) for 1 hour at 37℃.  Non-specific binding 
was determined in the presence of 1µM atropine.  Samples were collected by 
vacuum filtration on GF/B glass fiber filters (Whatman) presoaked 1 hour in 
0.05% (w/v) polyethylenimine.  Filters were rapidly washed with 5ml ice-cold SV 
buffer, dried, and bound radioactivity determined by liquid scintillation 
spectrometry. 
  Analysis of M5 transport to lysosomes was performed by self-forming 
Percoll density gradient centrifugation essentially as described (Schaub et al., 
2005).  Rat cortico-hippocampal neurons (15 million cells) were nucleofected with 
M5wt-GFP and M5∆-GFP and cultured for 19 days as described.  Cells were 
treated with 1mM CCh in the presence of the lysosomal protease inhibitor 
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leupeptin (Sigma; 100µM) for 4.5 hours.  Cells were collected in HB (250mM 
sucrose, 1mM EDTA) and homogenized by 12 passes through a 1-ml syringe 
attached to a 25-gauge needle.  Homogenates were adjusted to 1.7ml with HB 
and centrifuged for 10 minutes at 370g.  The post-nuclear supernatant was 
loaded on top of 8.5ml 17.5% (w/v) Percoll (sigma) / 1X HB, underlayered with 
1.2ml 10X HB, and centrifuged for 30 minutes at 26,500g in an SS-34 rotor 
(Sorvall / Thermo Scientific).  Nine 1.2ml fractions were collected from the top of 
the gradient, and fractions were ultracentrifuged at 200,000g for 30 minutes.  
Membrane layers were collected, solubilized in 1X LDS/DTT, and analyzed by 
immunoblotting as described above.
Fractionation of rat brain homogenate by density gradient using the iso-
osmotic centrifugation medium iodixanol was performed generally as described 
(Lee et al., 2003).  1/2 of an adult female rat brain was homogenized in HM 
(0.25M sucrose, 20mM tris, pH=7.4, 1mM EDTA, 1mM EGTA) with a tight-pestle 
dounce homogenizer (20 strokes) followed by passage through 20- and 25- 
gauge needles (20 and 10 times, respectively).  Homogenates were centrifuged 
for 10 minutes at 500g, and then the post-nuclear supernatant adjusted to 25% 
(w/v) iodixanol (OptiPrep; Axis-Shield) / 1X HB and overlayered with an 
iodixanol / 1X HB step gradient (20, 18.5, 16.5, 14.5, 12.5, 10.5, 8.5, 6.5, 5% (w/
v)).  Gradients were centrifuged at 27,000 RPM for 20 hours at 4℃ in an SW41 
rotor (Beckman Coulter), and 26 fractions collected from the top.  Fractions were 
solubilized in LDS sample buffer / DTT and analyzed by immunoblot as described 
above.     
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8.19  [N-methyl-3H]-Scopolamine Radioligand Binding Assay
For experiments in tissue culture cells, cells were plated in 12- or 24-well 
dishes pre-coated with PLL.  For transient plasmid transfection or siRNA 
experiments, cells were transfected 24 hours after plating with expression 
plasmids or siRNA duplexes as described above.  Forty eight hours after 
transfection, cells were treated as indicated, transferred to ice, and washed once 
in ice-cold HEPES-HBSS (118 mM NaCl, 5mM KCl, 1mM CaCl2, 1mM MgCl2, 
5mM Glucose, 15mM HEPES, pH=7.4).  Cells were incubated for 3 hours at 4℃ 
in HHBS containing 1nM of the cell-impermeant MR antagonist [N-methyl-3H]-
scopolamine ([3H]NMS; Perkin Elmer).  For heterologous competition binding 
experiments, various concentrations of unlabeled drugs were added.  Non-
specific binding was determined by addition of 10µM benztropine mesylate 
(Sigma).  Binding was terminated by aspiration and 3 rapid washes with ice-cold 
HEPES-HBSS.  Cells were solubilized overnight in 0.1% SDS, lysates were 
removed to vials containing 5ml scintillation cocktail (Ready-Safe, Beckman 
Coulter) and total radioactivity measured by liquid scintillation spectrometry.  
Assays were performed in triplicate, with specific binding determined by 
subtraction of NSB from all values. Non-linear regression analysis of competition 
binding data was performed with curve-fitting software (GraphPad Prism).  When 
indicated, cell lysates were collected in RIPA buffer and stored at -20℃.
For radioligand binding experiments in primary cultured rat neurons, 
mature cultures (DIV 12-13) were assayed essentially as described above.  
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Neurons were nucleofected before plating with expression and/or shRNA 
plasmids as indicated.  Heterologous [3H]NMS competition binding pilot 
experiments examining IC50 values of the muscarinic antagonist AF-DX 384 
(Tocris) in control-, M5wt-, and M5∆- nucleofected cultures were performed as 
described above.  Thereafter, all M5 [3H]NMS binding experiments were 
performed in the presence of 5µM AF-DX 384.  M5-specific [3H]NMS binding was 
defined by subtracting control (empty vector) values from those of M5wt- or M5∆- 
nucleofected wells.  All assays were performed in triplicate.
8.20  Muscarinic Receptor Internalization and Recycling Assays
For experiments in tissue culture cells, cells were pre-incubated 2 hours in 
growth media containing 10µg/ml cycloheximide (CHX) in order to arrest 
synthesis of receptor proteins.  CHX was included in all washes and incubations 
thereafter.  To induce receptor endocytosis, the non-hydrolyzable acetylcholine 
analogue carbachol (CCh) (100µM) was added, and cells were incubated for 
various times.  To measure recycling of internalized muscarinic receptors, CCh-
treated cells were rinsed 3 times in 37℃ Ca2+- and Mg2+- free HBSS, and then 
incubated in CCh-free growth media for various times.  At the end of the 
treatment period, cells not subjected to recycling conditions were rinsed 3 times 
in 37℃ HBSS, all wells were washed with ice-cold HEPES-HBSS, and cells were 
assayed for surface muscarinic receptor binding with [3H]NMS as described 
above.
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For experiments in primary cultured neurons, growth media was replaced 
with HABG (pH=7.3) and cells were pre-incubated 1 hour at 37℃ in an ambient-
CO2 incubator.  For Brefeldin-A (BFA) inhibition experiments, cells were pre-
incubated 2 hours in HABG with (5µM) BFA or EtOH solvent only; BFA / EtOH 
was also present in all subsequent washes and incubations.  Internalization was 
induced by incubation with 100µM CCh for 30 minutes.  Recycling of internalized 
receptors was induced by washing 3 times with with 37℃ MOPS rinse buffer 
(10mM MOPS, pH=7.3, 90mM NaCl, 1.8 mM CaCl2, 5.4 mM KCl, 0.8mM MgCl2, 
0.9mM NaHCO3, 0.9mM NaH2PO4, 25mM glucose) and incubation for 1 hour in 
new HABG.  Control- and non-recycled- wells were rinsed 3 times with MOPS 
rinse buffer, all cells were washed with ice-cold HEPES-HBSS, and surface [3H]-
NMS binding was performed as described above.  For K+ depolarization 
treatments, cells were treated with depolarization buffer (10mM MOPS, pH=7.3, 
45mM KCl, 50.4mM NaCl, 0.8mM MgCl2, 0.9mM NaHCO3, 0.9 mM NaH2PO4, 
25mM glucose) for 1 or 5 minutes, with or without standard media washout as 
indicated.
8.21  Mouse Cerebral Vasculature Isolation and Radioligand Binding
Microvessels from wild-type, M5∆/∆ and M5-/- mouse brains were isolated 
according to a published protocol (Jung and Levy, 2005).  Two mice from each 
genotype were sacrificed by CO2 inhalation, and pooled brains were minced in 
ice-cold DMEM / 20mM HEPES (pH=7.5).  Tissue was collected by centrifugation 
(5 minutes, 500g) and digested in 0.05% collagenase/dispase (Roche) in PBS for 
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30 minutes at 37℃.  The digestions were stopped by addition of 1mM EDTA, and 
tissue was collected by centrifugation (10 minutes, 1000g) and resuspended in 
DMEM / HEPES containing 17% dextran (molecular weight 60,000-90,000 
daltons; Sigma).  Tissue suspensions were centrifuged for 30 minutes at 
10,000g, and blood vessel-containing pellets were collected, resuspended in 4℃ 
THM buffer (50mM Tris-HCl, pH=7.4, 2mM MgCl2) and re-centrifuged at 10,000g 
for 15 minutes.  Pellets were resuspended in 2.5ml THM, homogenized with a 
Polytron device (Kinematica GmbH), and total protein measured by BCA assay.  
Vessel homogenates were adjusted for equal protein content, and incubated in 
triplicate with 1nM [3H]NMS at 4℃ for 3 hours.  Non-specific binding was defined 
by the addition of 10µM benztropine mesylate.  Binding was terminated by 
centrifugation at 10,000g for 5 minutes at 4℃.  The supernatant was aspirated, 
tubes rapidly washed with 1.5ml ice-cold THM buffer, and pellets incubated in 
0.1% SDS overnight.  [3H] content in solubilized pellets was measured by liquid 
scintillation spectrometry, and specific [3H]NMS binding determined by 
subtraction of non-specific DPM values from total binding.    
8.22  MAP Kinase Activation Assay
HEK-293T cells transfected with MR-coding constructs were grown to 
confluence in 24-well dishes and pretreated 30 minutes in serum-free Opti-Mem 
(Invitrogen).  Cells were treated with various concentrations of CCh for 10 
minutes, rinsed once in ice-cold PBS, and lysed in phospho-triton buffer (PBS 
pH=7.4, 0.5% Triton X-100, 2mM EDTA, 200µM Na3VO4, 50mM NaF, 5mM 
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Na4P2O7, 1% (v/v) protease inhibitor cocktail III (Calbiochem), 0.5mM PMSF) at 
4℃ for 1 hour.  Lysates were cleared by centrifugation at 10,000g for 15 minutes 
and processed for immunoblotting as described above.  Total and 
phosphorylated (pT202 / pY204) forms of p44/42 MAP kinase were detected by 
Odyssey imaging (Li-Cor) with indicated antibodies. 
8.23  Inositol Monophosphate Accumulation Assay
Activation of PLC-β by Gαq-coupled MRs was monitored via the 
accumulation of the D-myo-inositol 1,4,5 triphosphate metabolite inositol 
monophosphate (IP1) in the presence of the inositol monophosphatase inhibitor 
LiCl (Trinquet et al., 2006).  HEK-293T cells plated on poly-L-lysine -coated 24-
dishes were transfected with MR expression plasmids (0.25µg/well).  Forty eight 
hours later, growth media was replaced with IP-One stimulation buffer (10mM 
HEPES , pH=7.4, 1mM CaCl2, 0.5mM MgCl2, 4.2mM KCl, 146 mM NaCl, 5.5 
mM glucose, 50mM LiCl) containing various concentrations of carbachol.  After 1 
hour of incubation at 37℃, cells were lysed and assayed for IP1 content with the 
IP-One ELISA kit (Cisbio) according to the manufacturerʼs protocol.  Unknown 
IP1 values were interpolated from a standard curve, and EC50 values for CCh 
determined by curve-fitting to a dose-response model with nonlinear regression 
software (GraphPad Prism).
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8.24  Fluo-3 Calcium Assays
Fluorometric measurement of intracellular Ca2+ concentration was 
performed essentially as described (Cypess et al., 1999).  CHO cells transfected 
with MR expression plasmids 48 hours previously were harvested in PBS and 
incubated at 37℃ for 1 hour.  Cells were collected by centrifugation at 2000g for 
2 minutes, and washed 3 times in EBSSH-P (26mM HEPES, pH=7.4, 125mM 
NaCl, 5mM KCl, 1mM MgSO4, 1mM NaH2PO4, 5.6mM glucose, 2mM CaCl2, 
0.1% (w/v) BSA, 2.5mM probenecid (Invitrogen)).  Cells were resuspended in 
EBSSH-P and loaded with 2µM of the cell-permeant fluorescent Ca2+ indicator 
Fluo-3/AM (Invitrogen) for 1 hour at 24℃.  Cells were washed once in EBSSH-P, 
and pre-treated with 100µM CCh for 30 minutes when indicated.  Cells were 
washed twice more, resuspended in 1.5ml EBSSH-P, and Fluo-3 fluorescence 
(excitation = 505nm, emission = 525nm) was monitored with a F-2000 
fluorescence spectrophotometer (Hitachi) with constant stirring.  MR stimulation 
with 100µM CCh was performed after baseline fluorescence values had been 
established (1 minute or greater).  At the end of recordings, fluorescence maxima 
and minima (Emax and Emin) were determined by cell lysis   (.07% (v/v) Triton 
X-100) and Ca2+ chelation (5mM EGTA, 37.5mM Tris, pH=8.7), respectively.  
Fluorescence emission at each 0.1 second time point was normalized to Emax 
and Emin and data were plotted as F/F0 ratios.  
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8.25  In situ Hybridization
15µm thick coronal and sagittal sections of fresh-frozen C57Bl/6 wild-type 
mouse brain were mounted on slides, fixed in 4% paraformaldehyde for 10 
minutes, rinsed in PBS, acetylated with acetic anhydride in triethanolamine buffer 
for 10 minutes, rinsed in PBS, dehydrated in ascending concentrations of EtOH, 
and dried.  A 772-bp region of the AGAP1 3ʼ UTR was amplified from a mouse 
brain cDNA library by PCR (forward 5ʼ-AAG TTG CAA CCA CCA CGT GAG TCC 
CTC AGT TCC CTC, reverse 5ʼ-CCA AGT AAG GGG ACT GAA GTC AAA TAA 
TAC CCA GC) and cloned into pCRII.  The plasmid was linearized and used as 
template to prepare [33P]-labeled riboprobe using a Maxiscript kit (Ambion) and 
either T7 (sense) or SP6 (antisense) RNA polymerase.  Riboprobes were column 
purified (NucAway, Ambion), and prepared slides were hybridized for 17 hours at 
60℃ with 1x106 Ci of probe in hybridization buffer (50% (v/v) formamide, 0.6M 
NaCl, 50µg/ml salmon sperm DNA, 1X Denhardtʼs solution (Invitrogen), 10%    
(w/v) dextran sulfate, 250µg/ml tRNA, 100mM Tris-Cl pH=8, 2mM EDTA).  Slides 
were washed 3 times for 5 minutes with 2X SSC (30mM Na citrate, pH=7.0, 
300mM NaCl) and treated for 1 hour at 37℃ with RNase A (2µg/ml).  Slides were 
rinsed twice in ddH2O, washed once in 2X SSC for 20 minutes, washed once 
each in 0.5X and 0.2X SSC at 50℃ for 30 minutes, dehydrated in ascending 
concentrations of EtOH, dried, and exposed to Kodak MR film at -80℃.
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8.26  Northern Blotting
For the mAGAP1 Northern blot, antisense [33P]-labeled riboprobe to the 
AGAP1 3ʼ-UTR was synthesized and purified as described for in situ 
hybridization.  A mouse Multiple Tissue Northern blot (BD Biosciences) was pre-
hybridized in Ultrahyb buffer (Ambion) for 30 minutes at 68℃, and then 
hybridized with 8x106 Ci probe in 8ml Ultrahyb at 68℃ overnight.  The blot was 
washed twice for 5 minutes at 68℃ in 2X SSC / 0.1% (w/v)  SDS, washed twice 
for 15 minutes at 68℃ with 0.1X SSC / 0.1% SDS, and was then exposed to 
Biomax XAR film (Kodak).
8.27  Phospholipid Binding Assay
The TNT T7 Quick coupled transcription/translation system (Promega) 
was used to synthesize in vitro [35S]methionine-labeled full-length and truncated 
AGAP1 proteins from AGAP1 cDNAs (full-length and 552-861 truncation mutant) 
cloned in the T7 promoter-containing pcDNA3.1 vector.  Reactions were 
incubated at 30℃ for 2 hours, and product synthesis was confirmed by 
autoradiography: One µl of reaction mixture was separated by SDS-PAGE as 
described above, and the gel was fixed for 30 minutes in 40% MeOH / 10% 
HOAc / 3% glycerol.  The gel was dried and imaged by storage phosphor 
autoradiography with a Storm scanner (GE Life Sciences) after overnight 
exposure.  Phospholipid dot-blot arrays (PIP strips; Echelon Biosciences) were 
blocked 1 hour at 24℃ in PIP blocking buffer (TBS pH=8, 3% (w/v) fatty acid-free 
BSA, 0.1% (v/v) Tween-20).  Arrays were incubated with remaining 
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[35S]methionine-labeled proteins in PIP blocking buffer for 3 hours, washed 6 
times for 5 minutes in PIP blocking buffer, dried, and imaged by storage 
phosphor autoradiography.       
8.28  Superfused Mouse Striatal Synaptosome Neurotransmitter Release
Experiments measuring stimulated release of [3H]dopamine from striatal 
synaptosomes were performed according to previously described protocols 
(Yamada et al., 2001a; Westphalen and Hemmings, 2003; Martire et al., 2007) in 
collaboration with Dr. Hugh Hemmings (Weill Cornell Medical School, New York 
NY).  Mice were sacrificed by cervical dislocation, and striata rapidly dissected on 
ice.  Striatal tissue was homogenized in 0.32M sucrose with a motor-driven 
teflon-glass homogenizer (500rpm, 10 strokes, 4℃).  The homogenate was 
centrifuged at 4,000g for 2 minutes, the resulting supernatant layered on top of 
0.8M sucrose, and was re-centrifuged at 36,000g for 30 minutes.  The resulting 
pellet, containing demyelinated nerve terminals (synaptosomes), was 
resuspended in ice-cold 0.32M sucrose.  Synaptosomes were suspended in 
Krebs-HEPES buffer (20mM HEPES, pH=7.4, 140mM NaCl, 5mM KCl, 1mM 
MgCl2, 1.2mM Na2HPO4, 5mM NaHCO3, 10mM glucose) containing 10µM 
pargyline and 500nM desipramine, and were loaded with [14C]glutamate (Perkin 
Elmer) for 45 minutes and with [3H]dopamine (Perkin Elmer) for 15 minutes at 
35℃.  [3H]/[14C]-Loaded synaptosomes were centrifuged at 20,000g for 10 
minutes, resuspended in 0.32M sucrose, loaded into superfusion chambers 
(Brandel) capped with GF/B glass fiber filters (Whatman), and superfused with 
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superfusion buffer (Krebs-HEPES, 2mM CaCl2, 20µM pargyline) at 37℃ with a 
modified Brandel SF12 superfusion apparatus (Westphalen and Hemmings, 
2003) operating at a flow rate of 0.25ml/min and collecting fractions at 2-minute 
intervals.  After a 30-minute equilibration period, neurotransmitter release was 
stimulated with a 2-minute pulse of superfusion buffer containing 15mM KCl.  
After an additional 12 minute interval with standard (5mM KCl) superfusion 
buffer, a second 2-minute pulse of superfusion buffer containing either 15mM KCl 
or 15mM KCl + 100µM oxotremorine-M (Tocris) was applied.  At the end of the 
experiment, synaptosomes were lysed with 0.2M perchloric acid.  [3H]Dopamine 
and [14C]glutamate were quantified in collected fractions (including 
synaptosomal lysate) added to Biosafe II scintillation cocktail (Research Products 
International) using liquid scintillation spectrometry with dual isotope quench 
correction.  
Raw data were converted to fractional release values (CPM [3H]dopamine 
or [14C]glutamate released as a % of total remaining labeled neurotransmitter at 
the start of fraction collection) and plotted against fraction collection time.  Basal 
release curves were interpolated from pre-, inter-, and post K+ stimulation pulse 
periods, and used to calculate the cumulative fractional release above baseline 
after the 2 stimulation pulses.  
   
8.29  Fast Scan Cyclic Voltammetry
Fast scan cyclic voltammetric measurement of dopamine release was 
performed in the laboratory of Dr. David Sulzer (Columbia University, New York 
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NY) according to previously published protocols (Zhang and Sulzer, 2003).  For 
the preparation of acute striatal slices, mice were sacrificed by cervical 
dislocation, decapitated, and brains were washed in ice-cold oxygenated artificial 
cerebrospinal fluid (aCSF in mM: 119 NaCl, 2.5 KCl, 23.8 NaHCO3, 2.4 CaCl2, 
1.2 MgCl2, 1.2 NaH2PO4, 10 glucose, and saturated with 95% O2 / 5 % CO2).  
Striatal brain slices were cut on a vibratome at 250µm thickness from the second 
to fourth frontal slice of caudate–putamen (bregma, +1.54 mm to +0.62 mm) 
(Franklin and Paxinos, 1997).  Slices were allowed to recover for 1.5 hr in a 
holding chamber in aCSF at room temperature. 
For cyclic voltammetry recordings, striatal slices were placed in a 
recording chamber and superfused (~1 ml/min) with aCSF at ~30 °C.  Disk 
carbon fiber electrodes of 5µm in diameter with a freshly cut surface were placed 
close to corpus callosum in the dorsal striatum (laterodorsal to dorsal section).  
Consistent insertion of the recording electrode into the tissue was achieved by 
using geometrical feature of the stimulating electrode and changes in basal 
currents associated to transition from solution to tissue.  For cyclic voltammetry 
(CV), triangular voltage waves (+450 to +800 mV at 294 V/s vs Ag/AgCl, every 
100 ms) were generated using Igorʼs application (Data Acquisition) created by 
Eugene V. Mosharov (Igor v5.0; WaveMetrics, Inc., www.wavemetrics.com),and 
were applied to the recording electrode using an ITC-18 analog–digital interface 
(HEKA Instruments Inc., Bellmore, NY)and the Axopatch 200B amplifier 
(Molecular Devices, Burlingame, CA).  Striatal slices were electrically stimulated 
with a bipolar stimulating electrode using an Iso-Flex stimulus isolator triggered 
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by a Master-8 pulse generator (A.M.P.I., Jerusalem, Israel).  Currents were 
recorded with an Axopatch 200B amplifier with a low-pass Bessel Filter setting at 
10 kHz, digitized at 25 kHz, and acquired with the Igorʼs application. DA signals 
were identified by background-subtracted cyclic voltammograms, and DA peak 
currents were determined using an IGORʼs application (Quanta Analysis) created 
by E. Mosharov (www.sulzerlab.org/download.html).  Recording electrodes were 
calibrated before and after each experiment to determine the concentration of 
dopamine released by each stimulus.  Eight prepulses were delivered every two 
minutes before each experiment to achieve constant dopamine release.  For 
oxotremorine-M (Oxo-M) incubations, a single stimulus was applied every two 
minutes.  Four prepulses were used as preincubation controls. Oxo-M was either 
applied for ten pulses (20 minutes), or for five pulses (10 minutes) followed by a 
ten pulse (20 minute) washout with aCSF.
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Table 9.1 Immunocytochemistry antibody list
antigen (Ab name) source host dilution - IF
adaptin δ (SA4) DSHB (A. Peden) mouse 1:100
c-myc (ab9106) Abcam rabbit 1:200
c-myc (9E10) Covance mouse 1:500
EEA1 (610456) BD Transduction Labs mouse 1:500
GFP (ab6556) Abcam rabbit 1:10000
GFP (ab13970) Abcam chicken 1:2000
HA (3F10) Roche rat 1:50
HA (HA.11) Covance mouse 1:100
KIAA0701 (ab26176) Abcam chicken 1:500
MAP-2 (AB5622) Chemicon rabbit 1:1000
rab5 (108011) Synaptic Systems mouse 1:150
rab7 (ab50533) Abcam mouse 1:150
synapsin I (ab8) Abcam rabbit 1:500
transferrin receptor Zymed mouse 1:500
tyrosine hydroxylase Abcam mouse 1:250
tyrosine hydroxylase Chemicon rabbit 1:1000
Table 9.2 Immunoblotting antibody list
antigen (antibody) source host dliution - IB
β-actin (AC-15) Abcam mouse 1:10000
adaptin α (610501) BD Transduction Labs mouse 1:1000
adaptin β2 (610381) BD Transduction Labs mouse 1:10000
adaptin γ (610385) BD Transduction Labs mouse 1:5000
adaptin δ (SA4) DSHB (A. Peden) mouse 1:1000
Adaptin σ3A (611272) BD Transduction Labs mouse 1:250
rAGAP1 (AS625) S. Meurer rabbit 1:1000
c-myc (9E10) Covance mouse 1:1000
EEA1 (610456) BD Transduction Labs mouse 1:2500
GAL4 AD (345765) Calbiochem mouse 1:500
GAL4 DNA-BD (5399) Clontech mouse 1:4000
GFP (ab6556) Abcam rabbit 1:5000
HA (3F10) Roche rat 1:500
HA (HA.11) Covance mouse 1:1000
KIAA0701 (ab26176) Abcam chicken 1:2000
M3 pS577 (RU1653) (affinity purified) rabbit 1:1000
Na+, K+ ATPase β2 (610914) BD Transduction Labs mouse 1:500
β-NAP (610892) BD Transduction Labs mouse 1:500
p44/42 MAPK (9102) Cell Signalling rabbit 1:1000
Phospho-p44/42 MAPK (9106) Cell Signalling mouse 1:1000
p47A (610890) BD Transduction Labs mouse 1:250
rab5 (610281) BD Transduction Labs mouse 1:250
synaptophysin (611880) BD Transduction Labs mouse 1:20000
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Table 9.3 RNA and DNA oligos used for siRNA transfection and 
construction of shRNA plasmids
oligo sequence
hAGAP1 1 + CCGUGCACAUCAGCCAGACAAGUAA
hAGAP1 1 - UUACUUGUCUGGCUGAUGUGCACGG
hAGAP1 2 + GGUGGGAGUUUAAGCGACUAUUCCU
hAGAP1 2- AGGAAUAGUCGCUUAAACUCCCACC
hAGAP1 3 + GCGUGCUGACCUAUCAUCCCAGUUU
hAGAP1 3 - AAACUGGGAUGAUAGGUCAGCACGC
shRNA ctl + GATCCCCGTTCCGAACACACGCACAATTCAAGAGATTGTGCGTGTGTTCGGAACTTTTTC
shRNA ctl - TCGAGAAAAAGTTCCGAACACACGCACAATCTCTTGAATTGTGCGTGTGTTCGGAACGGG
rAP3b2 1374 + GATCCCCATTCCAGACCTACATTCGCTTCAAGAGAGCGAATGTAGGTCTGGAATTTTTTC 
rAP3b2 1374 - TCGAGAAAAAATTCCAGACCTACATTCGCTCTCTTGAAGCGAATGTAGGTCTGGAATGGG 
rAP3b2 1611 + GATCCCCAGACAACATCCAGGTACCCTTCAAGAGAGGGTACCTGGATGTTGTCTTTTTTC 
rAP3b2 1611 - TCGAGAAAAAAGACAACATCCAGGTACCCTCTCTTGAAGGGTACCTGGATGTTGTCTGGG
rAP3b2 770 + GATCCCCAACGCATCGACCTGATTCATTCAAGAGATGAATCAGGTCGATGCGTTTTTTTC
rAP3b2 770 - TCGAGAAAAAAACGCATCGACCTGATTCATCTCTTGAATGAATCAGGTCGATGCGTTGGG
rAGAP1 2680 + GATCCCCGACGCCATAAGTTCCACCATTCAAGAGATGGTGGAACTTATGGCGTCTTTTTC
rAGAP1 2680 - TCGAGAAAAAGACGCCATAAGTTCCACCATCTCTTGAATGGTGGAACTTATGGCGTCGGG
rAGAP1 135 + GATCCCCCGTGAGTCTCTCAGTTCCCTTCAAGAGAGGGAACTGAGAGACTCACGTTTTTC 
rAGAP1 135 - TCGAGAAAAACGTGAGTCTCTCAGTTCCCTCTCTTGAAGGGAACTGAGAGACTCACGGGG
rAGAP1 2059 + GATCCCCACCCTAGACGTGTCTCTCCTTCAAGAGAGGAGAGACACGTCTAGGGTTTTTTC
rAGAP1 2059 - TCGAGAAAAAACCCTAGACGTGTCTCTCCTCTCTTGAAGGAGAGACACGTCTAGGGTGGG 
rAp3d1 3582 + GATCCCCCACCTATCGTGACGAGCTGTTCAAGAGACAGCTCGTCACGATAGGTGTTTTTC
rAp3d1 3582 - TCGAGAAAAACACCTATCGTGACGAGCTGTCTCTTGAACAGCTCGTCACGATAGGTGGGG 
rAp3d1 3288 + GATCCCCTCGTACCTGATCACCACCCTTCAAGAGAGGGTGGTGATCAGGTACGATTTTTC 
rAp3d1 3288 - TCGAGAAAAATCGTACCTGATCACCACCCTCTCTTGAAGGGTGGTGATCAGGTACGAGGG
rAp3d1 1169 + GATCCCCGAGGAAATGAAGACCACGCTTCAAGAGAGCGTGGTCTTCATTTCCTCTTTTTC 
rAp3d1 1169 - TCGAGAAAAAGAGGAAATGAAGACCACGCTCTCTTGAAGCGTGGTCTTCATTTCCTCGGG 
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Table 9.4 PCR mutagenesis primers
primer sequence
rAGAP1 S600A + CAGCCTGCAGTCCTGTGAGGCCAGCAAGAATAAGTCCCG
rAGAP1 S600A - CGGGACTTATTCTTGCTGGCCTCACAGGACTGCAGGCTG
rAGAP1 S605A + GAGAGCAGCAAGAATAAGGCCCGACTCACCAGCCAGAGC
rAGAP1 S605A - GCTCTGGCTGGTGAGTCGGGCCTTATTCTTGCTGCTCTC
rAGAP1 T608A + CAAGAATAAGTCCCGACTCGCCAGCCAGAGCGAAGCCATG
rAGAP1 T608A - CATGGCTTCGCTCTGGCTGGCGAGTCGGGACTTATTCTTG
rAGAP1 S609A + GAATAAGTCCCGACTCACCGCCCAGAGCGAAGCCATGGC
rAGAP1 S609A - GCCATGGCTTCGCTCTGGGCGGTGAGTCGGGACTTATTC
rM5 K371A S372A + GCTGCTCACAGACTCGCGGCTCAGAAGTGTGTTGCC
rM5 K371A S372A - GGCAACACACTTCTGAGCCGCGAGTCTGTGAGCAGC
rM5 K374A C375A + CTCACAGACTCAAGAGTCAGGCGGCTGTTGCCTATAAGTTCCG
rM5 K374A C375A - CGGAACTTATAGGCAACAGCCGCCTGACTCTTGAGTCTGTGAG
rM5 Y378A K379A F380A + CAGAAGTGTGTTGCCGCTGCGGCCCGATTGGTGGTAAAAG
rM5 Y378A K379A F380A - CTTTTACCACCAATCGGGCCGCAGCGGCAACACACTTCTG
rM5 K371A K374A + GCTGCTCACAGACTCGCGAGTCAGGCGTGTGTTGCCTATAAG
rM5 K371A K374A - CTTATAGGCAACACACGCCTGACTCGCGAGTCTGTGAGCAGC
rM5 K379A K385A + GAAGTGTGTTGCCTATGCGTTCCGATTGGTGGTAGCAGCCGATGGGACCCAGG
rM5 K379A K385A - CCTGGGTCCCATCGGCTGCTACCACCAATCGGAACGCATAGGCAACACACTTC
rM5 L382A V383A + GTTGCCTATAAGTTCCGAGCGGCGGTAAAAGCCGATGGGACC
rM5 L382A V383A - GGTCCCATCGGCTTTTACCGCCGCTCGGAACTTATAGGCAAC
rM5 deletion mutant BbsI - ATATGAAGACCTGTGAGCAGCAGCTGGAGA
rM5 deletion mutant BbsI + ATATGAAGACGCTCACGATGGGACCCAGGAGACTAACAATGGC
rM5 HA 1 HindIII + ATATAAGCTTACCACCATGGAAGGGGAGTCTTACAATGAA
rM5 HA 1 BbsI  - ATATGAAGACTGGGACGTCATATGGATATCCATGGCGTTCCAAAGCCTGGTGATTTAC
rM5 HA 2 BbsI + ATATGAAGACACGTCCCAGACTATGCCCTGTGGGAAGTCATTACTATTGCAGTTGTG
rM5 HA 2 Xho - ATATCTCGAGTCAGGGTAGCTTGCTGTTTCCTTGCCAATACAA
rM5 e2 HA 1 EcoRI + ATATGAATTCACCACCATGGAAGGGGAGTCTTACA
rM5 e2 HA 1 Bbs - ATATGAAGACTGGGACGTCATATGGATAGAGGAACTGGATCTGGCACTCATCA
rM5 e2 HA 2 Bbs + ATATGAAGACACGTCCCAGACTATGCCTCTGAACCCACCATCACTTTTGGGACTGCCATTGCT
rM3 C-tail T549A + CCCCGAATTCAACAAAGCATTCAGAACCACCTTC
rM3 C-tail T549A - GAAGGTGGTTCTGAATGCTTTGTTGAATTCGGGG
rM3 C-tail T552A + CAACAAAACATTCAGAGCCACCTTCAAGACGCTC
rM3 C-tail T552A - GAGCGTCTTGAAGGTGGCTCTGAATGTTTTGTTG
rM3 C-tail T553A + CAAAACATTCAGAACCGCCTTCAAGACGCTCCTC
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primer sequence
rM3 C-tail T553A - GAGGAGCGTCTTGAAGGCGGTTCTGAATGTTTTG
rM3 C-tail T556A + CAGAACCACCTTCAAGGCGCTCCTCTTGTGCCAG
rM3 C-tail T556A - CTGGCACAAGAGGAGCGCCTTGAAGGTGGTTCTG
rM3 C-tail S577A + GTACCAGCAGAGACAGGCGGTCATTTTTCACAAG
rM3 C-tail S577A - CTTGTGAAAAATGACCGCCTGTCTCTGCTGGTAC
rM3 C-tail S577D + GTACCAGCAGAGACAGGATGTCATTTTTCACAAG
rM3 C-tail S577D - CTTGTGAAAAATGACATCCTGTCTCTGCTGGTAC
rM3 C-tail S577E + GTACCAGCAGAGACAGGAGGTCATTTTTCACAAG
rM3 C-tail S577E - CTTGTGAAAAATGACCTCCTGTCTCTGCTGGTAC
Table 9.5 PCR Primers for cloning from cDNA libraries
primer sequence
rM1 XhoI + ATATCTCGAGGCCACCATGAACACCTCAGTGCCCCCTGCTGTCAGTCCCAACAT
rM1 no stop HindIII - ATATAAGCTTCGCATTGGCGGGAGGGGGTGCGGTGCACAGAGCCAG
rM1 FLAG HindIII + ATATATAAGCTTATGGATTACAAGGATGACGACGATAAGAACACCTCAGTGCCCCCTGC
rM1 XhoI - ATATATCTCGAGTTAGCATTGGCGGGAGGGGGTGCGGTGCAC
rM2 outer + GGCCACTTGACTACTGAACACAAAA
rM2 outer - TCACCGTGTAGCGCCTATGTTCTTG
rM2 + xhoI ATATCTCGAGACCACCATGAATAACTCAACAAAC
rM2 Hind III- no stop TATAAAGCTTCCCGTGTAGCGCCTAT
rM2 FLAG Hind III + ATATAAGCTTACCATGGATTACAAGGATGACGACGATAAGAATAACTCAACAAACTCC
rM2 XhoI - ATATCTCGAGTCACCGTGTAGCGCCTATGTTCTTGTAATG
rM3 outer + ATGACCTTGCACAGTAACAGTACAA
rM3 outer - TCCTTGAAGGACAGAGGTAGAGTAG
rM3 Asp718 I + ATATGGTACCGCCACCATGACCTTGCACAGTAACAGTACAACCTCGCCTTTGTT
rM3 N-term HA EcoRI + ATATGAATTCGCCACCATGTATCCATATGACGTCCCAGACTATGCCACCTTGCACAGTAACAGTACAACC
rM3 FLAG Asp718 + ATATGGTACCATGGATTACAAGGATGACGACGATAAGACCTTGCACAGTAACAGT
rM3 PspOM I - ATATGGGCCCCTACAAGGCCTGCTCCGGCACTCGCTTGTG
rM3 no stop PspOM I - ATATGGGCCCATCAAGGCCTGCTCCGGCACTCGCTTGTGAAAAATGA
rM4 HindIII + ATATAAGCTTGCCACCATGGCCAACTTCACGCCTGTCAATGGCAGCTCAGCCAA
rM4 no stop EcoR I - ATATGAATTCTCCCTGGCTGTGCCGATGTTCCGATACTGGCACAGCA
rM4 EcoRI - ATATATGAATTCCTACCTGGCTGTGCCGATGTTCCGATACTG
rM4 FLAG HindIII + ATATATAAGCTTATGGATTACAAGGATGACGACGATAAGGCCAACTTCACGCCTGTCAA
rM4 EcoRI - ATATATGAATTCCTACCTGGCTGTGCCGATGTTCCGATACTG
rM5 outer + ATGGAAGGGGAGTCTTACAATGAAAGC
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primer sequence
rM5 outer - GGGTAGCTTGCTGTTTCCTTGCCAA
rM5 XhoI + ATATCTCGAGACCACCATGGAAGGGGAGTCTTACAATGA
rM5 HindIII - no stop ATATAAGCTTGGGGTAGCTTGCTGTTTCCTT
rM5 N-term HA EcoR I + ATATGAATTCACCACCATGTATCCATATGACGTCCCAGACTATGCCGAAGGGGAGTCTTACAATGAAA
rM5 N-term HA Xho I - ATATCTCGAGTCAGGGTAGCTTGC
rM5 FLAG HindIII + ATATAAGCTTACCATGGATTACAAGGATGACGACGATAAGGAAGGGGAGTCTTACAAT
rM5 XhoI - ATATCTCGAGTCAGGGTAGCTTGCTGTTTCCTTGCCAATA
rM1 c-tail EcoRI + ATATGAATTCAACAAAGCCTTCCGGGACACG
rM1 c-tail XhoI - ATATCTCGAGTTAGCATTGGCGGGAGGGGG
rM2 c-tail EcoRI linker + AATTCAATGCCACCTTCAAAAAGACTTTTAAGCACCTCCTCATGTGTCATTACAAGAACATAGGCGCTACACGGTGAC
rM2 c-tail XhoI linker - TCGAGTCACCGTGTAGCGCCTATGTTCTTGTAATGACACATGAGGAGGTGCTTAAAAGTCTTTTTGAAGGTGGCATTG
rM3 c-tail EcoRI + ATATGAATTCAACAAAACATTCAGAACCACCTTCAAGACG
rM3 c-tail XhoI - ATATCTCGAGCTACAAGGCCTGCTCCGGCA
rM4 c-tail EcoRI linker + AATTCAATGCCACTTTCAAAAAGACCTTCCGGCACCTTTTGCTGTGCCAGTATCGGAACATCGGCACAGCCAGGTAGC
rM4 c-tail XhoI linker - TCGAGCTACCTGGCTGTGCCGATGTTCCGATACTGGCACAGCAAAAGGTGCCGGAAGGTCTTTTTGAAAGTGGCATTG
rM5 c-tail EcoRI + ATATGAATTCAACAGAACTTTCAGGAAAACC
rM5 c-tail XhoI - ATATCTCGAGTCAGGGTAGCTTGCTGTTTC
rNRBP2 5', Bgl II, pACT in-
frame ATATATAGATCTTAGCGGCCCCGGAGCCGGCGCC
rNRBP2 3' Bgl II w/ stop ATATATAGATCTCTACGCTTGTGTCCCACGGTACTTG
rNRBP2 5' w/UTR, HindIII ATATATAAGCTTCGAGCCATGGCGGCCCCGGAGCCG
rNRBP2 internal EcoR I - TTGTGGGCTGAGGGTCGGCGGGCAGGGTCC
rAGAP1 + outer TTTTTTTAGCGCCTCCTCGG
rAGAP1 - outer TTCCACCTGGAAGAGGGAGG
rAGAP1 + inner EcoRI ATATATGAATTCTGCACCATGAACTACCAGCAGCAGCTGGCCAACTCGGC
rAGAP1 - inner XhoI ATATATCTCGAGGATGACACTGGGCGCCCTCCCGCTACTGTTGTTCCTGC
rSNX20 outer + GCTGCATTTAGAAGGCACCC
rSNX20 outer - ACTGTCTGCGCAGCCTGGAT
rSNX20 inner EcoRI + ATATATGAATTCGCCGCCATGGCAAGTCCACAGCATCCTGGGGGCCCTGG
rSNX20 inner XhoI - ATATATCTCGAGGGACAGATACTCCCGCACGGTGAGCTCCTTCAGGGTGG
mAP3b2 outer + TTCCTCGACCAAAGCCCAACCCGGCCGCTCAGCCACCCCTCAGCGCAGATCCATGT
mAP3b2 outer - GAGGCGAGGGGGAGAGATCTGTGAGCAGATGTCAC
mAP3b2 inner XhoI + ATATCTCGAGTTCGGCCGCTCCGGCCTACAGCGAAGACAAGGG
mAP3b2 inner PspOMI - ATATGGGCCCTCACTGGGTCAGAGCCTGAATCACATCCTT
mAP3b1 outer + TTGGTTCGGTGTCCTCCGAACGCCAGCCATCCGTAGA
mAP3b1 outer - GCCAGATTCTGAAGTCCAGATGTAAGCAGG
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primer sequence
mAP3b1 inner no start EcoRI + ATATGAATTCTTCTAGCAACAGTTTCGCCTACAACGAGCAGTCGGGA
mAP3b1 inner PspOM I - ATATGGGCCCTTACCCCTGGGACAGGACAGGCTTCAGCTC
rKIAA0701 outer + AGTCTCTCCCGAGAGTGAGCTCTCCGGCGCCTCTCCT
rKIAA0701 outer - GGTCTGGAACAGCCACACTTTACCACACGC
rKIAA0701 inner + ATATGGTACCGGCACCATGGCTGGGATCATTAAGAAACAG
rKIAA0701 inner no stop - ATATGGGCCCCGGCCGCTGCAGCTGGCCCAGGGCCAGCCT
mCherry PspOMI + ATATGGGCCCATGGTGAGCAAGGGCGAGGAGGATAACATGGCCATC
mCherry NotI - ATATGCGGCCGCTGCTTGTACAGCTCGTCCATGCCGCCGGTGGAGTGGC
Table 9.6 PCR primers for cloning of Y2H constructs
primer sequence
rM1 i3 loop BamHI + ATATGGATCCTGCGCATCTACCGGGAGACAGAAA
rM1 i3 loop SalI - ATATGTCGACTCAGGTCCGAGCTGCCTTCTTCTCC
rM2 i3 loop NcoI + ATATCCATGGCGCATATATCCCGGGCAAGCAAGA
rM2 i3 loop BamHI - ATATGGATCCTCATGTCCTGGTCACTTTCTTTTCC
rM3 i3 loop NcoI + ATATCCATGGCGAGGATCTATAAGGAAACTGAGA
rM3 i3 loop BamHI - ATATGGATCCTCACGTCTGGGCGGCCTTCTTCTCC
rM4 i3 loop NcoI + ATATCCATGGCGCACATCTCACTGGCCAGCCGCA
rM4 i3 loop BamHI - ATATGGATCCTCATGTCCGAGTCACTTTGCGCTCC
rM5 i3 loop NcoI + ATATCCATGGCGCGGATCTACCGGGAGACAGAGA
rM5 i3 loop SalI - ATATGTCGACTCAGGTCTGAGCCGCTTTCCTCTCT
hM2 i3 loop NcoI + ATATCCATGGCGCACATATCCCGAGCCAGCAAGA
hM2 i3 loop SalI - ATATGTCGACTCATGTCCTGGTGACTTTCTTTTCC
hM3 i3 loop NcoI + ATATCCATGGCGAGGATCTATAAGGAAACTGAAA
hM3 i3 loop BamHI - ATATGGATCCTCAGGTCTGGGCCGCTTTCTTCTCC
hM5 i3 loop NcoI + ATATCCATGGCGCGAATCTACCGGGAAACAGAGA
hM5 i3 loop BamHI - ATATGGATCCTCATGTCTGGGCTGCTTTCCTCTCT
rM5i3 (1) NcoI + ATATCCATGGGACGGATCTACCGGGAGACAGAGAAG
rM5i3 (91) BamHI - ATATGGATCCTCAGCTGCTACAGGTAGTAACCT
rM5i3 (73) NcoI + ATATCCATGGGAGCCACTGACCTAAGTGCTGA
rM5i3 (162) BamHI - ATATGGATCCTCAACACTTCTGACTCTTGAGTC
rM5i3 (141) NcoI + ATATCCATGGGAGACTATGACACTCCCAAATAC
rM5i3 (229) SalI - ATATGTCGACTCAGGTCTGAGCCGCTTTCCTCT
rM5i3 (18) NcoI + ATATCCATGGGAGGTTCTGATTCTGTGGCAGA
rM5i3 (220) SalI - ATATGTCGACTCACAGAACCATTCTCTTTCGTT
rM5i3 (210) SalI - ATATGTCGACTCAATGACTGAGGTTGGGATCCG
rM5i3 (200) SalI - ATATGTCGACTCATGAAGGGTCTTTGGACACTG
rM5i3 (190) SalI - ATATGTCGACTCAGGGCATGATTTTCACCTTTC
rM5i3 (180) SalI - ATATGTCGACTCAGTTAGTCTCCTGGGTCCCAT
rM5i3 (170) SalI - ATATGTCGACTCACACCAATCGGAACTTATAGG
rM5i3 (173) SalI - ATATGTCGACTCAGGCTTTTACCACCAATCGGA
rM5i3 (146) NcoI + ATATCCATGGGAAAATACTTTCTGTCTCCAGC
rM5i3 (151) NcoI + ATATCCATGGGACCAGCTGCTGCTCACAGACT
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primer sequence
rM5i3 (156) NcoI + ATATCCATGGGAAGACTCAAGAGTCAGAAGTG
rM5i3 (161-180) NcoI + linker CATGGGAAAGTGTGTTGCCTATAAGTTCCGATTGGTGGTAAAAGCCGATGGGACCCAGGAGACTAACTGAG
rM5i3 (161-180) SalI - linker TCGACTCAGTTAGTCTCCTGGGTCCCATCGGCTTTTACCACCAATCGGAACTTATAGGCAACACACTTTCC
rM5i3 (166-180) NcoI + linker CATGGGAAAGTTCCGATTGGTGGTAAAAGCCGATGGGACCCAGGAGACTAACTGAG
rM5i3 (166-180) SalI - linker TCGACTCAGTTAGTCTCCTGGGTCCCATCGGCTTTTACCACCAATCGGAACTTTCC
rM2 i3 (5) EcoRI + ATATGAATTCGCAAGCAAGAGTAGAATAAAGAAGGAAAAGAAGGAACCTGTGG
rM2 i3 (30) EcoRI + ATATGAATTCGGAAGAATTGTAAAGCCAAACAATAACAATATGCCTGGTGGTGATGG
rM2 i3 (60) EcoRI + ATATGAATTCGACGGCGTGACTGAAAACTGTGTTCAGGGGGAGGAGAAAGA
rM2 i3 (90) EcoRI + ATATGAATTCGATGATGAGATAACCCAGGATGAAAACACAGTTTCCACTTCGCTG
rM2 i3 (120) EcoRI + ATATGAATTCGTCACCAAGGCCCAAAAGGGTGATGTGTGCACCCCAACGAGTACC
rM2 i3 (150) EcoRI + ATATGAATTCCAGAACATTGTAGCCCGCAAAATCGTGAAGATGACCAAG
rAGAP1 (520) BamHI + ATATGGATCCAGCTCGACCCACCCC
rAGAP1 (591) XhoI - ATATCTCGAGTCAGATCTGGCTCTCGAT
rAGAP1 (552) BamHI + ATATGGATCCCTGAAGAGCAAGAAGA
rAGAP1 (645) XhoI - ATATCTCGAGTCAGGCTCCCAAGTTCAA
rAGAP1 (592-611) BamHI + 
linker
GATCCTAGCCAGCCTGCAGTCCTGTGAGAGCAGCAAGAAT
AAGTCCCGACTCACCAGCCAGAGCTGAC
rAGAP1 (592-611) XhoI - linker TCGAGTCAGCTCTGGCTGGTGAGTCGGGACTTATTCTTGCTGCTCTCACAGGACTGCAGGCTGGCTAG
rAGAP1 (602-621) BamHI + 
linker
GATCCTAAAGAATAAGTCCCGACTCACCAGCCAGAGCGAA
GCCATGGCACTGCAGTCAATCCGTAACTGAC
rAGAP1 (602-621) XhoI - 
linker
TCGAGTCAGTTACGGATTGACTGCAGTGCCATGGCTTCGC
TCTGGCTGGTGAGTCGGGACTTATTCTTTAG
rAGAP1 (612-631) BamHI + 
linker
GATCCTAGAAGCCATGGCACTGCAGTCAATCCGTAACATGA
GAGGGAACTCGCACTGCGTGGACTGTTGAC
rAGAP1 (612-631) XhoI - 
linker
TCGAGTCAACAGTCCACGCAGTGCGAGTTCCCTCTCATGT
TACGGATTGACTGCAGTGCCATGGCTTCTAG
rAGAP1 (622-641) BamHI + 
linker
GATCCTAAACATGAGAGGGAACTCGCACTGCGTGGACTGT
GACACCCAGAACCCCAACTGGGCCAGTTGAC
rAGAP1 (622-641) XhoI - 
linker
TCGAGTCAACTGGCCCAGTTGGGGTTCTGGGTGTCACAG
TCCACGCAGTGCGAGTTCCCTCTCATGTTTAG
rAGAP1 (552) BamHI + ATATGGATCCCTGAAGAGCAAGAAGAAAACTTG
rAGAP1 (600) XhoI - ATATCTCGAGTCAGCTCTCACAGGACTGCAGGC
rAGAP1 (596) BamHI + ATATGGATCCAGTCCTGTGAGAGCAGCAAG
rAGAP1 (645) XhoI - ATATCTCGAGTCAGGCTCCCAAGTTCAAACTGG
rAGAP1 (609)XhoI - ATATCTCGAGTCAGCTGGTGAGTCGGGACTTAT
rAGAP1 (618) XhoI - ATATCTCGAGTCATGACTGCAGTGCCATGGCTT
rAGAP1 (627) XhoI - ATATCTCGAGTCAGTGCGAGTTCCCTCTCATGT
rAGAP1 (636) XhoI - ATATCTCGAGTCAGGGGTTCTGGGTGTCACAGT
rAGAP1 (560) BamHI + ATATGGATCCTGTTTATCATTGTGTCCCTCAC
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primer sequence
rAGAP1 (568) BamHI + ATATGGATCCTGCAGACGTGGCACTTTGAAGC
rAGAP1 (576) BamHI + ATATGGATCCTGACATACGAGGAGCGAGACGC
rAGAP1 (584) BamHI + ATATGGATCCTGGTCCAAGCCATCGAGAGCCA
rAGAP1 (614-861) Hind III + ATATAAGCTTGCCACCATGGCACTGCAGTCAATCCGTAACATGAGAGGGAACTC
rAGAP1 (1-613) XhoI - ATATCTCGAGGGCTTCGCTCTGGCTGGTGAGTCGGGACTT
rSNX20 (2) EcoRI + ATATGAATTCTAGCAAGTCCACAGCATCCTGGGGGCCCTGGCTGG
rSNX20 (313) XhoI - ATATCTCGAGTCAGGACAGATACTCCCGCACGGTGAGC
rSNX20 (2-156) XhoI - ATATCTCGAGTCACAGGCGCCGTTCGCAGATGGTCTCG
rSNX20 (78) EcoRI + ATATGAATTCTAGCCTCAGCCAGAATCGAGGAGAGGAAAGTCTC
rSNX20 (234) XhoI- ATATCTCGAGTCACAGGCACACGAGCATGGCGCAGAGA
rSNX20 (157) EcoRI + ATATGAATTCTAGAGCTGCGCGAGTACCTGCGGCTGC
rSNX20 (87) EcoRI + ATATGAATTCTAGTCTCCAAGTTTGTGATGTACCAGGTCGTGGT
rSNX20 (97) EcoRI + ATATGAATTCTAGTCATCCAGACTGGGAGCTTCGACAGC
rSNX20 (107) EcoRI + ATATGAATTCTAAAGGCTGTGGTGGAGCGGCGCTACT
rSNX20 (117) EcoRI + ATATGAATTCTATTCGAGAGGCTGCAGAGGGCCCTCC
rSNX20 (127) EcoRI + ATATGAATTCTACGCTTCGGGCCGGAGCTGGAGGACG
rSNX20 (137) EcoRI + ATATGAATTCTATTCCCGCGGAAGCGCCTGACCGGGA
rSNX20 (147) EcoRI + ATATGAATTCTATCGGCCGAGACCATCTGCGAACGGC
rNRBP2 (79) BamHI + ATATGGATCCTTGCGGCCCCGGAGCCGGCGCCGAGGAGAG
rNRBP2 (491) XhoI - ATATCTCGAGTCACGCTTGTGTCCC
rNRBP2 (395) BamHI + ATATGGATCCTGTTGGCCCCACCCC
rNRBP2 (453) XhoI - ATATCTCGAGTCAGGTCAGCTGCCGATG
rNRBP2 (442) BamHI + ATATGGATCCTTTTGGTGCTTGAGG
rKIAA0701 (1469) XhoI - ATATCTCGAGTCAGGGCCCCGGCCGCTGCAGCTGGCCCAGGGC
rKIAA0701 (1117) EcoRI + ATATGAATTCTACTGGACAGCGTGGGATTCGAAGAGCAGCTG
rKIAA0701 (1188) EcoRI + ATATGAATTCTAATGTCGGTCGTGGTGTTTAAAATCATTGGTGTTAGTGG
rKIAA0701 (1258) EcoRI + ATATGAATTCTAGAAAGTGGGCCAGGTGCTGTCGTACACTCT
rKIAA0701 (1328) EcoRI + ATATGAATTCTAGGTAGCACAGTGTCCCTCCAGCCAAGTCCC
rKIAA0701 (1399) EcoRI + ATATGAATTCTAACGAGCCCAGAGGTTCCTTTGCCTTCACAG
rCentg1 (1095-1186) outer + TTCTGCTGCTTCTGGCCCACGCGCGACATG
rCentg1 (1095-1186) outer - AATGGTCCACCCGGTGTAGTCGTGCCTGGCC
rCentg1 (1095-1186) inner 
BamHI + ATATGGATCCCTCGCCCACGTTGTTATTACACAGCTGCTG
rCentg1 (1095-1186) inner 
XhoI - ATATCTCGAGCTATACCAGCGCGATCGTGGTGTCCACGCG
rCentg3 (1299-1377) outer + GGGTCCAAGGAGGAGGTGAACGAGACCTACGGGGATGG
rCentg3 (1299-1377) outer - TTCATCCCTGCGCCCTCGTCACCCCTCTTCTCTGCACCCCTGCT
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primer sequence
rCentg3 (1299-1377) inner 
BamHI + ATATGGATCCGCCAACGTCGTTTTCACACAGCTGCTCATC
rCentg3 (1299-1377) inner 
XhoI - ATATCTCGAGTCATAGGATACTAGGGCTGCGGTGCAGTTC
hCtglf1 outer + ATGGGGAACATACTGACCTGTCGTGTGCAC
hCtglf1 outer - CAGATACTACACGCACTCGTCGGGGCAGCC
hCtglf1 (379-437) BamHI + ATATGGATCCGACACCTAAAGAAGAAAAGCACCAACAACTTTATGATTGTGTCTGCCACTGGC
hCtglf1 (379-437) XhoI - ATATCTCGAGTCAGCTGGTCAGCTGGGACTTGCTTTTACTGCTCTCGC
rDynlt1 (2-113) BamHI + ATATGGATCCTAGAAGACTTCCAGGCCTCCGAGGAGACTGCATTTGT
rDynlt1 (2-113) XhoI - ATATCTCGAGTCAGATGGACAGTCCGAAGGCACTGACGATGCAGT
Table 9.7 Genotypes of yeast strains
strain genotype reference
CG1945
MATa, ura3, his3, ade2, 
lys2, trp1, leu2, 112, 
gal4-542, gal80-538, 
cyhr2, LYS::GAL1UAS-
GAL1TATA-HIS3, 
URA3::GAL417-mers(x3)-
CYC1TATA-lacZ
(Feilotter et al., 1994)
Y187
MATα, ura3, his3, ade2, 
trp1, leu2, 112, gal4∆, 
met-, gal80∆, 
URA3::GAL1UAS-
GAL1TATA-lacZ
(Harper et al., 1993)
L40
MATa, trp1, leu2, his3, 
LYS2::lexA-HIS3, 
URA3::lexA-LacZ
(Vojtek et al., 1993)
223
9 REFERENCES
Abdul-Ghani, M., Hartman, K. L. and Ngsee, J. K. (2005). Abstrakt interacts with 
and regulates the expression of sorting nexin-2. J Cell Physiol 204, 210-8.
Achour, L., Labbe-Jullie, C., Scott, M. G. and Marullo, S. (2008). An escort for 
GPCRs: implications for regulation of receptor density at the cell surface. Trends 
Pharmacol Sci 29, 528-35.
Araya, R., Noguchi, T., Yuhki, M., Kitamura, N., Higuchi, M., Saido, T. C., Seki, 
K., Itohara, S., Kawano, M., Tanemura, K., Takashima, A., Yamada, K., Kondoh, 
Y., Kanno, I., Wess, J. and Yamada, M. (2006). Loss of M5 muscarinic 
acetylcholine receptors leads to cerebrovascular and neuronal abnormalities and 
cognitive deficits in mice. Neurobiol Dis 24, 334-44.
Auld, D. S., Kornecook, T. J., Bastianetto, S. and Quirion, R. (2002). Alzheimer's 
disease and the basal forebrain cholinergic system: relations to beta-amyloid 
peptides, cognition, and treatment strategies. Prog Neurobiol 68, 209-45.
Badtke, M. P., Cao, F. and Tavis, J. E. (2006). Combining genetic and 
biochemical approaches to identify functional molecular contact points. Biol 
Proced Online 8, 77-86.
Barembaum, M., Moreno, T. A., LaBonne, C., Sechrist, J. and Bronner-Fraser, M. 
(2000). Noelin-1 is a secreted glycoprotein involved in generation of the neural 
crest. Nat Cell Biol 2, 219-25.
Basile, A. S., Fedorova, I., Zapata, A., Liu, X., Shippenberg, T., Duttaroy, A., 
Yamada, M. and Wess, J. (2002). Deletion of the M5 muscarinic acetylcholine 
receptor attenuates morphine reinforcement and withdrawal but not morphine 
analgesia. Proc Natl Acad Sci U S A 99, 11452-7.
Becamel, C., Alonso, G., Galeotti, N., Demey, E., Jouin, P., Ullmer, C., Dumuis, 
A., Bockaert, J. and Marin, P. (2002). Synaptic multiprotein complexes associated 
with 5-HT(2C) receptors: a proteomic approach. EMBO J 21, 2332-42.
Bendixen, C., Gangloff, S. and Rothstein, R. (1994). A yeast mating-selection 
scheme for detection of protein-protein interactions. Nucleic Acids Res 22, 
1778-9.
224
Berkeley, J. L., Gomeza, J., Wess, J., Hamilton, S. E., Nathanson, N. M. and 
Levey, A. I. (2001). M1 muscarinic acetylcholine receptors activate extracellular 
signal-regulated kinase in CA1 pyramidal neurons in mouse hippocampal slices. 
Mol Cell Neurosci 18, 512-24.
Bermak, J. C., Li, M., Bullock, C. and Zhou, Q. Y. (2001). Regulation of transport 
of the dopamine D1 receptor by a new membrane-associated ER protein. Nat 
Cell Biol 3, 492-8.
Bernstein, L. S., Ramineni, S., Hague, C., Cladman, W., Chidiac, P., Levey, A. I. 
and Hepler, J. R. (2004). RGS2 binds directly and selectively to the M1 
muscarinic acetylcholine receptor third intracellular loop to modulate Gq/11alpha 
signaling. J Biol Chem 279, 21248-56.
Bhoumik, A., Singha, N., O'Connell, M. J. and Ronai, Z. A. (2008). Regulation of 
TIP60 by ATF2 modulates ATM activation. J Biol Chem 283, 17605-14.
Bluml, K., Mutschler, E. and Wess, J. (1994). Insertion mutagenesis as a tool to 
predict the secondary structure of a muscarinic receptor domain determining 
specificity of G-protein coupling. Proc Natl Acad Sci U S A 91, 7980-4.
Blumstein, J., Faundez, V., Nakatsu, F., Saito, T., Ohno, H. and Kelly, R. B. 
(2001). The neuronal form of adaptor protein-3 is required for synaptic vesicle 
formation from endosomes. J Neurosci 21, 8034-42.
Boeuf, J., Trigo, J. M., Moreau, P. H., Lecourtier, L., Vogel, E., Cassel, J. C., 
Mathis, C., Klosen, P., Maldonado, R. and Simonin, F. (2009). Attenuated 
behavioural responses to acute and chronic cocaine in GASP-1-deficient mice. 
Eur J Neurosci 30, 860-8.
Bonifacino, J. S. and Dell'Angelica, E. C. (1999). Molecular bases for the 
recognition of tyrosine-based sorting signals. J Cell Biol 145, 923-6.
Bonifacino, J. S. and Traub, L. M. (2003). Signals for sorting of transmembrane 
proteins to endosomes and lysosomes. Annu Rev Biochem 72, 395-447.
Bonner, T. I., Buckley, N. J., Young, A. C. and Brann, M. R. (1987). Identification 
of a family of muscarinic acetylcholine receptor genes. Science 237, 527-32.
Brady, A. E., Wang, Q., Colbran, R. J., Allen, P. B., Greengard, P. and Limbird, L. 
E. (2003). Spinophilin stabilizes cell surface expression of alpha 2B-adrenergic 
receptors. J Biol Chem 278, 32405-12.
225
Brent, R. and Ptashne, M. (1985). A eukaryotic transcriptional activator bearing 
the DNA specificity of a prokaryotic repressor. Cell 43, 729-36.
Brewer, G. J. and Torricelli, J. R. (2007). Isolation and culture of adult neurons 
and neurospheres. Nat Protoc 2, 1490-8.
Bridges, T. M., Marlo, J. E., Niswender, C. M., Jones, C. K., Jadhav, S. B., 
Gentry, P. R., Plumley, H. C., Weaver, C. D., Conn, P. J. and Lindsley, C. W. 
(2009). Discovery of the first highly M5-preferring muscarinic acetylcholine 
receptor ligand, an M5 positive allosteric modulator derived from a series of 5-
trifluoromethoxy N-benzyl isatins. J Med Chem 52, 3445-8.
Bronner, C., Achour, M., Arima, Y., Chataigneau, T., Saya, H. and Schini-Kerth, V. 
B. (2007). The UHRF family: oncogenes that are drugable targets for cancer 
therapy in the near future? Pharmacol Ther 115, 419-34.
Budd, D. C., McDonald, J. E. and Tobin, A. B. (2000). Phosphorylation and 
regulation of a Gq/11-coupled receptor by casein kinase 1alpha. J Biol Chem 
275, 19667-75.
Burwinkel, B., Miglierini, G., Jenne, D. E., Gilbert, D. J., Copeland, N. G., 
Jenkins, N. A., Ring, H. Z., Francke, U. and Kilimann, M. W. (1998). Structure of 
the human paralemmin gene (PALM), mapping to human chromosome 19p13.3 
and mouse chromosome 10, and exclusion of coding mutations in grizzled, 
mocha, jittery, and hesitant mice. Genomics 49, 462-6.
Bymaster, F. P., McKinzie, D. L., Felder, C. C. and Wess, J. (2003). Use of M1-
M5 muscarinic receptor knockout mice as novel tools to delineate the 
physiological roles of the muscarinic cholinergic system. Neurochem Res 28, 
437-42.
Caccamo, A., Oddo, S., Billings, L. M., Green, K. N., Martinez-Coria, H., Fisher, 
A. and LaFerla, F. M. (2006). M1 receptors play a central role in modulating AD-
like pathology in transgenic mice. Neuron 49, 671-82.
Cachero, T. G., Morielli, A. D. and Peralta, E. G. (1998). The small GTP-binding 
protein RhoA regulates a delayed rectifier potassium channel. Cell 93, 1077-85.
Calabresi, P., Centonze, D., Gubellini, P., Pisani, A. and Bernardi, G. (2000). 
Acetylcholine-mediated modulation of striatal function. Trends Neurosci 23, 
120-6.
226
Canfield, W. M., Johnson, K. F., Ye, R. D., Gregory, W. and Kornfeld, S. (1991). 
Localization of the signal for rapid internalization of the bovine cation-
independent mannose 6-phosphate/insulin-like growth factor-II receptor to amino 
acids 24-29 of the cytoplasmic tail. J Biol Chem 266, 5682-8.
Cao, T. T., Deacon, H. W., Reczek, D., Bretscher, A. and von Zastrow, M. (1999). 
A kinase-regulated PDZ-domain interaction controls endocytic sorting of the 
beta2-adrenergic receptor. Nature 401, 286-90.
Carlson, A. and Bok, D. (1992). Promotion of the release of 11-cis-retinal from 
cultured retinal pigment epithelium by interphotoreceptor retinoid-binding protein. 
Biochemistry 31, 9056-62.
Chen, C., Li, J. G., Chen, Y., Huang, P., Wang, Y. and Liu-Chen, L. Y. (2006). 
GEC1 interacts with the kappa opioid receptor and enhances expression of the 
receptor. J Biol Chem 281, 7983-93.
Cheng, K., Samimi, R., Xie, G., Shant, J., Drachenberg, C., Wade, M., Davis, R. 
J., Nomikos, G. and Raufman, J. P. (2008). Acetylcholine release by human 
colon cancer cells mediates autocrine stimulation of cell proliferation. Am J 
Physiol Gastrointest Liver Physiol 295, G591-7.
Chernyavsky, A. I., Arredondo, J., Wess, J., Karlsson, E. and Grando, S. A. 
(2004). Novel signaling pathways mediating reciprocal control of keratinocyte 
migration and wound epithelialization through M3 and M4 muscarinic receptors. J 
Cell Biol 166, 261-72.
Chien, C. T., Bartel, P. L., Sternglanz, R. and Fields, S. (1991). The two-hybrid 
system: a method to identify and clone genes for proteins that interact with a 
protein of interest. Proc Natl Acad Sci U S A 88, 9578-82.
Coleman, M. L., Sahai, E. A., Yeo, M., Bosch, M., Dewar, A. and Olson, M. F. 
(2001). Membrane blebbing during apoptosis results from caspase-mediated 
activation of ROCK I. Nat Cell Biol 3, 339-45.
Cullen, P. J. (2008). Endosomal sorting and signalling: an emerging role for 
sorting nexins. Nat Rev Mol Cell Biol 9, 574-82.
Curran, T. and Franza, B. R., Jr. (1988). Fos and Jun: the AP-1 connection. Cell 
55, 395-7.
227
Cypess, A. M., Unson, C. G., Wu, C. R. and Sakmar, T. P. (1999). Two 
cytoplasmic loops of the glucagon receptor are required to elevate cAMP or 
intracellular calcium. J Biol Chem 274, 19455-64.
D'Souza-Schorey, C. and Chavrier, P. (2006). ARF proteins: roles in membrane 
traffic and beyond. Nat Rev Mol Cell Biol 7, 347-58.
Daaka, Y., Luttrell, L. M. and Lefkowitz, R. J. (1997). Switching of the coupling of 
the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 
390, 88-91.
Dagher, M. C. and Filhol-Cochet, O. (1997). Making hybrids of two-hybrid 
systems. Biotechniques 22, 916-8, 920-2.
Dai, J., Li, J., Bos, E., Porcionatto, M., Premont, R. T., Bourgoin, S., Peters, P. J. 
and Hsu, V. W. (2004). ACAP1 promotes endocytic recycling by recognizing 
recycling sorting signals. Dev Cell 7, 771-6.
Dajas-Bailador, F. and Wonnacott, S. (2004). Nicotinic acetylcholine receptors 
and the regulation of neuronal signalling. Trends Pharmacol Sci 25, 317-24.
Danglot, L. and Galli, T. (2007). What is the function of neuronal AP-3? Biol Cell 
99, 349-61.
Daulat, A. M., Maurice, P., Froment, C., Guillaume, J. L., Broussard, C., 
Monsarrat, B., Delagrange, P. and Jockers, R. (2007). Purification and 
identification of G protein-coupled receptor protein complexes under native 
conditions. Mol Cell Proteomics 6, 835-44.
Daulat, A. M., Maurice, P. and Jockers, R. (2009). Recent methodological 
advances in the discovery of GPCR-associated protein complexes. Trends 
Pharmacol Sci 30, 72-8.
De Luca, V., Wang, H., Squassina, A., Wong, G. W., Yeomans, J. and Kennedy, 
J. L. (2004). Linkage of M5 muscarinic and alpha7-nicotinic receptor genes on 
15q13 to schizophrenia. Neuropsychobiology 50, 124-7.
Delaney, K. A., Murph, M. M., Brown, L. M. and Radhakrishna, H. (2002). 
Transfer of M2 muscarinic acetylcholine receptors to clathrin-derived early 
endosomes following clathrin-independent endocytosis. J Biol Chem 277, 
33439-46.
228
Dell'Angelica, E. C., Klumperman, J., Stoorvogel, W. and Bonifacino, J. S. 
(1998). Association of the AP-3 adaptor complex with clathrin. Science 280, 
431-4.
Dell'Angelica, E. C., Ohno, H., Ooi, C. E., Rabinovich, E., Roche, K. W. and 
Bonifacino, J. S. (1997). AP-3: an adaptor-like protein complex with ubiquitous 
expression. EMBO J 16, 917-28.
Dell'Angelica, E. C., Shotelersuk, V., Aguilar, R. C., Gahl, W. A. and Bonifacino, J. 
S. (1999). Altered trafficking of lysosomal proteins in Hermansky-Pudlak 
syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol Cell 
3, 11-21.
Dessy, C., Kelly, R. A., Balligand, J. L. and Feron, O. (2000). Dynamin mediates 
caveolar sequestration of muscarinic cholinergic receptors and alteration in NO 
signaling. EMBO J 19, 4272-80.
Dolphin, A. C. (2003). G protein modulation of voltage-gated calcium channels. 
Pharmacol Rev 55, 607-27.
Domon, B. and Aebersold, R. (2006). Mass spectrometry and protein analysis. 
Science 312, 212-7.
Donaldson, J. G., Finazzi, D. and Klausner, R. D. (1992). Brefeldin A inhibits 
Golgi membrane-catalysed exchange of guanine nucleotide onto ARF protein. 
Nature 360, 350-2.
Dong, C. and Wu, G. (2006). Regulation of anterograde transport of alpha2-
adrenergic receptors by the N termini at multiple intracellular compartments. J 
Biol Chem 281, 38543-54.
Dorje, F., Wess, J., Lambrecht, G., Tacke, R., Mutschler, E. and Brann, M. R. 
(1991). Antagonist binding profiles of five cloned human muscarinic receptor 
subtypes. J Pharmacol Exp Ther 256, 727-33.
Durfee, T., Becherer, K., Chen, P. L., Yeh, S. H., Yang, Y., Kilburn, A. E., Lee, W. 
H. and Elledge, S. J. (1993). The retinoblastoma protein associates with the 
protein phosphatase type 1 catalytic subunit. Genes Dev 7, 555-69.
Earnshaw, W. C., Sullivan, K. F., Machlin, P. S., Cooke, C. A., Kaiser, D. A., 
Pollard, T. D., Rothfield, N. F. and Cleveland, D. W. (1987). Molecular cloning of 
229
cDNA for CENP-B, the major human centromere autoantigen. J Cell Biol 104, 
817-29.
Fam, S. R., Paquet, M., Castleberry, A. M., Oller, H., Lee, C. J., Traynelis, S. F., 
Smith, Y., Yun, C. C. and Hall, R. A. (2005). P2Y1 receptor signaling is controlled 
by interaction with the PDZ scaffold NHERF-2. Proc Natl Acad Sci U S A 102, 
8042-7.
Farr, C. D., Gafken, P. R., Norbeck, A. D., Doneanu, C. E., Stapels, M. D., 
Barofsky, D. F., Minami, M. and Saugstad, J. A. (2004). Proteomic analysis of 
native metabotropic glutamate receptor 5 protein complexes reveals novel 
molecular constituents. J Neurochem 91, 438-50.
Faundez, V., Horng, J. T. and Kelly, R. B. (1998). A function for the AP3 coat 
complex in synaptic vesicle formation from endosomes. Cell 93, 423-32.
Feilotter, H. E., Hannon, G. J., Ruddell, C. J. and Beach, D. (1994). Construction 
of an improved host strain for two hybrid screening. Nucleic Acids Res 22, 
1502-3.
Feng, L., Seymour, A. B., Jiang, S., To, A., Peden, A. A., Novak, E. K., Zhen, L., 
Rusiniak, M. E., Eicher, E. M., Robinson, M. S., Gorin, M. B. and Swank, R. T. 
(1999). The beta3A subunit gene (Ap3b1) of the AP-3 adaptor complex is altered 
in the mouse hypopigmentation mutant pearl, a model for Hermansky-Pudlak 
syndrome and night blindness. Hum Mol Genet 8, 323-30.
Fibiger, H. C., Damsma, G. and Day, J. C. (1991). Behavioral pharmacology and 
biochemistry of central cholinergic neurotransmission. Adv Exp Med Biol 295, 
399-414.
Fields, S. and Song, O. (1989). A novel genetic system to detect protein-protein 
interactions. Nature 340, 245-6.
Fiorillo, C. D. and Williams, J. T. (2000). Cholinergic inhibition of ventral midbrain 
dopamine neurons. J Neurosci 20, 7855-60.
Fisahn, A., Yamada, M., Duttaroy, A., Gan, J. W., Deng, C. X., McBain, C. J. and 
Wess, J. (2002). Muscarinic induction of hippocampal gamma oscillations 
requires coupling of the M1 receptor to two mixed cation currents. Neuron 33, 
615-24.
230
Flajolet, M., Rotondo, G., Daviet, L., Bergametti, F., Inchauspe, G., Tiollais, P., 
Transy, C. and Legrain, P. (2000). A genomic approach of the hepatitis C virus 
generates a protein interaction map. Gene 242, 369-79.
Flajolet, M., Wang, Z., Futter, M., Shen, W., Nuangchamnong, N., Bendor, J., 
Wallach, I., Nairn, A. C., Surmeier, D. J. and Greengard, P. (2008). FGF acts as a 
co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. 
Nat Neurosci 11, 1402-9.
Foord, S. M., Bonner, T. I., Neubig, R. R., Rosser, E. M., Pin, J. P., Davenport, A. 
P., Spedding, M. and Harmar, A. J. (2005). International Union of Pharmacology. 
XLVI. G protein-coupled receptor list. Pharmacol Rev 57, 279-88.
Forster, G. L., Yeomans, J. S., Takeuchi, J. and Blaha, C. D. (2002). M5 
muscarinic receptors are required for prolonged accumbal dopamine release 
after electrical stimulation of the pons in mice. J Neurosci 22, RC190.
Frank, S. R., Parisi, T., Taubert, S., Fernandez, P., Fuchs, M., Chan, H. M., 
Livingston, D. M. and Amati, B. (2003). MYC recruits the TIP60 histone 
acetyltransferase complex to chromatin. EMBO Rep 4, 575-80.
Fredriksson, R., Lagerstrom, M. C., Lundin, L. G. and Schioth, H. B. (2003). The 
G-protein-coupled receptors in the human genome form five main families. 
Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63, 
1256-72.
Fromont-Racine, M., Rain, J. C. and Legrain, P. (1997). Toward a functional 
analysis of the yeast genome through exhaustive two-hybrid screens. Nat Genet 
16, 277-82.
Funayama, T., Mashima, Y., Ohtake, Y., Ishikawa, K., Fuse, N., Yasuda, N., 
Fukuchi, T., Murakami, A., Hotta, Y. and Shimada, N. (2006). SNPs and 
interaction analyses of noelin 2, myocilin, and optineurin genes in Japanese 
patients with open-angle glaucoma. Invest Ophthalmol Vis Sci 47, 5368-75.
Gainetdinov, R. R., Premont, R. T., Bohn, L. M., Lefkowitz, R. J. and Caron, M. G. 
(2004). Desensitization of G protein-coupled receptors and neuronal functions. 
Annu Rev Neurosci 27, 107-44.
Gartner, A., Collin, L. and Lalli, G. (2006). Nucleofection of primary neurons. 
Methods Enzymol 406, 374-88.
231
Gautam, D., Han, S. J., Hamdan, F. F., Jeon, J., Li, B., Li, J. H., Cui, Y., Mears, 
D., Lu, H., Deng, C., Heard, T. and Wess, J. (2006). A critical role for beta cell M3 
muscarinic acetylcholine receptors in regulating insulin release and blood 
glucose homeostasis in vivo. Cell Metab 3, 449-61.
Gautam, D., Jeon, J., Starost, M. F., Han, S. J., Hamdan, F. F., Cui, Y., Parlow, A. 
F., Gavrilova, O., Szalayova, I., Mezey, E. and Wess, J. (2009). Neuronal M3 
muscarinic acetylcholine receptors are essential for somatotroph proliferation and 
normal somatic growth. Proc Natl Acad Sci U S A 106, 6398-403.
Gingras, A. C., Gstaiger, M., Raught, B. and Aebersold, R. (2007). Analysis of 
protein complexes using mass spectrometry. Nat Rev Mol Cell Biol 8, 645-54.
Godi, A., Di Campli, A., Konstantakopoulos, A., Di Tullio, G., Alessi, D. R., Kular, 
G. S., Daniele, T., Marra, P., Lucocq, J. M. and De Matteis, M. A. (2004). FAPPs 
control Golgi-to-cell-surface membrane traffic by binding to ARF and PtdIns(4)P. 
Nat Cell Biol 6, 393-404.
Goldman, P. S. and Nathanson, N. M. (1994). Differential role of the carboxyl-
terminal tyrosine in down-regulation and sequestration of the m2 muscarinic 
acetylcholine receptor. J Biol Chem 269, 15640-5.
Gomeza, J., Shannon, H., Kostenis, E., Felder, C., Zhang, L., Brodkin, J., 
Grinberg, A., Sheng, H. and Wess, J. (1999a). Pronounced pharmacologic 
deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad 
Sci U S A 96, 1692-7.
Gomeza, J., Zhang, L., Kostenis, E., Felder, C., Bymaster, F., Brodkin, J., 
Shannon, H., Xia, B., Deng, C. and Wess, J. (1999b). Enhancement of D1 
dopamine receptor-mediated locomotor stimulation in M(4) muscarinic 
acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A 96, 10483-8.
Gomeza, J., Zhang, L., Kostenis, E., Felder, C. C., Bymaster, F. P., Brodkin, J., 
Shannon, H., Xia, B., Duttaroy, A., Deng, C. X. and Wess, J. (2001). Generation 
and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice. 
Life Sci 68, 2457-66.
Gonzalez-Fernandez, F. (2003). Interphotoreceptor retinoid-binding protein--an 
old gene for new eyes. Vision Res 43, 3021-36.
Gorrini, C., Squatrito, M., Luise, C., Syed, N., Perna, D., Wark, L., Martinato, F., 
Sardella, D., Verrecchia, A., Bennett, S., Confalonieri, S., Cesaroni, M., Marchesi, 
F., Gasco, M., Scanziani, E., Capra, M., Mai, S., Nuciforo, P., Crook, T., Lough, J. 
232
and Amati, B. (2007). Tip60 is a haplo-insufficient tumour suppressor required for 
an oncogene-induced DNA damage response. Nature 448, 1063-7.
Goslin, K., Asmussen, H. and Banker, G. (1998). Rat hippocampal neurons in 
low-density culture. Culturing Nerve Cells. G. Banker and K. Goslin. Cambridge, 
MA, MIT Press, 339-370.
Grant, B. D. and Donaldson, J. G. (2009). Pathways and mechanisms of 
endocytic recycling. Nat Rev Mol Cell Biol 10, 597-608.
Greengard, P. (2001). The neurobiology of slow synaptic transmission. Science 
294, 1024-30.
Gronier, B. and Rasmussen, K. (1998). Activation of midbrain presumed 
dopaminergic neurones by muscarinic cholinergic receptors: an in vivo 
electrophysiological study in the rat. Br J Pharmacol 124, 455-64.
Gulledge, A. T., Bucci, D. J., Zhang, S. S., Matsui, M. and Yeh, H. H. (2009). M1 
receptors mediate cholinergic modulation of excitability in neocortical pyramidal 
neurons. J Neurosci 29, 9888-902.
Gurevich, V. V. and Gurevich, E. V. (2008). How and why do GPCRs dimerize? 
Trends Pharmacol Sci 29, 234-40.
Gyuris, J., Golemis, E., Chertkov, H. and Brent, R. (1993). Cdi1, a human G1 and 
S phase protein phosphatase that associates with Cdk2. Cell 75, 791-803.
Haga, K. and Haga, T. (1985). Purification of the muscarinic acetylcholine 
receptor from porcine brain. J Biol Chem 260, 7927-35.
Hall, R. A. (2004). Studying protein-protein interactions via blot overlay or Far 
Western blot. Methods Mol Biol 261, 167-74.
Hall, R. A. (2005). Co-Immunoprecipitation as a strategy to evaluate receptor-
receptor or receptor-protein interactions. G Protein-Coupled Receptor-Protein 
Interactions. S. R. George and B. F. O'Dowd. Hoboken, NJ, John Wiley & Sons, 
165-178.
Hamilton, S. E., Loose, M. D., Qi, M., Levey, A. I., Hille, B., McKnight, G. S., 
Idzerda, R. L. and Nathanson, N. M. (1997). Disruption of the m1 receptor gene 
ablates muscarinic receptor-dependent M current regulation and seizure activity 
in mice. Proc Natl Acad Sci U S A 94, 13311-6.
233
Hanyaloglu, A. C. and von Zastrow, M. (2008). Regulation of GPCRs by 
endocytic membrane trafficking and its potential implications. Annu Rev 
Pharmacol Toxicol 48, 537-68.
Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elledge, S. J. (1993). 
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent 
kinases. Cell 75, 805-16.
Harrison, P. J. and Weinberger, D. R. (2005). Schizophrenia genes, gene 
expression, and neuropathology: on the matter of their convergence. Mol 
Psychiatry 10, 40-68; image 5.
Hashimoto, H., Horton, J. R., Zhang, X., Bostick, M., Jacobsen, S. E. and Cheng, 
X. (2008a). The SRA domain of UHRF1 flips 5-methylcytosine out of the DNA 
helix. Nature 455, 826-9.
Hashimoto, Y., Morisawa, K., Saito, H., Jojima, E., Yoshida, N. and Haga, T. 
(2008b). Muscarinic M4 receptor recycling requires a motif in the third 
intracellular loop. J Pharmacol Exp Ther 325, 947-53.
Hepler, J. R. (1999). Emerging roles for RGS proteins in cell signalling. Trends 
Pharmacol Sci 20, 376-82.
Heydorn, A., Sondergaard, B. P., Ersboll, B., Holst, B., Nielsen, F. C., Haft, C. R., 
Whistler, J. and Schwartz, T. W. (2004). A library of 7TM receptor C-terminal tails. 
Interactions with the proposed post-endocytic sorting proteins ERM-binding 
phosphoprotein 50 (EBP50), N-ethylmaleimide-sensitive factor (NSF), sorting 
nexin 1 (SNX1), and G protein-coupled receptor-associated sorting protein 
(GASP). J Biol Chem 279, 54291-303.
Hope, I. A. and Struhl, K. (1986). Functional dissection of a eukaryotic 
transcriptional activator protein, GCN4 of yeast. Cell 46, 885-94.
Hsu, L. J., Schultz, L., Hong, Q., Van Moer, K., Heath, J., Li, M. Y., Lai, F. J., Lin, 
S. R., Lee, M. H., Lo, C. P., Lin, Y. S., Chen, S. T. and Chang, N. S. (2009). 
Transforming growth factor beta1 signaling via interaction with cell surface Hyal-2 
and recruitment of WWOX/WOX1. J Biol Chem 284, 16049-59.
Hu, L. A., Tang, Y., Miller, W. E., Cong, M., Lau, A. G., Lefkowitz, R. J. and Hall, 
R. A. (2000). beta 1-adrenergic receptor association with PSD-95. Inhibition of 
receptor internalization and facilitation of beta 1-adrenergic receptor interaction 
with N-methyl-D-aspartate receptors. J Biol Chem 275, 38659-66.
234
Huizing, M., Sarangarajan, R., Strovel, E., Zhao, Y., Gahl, W. A. and Boissy, R. E. 
(2001). AP-3 mediates tyrosinase but not TRP-1 trafficking in human 
melanocytes. Mol Biol Cell 12, 2075-85.
Iida, S., Seto, M., Yamamoto, K., Komatsu, H., Tojo, A., Asano, S., Kamada, N., 
Ariyoshi, Y., Takahashi, T. and Ueda, R. (1993). MLLT3 gene on 9p22 involved in 
t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 
19p13. Oncogene 8, 3085-92.
Ito, Y., Oyunzul, L., Seki, M., Fujino Oki, T., Matsui, M. and Yamada, S. (2009). 
Quantitative analysis of the loss of muscarinic receptors in various peripheral 
tissues in M1-M5 receptor single knockout mice. Br J Pharmacol 156, 1147-53.
Jackson, T. R., Kearns, B. G. and Theibert, A. B. (2000). Cytohesins and 
centaurins: mediators of PI 3-kinase-regulated Arf signaling. Trends Biochem Sci 
25, 489-95.
Janvier, K., Kato, Y., Boehm, M., Rose, J. R., Martina, J. A., Kim, B. Y., 
Venkatesan, S. and Bonifacino, J. S. (2003). Recognition of dileucine-based 
sorting signals from HIV-1 Nef and LIMP-II by the AP-1 gamma-sigma1 and AP-3 
delta-sigma3 hemicomplexes. J Cell Biol 163, 1281-90.
Jiang, M. and Chen, G. (2006). High Ca2+-phosphate transfection efficiency in 
low-density neuronal cultures. Nat Protoc 1, 695-700.
Jin, M., Li, S., Nusinowitz, S., Lloyd, M., Hu, J., Radu, R. A., Bok, D. and Travis, 
G. H. (2009). The role of interphotoreceptor retinoid-binding protein on the 
translocation of visual retinoids and function of cone photoreceptors. J Neurosci 
29, 1486-95.
Johnson, K. F. and Kornfeld, S. (1992). A His-Leu-Leu sequence near the 
carboxyl terminus of the cytoplasmic domain of the cation-dependent mannose 
6-phosphate receptor is necessary for the lysosomal enzyme sorting function. J 
Biol Chem 267, 17110-5.
Jordan, B. A., Trapaidze, N., Gomes, I., Nivarthi, R. and Devi, L. A. (2001). 
Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in 
trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci U 
S A 98, 343-8.
Jositsch, G., Papadakis, T., Haberberger, R. V., Wolff, M., Wess, J. and Kummer, 
W. (2009). Suitability of muscarinic acetylcholine receptor antibodies for 
235
immunohistochemistry evaluated on tissue sections of receptor gene-deficient 
mice. Naunyn Schmiedebergs Arch Pharmacol 379, 389-95.
Jung, S. S. and Levy, E. (2005). Murine cerebrovascular cells as a cell culture 
model for cerebral amyloid angiopathy: isolation of smooth muscle and 
endothelial cells from mouse brain. Methods Mol Biol 299, 211-9.
Kahn, R. A., Bruford, E., Inoue, H., Logsdon, J. M., Jr., Nie, Z., Premont, R. T., 
Randazzo, P. A., Satake, M., Theibert, A. B., Zapp, M. L. and Cassel, D. (2008). 
Consensus nomenclature for the human ArfGAP domain-containing proteins. J 
Cell Biol 182, 1039-44.
Kaneko, T., Li, L. and Li, S. S. (2008). The SH3 domain--a family of versatile 
peptide- and protein-recognition module. Front Biosci 13, 4938-52.
Kantheti, P., Qiao, X., Diaz, M. E., Peden, A. A., Meyer, G. E., Carskadon, S. L., 
Kapfhamer, D., Sufalko, D., Robinson, M. S., Noebels, J. L. and Burmeister, M. 
(1998). Mutation in AP-3 delta in the mocha mouse links endosomal transport to 
storage deficiency in platelets, melanosomes, and synaptic vesicles. Neuron 21, 
111-22.
Kaupmann, K., Malitschek, B., Schuler, V., Heid, J., Froestl, W., Beck, P., 
Mosbacher, J., Bischoff, S., Kulik, A., Shigemoto, R., Karschin, A. and Bettler, B. 
(1998). GABA(B)-receptor subtypes assemble into functional heteromeric 
complexes. Nature 396, 683-7.
Keegan, L., Gill, G. and Ptashne, M. (1986). Separation of DNA binding from the 
transcription-activating function of a eukaryotic regulatory protein. Science 231, 
699-704.
Kim, E. and Sheng, M. (2004). PDZ domain proteins of synapses. Nat Rev 
Neurosci 5, 771-81.
Kim, O. J., Ariano, M. A., Namkung, Y., Marinec, P., Kim, E., Han, J. and Sibley, 
D. R. (2008). D2 dopamine receptor expression and trafficking is regulated 
through direct interactions with ZIP. J Neurochem 106, 83-95.
Kohn, E. C., Alessandro, R., Probst, J., Jacobs, W., Brilley, E. and Felder, C. C. 
(1996). Identification and molecular characterization of a m5 muscarinic receptor 
in A2058 human melanoma cells. Coupling to inhibition of adenylyl cyclase and 
stimulation of phospholipase A2. J Biol Chem 271, 17476-84.
236
Kornau, H. C., Schenker, L. T., Kennedy, M. B. and Seeburg, P. H. (1995). 
Domain interaction between NMDA receptor subunits and the postsynaptic 
density protein PSD-95. Science 269, 1737-40.
Kostenis, E., Conklin, B. R. and Wess, J. (1997). Molecular basis of receptor/G 
protein coupling selectivity studied by coexpression of wild type and mutant m2 
muscarinic receptors with mutant G alpha(q) subunits. Biochemistry 36, 1487-95.
Kostenis, E., Zeng, F. Y. and Wess, J. (1999). Structure-function analysis of 
muscarinic receptors and their associated G proteins. Life Sci 64, 355-62.
Krudewig, R., Langer, B., Vogler, O., Markschies, N., Erl, M., Jakobs, K. H. and 
van Koppen, C. J. (2000). Distinct internalization of M2 muscarinic acetylcholine 
receptors confers selective and long-lasting desensitization of signaling to 
phospholipase C. J Neurochem 74, 1721-30.
Kung, L. A. and Snyder, M. (2006). Proteome chips for whole-organism assays. 
Nat Rev Mol Cell Biol 7, 617-22.
Kurten, R. C., Cadena, D. L. and Gill, G. N. (1996). Enhanced degradation of 
EGF receptors by a sorting nexin, SNX1. Science 272, 1008-10.
Kyttala, A., Yliannala, K., Schu, P., Jalanko, A. and Luzio, J. P. (2005). AP-1 and 
AP-3 facilitate lysosomal targeting of Batten disease protein CLN3 via its 
dileucine motif. J Biol Chem 280, 10277-83.
LaCount, D. J., Vignali, M., Chettier, R., Phansalkar, A., Bell, R., Hesselberth, J. 
R., Schoenfeld, L. W., Ota, I., Sahasrabudhe, S., Kurschner, C., Fields, S. and 
Hughes, R. E. (2005). A protein interaction network of the malaria parasite 
Plasmodium falciparum. Nature 438, 103-7.
Lane, P. W. and Deol, M. S. (1974). Mocha, a new coat color and behavior 
mutation on chromosome 10 of the mouse. J Hered 65, 362-4.
Lawrence, J., Mundell, S. J., Yun, H., Kelly, E. and Venkateswarlu, K. (2005). 
Centaurin-alpha 1, an ADP-ribosylation factor 6 GTPase activating protein, 
inhibits beta 2-adrenoceptor internalization. Mol Pharmacol 67, 1822-8.
Lee, F. J. S. and Liu, F. (2005). GST fusion protein and pull-down strategies to 
evaluate receptor-receptor or receptor-protein interactions. G Protein-Coupled 
Receptor-Protein Interactions. S. R. George and B. F. O'Dowd. Hoboken, NJ, 
John Wiley & Sons, 221-231.
237
Lee, J. A., Anholt, R. R. and Cole, G. J. (2008). Olfactomedin-2 mediates 
development of the anterior central nervous system and head structures in 
zebrafish. Mech Dev 125, 167-81.
Lee, M. S., Kao, S. C., Lemere, C. A., Xia, W., Tseng, H. C., Zhou, Y., Neve, R., 
Ahlijanian, M. K. and Tsai, L. H. (2003). APP processing is regulated by 
cytoplasmic phosphorylation. J Cell Biol 163, 83-95.
Lefrancois, S., Janvier, K., Boehm, M., Ooi, C. E. and Bonifacino, J. S. (2004). An 
ear-core interaction regulates the recruitment of the AP-3 complex to 
membranes. Dev Cell 7, 619-25.
Lein, E. S., Hawrylycz, M. J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, 
A. F., Boguski, M. S., Brockway, K. S., Byrnes, E. J., Chen, L., Chen, T. M., Chin, 
M. C., Chong, J., Crook, B. E., Czaplinska, A., Dang, C. N., Datta, S., Dee, N. R., 
Desaki, A. L., Desta, T., Diep, E., Dolbeare, T. A., Donelan, M. J., Dong, H. W., 
Dougherty, J. G., Duncan, B. J., Ebbert, A. J., Eichele, G., Estin, L. K., Faber, C., 
Facer, B. A., Fields, R., Fischer, S. R., Fliss, T. P., Frensley, C., Gates, S. N., 
Glattfelder, K. J., Halverson, K. R., Hart, M. R., Hohmann, J. G., Howell, M. P., 
Jeung, D. P., Johnson, R. A., Karr, P. T., Kawal, R., Kidney, J. M., Knapik, R. H., 
Kuan, C. L., Lake, J. H., Laramee, A. R., Larsen, K. D., Lau, C., Lemon, T. A., 
Liang, A. J., Liu, Y., Luong, L. T., Michaels, J., Morgan, J. J., Morgan, R. J., 
Mortrud, M. T., Mosqueda, N. F., Ng, L. L., Ng, R., Orta, G. J., Overly, C. C., Pak, 
T. H., Parry, S. E., Pathak, S. D., Pearson, O. C., Puchalski, R. B., Riley, Z. L., 
Rockett, H. R., Rowland, S. A., Royall, J. J., Ruiz, M. J., Sarno, N. R., Schaffnit, 
K., Shapovalova, N. V., Sivisay, T., Slaughterbeck, C. R., Smith, S. C., Smith, K. 
A., Smith, B. I., Sodt, A. J., Stewart, N. N., Stumpf, K. R., Sunkin, S. M., Sutram, 
M., Tam, A., Teemer, C. D., Thaller, C., Thompson, C. L., Varnam, L. R., Visel, A., 
Whitlock, R. M., Wohnoutka, P. E., Wolkey, C. K., Wong, V. Y., Wood, M., 
Yaylaoglu, M. B., Young, R. C., Youngstrom, B. L., Yuan, X. F., Zhang, B., 
Zwingman, T. A. and Jones, A. R. (2007). Genome-wide atlas of gene expression 
in the adult mouse brain. Nature 445, 168-76.
Lemmon, M. A. (2004). Pleckstrin homology domains: not just for 
phosphoinositides. Biochem Soc Trans 32, 707-11.
Letourneur, F. and Klausner, R. D. (1992). A novel di-leucine motif and a tyrosine-
based motif independently mediate lysosomal targeting and endocytosis of CD3 
chains. Cell 69, 1143-57.
Li, J., Ballif, B. A., Powelka, A. M., Dai, J., Gygi, S. P. and Hsu, V. W. (2005). 
Phosphorylation of ACAP1 by Akt regulates the stimulation-dependent recycling 
of integrin beta1 to control cell migration. Dev Cell 9, 663-73.
238
Li, J., Mahajan, A. and Tsai, M. D. (2006). Ankyrin repeat: a unique motif 
mediating protein-protein interactions. Biochemistry 45, 15168-78.
Li, S., Armstrong, C. M., Bertin, N., Ge, H., Milstein, S., Boxem, M., Vidalain, P. 
O., Han, J. D., Chesneau, A., Hao, T., Goldberg, D. S., Li, N., Martinez, M., Rual, 
J. F., Lamesch, P., Xu, L., Tewari, M., Wong, S. L., Zhang, L. V., Berriz, G. F., 
Jacotot, L., Vaglio, P., Reboul, J., Hirozane-Kishikawa, T., Li, Q., Gabel, H. W., 
Elewa, A., Baumgartner, B., Rose, D. J., Yu, H., Bosak, S., Sequerra, R., Fraser, 
A., Mango, S. E., Saxton, W. M., Strome, S., Van Den Heuvel, S., Piano, F., 
Vandenhaute, J., Sardet, C., Gerstein, M., Doucette-Stamm, L., Gunsalus, K. C., 
Harper, J. W., Cusick, M. E., Roth, F. P., Hill, D. E. and Vidal, M. (2004). A map of 
the interactome network of the metazoan C. elegans. Science 303, 540-3.
Li, W., Zhang, Q., Oiso, N., Novak, E. K., Gautam, R., O'Brien, E. P., Tinsley, C. 
L., Blake, D. J., Spritz, R. A., Copeland, N. G., Jenkins, N. A., Amato, D., Roe, B. 
A., Starcevic, M., Dell'Angelica, E. C., Elliott, R. W., Mishra, V., Kingsmore, S. F., 
Paylor, R. E. and Swank, R. T. (2003). Hermansky-Pudlak syndrome type 7 
(HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-
related organelles complex 1 (BLOC-1). Nat Genet 35, 84-9.
Lim, S., Sala, C., Yoon, J., Park, S., Kuroda, S., Sheng, M. and Kim, E. (2001). 
Sharpin, a novel postsynaptic density protein that directly interacts with the shank 
family of proteins. Mol Cell Neurosci 17, 385-97.
Lin, R., Kabbani, N., Binda, A., Canfield, V. and Levenson, R. (2005). Use of the 
yeast two-hybrid system to detect receptor-protein interactions. G Protein-
Coupled Receptor-Protein Interactions. S. R. George and B. F. O'Dowd. 
Hoboken, NJ, John Wiley & Sons, 201-219.
Lin, R., Karpa, K., Kabbani, N., Goldman-Rakic, P. and Levenson, R. (2001). 
Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via 
interaction with filamin A. Proc Natl Acad Sci U S A 98, 5258-63.
Liou, G. I., Bridges, C. D., Fong, S. L., Alvarez, R. A. and Gonzalez-Fernandez, 
F. (1982). Vitamin A transport between retina and pigment epithelium--an 
interstitial protein carrying endogenous retinol (interstitial retinol-binding protein). 
Vision Res 22, 1457-67.
Liu, L., Zhao, R., Bai, Y., Stanish, L. F., Evans, J. E., Sanderson, M. J., 
Bonventre, J. V. and Rittenhouse, A. R. (2006). M1 muscarinic receptors inhibit L-
type Ca2+ current and M-current by divergent signal transduction cascades. J 
Neurosci 26, 11588-98.
239
Lodowski, D. T., Pitcher, J. A., Capel, W. D., Lefkowitz, R. J. and Tesmer, J. J. 
(2003). Keeping G proteins at bay: a complex between G protein-coupled 
receptor kinase 2 and Gbetagamma. Science 300, 1256-62.
Lohse, M. J., Benovic, J. L., Codina, J., Caron, M. G. and Lefkowitz, R. J. (1990). 
beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science 
248, 1547-50.
Luo, J., Busillo, J. M. and Benovic, J. L. (2008). M3 muscarinic acetylcholine 
receptor-mediated signaling is regulated by distinct mechanisms. Mol Pharmacol 
74, 338-47.
Luttrell, L. M. and Lefkowitz, R. J. (2002). The role of beta-arrestins in the 
termination and transduction of G-protein-coupled receptor signals. J Cell Sci 
115, 455-65.
Lyssand, J. S., DeFino, M. C., Tang, X. B., Hertz, A. L., Feller, D. B., Wacker, J. 
L., Adams, M. E. and Hague, C. (2008). Blood pressure is regulated by an 
alpha1D-adrenergic receptor/dystrophin signalosome. J Biol Chem 283, 
18792-800.
Ma, J. and Ptashne, M. (1988). Converting a eukaryotic transcriptional inhibitor 
into an activator. Cell 55, 443-6.
Madziva, M. T., Bai, J., Bhalla, A., Chapman, E. R. and Edwardson, J. M. (2005). 
Effects of synaptotagmin reveal two distinct mechanisms of agonist-stimulated 
internalization of the M4 muscarinic acetylcholine receptor. Br J Pharmacol 144, 
761-71.
Maeda, S., Lameh, J., Mallet, W. G., Philip, M., Ramachandran, J. and Sadee, 
W. (1990). Internalization of the Hm1 muscarinic cholinergic receptor involves the 
third cytoplasmic loop. FEBS Lett 269, 386-8.
Mahlknecht, U., Ottmann, O. G. and Hoelzer, D. (2001). Far-Western based 
protein-protein interaction screening of high-density protein filter arrays. J 
Biotechnol 88, 89-94.
Marchese, A., Paing, M. M., Temple, B. R. and Trejo, J. (2008). G protein-coupled 
receptor sorting to endosomes and lysosomes. Annu Rev Pharmacol Toxicol 48, 
601-29.
240
Margeta-Mitrovic, M., Jan, Y. N. and Jan, L. Y. (2000). A trafficking checkpoint 
controls GABA(B) receptor heterodimerization. Neuron 27, 97-106.
Martinez-Arca, S., Rudge, R., Vacca, M., Raposo, G., Camonis, J., Proux-
Gillardeaux, V., Daviet, L., Formstecher, E., Hamburger, A., Filippini, F., 
D'Esposito, M. and Galli, T. (2003). A dual mechanism controlling the localization 
and function of exocytic v-SNAREs. Proc Natl Acad Sci U S A 100, 9011-6.
Martire, M., D'Amico, M., Panza, E., Miceli, F., Viggiano, D., Lavergata, F., 
Iannotti, F. A., Barrese, V., Preziosi, P., Annunziato, L. and Taglialatela, M. (2007). 
Involvement of KCNQ2 subunits in [3H]dopamine release triggered by 
depolarization and pre-synaptic muscarinic receptor activation from rat striatal 
synaptosomes. J Neurochem 102, 179-93.
Maudsley, S., Martin, B. and Luttrell, L. M. (2007). G protein-coupled receptor 
signaling complexity in neuronal tissue: implications for novel therapeutics. Curr 
Alzheimer Res 4, 3-19.
Maurice, P., Daulat, A. M., Broussard, C., Mozo, J., Clary, G., Hotellier, F., 
Chafey, P., Guillaume, J. L., Ferry, G., Boutin, J. A., Delagrange, P., Camoin, L. 
and Jockers, R. (2008). A generic approach for the purification of signaling 
complexes that specifically interact with the carboxyl-terminal domain of G 
protein-coupled receptors. Mol Cell Proteomics 7, 1556-69.
Maxfield, F. R. and McGraw, T. E. (2004). Endocytic recycling. Nat Rev Mol Cell 
Biol 5, 121-32.
McClatchy, D. B., Knudsen, C. R., Clark, B. F., Kahn, R. A., Hall, R. A. and Levey, 
A. I. (2002). Novel interaction between the M4 muscarinic acetylcholine receptor 
and elongation factor 1A2. J Biol Chem 277, 29268-74.
McDonald, P. H., Chow, C. W., Miller, W. E., Laporte, S. A., Field, M. E., Lin, F. T., 
Davis, R. J. and Lefkowitz, R. J. (2000). Beta-arrestin 2: a receptor-regulated 
MAPK scaffold for the activation of JNK3. Science 290, 1574-7.
McGraw, T. E., Pytowski, B., Arzt, J. and Ferrone, C. (1991). Mutagenesis of the 
human transferrin receptor: two cytoplasmic phenylalanines are required for 
efficient internalization and a second-site mutation is capable of reverting an 
internalization-defective phenotype. J Cell Biol 112, 853-61.
Mesulam, M. M. (2004). The cholinergic innervation of the human cerebral 
cortex. Prog Brain Res 145, 67-78.
241
Meurer, S., Pioch, S., Wagner, K., Muller-Esterl, W. and Gross, S. (2004). 
AGAP1, a novel binding partner of nitric oxide-sensitive guanylyl cyclase. J Biol 
Chem 279, 49346-54.
Miller, A. D. and Blaha, C. D. (2005). Midbrain muscarinic receptor mechanisms 
underlying regulation of mesoaccumbens and nigrostriatal dopaminergic 
transmission in the rat. Eur J Neurosci 21, 1837-46.
Miller, K. A., Sawicka, D., Barsky, D. and Albala, J. S. (2004). Domain mapping of 
the Rad51 paralog protein complexes. Nucleic Acids Res 32, 169-78.
Mitchell, R., Robertson, D. N., Holland, P. J., Collins, D., Lutz, E. M. and 
Johnson, M. S. (2003). ADP-ribosylation factor-dependent phospholipase D 
activation by the M3 muscarinic receptor. J Biol Chem 278, 33818-30.
Miyakawa, T., Yamada, M., Duttaroy, A. and Wess, J. (2001). Hyperactivity and 
intact hippocampus-dependent learning in mice lacking the M1 muscarinic 
acetylcholine receptor. J Neurosci 21, 5239-50.
Moreno, T. A. and Bronner-Fraser, M. (2002). Neural expression of mouse 
Noelin-1/2 and comparison with other vertebrates. Mech Dev 119, 121-5.
Morris, S. M. and Cooper, J. A. (2001). Disabled-2 colocalizes with the LDLR in 
clathrin-coated pits and interacts with AP-2. Traffic 2, 111-23.
Nadler, L. S., Kumar, G. and Nathanson, N. M. (2001). Identification of a 
basolateral sorting signal for the M3 muscarinic acetylcholine receptor in Madin-
Darby canine kidney cells. J Biol Chem 276, 10539-47.
Nakatsu, F. and Ohno, H. (2003). Adaptor protein complexes as the key 
regulators of protein sorting in the post-Golgi network. Cell Struct Funct 28, 
419-29.
Nakatsu, F., Okada, M., Mori, F., Kumazawa, N., Iwasa, H., Zhu, G., Kasagi, Y., 
Kamiya, H., Harada, A., Nishimura, K., Takeuchi, A., Miyazaki, T., Watanabe, M., 
Yuasa, S., Manabe, T., Wakabayashi, K., Kaneko, S., Saito, T. and Ohno, H. 
(2004). Defective function of GABA-containing synaptic vesicles in mice lacking 
the AP-3B clathrin adaptor. J Cell Biol 167, 293-302.
Nathanson, N. M. (2000). A multiplicity of muscarinic mechanisms: enough 
signaling pathways to take your breath away. Proc Natl Acad Sci U S A 97, 
6245-7.
242
Newell-Litwa, K., Seong, E., Burmeister, M. and Faundez, V. (2007). Neuronal 
and non-neuronal functions of the AP-3 sorting machinery. J Cell Sci 120, 
531-41.
Newman, L. S., McKeever, M. O., Okano, H. J. and Darnell, R. B. (1995). Beta-
NAP, a cerebellar degeneration antigen, is a neuron-specific vesicle coat protein. 
Cell 82, 773-83.
Nie, Z., Boehm, M., Boja, E. S., Vass, W. C., Bonifacino, J. S., Fales, H. M. and 
Randazzo, P. A. (2003). Specific regulation of the adaptor protein complex AP-3 
by the Arf GAP AGAP1. Dev Cell 5, 513-21.
Nie, Z., Fei, J., Premont, R. T. and Randazzo, P. A. (2005). The Arf GAPs AGAP1 
and AGAP2 distinguish between the adaptor protein complexes AP-1 and AP-3. J 
Cell Sci 118, 3555-66.
Nie, Z., Hirsch, D. S., Luo, R., Jian, X., Stauffer, S., Cremesti, A., Andrade, J., 
Lebowitz, J., Marino, M., Ahvazi, B., Hinshaw, J. E. and Randazzo, P. A. (2006). 
A BAR domain in the N terminus of the Arf GAP ASAP1 affects membrane 
structure and trafficking of epidermal growth factor receptor. Curr Biol 16, 130-9.
Nie, Z. and Randazzo, P. A. (2006). Arf GAPs and membrane traffic. J Cell Sci 
119, 1203-11.
Nie, Z., Stanley, K. T., Stauffer, S., Jacques, K. M., Hirsch, D. S., Takei, J. and 
Randazzo, P. A. (2002). AGAP1, an endosome-associated, phosphoinositide-
dependent ADP-ribosylation factor GTPase-activating protein that affects actin 
cytoskeleton. J Biol Chem 277, 48965-75.
Novak, E. K., Hui, S. W. and Swank, R. T. (1984). Platelet storage pool deficiency 
in mouse pigment mutations associated with seven distinct genetic loci. Blood 
63, 536-44.
Obsilova, V., Silhan, J., Boura, E., Teisinger, J. and Obsil, T. (2008). 14-3-3 
proteins: a family of versatile molecular regulators. Physiol Res 57 Suppl 3, 
S11-21.
Ohno, H., Aguilar, R. C., Yeh, D., Taura, D., Saito, T. and Bonifacino, J. S. (1998). 
The medium subunits of adaptor complexes recognize distinct but overlapping 
sets of tyrosine-based sorting signals. J Biol Chem 273, 25915-21.
243
Oki, T., Takagi, Y., Inagaki, S., Taketo, M. M., Manabe, T., Matsui, M. and 
Yamada, S. (2005). Quantitative analysis of binding parameters of [3H]N-
methylscopolamine in central nervous system of muscarinic acetylcholine 
receptor knockout mice. Brain Res Mol Brain Res 133, 6-11.
Oksche, A., Boese, G., Horstmeyer, A., Furkert, J., Beyermann, M., Bienert, M. 
and Rosenthal, W. (2000). Late endosomal/lysosomal targeting and lack of 
recycling of the ligand-occupied endothelin B receptor. Mol Pharmacol 57, 
1104-13.
Oldham, W. M. and Hamm, H. E. (2008). Heterotrimeric G protein activation by 
G-protein-coupled receptors. Nat Rev Mol Cell Biol 9, 60-71.
Ooi, C. E., Dell'Angelica, E. C. and Bonifacino, J. S. (1998). ADP-Ribosylation 
factor 1 (ARF1) regulates recruitment of the AP-3 adaptor complex to 
membranes. J Cell Biol 142, 391-402.
Ooi, C. E., Moreira, J. E., Dell'Angelica, E. C., Poy, G., Wassarman, D. A. and 
Bonifacino, J. S. (1997). Altered expression of a novel adaptin leads to defective 
pigment granule biogenesis in the Drosophila eye color mutant garnet. EMBO J 
16, 4508-18.
Pals-Rylaarsdam, R., Gurevich, V. V., Lee, K. B., Ptasienski, J. A., Benovic, J. L. 
and Hosey, M. M. (1997). Internalization of the m2 muscarinic acetylcholine 
receptor. Arrestin-independent and -dependent pathways. J Biol Chem 272, 
23682-9.
Parent, A., Laroche, G., Hamelin, E. and Parent, J. L. (2008). RACK1 regulates 
the cell surface expression of the G protein-coupled receptor for thromboxane 
A(2). Traffic 9, 394-407.
Park, M., Penick, E. C., Edwards, J. G., Kauer, J. A. and Ehlers, M. D. (2004). 
Recycling endosomes supply AMPA receptors for LTP. Science 305, 1972-5.
Park, M., Salgado, J. M., Ostroff, L., Helton, T. D., Robinson, C. G., Harris, K. M. 
and Ehlers, M. D. (2006). Plasticity-induced growth of dendritic spines by 
exocytic trafficking from recycling endosomes. Neuron 52, 817-30.
Park, P. S. and Wells, J. W. (2003). Monomers and oligomers of the M2 
muscarinic cholinergic receptor purified from Sf9 cells. Biochemistry 42, 
12960-71.
244
Pawson, T. and Nash, P. (2003). Assembly of cell regulatory systems through 
protein interaction domains. Science 300, 445-52.
Peden, A. A., Oorschot, V., Hesser, B. A., Austin, C. D., Scheller, R. H. and 
Klumperman, J. (2004). Localization of the AP-3 adaptor complex defines a novel 
endosomal exit site for lysosomal membrane proteins. J Cell Biol 164, 1065-76.
Peden, A. A., Rudge, R. E., Lui, W. W. and Robinson, M. S. (2002). Assembly 
and function of AP-3 complexes in cells expressing mutant subunits. J Cell Biol 
156, 327-36.
Perez-Burgos, A., Perez-Rosello, T., Salgado, H., Flores-Barrera, E., Prieto, G. 
A., Figueroa, A., Galarraga, E. and Bargas, J. (2008). Muscarinic M(1) 
modulation of N and L types of calcium channels is mediated by protein kinase C 
in neostriatal neurons. Neuroscience 155, 1079-97.
Peterson, G. L., Toumadje, A., Johnson, W. C., Jr. and Schimerlik, M. I. (1995). 
Purification of recombinant porcine m2 muscarinic acetylcholine receptor from 
Chinese hamster ovary cells. Circular dichroism spectra and ligand binding 
properties. J Biol Chem 270, 17808-14.
Phizicky, E., Bastiaens, P. I., Zhu, H., Snyder, M. and Fields, S. (2003). Protein 
analysis on a proteomic scale. Nature 422, 208-15.
Phizicky, E. M. and Fields, S. (1995). Protein-protein interactions: methods for 
detection and analysis. Microbiol Rev 59, 94-123.
Pina, C., May, G., Soneji, S., Hong, D. and Enver, T. (2008). MLLT3 regulates 
early human erythroid and megakaryocytic cell fate. Cell Stem Cell 2, 264-73.
Pisani, A., Bernardi, G., Ding, J. and Surmeier, D. J. (2007). Re-emergence of 
striatal cholinergic interneurons in movement disorders. Trends Neurosci 30, 
545-53.
Popova, J. S. and Rasenick, M. M. (2004). Clathrin-mediated endocytosis of m3 
muscarinic receptors. Roles for Gbetagamma and tubulin. J Biol Chem 279, 
30410-8.
Porter, A. C., Bymaster, F. P., DeLapp, N. W., Yamada, M., Wess, J., Hamilton, S. 
E., Nathanson, N. M. and Felder, C. C. (2002). M1 muscarinic receptor signaling 
in mouse hippocampus and cortex. Brain Res 944, 82-9.
245
Qtaishat, N. M., Wiggert, B. and Pepperberg, D. R. (2005). Interphotoreceptor 
retinoid-binding protein (IRBP) promotes the release of all-trans retinol from the 
isolated retina following rhodopsin bleaching illumination. Exp Eye Res 81, 
455-63.
Rapoport, I., Chen, Y. C., Cupers, P., Shoelson, S. E. and Kirchhausen, T. (1998). 
Dileucine-based sorting signals bind to the beta chain of AP-1 at a site distinct 
and regulated differently from the tyrosine-based motif-binding site. EMBO J 17, 
2148-55.
Rapoport, I., Miyazaki, M., Boll, W., Duckworth, B., Cantley, L. C., Shoelson, S. 
and Kirchhausen, T. (1997). Regulatory interactions in the recognition of 
endocytic sorting signals by AP-2 complexes. EMBO J 16, 2240-50.
Rasmussen, S. G., Choi, H. J., Rosenbaum, D. M., Kobilka, T. S., Thian, F. S., 
Edwards, P. C., Burghammer, M., Ratnala, V. R., Sanishvili, R., Fischetti, R. F., 
Schertler, G. F., Weis, W. I. and Kobilka, B. K. (2007). Crystal structure of the 
human beta2 adrenergic G-protein-coupled receptor. Nature 450, 383-7.
Rayport, S., Sulzer, D., Shi, W. X., Sawasdikosol, S., Monaco, J., Batson, D. and 
Rajendran, G. (1992). Identified postnatal mesolimbic dopamine neurons in 
culture: morphology and electrophysiology. J Neurosci 12, 4264-80.
Regard, J. B., Sato, I. T. and Coughlin, S. R. (2008). Anatomical profiling of G 
protein-coupled receptor expression. Cell 135, 561-71.
Rong, R., Ahn, J. Y., Huang, H., Nagata, E., Kalman, D., Kapp, J. A., Tu, J., 
Worley, P. F., Snyder, S. H. and Ye, K. (2003). PI3 kinase enhancer-Homer 
complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat 
Neurosci 6, 1153-61.
Rosenbaum, D. M., Cherezov, V., Hanson, M. A., Rasmussen, S. G., Thian, F. S., 
Kobilka, T. S., Choi, H. J., Yao, X. J., Weis, W. I., Stevens, R. C. and Kobilka, B. 
K. (2007). GPCR engineering yields high-resolution structural insights into beta2-
adrenergic receptor function. Science 318, 1266-73.
Rosenbaum, D. M., Rasmussen, S. G. and Kobilka, B. K. (2009). The structure 
and function of G-protein-coupled receptors. Nature 459, 356-63.
Rozenfeld, R. and Devi, L. A. (2008). Regulation of CB1 cannabinoid receptor 
trafficking by the adaptor protein AP-3. FASEB J 22, 2311-22.
246
Ruden, D. M., Ma, J., Li, Y., Wood, K. and Ptashne, M. (1991). Generating yeast 
transcriptional activators containing no yeast protein sequences. Nature 350, 
250-2.
Ryan, X. P., Alldritt, J., Svenningsson, P., Allen, P. B., Wu, G. Y., Nairn, A. C. and 
Greengard, P. (2005). The Rho-specific GEF Lfc interacts with neurabin and 
spinophilin to regulate dendritic spine morphology. Neuron 47, 85-100.
Salazar, G., Craige, B., Love, R., Kalman, D. and Faundez, V. (2005a). Vglut1 
and ZnT3 co-targeting mechanisms regulate vesicular zinc stores in PC12 cells. 
J Cell Sci 118, 1911-21.
Salazar, G., Craige, B., Styers, M. L., Newell-Litwa, K. A., Doucette, M. M., 
Wainer, B. H., Falcon-Perez, J. M., Dell'Angelica, E. C., Peden, A. A., Werner, E. 
and Faundez, V. (2006). BLOC-1 complex deficiency alters the targeting of 
adaptor protein complex-3 cargoes. Mol Biol Cell 17, 4014-26.
Salazar, G., Craige, B., Wainer, B. H., Guo, J., De Camilli, P. and Faundez, V. 
(2005b). Phosphatidylinositol-4-kinase type II alpha is a component of adaptor 
protein-3-derived vesicles. Mol Biol Cell 16, 3692-704.
Salazar, G., Love, R., Styers, M. L., Werner, E., Peden, A., Rodriguez, S., 
Gearing, M., Wainer, B. H. and Faundez, V. (2004a). AP-3-dependent 
mechanisms control the targeting of a chloride channel (ClC-3) in neuronal and 
non-neuronal cells. J Biol Chem 279, 25430-9.
Salazar, G., Love, R., Werner, E., Doucette, M. M., Cheng, S., Levey, A. and 
Faundez, V. (2004b). The zinc transporter ZnT3 interacts with AP-3 and it is 
preferentially targeted to a distinct synaptic vesicle subpopulation. Mol Biol Cell 
15, 575-87.
Salazar, G., Zlatic, S., Craige, B., Peden, A. A., Pohl, J. and Faundez, V. (2009). 
Hermansky-Pudlak syndrome protein complexes associate with 
phosphatidylinositol 4-kinase type II alpha in neuronal and non-neuronal cells. J 
Biol Chem 284, 1790-802.
Santiago, M. P. and Potter, L. T. (2001). Biotinylated m4-toxin demonstrates more 
M4 muscarinic receptor protein on direct than indirect striatal projection neurons. 
Brain Res 894, 12-20.
Satake, H. and Sakai, T. (2008). Recent advances and perceptions in studies of 
heterodimerization between G protein-coupled receptors. Protein Pept Lett 15, 
300-8.
247
Scarselli, M. and Donaldson, J. G. (2009). Constitutive internalization of G 
protein-coupled receptors and G proteins via clathrin-independent endocytosis. J 
Biol Chem 284, 3577-85.
Schaff, U. Y., Shih, H. H., Lorenz, M., Sako, D., Kriz, R., Milarski, K., Bates, B., 
Tchernychev, B., Shaw, G. D. and Simon, S. I. (2008). SLIC-1/sorting nexin 20: a 
novel sorting nexin that directs subcellular distribution of PSGL-1. Eur J Immunol 
38, 550-64.
Schaub, B. E., Nair, P. and Rohrer, J. (2005). Analysis of protein transport to 
lysosomes. Curr Protoc Cell Biol Chapter 15, Unit 15 8.
Scheerer, P., Park, J. H., Hildebrand, P. W., Kim, Y. J., Krauss, N., Choe, H. W., 
Hofmann, K. P. and Ernst, O. P. (2008). Crystal structure of opsin in its G-protein-
interacting conformation. Nature 455, 497-502.
Scheuber, A., Rudge, R., Danglot, L., Raposo, G., Binz, T., Poncer, J. C. and 
Galli, T. (2006). Loss of AP-3 function affects spontaneous and evoked release at 
hippocampal mossy fiber synapses. Proc Natl Acad Sci U S A 103, 16562-7.
Schoeber, J. P., Topala, C. N., Wang, X., Diepens, R. J., Lambers, T. T., 
Hoenderop, J. G. and Bindels, R. J. (2006). RGS2 inhibits the epithelial Ca2+ 
channel TRPV6. J Biol Chem 281, 29669-74.
Schwab, S. G., Knapp, M., Mondabon, S., Hallmayer, J., Borrmann-Hassenbach, 
M., Albus, M., Lerer, B., Rietschel, M., Trixler, M., Maier, W. and Wildenauer, D. 
B. (2003). Support for association of schizophrenia with genetic variation in the 
6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional 
sample of triad families. Am J Hum Genet 72, 185-90.
Seeger, T., Fedorova, I., Zheng, F., Miyakawa, T., Koustova, E., Gomeza, J., 
Basile, A. S., Alzheimer, C. and Wess, J. (2004). M2 muscarinic acetylcholine 
receptor knock-out mice show deficits in behavioral flexibility, working memory, 
and hippocampal plasticity. J Neurosci 24, 10117-27.
Seong, E., Wainer, B. H., Hughes, E. D., Saunders, T. L., Burmeister, M. and 
Faundez, V. (2005). Genetic analysis of the neuronal and ubiquitous AP-3 
adaptor complexes reveals divergent functions in brain. Mol Biol Cell 16, 128-40.
Shaner, N. C., Campbell, R. E., Steinbach, P. A., Giepmans, B. N., Palmer, A. E. 
and Tsien, R. Y. (2004). Improved monomeric red, orange and yellow fluorescent 
proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 22, 
1567-72.
248
Shapiro, M. S., Gomeza, J., Hamilton, S. E., Hille, B., Loose, M. D., Nathanson, 
N. M., Roche, J. P. and Wess, J. (2001). Identification of subtypes of muscarinic 
receptors that regulate Ca2+ and K+ channel activity in sympathetic neurons. 
Life Sci 68, 2481-7.
Sharif, J., Muto, M., Takebayashi, S., Suetake, I., Iwamatsu, A., Endo, T. A., 
Shinga, J., Mizutani-Koseki, Y., Toyoda, T., Okamura, K., Tajima, S., Mitsuya, K., 
Okano, M. and Koseki, H. (2007). The SRA protein Np95 mediates epigenetic 
inheritance by recruiting Dnmt1 to methylated DNA. Nature 450, 908-12.
Shenoy, S. K., McDonald, P. H., Kohout, T. A. and Lefkowitz, R. J. (2001). 
Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic 
receptor and beta-arrestin. Science 294, 1307-13.
Shi, J., Levinson, D. F., Duan, J., Sanders, A. R., Zheng, Y., Pe'er, I., Dudbridge, 
F., Holmans, P. A., Whittemore, A. S., Mowry, B. J., Olincy, A., Amin, F., 
Cloninger, C. R., Silverman, J. M., Buccola, N. G., Byerley, W. F., Black, D. W., 
Crowe, R. R., Oksenberg, J. R., Mirel, D. B., Kendler, K. S., Freedman, R. and 
Gejman, P. V. (2009). Common variants on chromosome 6p22.1 are associated 
with schizophrenia. Nature.
Siman, R. G. and Klein, W. L. (1983). Differential regulation of muscarinic and 
nicotinic receptors by cholinergic stimulation in cultured avian retina cells. Brain 
Res 262, 99-108.
Simon, M. I., Strathmann, M. P. and Gautam, N. (1991). Diversity of G proteins in 
signal transduction. Science 252, 802-8.
Simon, V., Guidry, J., Gettys, T. W., Tobin, A. B. and Lanier, S. M. (2006). The 
proto-oncogene SET interacts with muscarinic receptors and attenuates receptor 
signaling. J Biol Chem 281, 40310-20.
Simonin, F., Karcher, P., Boeuf, J. J., Matifas, A. and Kieffer, B. L. (2004). 
Identification of a novel family of G protein-coupled receptor associated sorting 
proteins. J Neurochem 89, 766-75.
Simpson, F., Peden, A. A., Christopoulou, L. and Robinson, M. S. (1997). 
Characterization of the adaptor-related protein complex, AP-3. J Cell Biol 137, 
835-45.
Singer-Lahat, D., Liu, J., Wess, J. and Felder, C. C. (1996). The third intracellular 
domain of the m3 muscarinic receptor determines coupling to calcium influx in 
transfected Chinese hamster ovary cells. FEBS Lett 386, 51-4.
249
Smith, G. P. (1985). Filamentous fusion phage: novel expression vectors that 
display cloned antigens on the virion surface. Science 228, 1315-7.
Squatrito, M., Gorrini, C. and Amati, B. (2006). Tip60 in DNA damage response 
and growth control: many tricks in one HAT. Trends Cell Biol 16, 433-42.
Stanasila, L., Abuin, L., Diviani, D. and Cotecchia, S. (2006). Ezrin directly 
interacts with the alpha1b-adrenergic receptor and plays a role in receptor 
recycling. J Biol Chem 281, 4354-63.
Stengel, P. W., Gomeza, J., Wess, J. and Cohen, M. L. (2000). M(2) and M(4) 
receptor knockout mice: muscarinic receptor function in cardiac and smooth 
muscle in vitro. J Pharmacol Exp Ther 292, 877-85.
Stenmark, H. (2009). Rab GTPases as coordinators of vesicle traffic. Nat Rev 
Mol Cell Biol 10, 513-25.
Stephen, C. W. and Lane, D. P. (1992). Mutant conformation of p53. Precise 
epitope mapping using a filamentous phage epitope library. J Mol Biol 225, 
577-83.
Stockinger, W., Sailler, B., Strasser, V., Recheis, B., Fasching, D., Kahr, L., 
Schneider, W. J. and Nimpf, J. (2002). The PX-domain protein SNX17 interacts 
with members of the LDL receptor family and modulates endocytosis of the LDL 
receptor. EMBO J 21, 4259-67.
Stoorvogel, W., Oorschot, V. and Geuze, H. J. (1996). A novel class of clathrin-
coated vesicles budding from endosomes. J Cell Biol 132, 21-33.
Sur, C., Mallorga, P. J., Wittmann, M., Jacobson, M. A., Pascarella, D., Williams, 
J. B., Brandish, P. E., Pettibone, D. J., Scolnick, E. M. and Conn, P. J. (2003). N-
desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-
methyl-D-aspartate receptor activity. Proc Natl Acad Sci U S A 100, 13674-9.
Svenningsson, P., Chergui, K., Rachleff, I., Flajolet, M., Zhang, X., El Yacoubi, 
M., Vaugeois, J. M., Nomikos, G. G. and Greengard, P. (2006). Alterations in 5-
HT1B receptor function by p11 in depression-like states. Science 311, 77-80.
Svenningsson, P., Nishi, A., Fisone, G., Girault, J. A., Nairn, A. C. and 
Greengard, P. (2004). DARPP-32: an integrator of neurotransmission. Annu Rev 
Pharmacol Toxicol 44, 269-96.
250
Szekeres, P. G., Koenig, J. A. and Edwardson, J. M. (1998a). Involvement of 
receptor cycling and receptor reserve in resensitization of muscarinic responses 
in SH-SY5Y human neuroblastoma cells. J Neurochem 70, 1694-703.
Szekeres, P. G., Koenig, J. A. and Edwardson, J. M. (1998b). The relationship 
between agonist intrinsic activity and the rate of endocytosis of muscarinic 
receptors in a human neuroblastoma cell line. Mol Pharmacol 53, 759-65.
Tahvanainen, J., Pykalainen, M., Kallonen, T., Lahteenmaki, H., Rasool, O. and 
Lahesmaa, R. (2006). Enrichment of nucleofected primary human CD4+ T cells: 
a novel and efficient method for studying gene function and role in human 
primary T helper cell differentiation. J Immunol Methods 310, 30-9.
Talbot, K., Eidem, W. L., Tinsley, C. L., Benson, M. A., Thompson, E. W., Smith, 
R. J., Hahn, C. G., Siegel, S. J., Trojanowski, J. Q., Gur, R. E., Blake, D. J. and 
Arnold, S. E. (2004). Dysbindin-1 is reduced in intrinsic, glutamatergic terminals 
of the hippocampal formation in schizophrenia. J Clin Invest 113, 1353-63.
Tan, C. M., Brady, A. E., Nickols, H. H., Wang, Q. and Limbird, L. E. (2004). 
Membrane trafficking of G protein-coupled receptors. Annu Rev Pharmacol 
Toxicol 44, 559-609.
Taneichi-Kuroda, S., Taya, S., Hikita, T., Fujino, Y. and Kaibuchi, K. (2009). Direct 
interaction of Dysbindin with the AP-3 complex via its mu subunit. Neurochem Int 
54, 431-8.
Tang, Y., Hu, L. A., Miller, W. E., Ringstad, N., Hall, R. A., Pitcher, J. A., 
DeCamilli, P. and Lefkowitz, R. J. (1999). Identification of the endophilins 
(SH3p4/p8/p13) as novel binding partners for the beta1-adrenergic receptor. Proc 
Natl Acad Sci U S A 96, 12559-64.
Thomsen, M., Woldbye, D. P., Wortwein, G., Fink-Jensen, A., Wess, J. and 
Caine, S. B. (2005). Reduced cocaine self-administration in muscarinic M5 
acetylcholine receptor-deficient mice. J Neurosci 25, 8141-9.
Thomsen, M., Wortwein, G., Fink-Jensen, A., Woldbye, D. P., Wess, J. and 
Caine, S. B. (2007). Decreased prepulse inhibition and increased sensitivity to 
muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor 
knockout mice. Psychopharmacology (Berl) 192, 97-110.
Tobin, A. B., Lambert, D. G. and Nahorski, S. R. (1992). Rapid desensitization of 
muscarinic m3 receptor-stimulated polyphosphoinositide responses. Mol 
Pharmacol 42, 1042-8.
251
Tobin, A. B. and Nahorski, S. R. (1993). Rapid agonist-mediated phosphorylation 
of m3-muscarinic receptors revealed by immunoprecipitation. J Biol Chem 268, 
9817-23.
Toby, G. G. and Golemis, E. A. (2001). Using the yeast interaction trap and other 
two-hybrid-based approaches to study protein-protein interactions. Methods 24, 
201-17.
Toews, M. L. (2000). Radioligand-binding assays for G protein-coupled receptor 
internalization. Regulation of G Protein-Coupled Receptor Function and 
Expression. New York, NY, Wiley-Liss, 199-230.
Tolbert, L. M. and Lameh, J. (1996). Human muscarinic cholinergic receptor Hm1 
internalizes via clathrin-coated vesicles. J Biol Chem 271, 17335-42.
Torrecilla, I., Spragg, E. J., Poulin, B., McWilliams, P. J., Mistry, S. C., Blaukat, A. 
and Tobin, A. B. (2007). Phosphorylation and regulation of a G protein-coupled 
receptor by protein kinase CK2. J Cell Biol 177, 127-37.
Trendelenburg, A. U., Gomeza, J., Klebroff, W., Zhou, H. and Wess, J. (2003). 
Heterogeneity of presynaptic muscarinic receptors mediating inhibition of 
sympathetic transmitter release: a study with M2- and M4-receptor-deficient 
mice. Br J Pharmacol 138, 469-80.
Triezenberg, S. J., LaMarco, K. L. and McKnight, S. L. (1988). Evidence of DNA: 
protein interactions that mediate HSV-1 immediate early gene activation by 
VP16. Genes Dev 2, 730-42.
Trinquet, E., Fink, M., Bazin, H., Grillet, F., Maurin, F., Bourrier, E., Ansanay, H., 
Leroy, C., Michaud, A., Durroux, T., Maurel, D., Malhaire, F., Goudet, C., Pin, J. 
P., Naval, M., Hernout, O., Chretien, F., Chapleur, Y. and Mathis, G. (2006). D-
myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to 
monitor G protein-coupled receptor activation. Anal Biochem 358, 126-35.
Tsao, P. and von Zastrow, M. (2000). Downregulation of G protein-coupled 
receptors. Curr Opin Neurobiol 10, 365-9.
Turrigiano, G. G. (2008). The self-tuning neuron: synaptic scaling of excitatory 
synapses. Cell 135, 422-35.
Tutor, A. S., Delpon, E., Caballero, R., Gomez, R., Nunez, L., Vaquero, M., 
Tamargo, J., Mayor, F., Jr. and Penela, P. (2006). Association of 14-3-3 proteins 
252
to beta1-adrenergic receptors modulates Kv11.1 K+ channel activity in 
recombinant systems. Mol Biol Cell 17, 4666-74.
Tzavara, E. T., Bymaster, F. P., Felder, C. C., Wade, M., Gomeza, J., Wess, J., 
McKinzie, D. L. and Nomikos, G. G. (2003). Dysregulated hippocampal 
acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 
muscarinic receptor knockout mice. Mol Psychiatry 8, 673-9.
Uetz, P., Dong, Y. A., Zeretzke, C., Atzler, C., Baiker, A., Berger, B., Rajagopala, 
S. V., Roupelieva, M., Rose, D., Fossum, E. and Haas, J. (2006). Herpesviral 
protein networks and their interaction with the human proteome. Science 311, 
239-42.
Van Criekinge, W. and Beyaert, R. (1999). Yeast Two-Hybrid: State of the Art. 
Biol Proced Online 2, 1-38.
van Koppen, C. J. and Kaiser, B. (2003). Regulation of muscarinic acetylcholine 
receptor signaling. Pharmacol Ther 98, 197-220.
Vargas, G. A. and Von Zastrow, M. (2004). Identification of a novel endocytic 
recycling signal in the D1 dopamine receptor. J Biol Chem 279, 37461-9.
Vaynberg, J. and Qin, J. (2006). Weak protein-protein interactions as probed by 
NMR spectroscopy. Trends Biotechnol 24, 22-7.
Vogler, O., Bogatkewitsch, G. S., Wriske, C., Krummenerl, P., Jakobs, K. H. and 
van Koppen, C. J. (1998). Receptor subtype-specific regulation of muscarinic 
acetylcholine receptor sequestration by dynamin. Distinct sequestration of m2 
receptors. J Biol Chem 273, 12155-60.
Voglmaier, S. M., Kam, K., Yang, H., Fortin, D. L., Hua, Z., Nicoll, R. A. and 
Edwards, R. H. (2006). Distinct endocytic pathways control the rate and extent of 
synaptic vesicle protein recycling. Neuron 51, 71-84.
Vojtek, A. B., Hollenberg, S. M. and Cooper, J. A. (1993). Mammalian Ras 
interacts directly with the serine/threonine kinase Raf. Cell 74, 205-14.
Volpicelli, L. A., Lah, J. J. and Levey, A. I. (2001). Rab5-dependent trafficking of 
the m4 muscarinic acetylcholine receptor to the plasma membrane, early 
endosomes, and multivesicular bodies. J Biol Chem 276, 47590-8.
253
Voorn, P., Vanderschuren, L. J., Groenewegen, H. J., Robbins, T. W. and 
Pennartz, C. M. (2004). Putting a spin on the dorsal-ventral divide of the striatum. 
Trends Neurosci 27, 468-74.
Vowels, J. J. and Payne, G. S. (1998). A dileucine-like sorting signal directs 
transport into an AP-3-dependent, clathrin-independent pathway to the yeast 
vacuole. EMBO J 17, 2482-93.
Wang, H., Ng, K., Hayes, D., Gao, X., Forster, G., Blaha, C. and Yeomans, J. 
(2004). Decreased amphetamine-induced locomotion and improved latent 
inhibition in mice mutant for the M5 muscarinic receptor gene found in the human 
15q schizophrenia region. Neuropsychopharmacology 29, 2126-39.
Wang, H., Westin, L., Nong, Y., Birnbaum, S., Bendor, J., Brismar, H., Nestler, E., 
Aperia, A., Flajolet, M. and Greengard, P. (2009a). Norbin is an endogenous 
regulator of metabotropic glutamate receptor 5 signaling. Science (in press).
Wang, H., Westin, L., Nong, Y., Birnbaum, S., Bendor, J., Brismar, H., Nestler, E., 
Aperia, A., Flajolet, M. and Greengard, P. (2009b). Norbin is an endogenous 
regulator of metabotropic glutamate receptor 5 signaling. Science.
Wang, X., Zeng, W., Soyombo, A. A., Tang, W., Ross, E. M., Barnes, A. P., 
Milgram, S. L., Penninger, J. M., Allen, P. B., Greengard, P. and Muallem, S. 
(2005). Spinophilin regulates Ca2+ signalling by binding the N-terminal domain of 
RGS2 and the third intracellular loop of G-protein-coupled receptors. Nat Cell 
Biol 7, 405-11.
Wang, Y., Zhou, Y., Szabo, K., Haft, C. R. and Trejo, J. (2002). Down-regulation 
of protease-activated receptor-1 is regulated by sorting nexin 1. Mol Biol Cell 13, 
1965-76.
Wang, Z., Edwards, J. G., Riley, N., Provance, D. W., Jr., Karcher, R., Li, X. D., 
Davison, I. G., Ikebe, M., Mercer, J. A., Kauer, J. A. and Ehlers, M. D. (2008). 
Myosin Vb mobilizes recycling endosomes and AMPA receptors for postsynaptic 
plasticity. Cell 135, 535-48.
Warner-Schmidt, J. L., Flajolet, M., Maller, A., Chen, E. Y., Qi, H., Svenningsson, 
P. and Greengard, P. (2009). Role of p11 in cellular and behavioral effects of 5-
HT4 receptor stimulation. J Neurosci 29, 1937-46.
Wei, M. L. (2006). Hermansky-Pudlak syndrome: a disease of protein trafficking 
and organelle function. Pigment Cell Res 19, 19-42.
254
Weigert, R., Yeung, A. C., Li, J. and Donaldson, J. G. (2004). Rab22a regulates 
the recycling of membrane proteins internalized independently of clathrin. Mol 
Biol Cell 15, 3758-70.
Weiner, D. M., Levey, A. I. and Brann, M. R. (1990). Expression of muscarinic 
acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad 
Sci U S A 87, 7050-4.
Wess, J., Blin, N., Mutschler, E. and Bluml, K. (1995). Muscarinic acetylcholine 
receptors: structural basis of ligand binding and G protein coupling. Life Sci 56, 
915-22.
Wess, J., Duttaroy, A., Zhang, W., Gomeza, J., Cui, Y., Miyakawa, T., Bymaster, 
F. P., McKinzie, L., Felder, C. C., Lamping, K. G., Faraci, F. M., Deng, C. and 
Yamada, M. (2003). M1-M5 muscarinic receptor knockout mice as novel tools to 
study the physiological roles of the muscarinic cholinergic system. Receptors 
Channels 9, 279-90.
Wess, J., Eglen, R. M. and Gautam, D. (2007). Muscarinic acetylcholine 
receptors: mutant mice provide new insights for drug development. Nat Rev Drug 
Discov 6, 721-33.
Wess, J., Liu, J., Blin, N., Yun, J., Lerche, C. and Kostenis, E. (1997). Structural 
basis of receptor/G protein coupling selectivity studied with muscarinic receptors 
as model systems. Life Sci 60, 1007-14.
Wessler, I., Kilbinger, H., Bittinger, F., Unger, R. and Kirkpatrick, C. J. (2003). The 
non-neuronal cholinergic system in humans: expression, function and 
pathophysiology. Life Sci 72, 2055-61.
Wessler, I., Kirkpatrick, C. J. and Racke, K. (1999). The cholinergic 'pitfall': 
acetylcholine, a universal cell molecule in biological systems, including humans. 
Clin Exp Pharmacol Physiol 26, 198-205.
West, A. E., Neve, R. L. and Buckley, K. M. (1997a). Identification of a 
somatodendritic targeting signal in the cytoplasmic domain of the transferrin 
receptor. J Neurosci 17, 6038-47.
West, A. E., Neve, R. L. and Buckley, K. M. (1997b). Targeting of the synaptic 
vesicle protein synaptobrevin in the axon of cultured hippocampal neurons: 
evidence for two distinct sorting steps. J Cell Biol 139, 917-27.
255
Westphalen, R. I. and Hemmings, H. C., Jr. (2003). Selective depression by 
general anesthetics of glutamate versus GABA release from isolated cortical 
nerve terminals. J Pharmacol Exp Ther 304, 1188-96.
Whistler, J. L., Enquist, J., Marley, A., Fong, J., Gladher, F., Tsuruda, P., Murray, 
S. R. and Von Zastrow, M. (2002). Modulation of postendocytic sorting of G 
protein-coupled receptors. Science 297, 615-20.
Wilkin, M., Tongngok, P., Gensch, N., Clemence, S., Motoki, M., Yamada, K., 
Hori, K., Taniguchi-Kanai, M., Franklin, E., Matsuno, K. and Baron, M. (2008). 
Drosophila HOPS and AP-3 complex genes are required for a Deltex-regulated 
activation of notch in the endosomal trafficking pathway. Dev Cell 15, 762-72.
Willets, J. M., Mistry, R., Nahorski, S. R. and Challiss, R. A. (2003). Specificity of 
g protein-coupled receptor kinase 6-mediated phosphorylation and regulation of 
single-cell m3 muscarinic acetylcholine receptor signaling. Mol Pharmacol 64, 
1059-68.
Wilson, S. J. and Smyth, E. M. (2006). Internalization and recycling of the human 
prostacyclin receptor is modulated through its isoprenylation-dependent 
interaction with the delta subunit of cGMP phosphodiesterase 6. J Biol Chem 
281, 11780-6.
Worby, C. A. and Dixon, J. E. (2002). Sorting out the cellular functions of sorting 
nexins. Nat Rev Mol Cell Biol 3, 919-31.
Worzfeld, T., Wettschureck, N. and Offermanns, S. (2008). G(12)/G(13)-mediated 
signalling in mammalian physiology and disease. Trends Pharmacol Sci 29, 
582-9.
Wruck, C. J., Funke-Kaiser, H., Pufe, T., Kusserow, H., Menk, M., Schefe, J. H., 
Kruse, M. L., Stoll, M. and Unger, T. (2005). Regulation of transport of the 
angiotensin AT2 receptor by a novel membrane-associated Golgi protein. 
Arterioscler Thromb Vasc Biol 25, 57-64.
Wu, G., Bogatkevich, G. S., Mukhin, Y. V., Benovic, J. L., Hildebrandt, J. D. and 
Lanier, S. M. (2000). Identification of Gbetagamma binding sites in the third 
intracellular loop of the M(3)-muscarinic receptor and their role in receptor 
regulation. J Biol Chem 275, 9026-34.
Xia, C., Ma, W., Stafford, L. J., Liu, C., Gong, L., Martin, J. F. and Liu, M. (2003). 
GGAPs, a new family of bifunctional GTP-binding and GTPase-activating 
proteins. Mol Cell Biol 23, 2476-88.
256
Xiao, B., Tu, J. C., Petralia, R. S., Yuan, J. P., Doan, A., Breder, C. D., Ruggiero, 
A., Lanahan, A. A., Wenthold, R. J. and Worley, P. F. (1998). Homer regulates the 
association of group 1 metabotropic glutamate receptors with multivalent 
complexes of homer-related, synaptic proteins. Neuron 21, 707-16.
Xu, J. and Chuang, D. M. (1987). Muscarinic acetylcholine receptor-mediated 
phosphoinositide turnover in cultured cerebellar granule cells: desensitization by 
receptor agonists. J Pharmacol Exp Ther 242, 238-44.
Xu, Y., Seet, L. F., Hanson, B. and Hong, W. (2001). The Phox homology (PX) 
domain, a new player in phosphoinositide signalling. Biochem J 360, 513-30.
Yamada, M., Lamping, K. G., Duttaroy, A., Zhang, W., Cui, Y., Bymaster, F. P., 
McKinzie, D. L., Felder, C. C., Deng, C. X., Faraci, F. M. and Wess, J. (2001a). 
Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic 
acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A 98, 14096-101.
Yamada, M., Miyakawa, T., Duttaroy, A., Yamanaka, A., Moriguchi, T., Makita, R., 
Ogawa, M., Chou, C. J., Xia, B., Crawley, J. N., Felder, C. C., Deng, C. X. and 
Wess, J. (2001b). Mice lacking the M3 muscarinic acetylcholine receptor are 
hypophagic and lean. Nature 410, 207-12.
Yan, Z., Song, W. J. and Surmeier, J. (1997). D2 dopamine receptors reduce N-
type Ca2+ currents in rat neostriatal cholinergic interneurons through a 
membrane-delimited, protein-kinase-C-insensitive pathway. J Neurophysiol 77, 
1003-15.
Yan, Z. and Surmeier, D. J. (1997). D5 dopamine receptors enhance Zn2+-
sensitive GABA(A) currents in striatal cholinergic interneurons through a PKA/
PP1 cascade. Neuron 19, 1115-26.
Yap, C. C., Wisco, D., Kujala, P., Lasiecka, Z. M., Cannon, J. T., Chang, M. C., 
Hirling, H., Klumperman, J. and Winckler, B. (2008). The somatodendritic 
endosomal regulator NEEP21 facilitates axonal targeting of L1/NgCAM. J Cell 
Biol 180, 827-42.
Yasuda, R. P., Ciesla, W., Flores, L. R., Wall, S. J., Li, M., Satkus, S. A., 
Weisstein, J. S., Spagnola, B. V. and Wolfe, B. B. (1993). Development of 
antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of 
m4 and m5 receptors in rat brain. Mol Pharmacol 43, 149-57.
257
Yeomans, J., Forster, G. and Blaha, C. (2001). M5 muscarinic receptors are 
needed for slow activation of dopamine neurons and for rewarding brain 
stimulation. Life Sci 68, 2449-56.
Yu, H., Braun, P., Yildirim, M. A., Lemmens, I., Venkatesan, K., Sahalie, J., 
Hirozane-Kishikawa, T., Gebreab, F., Li, N., Simonis, N., Hao, T., Rual, J. F., 
Dricot, A., Vazquez, A., Murray, R. R., Simon, C., Tardivo, L., Tam, S., Svrzikapa, 
N., Fan, C., de Smet, A. S., Motyl, A., Hudson, M. E., Park, J., Xin, X., Cusick, M. 
E., Moore, T., Boone, C., Snyder, M., Roth, F. P., Barabasi, A. L., Tavernier, J., 
Hill, D. E. and Vidal, M. (2008). High-quality binary protein interaction map of the 
yeast interactome network. Science 322, 104-10.
Zeitelhofer, M., Vessey, J. P., Xie, Y., Tubing, F., Thomas, S., Kiebler, M. and 
Dahm, R. (2007). High-efficiency transfection of mammalian neurons via 
nucleofection. Nat Protoc 2, 1692-704.
Zeng, F. Y. and Wess, J. (1999). Identification and molecular characterization of 
m3 muscarinic receptor dimers. J Biol Chem 274, 19487-97.
Zervos, A. S., Gyuris, J. and Brent, R. (1993). Mxi1, a protein that specifically 
interacts with Max to bind Myc-Max recognition sites. Cell 72, 223-32.
Zhan, L., Liu, B., Jose-Lafuente, M., Chibalina, M. V., Grierson, A., Maclean, A. 
and Nasir, J. (2008). ALG-2 interacting protein AIP1: a novel link between D1 and 
D3 signalling. Eur J Neurosci 27, 1626-33.
Zhang, H., Craciun, L. C., Mirshahi, T., Rohacs, T., Lopes, C. M., Jin, T. and 
Logothetis, D. E. (2003). PIP(2) activates KCNQ channels, and its hydrolysis 
underlies receptor-mediated inhibition of M currents. Neuron 37, 963-75.
Zhang, H. and Sulzer, D. (2003). Glutamate spillover in the striatum depresses 
dopaminergic transmission by activating group I metabotropic glutamate 
receptors. J Neurosci 23, 10585-92.
Zhang, H. and Sulzer, D. (2004). Frequency-dependent modulation of dopamine 
release by nicotine. Nat Neurosci 7, 581-2.
Zhang, W., Basile, A. S., Gomeza, J., Volpicelli, L. A., Levey, A. I. and Wess, J. 
(2002a). Characterization of central inhibitory muscarinic autoreceptors by the 
use of muscarinic acetylcholine receptor knock-out mice. J Neurosci 22, 1709-17.
258
Zhang, W., Yamada, M., Gomeza, J., Basile, A. S. and Wess, J. (2002b). Multiple 
muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, 
as studied with M1-M5 muscarinic receptor knock-out mice. J Neurosci 22, 
6347-52.
Zhou, F. M., Wilson, C. J. and Dani, J. A. (2002a). Cholinergic interneuron 
characteristics and nicotinic properties in the striatum. J Neurobiol 53, 590-605.
Zhou, H., Meyer, A., Starke, K., Gomeza, J., Wess, J. and Trendelenburg, A. U. 
(2002b). Heterogeneity of release-inhibiting muscarinic autoreceptors in heart 
atria and urinary bladder: a study with M(2)- and M(4)-receptor-deficient mice. 
Naunyn Schmiedebergs Arch Pharmacol 365, 112-22.
259
